[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n* Acrokeratosis paraneoplastic syndrome\nNote: The term \"paraneoplastic\" refers to a condition that is associated with a specific type of cancer, in this case, acrokeratosis is associated with various types of cancer, including breast, lung, and ovarian cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.\n2. Acrokeratosis paraneoplastica is a condition associated with various types of cancer.\n3. Types of cancer associated with Acrokeratosis paraneoplastica include breast, lung, and ovarian cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.",
      "Acrokeratosis paraneoplastica is a condition associated with various types of cancer.",
      "Types of cancer associated with Acrokeratosis paraneoplastica include breast, lung, and ovarian cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Acrokeratosis paraneoplastica is commonly associated with cancers such as gastrointestinal tract, particularly gastric adenocarcinoma, and squamous cell carcinoma of the esophagus. Breast, lung, and ovarian cancers are not typically the associated types mentioned in the context of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that affect brain development and can cause a range of physical and intellectual disabilities. However, they are distinct conditions with some differences in their underlying genetic causes and clinical features.\nWeaver syndrome is caused by mutations in the PPP1R1B gene, which encodes a protein called phosphatidylinositol-4,5-bisphosphate 3-kinase regulatory subunit beta (PIK3R1). This gene is involved in the PI3K signaling pathway, which plays a critical role in regulating cell growth, survival, and migration. Weaver syndrome is characterized by intellectual disability, seizures, delayed speech and language development, and a range of physical abnormalities, including dysmorphic features, growth delays, and congenital anomalies.\nSotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which encodes a protein called nuclear protein 3 (Np3). This gene is involved in the regulation of gene expression, particularly during fetal development. Sotos syndrome is characterized by intellectual disability, growth delays, seizures, and a range of physical abnormalities, including dysmorphic features, heart defects, and limb abnormalities.\nWhile both Weaver syndrome and Sotos syndrome can cause intellectual disability and other developmental delays, the clinical features of these conditions can vary significantly. Weaver syndrome tends to have a more severe impact on brain development and function, while Sotos syndrome can have a more mild to moderate impact. Additionally, the physical abnormalities associated with each condition can differ, with Weaver syndrome often presenting with more severe dysmorphic features and congenital anomalies, while Sotos syndrome can have a more variable range of physical abnormalities.\nIn summary, while both Weaver syndrome and Sotos syndrome are rare genetic disorders that can affect brain development and function, they are distinct conditions with different genetic causes and clinical features.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by mutations in the PPP1R1B gene.\n2. The PPP1R1B gene is involved in the PI3K signaling pathway, critical for cell growth, survival, and migration.\n3. Sotos syndrome is caused by mutations in the NSD1 gene.\n4. The NSD1 gene is involved in the regulation of gene expression during fetal development.\n5. Both Weaver syndrome and Sotos syndrome are characterized by intellectual disability, growth delays, and physical abnormalities, but they have differing clinical features and severity.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by mutations in the PPP1R1B gene.",
      "The PPP1R1B gene is involved in the PI3K signaling pathway, critical for cell growth, survival, and migration.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "The NSD1 gene is involved in the regulation of gene expression during fetal development.",
      "Both Weaver syndrome and Sotos syndrome are characterized by intellectual disability, growth delays, and physical abnormalities, but they have differing clinical features and severity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, not the PPP1R1B gene.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Junket Algorithm for the Prediction of Transcription Factor Binding Sites in DNA) is a database of transcription factor binding site (TFBS) predictions. Here are the releases of the JASPAR database:\n1. JASPAR Release 1 (2001): This was the first release of the JASPAR database, containing 145 TFBS profiles for 13 transcription factors.\n2. JASPAR Release 2 (2004): This release added 16 new transcription factors and increased the number of TFBS profiles to 331.\n3. JASPAR Release 3 (2008): This release included 40 new transcription factors and a total of 509 TFBS profiles.\n4. JASPAR Release 4 (2011): This release added 24 new transcription factors and increased the number of TFBS profiles to 753.\n5. JASPAR Release 5 (2014): This release included 32 new transcription factors and a total of 1,072 TFBS profiles.\n6. JASPAR Release 6 (2017): This release added 48 new transcription factors and increased the number of TFBS profiles to 1,230.\n7. JASPAR Release 7 (2020): This is the latest release of the JASPAR database, containing 1,353 TFBS profiles for 115 transcription factors.\nPlease note that each release of the JASPAR database includes updates and improvements to the TFBS predictions, as well as additional transcription factors and genomic sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1 was in 2001 and it contained 145 TFBS profiles for 13 transcription factors.\n2. JASPAR Release 2 was in 2004 and it increased the number of TFBS profiles to 331, with 16 new transcription factors added.\n3. JASPAR Release 3 was in 2008 and it included a total of 509 TFBS profiles with 40 new transcription factors added.\n4. JASPAR Release 4 was in 2011 and the number of TFBS profiles increased to 753.\n5. JASPAR Release 7, which is the latest mentioned release, was in 2020 and contains 1,353 TFBS profiles for 115 transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1 was in 2001 and it contained 145 TFBS profiles for 13 transcription factors.",
      "JASPAR Release 2 was in 2004 and it increased the number of TFBS profiles to 331, with 16 new transcription factors added.",
      "JASPAR Release 3 was in 2008 and it included a total of 509 TFBS profiles with 40 new transcription factors added.",
      "JASPAR Release 4 was in 2011 and the number of TFBS profiles increased to 753.",
      "JASPAR Release 7, which is the latest mentioned release, was in 2020 and contains 1,353 TFBS profiles for 115 transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: JASPAR Release 7 is not the latest mentioned release as of my knowledge cutoff in 2023. There have been more recent releases. For instance, JASPAR Release 8 (2022) contains over 1,800 TFBS profiles. The exact numbers for the 2020 release would need to be verified since the statement doesn't align with a known release version at my knowledge cutoff.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a regulatory protein found in certain viruses, including the poxvirus. It plays a crucial role in the regulation of viral gene expression, particularly during the lytic cycle of the virus. The KP4 protein inhibits the activity of the viral RNA-dependent RNA polymerase (RdRp) by binding to the catalytic subunit of the enzyme and preventing its activity. This results in a decrease in the production of viral RNA and a decrease in the replication of the virus. Additionally, the KP4 protein can also interact with host cell factors and modulate the host immune response, further contributing to the regulation of viral replication.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is found in certain viruses, including the poxvirus.\n2. KP4 plays a role in the regulation of viral gene expression during the lytic cycle.\n3. The KP4 protein inhibits the activity of the viral RNA-dependent RNA polymerase (RdRp).\n4. KP4 binds to the catalytic subunit of the RdRp enzyme to prevent its activity.\n5. The KP4 protein interacts with host cell factors to modulate the host immune response.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is found in certain viruses, including the poxvirus.",
      "KP4 plays a role in the regulation of viral gene expression during the lytic cycle.",
      "The KP4 protein inhibits the activity of the viral RNA-dependent RNA polymerase (RdRp).",
      "KP4 binds to the catalytic subunit of the RdRp enzyme to prevent its activity.",
      "The KP4 protein interacts with host cell factors to modulate the host immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is found in the plant pathogenic fungus Ustilago maydis, not in viruses.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-[2-(4-hydroxyphenyl)ethyl]-5-methyl-3-isoxazolepropionamide] is a synthetic thyroid hormone analog that has been utilized in both experimental and clinical studies. It is a potent agonist of the thyroid hormone receptor, and has been used to study the role of thyroid hormones in various physiological processes, including metabolism, growth, and development.\nIn experimental studies, DITPA has been used to investigate the mechanisms of thyroid hormone action, and to evaluate the effects of thyroid hormone deficiency or excess on various physiological processes. For example, DITPA has been used to study the effects of thyroid hormone deficiency on metabolism, growth, and development in animal models of hypothyroidism.\nIn clinical studies, DITPA has been used as a therapeutic agent for the treatment of thyroid hormone deficiency, particularly in the treatment of hypothyroidism. It has also been used to study the effects of thyroid hormone replacement therapy on various physiological processes, such as metabolism and growth.\nHowever, it is important to note that DITPA is not a naturally occurring thyroid hormone, and its use is limited due to its potential toxicity and side effects. As a result, it is not commonly used in clinical practice, and other thyroid hormone analogs or synthetic thyroid hormones are generally preferred for the treatment of thyroid hormone deficiency.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.\n2. It is an agonist of the thyroid hormone receptor.\n3. DITPA has been utilized to study the role of thyroid hormones in metabolism, growth, and development.\n4. It has been used experimentally to investigate thyroid hormone action and evaluate the effects of deficiency or excess of thyroid hormones.\n5. In clinical settings, DITPA has been employed as a therapeutic agent for treating hypothyroidism.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.",
      "It is an agonist of the thyroid hormone receptor.",
      "DITPA has been utilized to study the role of thyroid hormones in metabolism, growth, and development.",
      "It has been used experimentally to investigate thyroid hormone action and evaluate the effects of deficiency or excess of thyroid hormones.",
      "In clinical settings, DITPA has been employed as a therapeutic agent for treating hypothyroidism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: DITPA has not been approved as a therapeutic agent for treating hypothyroidism; rather, levothyroxine is commonly used for this purpose. While DITPA may have been studied for its potential effects, it is generally not employed clinically for hypothyroidism treatment.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (COunteracting Ubiquitin-like Modulators of Growth and Elongation Regulators) is a tool used to predict the effects of non-coding RNA (ncRNA) molecules on gene expression. It is a computational method that uses a combination of machine learning algorithms and molecular dynamics simulations to predict the binding affinity of ncRNAs to their target genes and their effects on gene expression. COUGER can be used to predict the effects of novel ncRNAs on gene expression and to identify potential therapeutic targets for diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for COunteracting Ubiquitin-like Modulators of Growth and Elongation Regulators.\n2. COUGER is a computational tool used to predict the effects of non-coding RNA on gene expression.\n3. The tool uses a combination of machine learning algorithms and molecular dynamics simulations.\n4. COUGER predicts the binding affinity of ncRNAs to their target genes.\n5. The tool can be used for identifying potential therapeutic targets for diseases.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for COunteracting Ubiquitin-like Modulators of Growth and Elongation Regulators.",
      "COUGER is a computational tool used to predict the effects of non-coding RNA on gene expression.",
      "The tool uses a combination of machine learning algorithms and molecular dynamics simulations.",
      "COUGER predicts the binding affinity of ncRNAs to their target genes.",
      "The tool can be used for identifying potential therapeutic targets for diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe acronym \"COUGER\" is not a standard term with a widely recognized meaning in biology or bioinformatics, and without additional context, the correctness of the detailed definition in statement 1 cannot be assessed. The same applies to statements 2, 3, and 4. However, assuming COUGER is indeed a computational tool related to gene expression prediction as stated in (2), it is reasonable to infer that such a tool could potentially be used for identifying therapeutic targets for diseases (5), which is a common application of bioinformatics tools in genomics research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE), which is caused by the TBE virus. The most commonly used drugs for TBE treatment are:\n1. Ribavirin: This drug is an antiviral drug that is effective against TBE virus. It is usually given intravenously or orally and has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\n2. Oseltamivir: This drug is an influenza virus neuraminidase inhibitor that has been shown to be effective against TBE virus. It is usually given orally and has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\n3. Zanamivir: This drug is also an influenza virus neuraminidase inhibitor and has been shown to be effective against TBE virus. It is usually given orally and has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\n4. Relenza (zanamivir): This drug is an influenza virus neuraminidase inhibitor that has been shown to be effective against TBE virus. It is usually given orally and has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\n5. Peramivir: This drug is an influenza virus neuraminidase inhibitor that has been shown to be effective against TBE virus. It is usually given intravenously and has been shown to reduce the severity of symptoms and the duration of illness in patients with TBE.\nIt is important to note that these drugs are most effective when started early in the course of illness, and may have side effects. It is also important to consult a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is an antiviral drug used for the treatment of tick-borne encephalitis (TBE).\n2. Oseltamivir has been shown to be effective against the TBE virus.\n3. Zanamivir is an influenza virus neuraminidase inhibitor that is effective against TBE virus.\n4. Peramivir, usually given intravenously, has been shown to reduce the severity of symptoms and duration of illness in TBE patients.\n5. Relenza (zanamivir) is an oral medication that is effective against the TBE virus.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is an antiviral drug used for the treatment of tick-borne encephalitis (TBE).",
      "Oseltamivir has been shown to be effective against the TBE virus.",
      "Zanamivir is an influenza virus neuraminidase inhibitor that is effective against TBE virus.",
      "Peramivir, usually given intravenously, has been shown to reduce the severity of symptoms and duration of illness in TBE patients.",
      "Relenza (zanamivir) is an oral medication that is effective against the TBE virus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Ribavirin is an antiviral drug, but its effectiveness against tick-borne encephalitis virus (TBEV) is not widely established. It's used for the treatment of some other viral infections, such as hepatitis C and some types of viral hemorrhagic fevers, but without specific context or current data, the effectiveness against TBE cannot be confirmed.\n\n2. FALSE [correction]: Oseltamivir, also known by the brand name Tamiflu, is primarily an antiviral medication used to treat and prevent influenza A and B, not tick-borne encephalitis virus.\n\n3. FALSE [correction]: Zanamivir is indeed an influenza virus neuraminidase inhibitor effective against influenza viruses, but there is no generally accepted evidence that it is effective against the TBE virus.\n\n4. FALSE [correction]: Peramivir is used for the treatment of influenza, and there is no widely accepted evidence suggesting it has been shown to reduce the severity of symptoms and duration of illness in TBE patients.\n\n5. FALSE [correction]: Relenza (zanamivir) is not an oral medication; it is administered by inhalation. Furthermore, it is used to treat influenza and there is no commonly accepted evidence stating it is effective against the TBE virus.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers and databases that provide DNA shape annotations, including:\n1. DNase-seq: This database contains information on the DNA accessibility profiles of various organisms, including humans, generated using the DNase-seq technique.\n2. FAIRE: The FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) database contains information on the 3D chromatin structure of various organisms, including humans, generated using the FAIRE technique.\n3. Hi-C: The Hi-C (High-Throughput Chromosome Conformation Capture) database contains information on the 3D chromatin structure of various organisms, including humans, generated using the Hi-C technique.\n4. 4C: The 4C (Chromatin Conformation Capture) database contains information on the 3D chromatin structure of various organisms, including humans, generated using the 4C technique.\n5. ChIA-PET: The Chromosome conformation assay-pull-down (ChIA-PET) database contains information on the 3D chromatin structure of various organisms, including humans, generated using the ChIA-PET technique.\n6. 3C-seq: The 3C-seq database contains information on the 3D chromatin structure of various organisms, including humans, generated using the 3C-seq technique.\n7. ChIP-exo: The Chromatin immunoprecipitation-exon (ChIP-exo) database contains information on the 3D chromatin structure of various organisms, including humans, generated using the ChIP-exo technique.\n8. Topo-map: The Topo-map database contains information on the 3D chromatin structure of various organisms, including humans, generated using the Topo-map technique.\n9. H3K27ac ChIP-seq: The H3K27ac Chromatin immunoprecipitation-sequencing (ChIP-seq) database contains information on the 3D chromatin structure of various organisms, including humans, generated using the H3K27ac ChIP-seq technique.\n10. H3K4me3 ChIP-seq: The H3K4me3 Chromatin immun",
    "llama-2-7b-chat-hf_fact_raw": "1. The DNase-seq database contains DNA accessibility profiles of various organisms, including humans.\n2. The FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) database provides information on 3D chromatin structures.\n3. The Hi-C database includes information on the 3D chromatin structure of various organisms, generated by the Hi-C technique.\n4. The ChIA-PET (Chromosome conformation assay-pull-down) database contains 3D chromatin structure information based on the ChIA-PET technique.\n5. The Topo-map database provides data on the 3D chromatin structure of various organisms.",
    "llama-2-7b-chat-hf_fact": [
      "The DNase-seq database contains DNA accessibility profiles of various organisms, including humans.",
      "The FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) database provides information on 3D chromatin structures.",
      "The Hi-C database includes information on the 3D chromatin structure of various organisms, generated by the Hi-C technique.",
      "The ChIA-PET (Chromosome conformation assay-pull-down) database contains 3D chromatin structure information based on the ChIA-PET technique.",
      "The Topo-map database provides data on the 3D chromatin structure of various organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) technique is used to identify regions of DNA that are not tightly bound to histones or other proteins, and thus likely to be regulatory elements; it doesn't specifically provide information on 3D chromatin structures.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes the enzyme enzyme histone methyltransferase 2 (EZH2), which plays a crucial role in regulating gene expression and chromatin modification. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Rubinstein-Taybi syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and various other physical abnormalities. EZH2 mutations are found in approximately 50% of Rubinstein-Taybi syndrome cases.\n2. Pallister-Hall syndrome: This is a rare genetic disorder characterized by intellectual disability, growth retardation, facial dysmorphism, and various other physical abnormalities. EZH2 mutations are found in approximately 25% of Pallister-Hall syndrome cases.\n3. Ectodermal dysplasia, ectropion, and microphthalmia (EDEM): This is a rare genetic disorder characterized by abnormalities of the skin, eyes, and ears. EZH2 mutations have been identified in approximately 25% of EDEM cases.\n4. Waardenburg syndrome: This is a rare genetic disorder characterized by hearing loss, pigmentation abnormalities, and various other physical abnormalities. EZH2 mutations have been identified in approximately 10% of Waardenburg syndrome cases.\n5. Oculocerebrorenal syndrome (OCWR): This is a rare genetic disorder characterized by kidney problems, intellectual disability, and various other physical abnormalities. EZH2 mutations have been identified in approximately 10% of OCWR cases.\nThese syndromes are caused by mutations in the EZH2 gene that disrupt its normal function, leading to changes in gene expression and chromatin modification that can have far-reaching consequences for cellular development and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are found in approximately 50% of Rubinstein-Taybi syndrome cases.\n2. Approximately 25% of Pallister-Hall syndrome cases have mutations in the EZH2 gene.\n3. EZH2 gene mutations have been identified in approximately 25% of Ectodermal dysplasia, ectropion, and microphthalmia (EDEM) cases.\n4. About 10% of Waardenburg syndrome cases are associated with EZH2 gene mutations.\n5. Roughly 10% of Oculocerebrorenal syndrome (OCWR) cases have identified mutations in the EZH2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are found in approximately 50% of Rubinstein-Taybi syndrome cases.",
      "Approximately 25% of Pallister-Hall syndrome cases have mutations in the EZH2 gene.",
      "EZH2 gene mutations have been identified in approximately 25% of Ectodermal dysplasia, ectropion, and microphthalmia (EDEM) cases.",
      "About 10% of Waardenburg syndrome cases are associated with EZH2 gene mutations.",
      "Roughly 10% of Oculocerebrorenal syndrome (OCWR) cases have identified mutations in the EZH2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the CREBBP gene, not the EZH2 gene, are found in a majority of Rubinstein-Taybi syndrome cases.\n2. FALSE [correction]: Pallister-Hall syndrome is primarily associated with mutations in the GLI3 gene, not the EZH2 gene.\n3. UNKNOWN\n4. FALSE [correction]: Waardenburg syndrome is associated with mutations in several genes, but EZH2 is not typically cited as one of them. Common genes associated with Waardenburg syndrome include PAX3, MITF, SOX10, and others.\n5. UNKNOWN\n(Note: Information regarding the EZH2 gene and its association with Ectodermal dysplasia, ectropion, and microphthalmia (EDEM) or Oculocerebrorenal syndrome (OCWR) would require specific medical literature or genetic databases, which is not provided here. It is important to refer to current and reliable genetic resources for the most accurate information.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, including:\n1. p53: The tumor suppressor protein p53 is a transcription factor that regulates various cellular processes, including cell cycle arrest, apoptosis, and DNA repair. p53 exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation and the regulation of downstream target genes.\n2. c-Myc: c-Myc is a transcription factor that regulates cellular processes such as cell proliferation, differentiation, and apoptosis. c-Myc exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation and the regulation of downstream target genes.\n3. Cyclin-dependent kinase 6 (Cdk6): Cdk6 is a key regulator of the cell cycle and is involved in the phosphorylation and inactivation of the retinoblastoma protein (Rb). Cdk6 exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon binding to its cyclin partners, leading to its activation and the progression of the cell cycle.\n4. Cyclin-dependent kinase 4 (Cdk4): Like Cdk6, Cdk4 is also a key regulator of the cell cycle and is involved in the phosphorylation and inactivation of Rb. Cdk4 exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon binding to its cyclin partners, leading to its activation and the progression of the cell cycle.\n5. Bcl-2 family proteins: The Bcl-2 family of proteins regulates apoptosis by modulating the permeability of the mitochondrial membrane to ionic currents. Bcl-2 exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation and the inhibition of apoptosis.\n6. NF-",
    "llama-2-7b-chat-hf_fact_raw": "1. The human protein p53 exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation.\n2. The human protein c-Myc also exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation.\n3. Cyclin-dependent kinase 6 (Cdk6) is a dimer in its inactive state and transitions to a tetramer upon binding to its cyclin partners.\n4. Cyclin-dependent kinase 4 (Cdk4) undergoes a dimer-to-tetramer transition upon binding to its cyclin partners.\n5. Bcl-2 family proteins exist as dimers in an inactive form and transition to tetramers upon phosphorylation, inhibiting apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "The human protein p53 exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation.",
      "The human protein c-Myc also exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation.",
      "Cyclin-dependent kinase 6 (Cdk6) is a dimer in its inactive state and transitions to a tetramer upon binding to its cyclin partners.",
      "Cyclin-dependent kinase 4 (Cdk4) undergoes a dimer-to-tetramer transition upon binding to its cyclin partners.",
      "Bcl-2 family proteins exist as dimers in an inactive form and transition to tetramers upon phosphorylation, inhibiting apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human protein p53 exists as a tetramer in its active form; it does not transition from a dimer to a tetramer upon phosphorylation. The tetramerization of p53 is necessary for its function as a transcription factor in response to various cellular stresses.\n2. FALSE [correction]: The human protein c-Myc forms a dimer with Max in its active form; however, it does not switch from a dimer to a tetramer upon phosphorylation. c-Myc/Max heterodimerization is essential for its role as a transcription factor.\n3. FALSE [correction]: Cyclin-dependent kinase 6 (Cdk6) forms a complex with cyclin D to be active but does not transition from a dimer to a tetramer. Its activation involves the formation of a binary complex with a regulatory cyclin, not a dimer-to-tetramer transition.\n4. FALSE [correction]: Cyclin-dependent kinase 4 (Cdk4) as well, forms a complex with cyclin D for its activation but does not undergo a dimer-to-tetramer transition. It operates as a binary complex with its regulatory cyclin partner.\n5. FALSE [correction]: Bcl-2 family proteins can exist as both monomers and dimers, but their mechanism of regulating apoptosis does not involve a transition to a tetramer upon phosphorylation. The anti-apoptotic and pro-apoptotic members of the Bcl-2 family regulate apoptosis through a complex interplay of dimerization and conformational changes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "One protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2 (B-cell lymphoma 2). Bcl-2 is a member of the Bcl-2 family of proteins, which play a crucial role in regulating apoptosis (programmed cell death) in various cell types, including cardiac myocytes. Bcl-2 inhibits apoptosis by binding to and neutralizing pro-apoptotic proteins, such as Bax and Bak, and preventing them from inducing cell death. PLN and Bcl-2 have been shown to interact in various studies, and PLN has been shown to promote the expression and activity of Bcl-2, suggesting that PLN may play a role in protecting cells against apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 interacts with phospholamban (PLN) and is an anti-apoptotic protein.\n2. Bcl-2 is a member of the Bcl-2 family of proteins.\n3. The Bcl-2 family of proteins regulates apoptosis in various types of cells, including cardiac myocytes.\n4. Bcl-2 functions by binding to and neutralizing pro-apoptotic proteins like Bax and Bak.\n5. Studies have shown an interaction between PLN and Bcl-2, with PLN promoting the expression and activity of Bcl-2.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 interacts with phospholamban (PLN) and is an anti-apoptotic protein.",
      "Bcl-2 is a member of the Bcl-2 family of proteins.",
      "The Bcl-2 family of proteins regulates apoptosis in various types of cells, including cardiac myocytes.",
      "Bcl-2 functions by binding to and neutralizing pro-apoptotic proteins like Bax and Bak.",
      "Studies have shown an interaction between PLN and Bcl-2, with PLN promoting the expression and activity of Bcl-2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Studies have shown an interaction between PLN and Bcl-2, but it is Bcl-2 that influences PLN. Specifically, Bcl-2 is known to have an anti-apoptotic effect, and through its interactions, it may modulate other proteins like PLN. However, the statement as given implies that PLN promotes Bcl-2 expression and activity, which is generally not how the relationship between these proteins is characterized. Instead, Bcl-2's anti-apoptotic effects can influence the function of PLN, particularly in the context of cardiac myocytes and their apoptotic regulation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2012 meta-analysis of 17 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults (RR = 0.73, 95% CI: 0.59-0.90).\n2. A 2014 trial published in the Journal of the American Geriatrics Society found that vitamin D and calcium supplementation reduced the incidence of falls in older adults with low baseline vitamin D levels (n = 307).\n3. A 2015 trial published in the Journal of Gerontology found that vitamin D supplementation reduced the incidence of falls in older adults with cognitive impairment (n = 240).\n4. A 2017 trial published in the Journal of the American Medical Directors Association found that vitamin D supplementation reduced the incidence of falls in older adults with chronic kidney disease (n = 160).\nIt's worth noting that the effectiveness of vitamin D supplementation in reducing falls may vary depending on factors such as baseline vitamin D levels, age, and underlying health conditions. However, the overall evidence suggests that vitamin D supplementation can be a useful strategy for reducing the risk of falls in older adults.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2012 meta-analysis of 17 randomized controlled trials concluded that vitamin D supplementation was significantly associated with a reduction in the risk of falls in older adults.\n2. A 2014 clinical trial published in the Journal of the American Geriatrics Society demonstrated that vitamin D and calcium supplementation reduced the incidence of falls in older adults with low baseline vitamin D levels.\n3. In 2015, a trial published in the Journal of Gerontology indicated that vitamin D supplementation decreased the incidence of falls among older adults with cognitive impairment.\n4. A 2017 study published in the Journal of the American Medical Directors Association found that vitamin D supplementation lowered the incidence of falls in older adults with chronic kidney disease.",
    "llama-2-7b-chat-hf_fact": [
      "A 2012 meta-analysis of 17 randomized controlled trials concluded that vitamin D supplementation was significantly associated with a reduction in the risk of falls in older adults.",
      "A 2014 clinical trial published in the Journal of the American Geriatrics Society demonstrated that vitamin D and calcium supplementation reduced the incidence of falls in older adults with low baseline vitamin D levels.",
      "In 2015, a trial published in the Journal of Gerontology indicated that vitamin D supplementation decreased the incidence of falls among older adults with cognitive impairment.",
      "A 2017 study published in the Journal of the American Medical Directors Association found that vitamin D supplementation lowered the incidence of falls in older adults with chronic kidney disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nThe first two statements sound plausible and correlate directly to publication years and findings from specific studies or journals related to vitamin D supplementation and falls in older adults. However, the exact findings of the 2015 and 2017 studies mentioned in statements 3 and 4 cannot be confirmed as true or false without access to the actual study results or additional context. Therefore, for those two statements, the answer is \"UNKNOWN\".",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells. Studies have shown that Jarid2 regulates the expression of miR-155 in Th17 cells, and that this regulation is involved in the differentiation and function of Th17 cells. Specifically, Jarid2 has been shown to bind to the 3'UTR of the miR-155 mRNA and prevent its degradation, leading to increased levels of miR-155 and its target genes in Th17 cells. This suggests that Jarid2 may play a role in the regulation of Th17 cell function by modulating the expression of miR-155.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is associated with miR-155 in Th17 cells.\n2. Jarid2 regulates the expression of miR-155 in Th17 cells.\n3. The regulation of miR-155 by Jarid2 is involved in the differentiation and function of Th17 cells.\n4. Jarid2 binds to the 3'UTR of the miR-155 mRNA and prevents its degradation.\n5. Increased levels of miR-155 due to Jarid2 activity can lead to increased expression of miR-155 target genes in Th17 cells.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is associated with miR-155 in Th17 cells.",
      "Jarid2 regulates the expression of miR-155 in Th17 cells.",
      "The regulation of miR-155 by Jarid2 is involved in the differentiation and function of Th17 cells.",
      "Jarid2 binds to the 3'UTR of the miR-155 mRNA and prevents its degradation.",
      "Increased levels of miR-155 due to Jarid2 activity can lead to increased expression of miR-155 target genes in Th17 cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Jarid2 typically does not bind to mRNA. Jarid2 (Jumonji AT-rich interactive domain 2) is a protein that is known to be involved in chromatin remodeling and regulation of gene expression, but it does not directly bind to mRNA. Binding to the 3'UTR and preventing mRNA degradation is typically a function of microRNAs or RNA-binding proteins, not chromatin remodelers like Jarid2.\n5. UNKNOWN\n\nThe statements about the relationship and regulatory roles of Jarid2 and miR-155, as well as the specific mechanisms by which Jarid2 influences the expression of miR-155 and its target genes in Th17 cells, are highly specific and would require confirmation through scientific research that is not provided in the context. Without specific references to scientific studies or articles, the truth of these statements cannot be validated. However, the fourth statement is generally false for the described function of a chromatin remodeler like Jarid2.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes: Hoxd-1 to Hoxd-9.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9-11 genes, depending on the sources. However, the most accepted number is 9 genes (HOXD1 to HOXD13, with HOXD2, HOXD3, HOXD7, and HOXD8 missing).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein kinase 1 (CK1) is a serine/threonine kinase that phosphorylates a wide range of substrates, including other kinases, transcription factors, and structural proteins. The phosphorylation consensus motifs for CK1 are:\n1. Ser/Thr-Pro-X-X-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the catalytic subunit of CK1 and is found in the phosphorylation sites of many target proteins.\n2. Ser/Thr-Pro-X-X-X-X-Ser/Thr-Pro (where X is any amino acid)\nThis motif is also recognized by CK1 and is found in the phosphorylation sites of some target proteins.\n3. Ser/Thr-Gly-X-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by CK1 and is found in the phosphorylation sites of some target proteins.\n4. Ser/Thr-Pro-X-X-X-X-Ser/Thr-Pro-Gly (where X is any amino acid)\nThis motif is recognized by CK1 and is found in the phosphorylation sites of some target proteins.\n5. Ser/Thr-X-X-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by CK1 and is found in the phosphorylation sites of some target proteins.\nIt's worth noting that the specific consensus motifs recognized by CK1 can vary depending on the isoform of the enzyme and the substrate being phosphorylated.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein kinase 1 (CK1) is a serine/threonine kinase.\n2. The first consensus motif for CK1 phosphorylation is Ser/Thr-Pro-X-X-X-X-Ser/Thr, where X represents any amino acid.\n3. Another CK1 consensus motif for phosphorylation is Ser/Thr-Pro-X-X-X-X-Ser/Thr-Pro.\n4. The third phosphorylation consensus motif for CK1 is Ser/Thr-Gly-X-X-X-Ser/Thr.\n5. A fourth consensus motif for CK1 is Ser/Thr-Pro-X-X-X-X-Ser/Thr-Pro-Gly.",
    "llama-2-7b-chat-hf_fact": [
      "Casein kinase 1 (CK1) is a serine/threonine kinase.",
      "The first consensus motif for CK1 phosphorylation is Ser/Thr-Pro-X-X-X-X-Ser/Thr, where X represents any amino acid.",
      "Another CK1 consensus motif for phosphorylation is Ser/Thr-Pro-X-X-X-X-Ser/Thr-Pro.",
      "The third phosphorylation consensus motif for CK1 is Ser/Thr-Gly-X-X-X-Ser/Thr.",
      "A fourth consensus motif for CK1 is Ser/Thr-Pro-X-X-X-X-Ser/Thr-Pro-Gly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Another CK1 consensus motif for phosphorylation is Ser/Thr-X-X-Ser/Thr-Pro, where X represents any amino acid.\n4. FALSE [correction]: The third phosphorylation consensus motif for CK1 is not well-established and the provided sequence does not fit known CK1 motifs. Typically, CK1 prefers substrates with Ser/Thr followed by Pro. Without specific literature to support this motif, the provided motif cannot be confirmed.\n5. FALSE [correction]: There is no well-documented consensus motif fitting this exact sequence for CK1 phosphorylation. CK1 generally recognizes motifs with Ser/Thr followed by Pro, and the full provided motif does not match established patterns.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several isoforms of the enzyme aspartate beta-hydroxylase, which is involved in the biosynthesis of the neurotransmitter serotonin. The different isoforms of ASPH are:\n1. ASPH: The full-length form of the enzyme, which is the most abundant isoform and the main source of serotonin biosynthesis.\n2. ASPH-B: A shorter isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the brain.\n3. ASPH-C: A third isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the placenta.\n4. ASPH-D: A fourth isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the testes.\n5. ASPH-E: A fifth isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the brain.\n6. ASPH-F: A sixth isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the testes.\n7. ASPH-G: A seventh isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the brain.\n8. ASPH-H: An eighth isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the testes.\n9. ASPH-I: A ninth isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the brain.\n10. ASPH-J: A tenth isoform of the enzyme that is produced through alternative splicing and is primarily expressed in the testes.\nEach isoform of ASPH has a distinct function and expression pattern, and they are involved in various cellular processes, including neurotransmitter biosynthesis, cell signaling, and gene regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes several isoforms of the enzyme aspartate beta-hydroxylase.\n2. ASPH-B is an isoform of aspartate beta-hydroxylase primarily expressed in the brain.\n3. ASPH-C is an isoform primarily expressed in the placenta.\n4. ASPH-D is an isoform primarily expressed in the testes.\n5. ASPH isoforms are involved in various cellular processes including neurotransmitter biosynthesis, cell signaling, and gene regulation.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes several isoforms of the enzyme aspartate beta-hydroxylase.",
      "ASPH-B is an isoform of aspartate beta-hydroxylase primarily expressed in the brain.",
      "ASPH-C is an isoform primarily expressed in the placenta.",
      "ASPH-D is an isoform primarily expressed in the testes.",
      "ASPH isoforms are involved in various cellular processes including neurotransmitter biosynthesis, cell signaling, and gene regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved in 2014. It was approved by the US Food and Drug Administration (FDA) on January 8, 2014, for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in 2014.\n2. The U.S. Food and Drug Administration (FDA) approved empagliflozin on January 8, 2014.\n3. Empagliflozin was approved for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in 2014.",
      "The U.S. Food and Drug Administration (FDA) approved empagliflozin on January 8, 2014.",
      "Empagliflozin was approved for the treatment of type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The U.S. Food and Drug Administration (FDA) approved empagliflozin on August 1, 2014.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis results in several phenotypes, including:\n1. Accelerated aging: Lon1-deficient plants exhibit premature aging, with shortened lifespan and reduced growth rate.\n2. DNA damage accumulation: Lon1 deficiency leads to increased sensitivity to DNA-damaging agents and accumulation of DNA damage.\n3. Chromatin alterations: Lon1 regulates chromatin structure and gene expression, and loss of Lon1 leads to changes in chromatin organization and gene expression.\n4. Impaired cellular stress responses: Lon1 deficiency affects the plant's ability to respond to various cellular stresses, including oxidative stress, heat stress, and salt stress.\n5. Altered hormone signaling: Lon1 regulates hormone signaling pathways, including auxin and cytokinin, and loss of Lon1 affects plant hormone homeostasis.\n6. Changes in flower and seed development: Lon1 deficiency affects floral and seed development, leading to reduced flower number and abnormal seed shape.\n7. Altered root architecture: Lon1 regulates root growth and branching, and loss of Lon1 leads to altered root architecture.\n8. Reduced tolerance to drought and salinity: Lon1 deficiency affects plant water relations and salt tolerance, leading to reduced drought and salt tolerance.\nThese phenotypes highlight the importance of Lon1 in maintaining proper cellular homeostasis and plant development, and suggest that Lon1 may be a promising target for improving crop stress tolerance and plant productivity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1-deficient plants in Arabidopsis exhibit premature aging.\n2. The deficiency of the protein Lon1 in Arabidopsis leads to increased sensitivity to DNA-damaging agents.\n3. Loss of the protein Lon1 affects chromatin structure and gene expression in Arabidopsis.\n4. Arabidopsis plants lacking Lon1 have impaired responses to cellular stresses such as oxidative stress, heat stress, and salt stress.\n5. Lon1 deficiency in Arabidopsis affects plant hormone signaling pathways and homeostasis.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1-deficient plants in Arabidopsis exhibit premature aging.",
      "The deficiency of the protein Lon1 in Arabidopsis leads to increased sensitivity to DNA-damaging agents.",
      "Loss of the protein Lon1 affects chromatin structure and gene expression in Arabidopsis.",
      "Arabidopsis plants lacking Lon1 have impaired responses to cellular stresses such as oxidative stress, heat stress, and salt stress.",
      "Lon1 deficiency in Arabidopsis affects plant hormone signaling pathways and homeostasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe specific effects of Lon1 deficiency in Arabidopsis are highly specialized pieces of information that relate to plant biology and genetics. Since the statements are consistent with what is known about the role of Lon proteins in cellular functions such as regulation of mitochondrial activities, proteolysis, and response to stress, and considering that plants have analogous mechanisms that could be affected by a deficiency in a Lon-type protease like Lon1, the statements are likely true. However, without access to the specific passage these statements were extracted from, the responses are based on general knowledge in the field up to the cutoff date. If the passage contains empirical data or research findings that exactly match these claims, then the statements would indeed be considered true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone called H3K5ac (histone H3 lysine 5 acetylation) exists in the yeast genome. H3K5ac is a linker histone that plays a role in the regulation of chromatin structure and gene expression in yeast, similar to its function in other organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is a linker histone in the yeast genome known as H3K5ac.\n2. H3K5ac plays a role in the regulation of chromatin structure in yeast.\n3. H3K5ac is involved in the regulation of gene expression in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "There is a linker histone in the yeast genome known as H3K5ac.",
      "H3K5ac plays a role in the regulation of chromatin structure in yeast.",
      "H3K5ac is involved in the regulation of gene expression in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: H3K5ac is not a linker histone but is an acronym for acetylation at the 5th lysine (K) of the histone H3 protein. A linker histone in yeast is commonly H1 or Hho1p.\n2. UNKNOWN\n3. TRUE (assuming H3K5ac refers to the acetylation modification on histone H3): Acetylation on histones, including H3K5ac, is involved in the regulation of chromatin structure and gene expression in yeast and other eukaryotes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is some evidence to suggest that tomato juice may help lower cholesterol levels. Tomato juice contains a compound called lycopene, which has been shown to have a number of potential health benefits, including reducing cholesterol levels.\nSome studies have found that consuming tomato juice can help lower LDL (bad) cholesterol levels, which is a major risk factor for heart disease. For example, a study published in the Journal of Nutrition found that drinking 8 ounces of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 10% in healthy adults.\nOther studies have also found similar results. A review of 13 clinical trials published in the journal Nutrition Reviews found that tomato juice consumption was associated with significant reductions in LDL cholesterol levels.\nIt's thought that the lycopene in tomato juice may be responsible for its cholesterol-lowering effects. Lycopene is a powerful antioxidant that can help reduce inflammation and improve the function of the endothelium, the lining of blood vessels. This can help improve blood flow and reduce the risk of heart disease.\nIt's worth noting that while these findings are promising, more research is needed to confirm the results and to better understand the mechanisms by which tomato juice may lower cholesterol levels. Additionally, it's important to remember that tomato juice is just one part of a healthy diet and lifestyle, and it's not a substitute for other cholesterol-lowering strategies, such as eating a heart-healthy diet, getting regular exercise, and managing stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lycopene, a compound in tomato juice, has been associated with potential health benefits, including the ability to reduce cholesterol levels.\n2. A study published in the Journal of Nutrition reported that drinking 8 ounces of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 10% in healthy adults.\n3. A review of 13 clinical trials published in the journal Nutrition Reviews found that tomato juice consumption was linked to significant reductions in LDL cholesterol levels.\n4. The antioxidant properties of lycopene may help reduce inflammation and improve the function of the endothelium, which is beneficial for blood flow and reducing heart disease risk.\n5. Further research is necessary to confirm the effects of tomato juice on cholesterol levels and to understand the mechanisms involved.",
    "llama-2-7b-chat-hf_fact": [
      "Lycopene, a compound in tomato juice, has been associated with potential health benefits, including the ability to reduce cholesterol levels.",
      "A study published in the Journal of Nutrition reported that drinking 8 ounces of tomato juice per day for 12 weeks reduced LDL cholesterol levels by 10% in healthy adults.",
      "A review of 13 clinical trials published in the journal Nutrition Reviews found that tomato juice consumption was linked to significant reductions in LDL cholesterol levels.",
      "The antioxidant properties of lycopene may help reduce inflammation and improve the function of the endothelium, which is beneficial for blood flow and reducing heart disease risk.",
      "Further research is necessary to confirm the effects of tomato juice on cholesterol levels and to understand the mechanisms involved."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nIt's essential to note that the details provided in statements 2 and 3 would require access to the specific studies to confirm their accuracy. As the information provided isn't enough to verify these claims, we must classify them as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are protein chaperones that play a crucial role in regulating mRNA stability by interacting with the 3' untranslated region (3' UTR) of target mRNAs. They can either stabilize or destabilize mRNAs by modulating the binding of microRNAs (miRNAs) and other regulatory factors to the 3' UTR.\nHsp70 can bind to the 3' UTR of target mRNAs and prevent the binding of miRNAs, leading to increased mRNA stability. Hsp110, on the other hand, can also bind to the 3' UTR of target mRNAs and promote the binding of miRNAs, leading to decreased mRNA stability.\nIn addition, Hsp70 and Hsp110 can also regulate mRNA stability by modulating the activity of other RNA-binding proteins, such as the RNA-binding protein AU-rich element (AUF1), which is involved in the regulation of mRNA stability.\nOverall, Hsp70 and Hsp110 play important roles in regulating mRNA stability by modulating the binding of miRNAs and other regulatory factors to the 3' UTR of target mRNAs, and by interacting with other RNA-binding proteins involved in mRNA metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are protein chaperones that interact with the 3' untranslated region (3' UTR) of mRNAs.\n2. The interaction of Hsp70 and Hsp110 with mRNAs can result in either stabilization or destabilization of the mRNAs.\n3. Hsp70 can prevent the binding of microRNAs (miRNAs) to the 3' UTR, leading to increased mRNA stability.\n4. Hsp110 can promote the binding of miRNAs to the 3' UTR, leading to decreased mRNA stability.\n5. Hsp70 and Hsp110 can regulate mRNA stability by modulating the activity of other RNA-binding proteins such as AUF1.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are protein chaperones that interact with the 3' untranslated region (3' UTR) of mRNAs.",
      "The interaction of Hsp70 and Hsp110 with mRNAs can result in either stabilization or destabilization of the mRNAs.",
      "Hsp70 can prevent the binding of microRNAs (miRNAs) to the 3' UTR, leading to increased mRNA stability.",
      "Hsp110 can promote the binding of miRNAs to the 3' UTR, leading to decreased mRNA stability.",
      "Hsp70 and Hsp110 can regulate mRNA stability by modulating the activity of other RNA-binding proteins such as AUF1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hsp70 and Hsp110 are protein chaperones, but they are not known for specifically interacting with the 3' untranslated region (3' UTR) of mRNAs. Chaperones like Hsp70 and Hsp110 primarily aid in protein folding and preventing aggregation.\n2. UNKNOWN: While protein chaperones can affect mRNA stability, it is not clear from this statement or general knowledge if Hsp70 and Hsp110 are directly involved in this process; this would likely depend on specific cellular context or additional factors.\n3. UNKNOWN: The effect of Hsp70 on the binding of microRNAs (miRNAs) to the 3' UTR and the consequent impact on mRNA stability is not commonly established in the literature, so the truth of this claim is uncertain without specific reference to support it.\n4. UNKNOWN: Similarly to statement 3, the specific role of Hsp110 in promoting the binding of miRNAs to the 3' UTR and its effect on mRNA stability is not well-established. Detailed evidence or context is needed to determine the veracity of this claim.\n5. UNKNOWN: While it is known that Hsp70 and other chaperones can interact with various proteins, including RNA-binding proteins, the specific regulatory interaction between Hsp70 or Hsp110 and AUF1 on mRNA stability would require precise scientific evidence to verify.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "There are three isoforms of deiodinase enzymes present in skeletal muscle:\n1. Deiodinase type 1 (D1): found primarily in the brain and peripheral tissues, including skeletal muscle. D1 is responsible for converting T4 to T3.\n2. Deiodinase type 2 (D2): primarily found in the liver, but also present in skeletal muscle. D2 is responsible for converting T4 to T3.\n3. Deiodinase type 3 (D3): primarily found in the brain, but also present in skeletal muscle. D3 is responsible for converting T3 to reverse T3 (rT3).\nIn skeletal muscle, D1 and D2 are the primary isoforms involved in the conversion of T4 to T3, which is important for maintaining adequate levels of T3 in the muscle for proper muscle function and metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is present in skeletal muscle and converts T4 to T3.\n2. Deiodinase type 2 (D2) is present in skeletal muscle and converts T4 to T3.\n3. Deiodinase type 3 (D3) is present in skeletal muscle and converts T3 to reverse T3 (rT3).\n4. Both deiodinase types D1 and D2 are primarily involved in converting T4 to T3 in skeletal muscle.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is present in skeletal muscle and converts T4 to T3.",
      "Deiodinase type 2 (D2) is present in skeletal muscle and converts T4 to T3.",
      "Deiodinase type 3 (D3) is present in skeletal muscle and converts T3 to reverse T3 (rT3).",
      "Both deiodinase types D1 and D2 are primarily involved in converting T4 to T3 in skeletal muscle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 1 (D1) is not present in skeletal muscle; it is primarily found in the liver and kidney and is involved in converting T4 to T3.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Deiodinase type 2 (D2) is involved in converting T4 to T3 in skeletal muscle, but deiodinase type 1 (D1) is not primarily involved in this process in skeletal muscle.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Inflammatory caspase proteins are a group of enzymes that play a role in the regulation of inflammation. Here are some examples of inflammatory caspase proteins:\n1. Caspase-1: Also known as interleukin-1 beta (IL-1) convertase, this enzyme is involved in the processing and activation of pro-inflammatory cytokines such as IL-1 and tumor necrosis factor-alpha (TNF-).\n2. Caspase-3: Also known as cytosolic factor C, this enzyme is involved in the regulation of apoptosis (programmed cell death) and the processing of pro-inflammatory cytokines such as TNF-.\n3. Caspase-7: Also known as apoptotic protease activator 1 (APAF-1), this enzyme is involved in the regulation of apoptosis and the processing of pro-inflammatory cytokines such as TNF-.\n4. Caspase-8: Also known as Fas-associated death domain protein (FADD), this enzyme is involved in the regulation of apoptosis and the processing of pro-inflammatory cytokines such as TNF-.\n5. Caspase-9: Also known as Bcl-2-associated X protein (BAX), this enzyme is involved in the regulation of apoptosis and the processing of pro-inflammatory cytokines such as TNF-.\n6. Caspase-12: Also known as inflammatory caspase-12 (ICasp-12), this enzyme is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines such as IL-1.\n7. Caspase-13: Also known as cytokine-induced ICE-like protein (CYIL), this enzyme is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines such as TNF-.\n8. Caspase-14: Also known as ICE-like protease 1 (IL-1L), this enzym",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1 and TNF-.\n2. Caspase-3 is involved in the regulation of apoptosis and the processing of pro-inflammatory cytokines such as TNF-.\n3. Caspase-4 (also mislabeled as Caspase-14 in the answer due to truncation) is involved in the regulation of inflammation but its role is not specified in the provided text.\n4. Caspase-12 is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines such as IL-1.\n5. Caspase-13 is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines such as TNF-. \n\n(Note: The last sentence in the answer was truncated and might refer to Caspase-4, which is not detailed in the response. The information related to Caspase-7, Caspase-8, and Caspase-9 involving the processing of cytokines such as TNF- or IL-1 and the descriptions involving 'Also known as APAF-1 (Caspase-7), FADD (Caspase-8),' and 'BAX (Caspase-9)' are inaccurate. APAF-1 is an apoptotic peptidase activating factor unrelated to Caspase-7, FADD is a different molecule that associates with Caspase-8 in the death-inducing signaling complex, and BAX is a pro-apoptotic Bcl-2 family protein, not Caspase-9. Therefore, these statements are not included as factual because they contain errors.)",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1 and TNF-.",
      "Caspase-3 is involved in the regulation of apoptosis and the processing of pro-inflammatory cytokines such as TNF-.",
      "Caspase-4 (also mislabeled as Caspase-14 in the answer due to truncation) is involved in the regulation of inflammation but its role is not specified in the provided text.",
      "Caspase-12 is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines such as IL-1.",
      "Caspase-13 is involved in the regulation of inflammation and the processing of pro-inflammatory cytokines such as TNF-.",
      "ote: The last sentence in the answer was truncated and might refer to Caspase-4, which is not detailed in the response. The information related to Caspase-7, Caspase-8, and Caspase-9 involving the processing of cytokines such as TNF- or IL-1 and the descriptions involving 'Also known as APAF-1 (Caspase-7), FADD (Caspase-8),' and 'BAX (Caspase-9)' are inaccurate. APAF-1 is an apoptotic peptidase activating factor unrelated to Caspase-7, FADD is a different molecule that associates with Caspase-8 in the death-inducing signaling complex, and BAX is a pro-apoptotic Bcl-2 family protein, not Caspase-9. Therefore, these statements are not included as factual because they contain errors.)"
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-3 is involved in the regulation of apoptosis but it is not involved in the processing of pro-inflammatory cytokines such as TNF-.\n3. UNKNOWN\n4. FALSE [correction]: Caspase-12 is implicated in the negative regulation of inflammation and has been suggested to have a role in the inhibition of caspase-1-dependent IL-1 processing.\n5. FALSE [correction]: Caspase-13 is not a human caspase. In humans, caspases involved in inflammation include caspase-1, caspase-4, caspase-5, and caspase-11.\n6. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and the Polycomb protein Ring1B. Both Aurora B and Ring1B are involved in the regulation of chromatin dynamics and gene expression, particularly during cell division. While they have distinct functions, they can interact and coordinate their actions to ensure proper chromosome segregation and gene expression during mitosis.\nAurora B is a serine/threonine kinase that plays a critical role in the regulation of chromosome segregation during mitosis by promoting the separation of sister chromatids and the proper alignment of chromosomes on the spindle apparatus.\nRing1B, on the other hand, is a Polycomb group protein that plays a critical role in the regulation of gene expression by modifying histone H3 lysine 27 (H3K27) and H3K27me3. Ring1B is involved in the maintenance of gene silencing and is required for the proper execution of cell fate decisions, including cell proliferation and differentiation.\nStudies have shown that Aurora B and Ring1B interact and coordinate their actions during mitosis. For example, Ring1B has been shown to interact with and be regulated by Aurora B, and the two proteins have been shown to collaborate in the regulation of chromatin dynamics and gene expression.\nIn summary, while Aurora B and Ring1B have distinct functions, they are linked in their regulation of chromatin dynamics and gene expression during cell division, and their coordination is critical for proper chromosome segregation and cell fate decisions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and the Polycomb protein Ring1B are involved in the regulation of chromatin dynamics and gene expression during cell division.\n2. Aurora B is a serine/threonine kinase that plays a role in chromosome segregation during mitosis.\n3. Ring1B is a Polycomb group protein that regulates gene expression by modifying histone H3 lysine 27 (H3K27) and H3K27me3.\n4. Ring1B has a role in the maintenance of gene silencing and is involved in cell fate decisions including cell proliferation and differentiation.\n5. Aurora B and Ring1B interact and coordinate their actions during mitosis, as shown in scientific studies.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and the Polycomb protein Ring1B are involved in the regulation of chromatin dynamics and gene expression during cell division.",
      "Aurora B is a serine/threonine kinase that plays a role in chromosome segregation during mitosis.",
      "Ring1B is a Polycomb group protein that regulates gene expression by modifying histone H3 lysine 27 (H3K27) and H3K27me3.",
      "Ring1B has a role in the maintenance of gene silencing and is involved in cell fate decisions including cell proliferation and differentiation.",
      "Aurora B and Ring1B interact and coordinate their actions during mitosis, as shown in scientific studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nNote: While statements 1-4 are in line with the known roles of Aurora B kinase and Ring1B, statement 5 claims a specific interaction and coordination between the two proteins during mitosis, which would require specific experimental evidence that is not provided here. Therefore, it is not possible to determine the veracity of this statement without access to the relevant scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs are alterations in the splice site consensus sequences that can lead to aberrant splicing. In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor splice site non-canonical motifs:\n1. GU-rich sequences: GU-rich sequences are found in the intron of the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n2. AG-rich sequences: AG-rich sequences are found in the intron of the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n3. T-rich sequences: T-rich sequences are found in the intron of the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n4. A-rich sequences: A-rich sequences are found in the intron of the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n5. GT-rich sequences: GT-rich sequences are found in the intron of the donor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\nAcceptor splice site non-canonical motifs:\n1. G-rich sequences: G-rich sequences are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n2. C-rich sequences: C-rich sequences are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n3. A-rich sequences: A-rich sequences are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n4. GT-rich sequences: GT-rich sequences are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n5. T-rich sequences: T-rich sequences are found in the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\nIt'",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich sequences are a non-canonical motif found in the intron of the donor splice site in vertebrates.\n2. AG-rich sequences are a non-canonical motif found in the intron of the donor splice site in vertebrates.\n3. T-rich sequences are a non-canonical motif found in the intron of the donor splice site in vertebrates.\n4. G-rich sequences are a non-canonical motif found in the acceptor splice site in vertebrates.\n5. C-rich sequences are a non-canonical motif found in the acceptor splice site in vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich sequences are a non-canonical motif found in the intron of the donor splice site in vertebrates.",
      "AG-rich sequences are a non-canonical motif found in the intron of the donor splice site in vertebrates.",
      "T-rich sequences are a non-canonical motif found in the intron of the donor splice site in vertebrates.",
      "G-rich sequences are a non-canonical motif found in the acceptor splice site in vertebrates.",
      "C-rich sequences are a non-canonical motif found in the acceptor splice site in vertebrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Generally, the most common consensus sequence at the donor splice site is 'GT' at the intron-exon boundary, and AG-rich sequences are not particularly known as a non-canonical motif.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific knowledge of the non-canonical motifs that might be associated with acceptor splice sites for statements 4 and 5 or the varying sequences that could be associated with donor splice sites for statement 3, it's not possible to determine the veracity of these statements. Non-canonical motifs can be diverse and context-dependent, and not all possible sequence motifs are necessarily well-documented in the scientific literature up to the knowledge cutoff date.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (70 kDa ribosomal protein S6 kinase 1) is acetylated in response to nutrient availability and growth factors, including insulin and insulin-like growth factor 1 (IGF-1). The acetylation of S6K1 is mediated by the enzyme histone acetyltransferase (HAT) and is a key event in the regulation of protein synthesis and cell growth.",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1 is acetylated in response to nutrient availability.\n2. Growth factors such as insulin and insulin-like growth factor 1 (IGF-1) can lead to the acetylation of S6K1.\n3. The enzyme histone acetyltransferase (HAT) mediates the acetylation of S6K1.\n4. Acetylation of S6K1 is involved in the regulation of protein synthesis and cell growth.",
    "llama-2-7b-chat-hf_fact": [
      "S6K1 is acetylated in response to nutrient availability.",
      "Growth factors such as insulin and insulin-like growth factor 1 (IGF-1) can lead to the acetylation of S6K1.",
      "The enzyme histone acetyltransferase (HAT) mediates the acetylation of S6K1.",
      "Acetylation of S6K1 is involved in the regulation of protein synthesis and cell growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene encodes a subunit of the calcium channel Cav2.2, which is involved in the regulation of neuronal excitability and muscle contraction. The mutations lead to an abnormal functioning of the calcium channels, resulting in episodes of ataxia (loss of coordination and balance) and other neurological symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is a rare genetic disorder.\n2. EA6 is caused by mutations in the CACNA1A gene.\n3. The CACNA1A gene encodes a subunit of the calcium channel Cav2.2.\n4. Cav2.2 is involved in the regulation of neuronal excitability and muscle contraction.\n5. Mutations in the CACNA1A gene lead to abnormal functioning of calcium channels, causing episodes of ataxia and other neurological symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is a rare genetic disorder.",
      "EA6 is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene encodes a subunit of the calcium channel Cav2.2.",
      "Cav2.2 is involved in the regulation of neuronal excitability and muscle contraction.",
      "Mutations in the CACNA1A gene lead to abnormal functioning of calcium channels, causing episodes of ataxia and other neurological symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The CACNA1A gene encodes a subunit of the calcium channel Cav2.1, not Cav2.2.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify chromatin structure by adding or removing methyl groups to histone proteins, which can alter chromatin dynamics and affect gene expression.\nIn animals, there are several types of chromomethylases that have been identified, including histone methyltransferases (HMTs) and lysine-specific demethylases (LSDs). These enzymes are involved in various cellular processes, such as gene expression, cell differentiation, and development.\nFor example, HMTs are known to be involved in the regulation of gene expression by modifying histone H3 and H4, leading to changes in chromatin structure and accessibility to transcription factors. LSDs, on the other hand, are involved in the demethylation of histone H3 lysine 4 (H3K4), which is a mark associated with active gene expression.\nDysregulation of chromomethylases has been implicated in various diseases, including cancer, where it can lead to changes in chromatin structure and gene expression that promote tumor progression. Therefore, understanding the function and regulation of chromomethylases in animals is important for understanding cellular processes and developing new therapeutic strategies for disease treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases modify chromatin structure by adding or removing methyl groups to histone proteins.\n2. Histone methyltransferases (HMTs) and lysine-specific demethylases (LSDs) are types of chromomethylases identified in animals.\n3. Histone methyltransferases (HMTs) are involved in the regulation of gene expression by modifying histone H3 and H4.\n4. Lysine-specific demethylases (LSDs) are involved in the demethylation of histone H3 lysine 4 (H3K4), which is associated with active gene expression.\n5. Dysregulation of chromomethylases has been implicated in diseases such as cancer, affecting chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases modify chromatin structure by adding or removing methyl groups to histone proteins.",
      "Histone methyltransferases (HMTs) and lysine-specific demethylases (LSDs) are types of chromomethylases identified in animals.",
      "Histone methyltransferases (HMTs) are involved in the regulation of gene expression by modifying histone H3 and H4.",
      "Lysine-specific demethylases (LSDs) are involved in the demethylation of histone H3 lysine 4 (H3K4), which is associated with active gene expression.",
      "Dysregulation of chromomethylases has been implicated in diseases such as cancer, affecting chromatin structure and gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases primarily refer to enzymes that add methyl groups to DNA rather than histones. The correct term for enzymes modifying chromatin structure by adding methyl groups to histone proteins is \"histone methyltransferases (HMTs).\"\n2. FALSE [correction]: Histone methyltransferases (HMTs) and lysine-specific demethylases (LSDs) are not types of chromomethylases. HMTs and LSDs specifically modify histones, whereas chromomethylases typically refer to DNA methyltransferases in plants.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS) data. Here are some of the popular packages:\n1. TFBSpred: This package uses a machine learning approach to predict TFBSs in a given DNA sequence. It can predict both protein-binding sites and transcription factor binding sites.\n2. TFSEARCH: This package uses a hidden Markov model (HMM) to identify TFBSs in a DNA sequence. It can also predict the binding specificity of transcription factors.\n3. TRANSFAC: This package is a comprehensive database of known TFBSs from a variety of organisms, including humans. It can be used to search for potential TFBSs in a given DNA sequence.\n4. ChIPseek: This package is designed for the analysis of ChIP-seq data, which is often used to identify TFBSs. It can be used to identify peaks of binding and predict the binding affinity of transcription factors.\n5. HISAT2: This package is a spliced aligner that can be used to identify TFBSs in ChIP-seq data. It can also be used to identify other types of genomic features.\n6. STAR: This package is another spliced aligner that can be used to identify TFBSs in ChIP-seq data. It is known for its high accuracy and can also be used to identify other types of genomic features.\n7. DeepTools: This package is a collection of tools for the analysis of ChIP-seq data. It includes tools for the identification of TFBSs, as well as tools for the analysis of the chromatin structure.\n8. ChIPster: This package is a tool for the analysis of ChIP-seq data that can be used to identify TFBSs and predict the binding affinity of transcription factors. It can also be used to identify other types of genomic features.\n9. GSEA: This package is a tool for the analysis of gene expression data that can be used to identify TFBSs. It can also be used to identify other types of genomic features.\n10. R/BioConductor: This package is a collection of tools for the analysis of genomic data. It includes tools for the analysis of ChIP",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSpred is an R/Bioconductor package that predicts transcription factor binding sites using a machine learning approach.\n2. TFSEARCH is an R/Bioconductor package that uses a hidden Markov model to identify transcription factor binding sites.\n3. TRANSFAC is an R/Bioconductor package that provides a database of known transcription factor binding sites.\n4. ChIPseek is an R/Bioconductor package designed for the analysis of ChIP-seq data to identify transcription factor binding sites.\n5. STAR is an R/Bioconductor spliced aligner package used to identify transcription factor binding sites in ChIP-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSpred is an R/Bioconductor package that predicts transcription factor binding sites using a machine learning approach.",
      "TFSEARCH is an R/Bioconductor package that uses a hidden Markov model to identify transcription factor binding sites.",
      "TRANSFAC is an R/Bioconductor package that provides a database of known transcription factor binding sites.",
      "ChIPseek is an R/Bioconductor package designed for the analysis of ChIP-seq data to identify transcription factor binding sites.",
      "STAR is an R/Bioconductor spliced aligner package used to identify transcription factor binding sites in ChIP-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While TFSEARCH is a tool used to predict transcription factor binding sites, it is not an R/Bioconductor package and does not use a hidden Markov model. It is based on a consensus sequence scoring method.\n3. FALSE [correction]: TRANSFAC is a database of transcription factor binding sites, but it is not an R/Bioconductor package. It is a commercial product with its own proprietary interface.\n4. FALSE [correction]: ChIPseeker (not ChIPseek) is an R/Bioconductor package designed for the analysis of ChIP-seq data, including identifying transcription factor binding sites.\n5. FALSE [correction]: STAR (Spliced Transcripts Alignment to a Reference) is an R/Bioconductor package that is a fast RNA-seq read mapper but is not specifically used to identify transcription factor binding sites. It aligns RNA-seq reads to a reference genome in preparation for downstream analysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Here are some clinical trials related to the prevention of sarcopenia:\n1. \"Exercise and Nutrition Intervention to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2019) - This trial, conducted by researchers at the University of California, Los Angeles, tested the effectiveness of a comprehensive exercise and nutrition program in preventing sarcopenia in older adults.\n2. \"Aerobic Exercise and Resistance Training to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) - This trial, conducted by researchers at the University of California, San Diego, evaluated the effectiveness of a combination of aerobic exercise and resistance training in preventing sarcopenia in older adults.\n3. \"Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2018) - This review, conducted by researchers at the University of Edinburgh, examined the evidence for various nutritional interventions aimed at preventing sarcopenia in older adults.\n4. \"Effects of Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2017) - This trial, conducted by researchers at the University of California, San Francisco, investigated the effects of omega-3 fatty acid supplementation on sarcopenia in older adults.\n5. \"Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2016) - This trial, conducted by researchers at the University of California, Los Angeles, evaluated the effectiveness of a combination of resistance training and nutritional interventions in preventing sarcopenia in older adults.\n6. \"Effects of a Multidomain Intervention on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2016) - This trial, conducted by researchers at the University of Edinburgh, evaluated the effectiveness of a multidomain",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"Exercise and Nutrition Intervention to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2019) was conducted by researchers at the University of California, Los Angeles.\n2. The \"Aerobic Exercise and Resistance Training to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) was conducted by researchers at the University of California, San Diego.\n3. The \"Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2018) was conducted by researchers at the University of Edinburgh.\n4. The \"Effects of Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2017) was conducted by researchers at the University of California, San Francisco.\n5. The \"Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2016) was conducted by researchers at the University of California, Los Angeles.",
    "llama-2-7b-chat-hf_fact": [
      "The \"Exercise and Nutrition Intervention to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2019) was conducted by researchers at the University of California, Los Angeles.",
      "The \"Aerobic Exercise and Resistance Training to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) was conducted by researchers at the University of California, San Diego.",
      "The \"Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2018) was conducted by researchers at the University of Edinburgh.",
      "The \"Effects of Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2017) was conducted by researchers at the University of California, San Francisco.",
      "The \"Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2016) was conducted by researchers at the University of California, Los Angeles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to specific databases or the actual research papers, I cannot confirm the accuracy of the statements regarding which university conducted each of the listed studies. Therefore, my response to these statements is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, but some of the most well-known and widely used include:\n1. The Membrane Protein Structural Database (MembraneProt): This database contains a collection of structurally resolved membrane protein structures, including their membrane-spanning segments and ligand-binding sites.\n2. The Protein Data Bank (PDB): The PDB is a comprehensive database of 3D structures of proteins, including many membrane proteins. It provides access to the structures of membrane proteins in their native lipid bilayers, as well as in complexes with ligands and other molecules.\n3. The Membrane Protein Interaction Database (MPI): This database contains information on the interactions between membrane proteins and their ligands, including the binding affinities and specificities of these interactions.\n4. The Membrane Protein Functional Site Database (MpFSD): This database provides information on the functional sites of membrane proteins, including their binding sites, active sites, and other functional regions.\n5. The Membrane Protein Topology Database (MpTopDB): This database provides information on the topological structure of membrane proteins, including their transmembrane segments, loop regions, and intracellular and extracellular domains.\n6. The Membrane Protein Sequence-Structure Database (MpSSD): This database provides information on the sequence-structure relationships of membrane proteins, including their secondary structure, tertiary structure, and functional sites.\n7. The Membrane Protein-Ligand Interaction Database (MPI-LID): This database contains information on the interactions between membrane proteins and their ligands, including the binding affinities and specificities of these interactions.\n8. The Membrane Protein-Protein Interaction Database (MPI-PID): This database provides information on the interactions between membrane proteins and other proteins, including the binding affinities and specificities of these interactions.\n9. The Membrane Protein-Nucleic Acid Interaction Database (MPI-NAI): This database provides information on the interactions between membrane proteins and nucleic acids, including the binding affinities and specificities of these interactions.\n10",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Structural Database (MembraneProt) contains a collection of structurally resolved membrane protein structures.\n2. The Protein Data Bank (PDB) is a comprehensive database of 3D structures of proteins, including membrane proteins.\n3. The Membrane Protein Interaction Database (MPI) contains information on the interactions between membrane proteins and their ligands.\n4. The Membrane Protein Functional Site Database (MpFSD) provides information on the functional sites of membrane proteins.\n5. The Membrane Protein Topology Database (MpTopDB) provides information on the topological structure of membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Structural Database (MembraneProt) contains a collection of structurally resolved membrane protein structures.",
      "The Protein Data Bank (PDB) is a comprehensive database of 3D structures of proteins, including membrane proteins.",
      "The Membrane Protein Interaction Database (MPI) contains information on the interactions between membrane proteins and their ligands.",
      "The Membrane Protein Functional Site Database (MpFSD) provides information on the functional sites of membrane proteins.",
      "The Membrane Protein Topology Database (MpTopDB) provides information on the topological structure of membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: While the statement suggests the existence of a database called \"Membrane Protein Structural Database (MembraneProt)\" that contains membrane protein structures, the actual name or existence of such a database needs verification, as it's not widely recognized as a standard resource in the scientific community.\n\n2. TRUE: The Protein Data Bank (PDB) is a well-known database that houses 3D structures of biological molecules, including both soluble and membrane proteins.\n\n3. UNKNOWN: The statement refers to a database called the \"Membrane Protein Interaction Database (MPI)\" containing interaction data. The existence and exact name of this database would need to be verified as it is not among the commonly cited databases.\n\n4. UNKNOWN: The statement about the \"Membrane Protein Functional Site Database (MpFSD)\" presents a database that would hold information on functional sites of membrane proteins. The validity of this statement depends on the existence of the database, which is not commonly known.\n\n5. UNKNOWN: The \"Membrane Protein Topology Database (MpTopDB)\" is mentioned as a resource for topological information on membrane proteins. Whether this database exists or not under this specific name is not immediately verifiable without more context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is metabolized by the liver and kidneys, with the liver being the primary site of metabolism. The kidneys play a minor role in the metabolism of rivaroxaban, but they are still important for its elimination from the body. The kidneys are responsible for removing the metabolites of rivaroxaban, which are then excreted in the urine.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by both the liver and the kidneys.\n2. The liver is the primary site of metabolism for rivaroxaban.\n3. The kidneys play a role in the metabolism of rivaroxaban.\n4. The kidneys are responsible for eliminating the metabolites of rivaroxaban.\n5. The metabolites of rivaroxaban are excreted in the urine.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by both the liver and the kidneys.",
      "The liver is the primary site of metabolism for rivaroxaban.",
      "The kidneys play a role in the metabolism of rivaroxaban.",
      "The kidneys are responsible for eliminating the metabolites of rivaroxaban.",
      "The metabolites of rivaroxaban are excreted in the urine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The liver is not the primary site of metabolism for rivaroxaban, but it is involved in the metabolism. The kidneys play an essential role in the excretion of the unchanged drug, and liver enzymes, mainly CYP3A4 and CYP2J2, along with P-gp and other transporters, are involved in the minor metabolic pathways.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 is a subtype of the thyroid hormone receptor (TR) that is primarily expressed in the heart and regulates the expression of genes involved in cardiac function and development. Some of the genes known to be regulated by TRalpha2 in the heart include:\n1. -myosin heavy chain (MHC-): TRalpha2 regulates the expression of MHC-, which is essential for cardiac muscle contractility.\n2. -myosin heavy chain (MHC-): TRalpha2 also regulates the expression of MHC-, which is involved in the contraction of cardiac muscle fibers.\n3. Tropomyosin (Tpm): TRalpha2 regulates the expression of Tpm, which is a protein that regulates the interaction between actin and myosin filaments in cardiac muscle.\n4. Cardiac troponin I (Cav1): TRalpha2 regulates the expression of Cav1, which is a protein that plays a critical role in the regulation of actin-myosin interaction in cardiac muscle.\n5. Calmodulin (CaM): TRalpha2 regulates the expression of CaM, which is a protein that regulates the contraction of cardiac muscle fibers by binding to and activating myosin light chain kinase.\n6. GATA4: TRalpha2 regulates the expression of GATA4, a transcription factor that is essential for the development and maintenance of the cardiac conduction system.\n7. NFAT (nuclear factor of activated T cells): TRalpha2 regulates the expression of NFAT, which is a transcription factor that plays a critical role in the regulation of cardiac hypertrophy and fibrosis.\n8. TNF-alpha (tumor necrosis factor-alpha): TRalpha2 regulates the expression of TNF-alpha, which is a pro-inflammatory cytokine that is involved in the regulation of cardiac inflammation and fibrosis.\n9. FOXO1 (forkhead box O1): TRalpha2 regulates the expression of FOXO1, a transcription factor that is involved in the regulation of cardiac metabolism and survival.\n10. PPAR (",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is expressed primarily in the heart.\n2. TRalpha2 regulates the expression of the -myosin heavy chain (MHC-) gene, which is essential for cardiac muscle contractility.\n3. TRalpha2 regulates the expression of the -myosin heavy chain (MHC-) gene, which is involved in the contraction of cardiac muscle fibers.\n4. TRalpha2 regulates the expression of the Tropomyosin (Tpm) gene, a protein that regulates the interaction between actin and myosin filaments in cardiac muscle.\n5. TRalpha2 regulates the expression of the GATA4 gene, a transcription factor essential for the development and maintenance of the cardiac conduction system.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is expressed primarily in the heart.",
      "TRalpha2 regulates the expression of the -myosin heavy chain (MHC-) gene, which is essential for cardiac muscle contractility.",
      "TRalpha2 regulates the expression of the -myosin heavy chain (MHC-) gene, which is involved in the contraction of cardiac muscle fibers.",
      "TRalpha2 regulates the expression of the Tropomyosin (Tpm) gene, a protein that regulates the interaction between actin and myosin filaments in cardiac muscle.",
      "TRalpha2 regulates the expression of the GATA4 gene, a transcription factor essential for the development and maintenance of the cardiac conduction system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The expression pattern of TRalpha2 (thyroid hormone receptor alpha 2) is not specified. TRalpha2 is a variant of the thyroid hormone receptor that can be expressed in multiple tissues, and the context provided does not offer specific information about its expression being primarily in the heart.\n   \n2. UNKNOWN: While thyroid hormone receptors, including TRalpha variants, are known to be involved in the regulation of cardiac muscle genes, the statement specifically about TRalpha2's regulation of -myosin heavy chain (MHC-) gene, which is essential for cardiac muscle contractility, cannot be confirmed as true or false without additional specific information.\n\n3. UNKNOWN: Similar to the previous statement, it is known that thyroid hormone receptors are involved in the regulation of myosin heavy chain genes, including possibly -MHC; however, the precise role of TRalpha2 in this regulation is not specified and cannot be confirmed from the provided context.\n\n4. UNKNOWN: The specific role of TRalpha2 in the regulation of the Tropomyosin (Tpm) gene is not stated in the general knowledge and requires specific scientific evidence to confirm or refute, which is not provided here.\n\n5. UNKNOWN: While GATA4 is a transcription factor critical for heart development and function, the exact connection between TRalpha2 and the regulation of the GATA4 gene requires detailed scientific evidence that is not provided in the context. \n\nFor statements 2 to 5, detailed molecular biology or scientific literature is needed to confirm or refute the roles of TRalpha2 as they relate to the specific genetic expressions mentioned. Without such information, their veracity remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "There are several biomedical question answering systems available, including:\n1. PubMed Central's \"Ask a Biologist\": This system uses natural language processing to answer questions on a variety of biology-related topics.\n2. The Biomedical Information and Retrieval System (BIRS): This system is designed to answer questions on biomedical topics by searching a large database of biomedical literature.\n3. The Biomedical Question Answering System (BQA): This system uses a combination of natural language processing and machine learning to answer biomedical questions.\n4. The Biomedical Information Retrieval System (BIRS): This system is designed to answer questions on biomedical topics by searching a large database of biomedical literature.\n5. The Biomedical Knowledge Retrieval System (BKRS): This system uses a combination of natural language processing and machine learning to answer biomedical questions.\n6. The Medical Information Retrieval System (MIRS): This system is designed to answer questions on medical topics by searching a large database of medical literature.\n7. The Biomedical Text Mining System (BTMS): This system uses natural language processing and machine learning to mine biomedical text and answer questions.\n8. The Biomedical Question Answering System (BQA): This system uses a combination of natural language processing and machine learning to answer biomedical questions.\n9. The Biomedical Information Retrieval System (BIRS): This system is designed to answer questions on biomedical topics by searching a large database of biomedical literature.\n10. The Biomedical Knowledge Retrieval System (BKRS): This system uses a combination of natural language processing and machine learning to answer biomedical questions.\nThese are just a few examples of the many biomedical question answering systems available. Each system has its own strengths and limitations, and the choice of which system to use will depend on the specific needs of the user.",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central's \"Ask a Biologist\" is a biomedical question answering system that uses natural language processing.\n2. The Biomedical Information and Retrieval System (BIRS) searches a large database of biomedical literature to answer questions on biomedical topics.\n3. The Biomedical Question Answering System (BQA) employs a combination of natural language processing and machine learning to provide answers to biomedical questions.\n4. The Medical Information Retrieval System (MIRS) is designed to answer medical questions by consulting a large database of medical literature.\n5. The Biomedical Text Mining System (BTMS) utilizes natural language processing and machine learning to mine biomedical text for answering questions.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central's \"Ask a Biologist\" is a biomedical question answering system that uses natural language processing.",
      "The Biomedical Information and Retrieval System (BIRS) searches a large database of biomedical literature to answer questions on biomedical topics.",
      "The Biomedical Question Answering System (BQA) employs a combination of natural language processing and machine learning to provide answers to biomedical questions.",
      "The Medical Information Retrieval System (MIRS) is designed to answer medical questions by consulting a large database of medical literature.",
      "The Biomedical Text Mining System (BTMS) utilizes natural language processing and machine learning to mine biomedical text for answering questions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMed Central is a free full-text archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine, but \"Ask a Biologist\" is an educational resource and does not seem to be a feature of PubMed Central.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the betalain pathway is called bHLH1 (basic helix-loop-helix transcription factor 1).",
    "llama-2-7b-chat-hf_fact_raw": "1. The transcription factor that activates the betalain pathway is bHLH1.\n2. bHLH1 stands for basic helix-loop-helix transcription factor 1.",
    "llama-2-7b-chat-hf_fact": [
      "The transcription factor that activates the betalain pathway is bHLH1.",
      "bHLH1 stands for basic helix-loop-helix transcription factor 1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Global quantitative phosphoproteomic analyses typically involve the enrichment of phosphorylated peptides before mass spectrometry analysis. There are several technologies that are commonly used for phosphoproteome enrichment, including:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to selectively capture phosphorylated peptides based on their charge and hydrophilicity.\n2. IMAC (Immobilized Metal Affinity Chromatography): This method uses metal ions (e.g., copper or nickel) immobilized on a resin to selectively bind phosphorylated peptides.\n3. Hydrophilic interaction liquid chromatography (HILIC): This method separates phosphorylated peptides based on their hydrophilicity, allowing for their enrichment.\n4. Reversed-phase HPLC: This method separates phosphorylated peptides based on their hydrophobicity, allowing for their enrichment.\n5. Enzyme-linked immunosorbent assay (ELISA): This method uses antibodies specific to phosphorylated peptides to capture and enrich them.\n6. Fluorescence-activated cell sorting (FACS): This method separates cells based on their fluorescence properties, allowing for the enrichment of phosphorylated peptides.\n7. Microfluidics-based enrichment: This method uses microfluidics to separate phosphorylated peptides based on their size and charge.\n8. Protein G-based enrichment: This method uses protein G to capture phosphorylated peptides based on their binding affinity.\n9. Magnetic nanoparticle-based enrichment: This method uses magnetic nanoparticles to capture phosphorylated peptides based on their binding affinity.\n10. Electrochemical enrichment: This method uses an electrochemical field to selectively capture phosphorylated peptides based on their charge and hydrophilicity.\nIt is important to note that the choice of technology will depend on the specific research question and experimental design.",
    "llama-2-7b-chat-hf_fact_raw": "1. Titanium dioxide (TiO2)-based enrichment is a method used to selectively capture phosphorylated peptides for phosphoproteome analysis.\n2. Immobilized Metal Affinity Chromatography (IMAC) employs metal ions to bind phosphorylated peptides.\n3. Hydrophilic interaction liquid chromatography (HILIC) enriches phosphorylated peptides based on hydrophilicity.\n4. Reversed-phase High-Performance Liquid Chromatography (HPLC) is used for the enrichment of phosphorylated peptides based on hydrophobicity.\n5. Enzyme-linked immunosorbent assay (ELISA) utilizes antibodies to capture and enrich phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "Titanium dioxide (TiO2)-based enrichment is a method used to selectively capture phosphorylated peptides for phosphoproteome analysis.",
      "Immobilized Metal Affinity Chromatography (IMAC) employs metal ions to bind phosphorylated peptides.",
      "Hydrophilic interaction liquid chromatography (HILIC) enriches phosphorylated peptides based on hydrophilicity.",
      "Reversed-phase High-Performance Liquid Chromatography (HPLC) is used for the enrichment of phosphorylated peptides based on hydrophobicity.",
      "Enzyme-linked immunosorbent assay (ELISA) utilizes antibodies to capture and enrich phosphorylated peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Titanium dioxide (TiO2) is used as an affinity reagent to selectively capture phosphorylated peptides in phosphoproteome analysis due to its high affinity for phosphate groups.\n   \n2. TRUE: Immobilized Metal Affinity Chromatography (IMAC) indeed employs metal ions such as Fe3+ or Ga3+ to bind phosphorylated peptides based on the affinity between the metal ions and the phosphoryl groups.\n\n3. TRUE: Hydrophilic interaction liquid chromatography (HILIC) is an alternative method for enriching phosphorylated peptides by exploiting their relatively higher hydrophilicity compared to non-phosphorylated peptides.\n\n4. FALSE [correction]: Reversed-phase High-Performance Liquid Chromatography (HPLC) is commonly used for the separation of peptides based on their hydrophobicity differences, not specifically for the enrichment of phosphorylated peptides.\n\n5. FALSE [correction]: Enzyme-linked immunosorbent assay (ELISA) is an assay that uses antibodies for detection and quantitation of substances, like peptides or proteins, but not specifically for the enrichment of phosphorylated peptides. ELISA typically involves attaching the antigens to a surface, then selectively binding an antibody to the antigen, and detecting this binding with a secondary antibody or another method, which differs from peptide enrichment.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini classification is used to rate the severity of Mucopolysaccharidosis (MPS), a group of genetic disorders that affect the body's ability to produce certain enzymes needed for sugar breakdown and storage. The Palmini classification system rates the severity of MPS based on the level of enzyme deficiency and the accumulation of sugar molecules in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Palmini classification is used to rate the severity of Mucopolysaccharidosis (MPS).\n2. Mucopolysaccharidosis is a group of genetic disorders.\n3. These disorders affect the body's ability to produce enzymes necessary for sugar breakdown and storage.\n4. The Palmini classification system considers enzyme deficiency levels in its severity rating.\n5. The Palmini classification system also considers the accumulation of sugar molecules in the body in its severity rating.",
    "llama-2-7b-chat-hf_fact": [
      "Palmini classification is used to rate the severity of Mucopolysaccharidosis (MPS).",
      "Mucopolysaccharidosis is a group of genetic disorders.",
      "These disorders affect the body's ability to produce enzymes necessary for sugar breakdown and storage.",
      "The Palmini classification system considers enzyme deficiency levels in its severity rating.",
      "The Palmini classification system also considers the accumulation of sugar molecules in the body in its severity rating."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to rate the severity of Mucopolysaccharidosis (MPS); it is used for classifying types of cortical dysplasia, a brain malformation.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Palmini classification system does not consider enzyme deficiency levels since it is not related to Mucopolysaccharidosis (MPS); rather, it classifies the histopathological features of cortical dysplasia.\n5. FALSE [correction]: The Palmini classification does not consider the accumulation of sugar molecules in the body since it is not related to the severity rating of Mucopolysaccharidosis (MPS).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory disorder of the thyroid gland that can cause pain, swelling, and thyroid hormone dysregulation. While the exact cause of subacute thyroiditis is not fully understood, several viruses have been linked to its development:\n1. Viruses:\na. Influenza virus: Studies have shown that influenza virus infection can trigger subacute thyroiditis in some individuals.\nb. Human papillomavirus (HPV): HPV has been linked to the development of subacute thyroiditis, particularly in young women.\nc. Herpesvirus: Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been implicated in the development of subacute thyroiditis.\nd. Adenovirus: Adenovirus infection has been associated with subacute thyroiditis in some studies.\nIt's important to note that not all cases of subacute thyroiditis are caused by viruses, and other factors such as autoimmune disorders, thyroid hormone imbalances, and iodine deficiency may also play a role. A comprehensive evaluation by a healthcare provider is necessary to determine the underlying cause of subacute thyroiditis in each individual case.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory disorder of the thyroid gland.\n2. Influenza virus infection can trigger subacute thyroiditis in some individuals.\n3. Human papillomavirus (HPV) has been linked to the development of subacute thyroiditis, particularly in young women.\n4. Herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6) have been implicated in the development of subacute thyroiditis.\n5. Adenovirus infection has been associated with subacute thyroiditis in some studies.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory disorder of the thyroid gland.",
      "Influenza virus infection can trigger subacute thyroiditis in some individuals.",
      "Human papillomavirus (HPV) has been linked to the development of subacute thyroiditis, particularly in young women.",
      "Herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6) have been implicated in the development of subacute thyroiditis.",
      "Adenovirus infection has been associated with subacute thyroiditis in some studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Human papillomavirus (HPV) has NOT been established as a known trigger for subacute thyroiditis. It is typically associated with conditions such as warts and cervical cancer.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in the EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2, leading to the suppression of global protein synthesis and the induction of autophagy. STAT3 is a transcription factor that is activated in response to various signals, including growth factors and cytokines, and plays a role in regulating cell survival, proliferation, and inflammation. Studies have shown that STAT3 is activated downstream of EIF2AK2 and plays a role in the regulation of autophagy, with STAT3 inhibition leading to the enhancement of autophagy in various cell types. Therefore, EIF2AK2-mediated suppression of autophagy is at least partially mediated by STAT3.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2.\n3. The phosphorylation of eIF2 by EIF2AK2 leads to the suppression of global protein synthesis.\n4. The phosphorylation of eIF2 by EIF2AK2 leads to the induction of autophagy.\n5. Inhibition of STAT3 leads to the enhancement of autophagy in various cell types.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2.",
      "The phosphorylation of eIF2 by EIF2AK2 leads to the suppression of global protein synthesis.",
      "The phosphorylation of eIF2 by EIF2AK2 leads to the induction of autophagy.",
      "Inhibition of STAT3 leads to the enhancement of autophagy in various cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The phosphorylation of eIF2 by EIF2AK2 is generally known to lead to the suppression of global protein synthesis, but it can also lead to the induction of autophagy under certain stress conditions. The statement as presented, therefore, could be misleading without additional context.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, particularly for the analysis of chromatin structure and gene regulation. It can be used for a variety of purposes, including:\n1. Chromatin structure analysis: Theatre can be used to predict the 3D structure of chromatin fibers based on chromatin immunoprecipitation sequencing (ChIP-seq) data. This can help researchers understand how different proteins and molecules interact with chromatin and how this affects gene regulation.\n2. Gene regulation analysis: Theatre can be used to predict the activity of genes based on their chromatin structure and the binding of transcription factors. This can help researchers understand how gene regulation works and how it is affected by different factors, such as disease-causing mutations.\n3. Epigenetic analysis: Theatre can be used to predict the epigenetic marks (such as histone modifications and DNA methylation) on a gene basis. This can help researchers understand how epigenetic marks are inherited and how they contribute to the regulation of gene expression.\n4. Drug target identification: Theatre can be used to predict the binding of drugs to their target proteins and to identify potential drug targets. This can help researchers develop new drugs and understand how they work.\n5. Personalized medicine: Theatre can be used to predict the activity of genes in different individuals based on their genetic background. This can help researchers develop personalized treatments for diseases.\n6. Cancer research: Theatre can be used to predict the activity of cancer-related genes and to identify potential cancer drug targets.\n7. Stem cell biology: Theatre can be used to predict the activity of stem cell-related genes and to identify potential stem cell therapeutic targets.\n8. Developmental biology: Theatre can be used to predict the activity of developmental genes and to identify potential developmental therapeutic targets.\n9. Neurobiology: Theatre can be used to predict the activity of neuro-related genes and to identify potential neurotherapeutic targets.\n10. Plant biology: Theatre can be used to predict the activity of plant-related genes and to identify potential plant therapeutic targets.\nOverall, Theatre is a powerful tool for understanding the complex interactions between genes, proteins, and other",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool designed for genomic analysis, specifically used for analyzing chromatin structure and gene regulation.\n2. It can predict the 3D structure of chromatin fibers using chromatin immunoprecipitation sequencing (ChIP-seq) data.\n3. Theatre is utilized to predict gene activity based on chromatin structure and transcription factor binding.\n4. The software can be used to predict epigenetic marks such as histone modifications and DNA methylation on genes.\n5. Theatre can aid in the identification of potential drug targets by predicting the binding of drugs to their target proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool designed for genomic analysis, specifically used for analyzing chromatin structure and gene regulation.",
      "It can predict the 3D structure of chromatin fibers using chromatin immunoprecipitation sequencing (ChIP-seq) data.",
      "Theatre is utilized to predict gene activity based on chromatin structure and transcription factor binding.",
      "The software can be used to predict epigenetic marks such as histone modifications and DNA methylation on genes.",
      "Theatre can aid in the identification of potential drug targets by predicting the binding of drugs to their target proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Theatre is described as a tool for analyzing chromatin structure and gene regulation; however, predicting the binding of drugs to their target proteins would be more related to pharmacodynamics and molecular docking analyses which is not explicitly stated as a function of Theatre for genomic analysis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, the general complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\nThe basic idea of the Smith-Waterman algorithm is to compute the similarity between two sequences by computing the similarity between their substrings. The algorithm scans the sequences one position at a time, and for each position, it computes the similarity between the two sequences using a scoring function. The score is based on the similarity between the two sequences at that position, and the score is computed using a weighted sum of the similarity between the corresponding positions in the two sequences.\nThe time complexity of the Smith-Waterman algorithm can be broken down into several components:\n1. Sequence access: The algorithm accesses the sequences one position at a time, so the time complexity of accessing the sequences is O(n), where n is the length of the shorter sequence.\n2. Similarity computation: The algorithm computes the similarity between the two sequences at each position, which involves computing a score based on the similarity between the two sequences at that position. The time complexity of computing the similarity is typically O(1), since the similarity is typically computed using a simple function such as the dot product of two vectors.\n3. Weighted sum: The algorithm computes a weighted sum of the similarity scores, where the weights are based on the similarity between the two sequences at each position. The time complexity of computing the weighted sum is typically O(n), since the algorithm needs to compute the weighted sum for each position in the sequence.\n4. Iterations: The algorithm iterates over the positions in the sequences, so the time complexity of the iterations is O(n).\nTherefore, the overall time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence. This means that the time complexity of the algorithm grows quadratically with the length of the sequences.\nIt's worth noting that the time complexity of the Smith-Waterman algorithm can be improved using techniques such as caching, parallel processing, or using a more efficient algorithm such as the Needleman-Wunsch algorithm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The general complexity of the Smith-Waterman algorithm is O(n^2).\n2. The time complexity of accessing the sequences in the Smith-Waterman algorithm is O(n).\n3. The time complexity of computing the similarity between two sequences at each position in the Smith-Waterman algorithm is typically O(1).\n4. The time complexity of computing the weighted sum in the Smith-Waterman algorithm is typically O(n).\n5. The overall time complexity of the Smith-Waterman algorithm grows quadratically with the length of the sequences.",
    "llama-2-7b-chat-hf_fact": [
      "The general complexity of the Smith-Waterman algorithm is O(n^2).",
      "The time complexity of accessing the sequences in the Smith-Waterman algorithm is O(n).",
      "The time complexity of computing the similarity between two sequences at each position in the Smith-Waterman algorithm is typically O(1).",
      "The time complexity of computing the weighted sum in the Smith-Waterman algorithm is typically O(n).",
      "The overall time complexity of the Smith-Waterman algorithm grows quadratically with the length of the sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The general complexity of the Smith-Waterman algorithm for sequence alignment is indeed O(n^2), where n is the length of the sequence.\n2. FALSE [correction]: The time complexity of accessing the sequences in the Smith-Waterman algorithm is O(1) if you are referring to a single access. However, if referring to accessing the entire length of a sequence, then it would be O(n).\n3. TRUE: The time complexity of computing the similarity between two sequences at each position in the Smith-Waterman algorithm is typically O(1), assuming that a constant time lookup is used for the scoring matrix.\n4. UNKNOWN: The statement about \"computing the weighted sum\" is vague without additional context on what \"weighted sum\" refers to. Typically, calculating a score based on a score matrix would be O(1) at each position. However, if referring to summing all the values in the scoring matrix, it would be O(n^2).\n5. TRUE: The overall time complexity of the Smith-Waterman algorithm indeed grows quadratically with the length of the sequences, which is represented as O(n^2). This is due to the need to fill in a scoring matrix that has dimensions proportional to the lengths of the two sequences being compared.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the solute carrier (SLC) family of transmembrane transporters. Specifically, it is a member of the SLC13 family, which is also known as the monocarboxylate transporter (MCT) family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the solute carrier (SLC) family of transmembrane transporters.\n2. FLVCR1 is a member of the SLC13 family.\n3. The SLC13 family is also known as the monocarboxylate transporter (MCT) family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the solute carrier (SLC) family of transmembrane transporters.",
      "FLVCR1 is a member of the SLC13 family.",
      "The SLC13 family is also known as the monocarboxylate transporter (MCT) family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: FLVCR1 is a member of the SLC35 family, not the SLC13 family.\n3. FALSE [correction]: The SLC13 family is known as the sodium-dependent dicarboxylate transporter family, whereas the monocarboxylate transporter (MCT) family is referred to as SLC16.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1, a transcription factor essential for erythroid cell development, has been shown to interact with several proteins involved in various cellular processes. The biotinylation tagging approach has been used to identify GATA-1 interacting partners. Some of the known GATA-1 interacting partners include:\n1. HDAC1 (histone deacetylase 1): GATA-1 binds to HDAC1 and represses its activity, leading to the deacetylation of histones and the condensation of chromatin.\n2. H3K9 histone methyltransferase complex: GATA-1 associates with the H3K9 histone methyltransferase complex, which is involved in the methylation of histone H3 at lysine 9, a mark that represses gene expression.\n3. KAT2A (lysine-specific demethylase 1A): GATA-1 interacts with KAT2A, which is involved in the demethylation of histone H3 at lysine 9, leading to the activation of gene expression.\n4. P504S (p504s): GATA-1 binds to P504S, a protein that is involved in the regulation of protein synthesis and degradation.\n5. PUF60 (Pumilio and FBF-interacting RNA-binding protein 60): GATA-1 interacts with PUF60, a protein that is involved in the regulation of mRNA translation and degradation.\n6. RBBP4 (RNA-binding protein 4): GATA-1 associates with RBBP4, which is involved in the regulation of mRNA splicing and degradation.\n7. RNA polymerase II: GATA-1 binds to RNA polymerase II, which is responsible for transcribing DNA into mRNA.\n8. TAF1 (TATA-binding protein 1): GATA-1 interacts with TAF1, which is involved in the regulation of RNA polymerase II transcription initiation.\n9. TFIIS (RNA polymerase II subunit S): GATA-1 associates",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 binds to HDAC1 (histone deacetylase 1), leading to the deacetylation of histones and chromatin condensation.\n2. GATA-1 associates with the H3K9 histone methyltransferase complex, which methylates histone H3 at lysine 9.\n3. GATA-1 interacts with KAT2A (lysine-specific demethylase 1A), which is involved in the demethylation of histone H3 at lysine 9.\n4. GATA-1 binds to P504S (p504s), a protein involved in the regulation of protein synthesis and degradation.\n5. GATA-1 interacts with PUF60 (Pumilio and FBF-interacting RNA-binding protein 60), which regulates mRNA translation and degradation.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 binds to HDAC1 (histone deacetylase 1), leading to the deacetylation of histones and chromatin condensation.",
      "GATA-1 associates with the H3K9 histone methyltransferase complex, which methylates histone H3 at lysine 9.",
      "GATA-1 interacts with KAT2A (lysine-specific demethylase 1A), which is involved in the demethylation of histone H3 at lysine 9.",
      "GATA-1 binds to P504S (p504s), a protein involved in the regulation of protein synthesis and degradation.",
      "GATA-1 interacts with PUF60 (Pumilio and FBF-interacting RNA-binding protein 60), which regulates mRNA translation and degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GATA-1 is known to bind to various co-regulators including HDAC1, which can lead to histone deacetylation and subsequent chromatin condensation, playing a role in regulating gene expression during erythropoiesis.\n   \n2. TRUE: GATA-1 has been reported to associate with histone methyltransferase complexes that can methylate histone H3 at lysine 9 (H3K9), which is a mark associated with gene repression.\n\n3. FALSE [correction]: KAT2A (also known as GCN5) is actually a histone acetyltransferase, not a demethylase. It acetylates lysine residues, which is generally associated with transcriptional activation. KDM1A, not KAT2A, is a lysine-specific demethylase that targets H3K4, not H3K9.\n\n4. UNKNOWN: Without context, it is difficult to assess the interaction between GATA-1 and P504S (which is also known as alpha-methylacyl-CoA racemase, AMACR). P504S/AMACR is more commonly associated with its role in bile acid synthesis and is a biomarker for prostate cancer, but its direct interaction with GATA-1 is not well-established in the literature.\n\n5. UNKNOWN: PUF60 is involved in RNA processing, but the direct interaction with GATA-1 is not commonly described. While it could be involved in processes related to mRNA translation and degradation, without specific evidence of an interaction with GATA-1, the accuracy of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-box protein associated factor 10) interacts with the GATA1 (GATA-binding protein 1) transcription factor to modulate the activity of GATA1 and regulate the expression of genes involved in erythroid cell development. The interaction between TAF10 and GATA1 leads to the recruitment of RNA polymerase II (RNAPII) to the promoter region of GATA1-regulated genes, allowing for the transcription of these genes to occur. This process is essential for the proper differentiation of erythroid cells, which are the cells responsible for producing red blood cells in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interacts with the GATA1 transcription factor to modulate the activity of GATA1.\n2. The interaction between TAF10 and GATA1 regulates genes involved in erythroid cell development.\n3. The TAF10-GATA1 interaction recruits RNA polymerase II to the promoter region of GATA1-regulated genes.\n4. RNA polymerase II recruitment by TAF10 and GATA1 allows for the transcription of genes necessary for erythroid cell development.\n5. Erythroid cells are responsible for producing red blood cells in the body.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interacts with the GATA1 transcription factor to modulate the activity of GATA1.",
      "The interaction between TAF10 and GATA1 regulates genes involved in erythroid cell development.",
      "The TAF10-GATA1 interaction recruits RNA polymerase II to the promoter region of GATA1-regulated genes.",
      "RNA polymerase II recruitment by TAF10 and GATA1 allows for the transcription of genes necessary for erythroid cell development.",
      "Erythroid cells are responsible for producing red blood cells in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. A DSS is a computer-based system that provides healthcare providers with clinical decision-making support, including guidelines, protocols, and clinical recommendations, to help them make informed decisions about patient care. Here are some examples of DSS for chronic pain management:\n1. Chronic Pain Management Decision Support System (CPM-DSS): This system was developed by the University of Washington and provides clinicians with evidence-based recommendations for managing chronic pain. It includes a database of clinical guidelines, treatment options, and patient-specific information.\n2. Pain Management Decision Support System (PMDSS): This system was developed by the University of California, San Francisco, and provides clinicians with a comprehensive framework for managing chronic pain. It includes a database of clinical guidelines, treatment options, and patient-specific information, as well as tools for evaluating patient function and quality of life.\n3. Pain Care Network (PCN): This system was developed by the University of Utah and provides clinicians with a web-based platform for managing chronic pain. It includes a database of clinical guidelines, treatment options, and patient-specific information, as well as tools for evaluating patient function and quality of life.\n4. Chronic Pain Management (CPM) System: This system was developed by the University of Texas Health Science Center at San Antonio and provides clinicians with a comprehensive framework for managing chronic pain. It includes a database of clinical guidelines, treatment options, and patient-specific information, as well as tools for evaluating patient function and quality of life.\n5. Pain Management Algorithm (PMA): This system was developed by the University of Florida and provides clinicians with a step-by-step algorithm for managing chronic pain. It includes a database of clinical guidelines, treatment options, and patient-specific information, as well as tools for evaluating patient function and quality of life.\n6. Pain Care Pathway (PCP): This system was developed by the University of Washington and provides clinicians with a comprehensive framework for managing chronic pain. It includes a database of clinical guidelines, treatment options, and patient-specific information, as well as tools for evaluating",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) are available for chronic pain management.\n2. The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.\n3. The Pain Management Decision Support System (PMDSS) was developed by the University of California, San Francisco.\n4. The Pain Care Network (PCN) is a web-based platform for managing chronic pain developed by the University of Utah.\n5. The Chronic Pain Management (CPM) System was developed by the University of Texas Health Science Center at San Antonio.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) are available for chronic pain management.",
      "The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.",
      "The Pain Management Decision Support System (PMDSS) was developed by the University of California, San Francisco.",
      "The Pain Care Network (PCN) is a web-based platform for managing chronic pain developed by the University of Utah.",
      "The Chronic Pain Management (CPM) System was developed by the University of Texas Health Science Center at San Antonio."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Decision support systems (DSS) are indeed developed and available for various medical fields, including chronic pain management to assist healthcare providers in making evidence-based clinical decisions.\n2. UNKNOWN - Without specific information about the development of the Chronic Pain Management Decision Support System (CPM-DSS), its attribution to the University of Washington cannot be verified.\n3. UNKNOWN - As with the previous statement, without specific details on the development of the Pain Management Decision Support System (PMDSS), it is not possible to confirm its creation by the University of California, San Francisco.\n4. UNKNOWN - The existence of the Pain Care Network (PCN) as a web-based platform for managing chronic pain attributed to the University of Utah cannot be confirmed or denied without additional information.\n5. UNKNOWN - The statement about the Chronic Pain Management (CPM) System being developed by the University of Texas Health Science Center at San Antonio requires more detail to verify its accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a secreted protein that is primarily localized to the cytoplasm and nucleus of cells, but it can also be found in the extracellular space, particularly in the context of angiogenesis (the formation of new blood vessels).",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein that can be localized to the cytoplasm of cells.\n2. Angiogenin can also be found localized to the nucleus of cells.\n3. Angiogenin is a secreted protein.\n4. Angiogenin can be present in the extracellular space.\n5. The presence of angiogenin is particularly noted during angiogenesis, which is the formation of new blood vessels.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein that can be localized to the cytoplasm of cells.",
      "Angiogenin can also be found localized to the nucleus of cells.",
      "Angiogenin is a secreted protein.",
      "Angiogenin can be present in the extracellular space.",
      "The presence of angiogenin is particularly noted during angiogenesis, which is the formation of new blood vessels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine, a cardiovascular drug, inhibits the activation of kinase signaling pathways in the heart, particularly the L-type calcium channel-dependent pathway. This leads to a decrease in the influx of calcium ions into the cardiac muscle cells, which in turn reduces the contractility of the heart and helps to treat conditions such as angina pectoris and heart failure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine is a cardiovascular drug.\n2. Ranolazine inhibits the activation of kinase signaling pathways in the heart.\n3. Ranolazine particularly affects the L-type calcium channel-dependent pathway.\n4. Ranolazine's action leads to a decrease in the influx of calcium ions into cardiac muscle cells.\n5. Ranolazine is used to treat conditions such as angina pectoris and heart failure.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine is a cardiovascular drug.",
      "Ranolazine inhibits the activation of kinase signaling pathways in the heart.",
      "Ranolazine particularly affects the L-type calcium channel-dependent pathway.",
      "Ranolazine's action leads to a decrease in the influx of calcium ions into cardiac muscle cells.",
      "Ranolazine is used to treat conditions such as angina pectoris and heart failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Ranolazine is known to inhibit late sodium currents in the heart, not kinase signaling pathways.\n3. UNKNOWN\n4. TRUE\n5. TRUE (but with precision for clarification): Ranolazine is used primarily to treat chronic angina pectoris. While it might be used in heart failure patients, it is not a first-line treatment for heart failure specifically.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria. While Vsr is constitutively expressed in some species of bacteria, its activity can be modulated in response to changes in the growth phase. For example, in E. coli, Vsr activity is highest during the logarithmic phase of growth and decreases during the stationary phase. This regulation is thought to be mediated by the binding of the transcriptional regulator, S, to the vsr promoter.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is not completely independent of the growth phase of bacteria.\n2. Vsr endonuclease is constitutively expressed in some species of bacteria.\n3. In E. coli, Vsr endonuclease activity is highest during the logarithmic phase of growth.\n4. The activity of Vsr endonuclease decreases during the stationary phase in E. coli.\n5. The transcriptional regulator S can bind to the vsr promoter, suggesting a regulatory mechanism for Vsr endonuclease.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is not completely independent of the growth phase of bacteria.",
      "Vsr endonuclease is constitutively expressed in some species of bacteria.",
      "In E. coli, Vsr endonuclease activity is highest during the logarithmic phase of growth.",
      "The activity of Vsr endonuclease decreases during the stationary phase in E. coli.",
      "The transcriptional regulator S can bind to the vsr promoter, suggesting a regulatory mechanism for Vsr endonuclease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt is known in molecular biology that expression of genes such as those coding for endonucleases can vary depending on the growth phase of bacteria. Vsr endonuclease, which recognizes specific DNA mismatches and initiates repair, is indeed subject to regulation that correlates with the bacterial growth phase. Bacteria like E. coli have sophisticated systems to regulate the expression of various genes, including vsr, in response to different environmental conditions and growth phases. Sigma factors, including S, are known to play key roles in the control of gene expression in response to growth phase and stress conditions. Hence, the involvement of a transcriptional regulator like S suggests a nuanced regulatory mechanism for Vsr endonuclease, which is consistent with the complex regulation of bacterial gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools and methods that can be used for the prediction of -barrel transmembrane proteins. Some of the commonly used tools include:\n1. TMHMM: TMHMM is a widely used tool for predicting the structure and function of transmembrane proteins. It uses a combination of sequence analysis and structural information to predict the presence of -barrels and other transmembrane structures.\n2. SignalP: SignalP is a tool for predicting the presence of signal peptides in proteins, which are often associated with -barrel transmembrane proteins. It uses a combination of sequence analysis and machine learning algorithms to make predictions.\n3. PredictProtein: PredictProtein is a tool that can be used to predict the structure and function of transmembrane proteins, including -barrels. It uses a combination of sequence analysis, structural information, and machine learning algorithms to make predictions.\n4. Transmembrane Helix Predictor (THP): THP is a tool that can be used to predict the presence of -barrels in transmembrane proteins. It uses a combination of sequence analysis and structural information to make predictions.\n5. Beta-Barrel Fold Recognition (BFR): BFR is a tool that can be used to predict the presence of -barrels in transmembrane proteins. It uses a combination of sequence analysis and machine learning algorithms to make predictions.\n6. PredictTMB: PredictTMB is a tool that can be used to predict the presence of -barrels in transmembrane proteins. It uses a combination of sequence analysis, structural information, and machine learning algorithms to make predictions.\n7. TMProPredict: TMProPredict is a tool that can be used to predict the presence of -barrels in transmembrane proteins. It uses a combination of sequence analysis and machine learning algorithms to make predictions.\n8. TM-align: TM-align is a tool that can be used to predict the presence of -barrels in transmembrane proteins. It uses a combination of sequence analysis and structural information to make predictions.\n9. PHD-TMB: PHD-TMB is a tool that",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is a tool used for predicting the structure and function of transmembrane proteins, including -barrels.\n2. SignalP is a predictive tool for the presence of signal peptides in proteins, which are often associated with -barrel transmembrane proteins.\n3. PredictProtein is a computational tool used to predict the structure and function of transmembrane proteins, including -barrels.\n4. Beta-Barrel Fold Recognition (BFR) is a tool designed to predict the presence of -barrels in transmembrane proteins.\n5. PredictTMB is a tool for predicting the presence of -barrels in transmembrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is a tool used for predicting the structure and function of transmembrane proteins, including -barrels.",
      "SignalP is a predictive tool for the presence of signal peptides in proteins, which are often associated with -barrel transmembrane proteins.",
      "PredictProtein is a computational tool used to predict the structure and function of transmembrane proteins, including -barrels.",
      "Beta-Barrel Fold Recognition (BFR) is a tool designed to predict the presence of -barrels in transmembrane proteins.",
      "PredictTMB is a tool for predicting the presence of -barrels in transmembrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TMHMM is a tool used for predicting the location and orientation of transmembrane helices in proteins, but it is not specifically used for predicting -barrels.\n2. TRUE: SignalP is a tool designed to predict the presence and location of signal peptide sequences in proteins, which can be found in proteins including transmembrane -barrel proteins.\n3. TRUE: PredictProtein is a multifunctional computational tool that can predict various aspects of protein structure and function, including features of transmembrane proteins.\n4. FALSE [correction]: Beta-Barrel Fold Recognition (BFR) does not appear to be a widely recognized or standard tool for predicting the presence of -barrels in transmembrane proteins. No correction can be made without specific information about such a tool.\n5. FALSE [correction]: The tool's name seems to be incorrect or misspelled. A tool for predicting -barrels in transmembrane proteins is known as PRED-TMBB, not PredictTMB.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify mutations associated with cystic fibrosis, a genetic disorder that affects the respiratory, digestive, and reproductive systems. The Galassi classification system categorizes CF mutations based on their location in the CFTR gene and their effect on the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Orsini syndrome, is a rare genetic disorder that affects the development of the brain and spinal cord. Here are some common features of Shapiro syndrome:\n1. Intellectual disability: Individuals with Shapiro syndrome typically have mild to moderate intellectual disability, which can range from mild to moderate.\n2. Seizures: Seizures are a common feature of Shapiro syndrome, and can vary in severity and frequency.\n3. Cerebellar hypoplasia: The cerebellum is the part of the brain that coordinates movement and balance. In Shapiro syndrome, the cerebellum is often underdeveloped or hypoplastic, leading to difficulties with coordination, balance, and movement.\n4. Ataxia: Ataxia is a loss of coordination and balance that can occur due to damage to the cerebellum or other parts of the brain. Individuals with Shapiro syndrome often have ataxia, which can range from mild to severe.\n5. Spasticity: Spasticity is a condition characterized by stiffness and rigidity of the muscles, which can make movement difficult. Individuals with Shapiro syndrome often have spasticity, particularly in the legs and feet.\n6. Scoliosis: Scoliosis is a condition in which the spine curves abnormally to one side. Shapiro syndrome can cause scoliosis, which can range from mild to severe.\n7. Other physical features: Individuals with Shapiro syndrome may have other physical features, such as small head size, narrow eyes, and a flat nasal bridge.\n8. Behavioral and psychiatric features: Shapiro syndrome can also cause behavioral and psychiatric problems, such as anxiety, depression, and autism spectrum disorder.\n9. Vision problems: Some individuals with Shapiro syndrome may have vision problems, including strabismus (crossed eyes) and nystagmus (involuntary eye movements).\n10. Hearing loss: Hearing loss is a relatively common feature of Shapiro syndrome, and can range from mild to severe.\nIt's important",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is a rare genetic disorder that affects the development of the brain and spinal cord.\n2. Individuals with Shapiro syndrome typically have mild to moderate intellectual disability.\n3. Seizures are a common feature of Shapiro syndrome.\n4. The cerebellum is often underdeveloped or hypoplastic in individuals with Shapiro syndrome, leading to difficulties with coordination, balance, and movement.\n5. Shapiro syndrome can cause scoliosis, an abnormal curvature of the spine.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is a rare genetic disorder that affects the development of the brain and spinal cord.",
      "Individuals with Shapiro syndrome typically have mild to moderate intellectual disability.",
      "Seizures are a common feature of Shapiro syndrome.",
      "The cerebellum is often underdeveloped or hypoplastic in individuals with Shapiro syndrome, leading to difficulties with coordination, balance, and movement.",
      "Shapiro syndrome can cause scoliosis, an abnormal curvature of the spine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is not primarily a genetic disorder; it is a rare neurologic disorder characterized by the triad of recurrent hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. FALSE [correction]: While some individuals with Shapiro syndrome may experience cognitive impairment, this is not a typical feature of the syndrome, so saying they typically have mild to moderate intellectual disability may not be accurate.\n3. UNKNOWN: Seizures are not one of the core features of Shapiro syndrome, but they can be present in some individuals with agenesis of the corpus callosum. Without specific information relating seizures directly to Shapiro syndrome, this is difficult to confirm as true or false.\n4. FALSE [correction]: The defining characteristic of Shapiro syndrome is agenesis or hypogenesis of the corpus callosum, not specifically underdevelopment of the cerebellum. While coordination and balance issues might occur, they are not due to cerebellar hypoplasia but due to agenesis of the corpus callosum.\n5. UNKNOWN: Although scoliosis can be associated with many neurological disorders, there is no specific information linking scoliosis as a common consequence of Shapiro syndrome. Scoliosis may or may not be present in individuals with this condition.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG-1-related gene 1) mutations have been linked to a rare genetic disorder called BRAG1-related disorder or BRAG1 syndrome. This disorder is characterized by a range of symptoms including intellectual disability, growth retardation, facial dysmorphism, and skeletal abnormalities.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAG1-related disorder, also known as BRAG1 syndrome, is associated with mutations in the BRAG1 gene.\n2. BRAG1-related disorder is a rare genetic disorder.\n3. Symptoms of BRAG1-related disorder include intellectual disability.\n4. Symptoms of BRAG1-related disorder include growth retardation.\n5. Symptoms of BRAG1-related disorder include facial dysmorphism and skeletal abnormalities.",
    "llama-2-7b-chat-hf_fact": [
      "BRAG1-related disorder, also known as BRAG1 syndrome, is associated with mutations in the BRAG1 gene.",
      "BRAG1-related disorder is a rare genetic disorder.",
      "Symptoms of BRAG1-related disorder include intellectual disability.",
      "Symptoms of BRAG1-related disorder include growth retardation.",
      "Symptoms of BRAG1-related disorder include facial dysmorphism and skeletal abnormalities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout specific medical literature or research references to validate the association of BRAG1-related disorder with mutations in the BRAG1 gene, I cannot confirm the first statement. The rarity and the symptoms listed (intellectual disability, growth retardation, facial dysmorphism, and skeletal abnormalities) are typical characteristics of many rare genetic disorders, so the rest of the statements are consistent with typical presentations of such conditions. However, without specific information on BRAG1-related disorder, one cannot absolutely confirm the detailed symptoms related only to this condition.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-phosphatase. PP1-phosphatase is a negative regulator of PP1 activity and helps to control the activity of PP1 in various cellular processes, including cell signaling and protein dephosphorylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. PP1-phosphatase is the main inhibitor of protein phosphatase 1 (PP1).\n2. PP1-phosphatase is a negative regulator of PP1 activity.\n3. PP1-phosphatase helps to control the activity of PP1 in cellular processes.\n4. PP1 is involved in cell signaling and protein dephosphorylation.",
    "llama-2-7b-chat-hf_fact": [
      "PP1-phosphatase is the main inhibitor of protein phosphatase 1 (PP1).",
      "PP1-phosphatase is a negative regulator of PP1 activity.",
      "PP1-phosphatase helps to control the activity of PP1 in cellular processes.",
      "PP1 is involved in cell signaling and protein dephosphorylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PP1-phosphatase is not the main inhibitor of protein phosphatase 1 (PP1); rather, it would be a nonsensical term since PP1 itself is a phosphatase. Endogenous inhibitors of PP1 include proteins such as Inhibitor-1 (I-1), Inhibitor-2 (I-2), and DARPP-32.\n2. FALSE [correction]: Since PP1-phosphatase is not a recognized term in the context of protein phosphatase 1 (PP1), this statement is incorrect. As stated above, PP1 has actual inhibitors that are distinct proteins, not a \"PP1-phosphatase.\"\n3. FALSE [correction]: The statement refers to a non-existent PP1-phosphatase. In reality, PP1 activity is regulated by various protein inhibitors, regulatory subunits, and targeting subunits that help to control its activity in cellular processes.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a mechanism by which bacteria increase their adaptability to changing environments by accumulating mutations during stationary phase. In Bacillus subtilis, several mechanisms underlie adaptive mutagenesis:\n1. DNA damage response: The stationary phase is characterized by high levels of DNA damage, which can arise from various sources, including oxidative stress, DNA replication stress, and the action of antibiotics. The DNA damage response pathways, such as the SOS response, can induce mutations to help the cell cope with these stressors.\n2. MutS and MutL homologs: MutS and MutL homologs are DNA mismatch repair proteins that play a key role in maintaining genome stability by correcting errors that occur during DNA replication and recombination. During stationary phase, these proteins can also induce mutations to help the cell adapt to changing conditions.\n3. RecA-mediated recombination: RecA is a DNA recombinase that plays a crucial role in repairing DNA double-strand breaks. During stationary phase, RecA can also induce mutations by recombining non-homologous DNA sequences, leading to the creation of new genetic combinations.\n4. Transposon-mediated mutagenesis: Transposons are mobile genetic elements that can insert into different locations within the genome, often leading to mutations. During stationary phase, transposons can become more active, leading to increased mutation rates.\n5. RNA-dependent DNA mutagenesis: Some RNA molecules, such as RNase P, can base-modify DNA, leading to mutations. This mechanism is more active during stationary phase, when the cell has a higher demand for DNA synthesis.\nThese mechanisms allow Bacillus subtilis to generate genetic diversity during stationary phase, which can help the cell adapt to changing environments and survive in a wide range of conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bacillus subtilis accumulates mutations during the stationary phase to increase its adaptability to changing environments.\n2. High levels of DNA damage during the stationary phase can induce mutations through DNA damage response pathways like the SOS response.\n3. MutS and MutL homologs, which are involved in DNA mismatch repair, can induce mutations in Bacillus subtilis during the stationary phase.\n4. RecA-mediated recombination can induce mutations by recombining non-homologous DNA sequences during the stationary phase in Bacillus subtilis.\n5. Transposons can insert into different locations within the Bacillus subtilis genome during the stationary phase, leading to increased mutation rates.",
    "llama-2-7b-chat-hf_fact": [
      "Bacillus subtilis accumulates mutations during the stationary phase to increase its adaptability to changing environments.",
      "High levels of DNA damage during the stationary phase can induce mutations through DNA damage response pathways like the SOS response.",
      "MutS and MutL homologs, which are involved in DNA mismatch repair, can induce mutations in Bacillus subtilis during the stationary phase.",
      "RecA-mediated recombination can induce mutations by recombining non-homologous DNA sequences during the stationary phase in Bacillus subtilis.",
      "Transposons can insert into different locations within the Bacillus subtilis genome during the stationary phase, leading to increased mutation rates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MutS and MutL homologs are involved in DNA mismatch repair, but they do not induce mutations. Instead, they work to correct DNA replication errors and prevent mutations.\n4. FALSE [correction]: RecA-mediated recombination generally involves the exchange of homologous DNA sequences rather than non-homologous ones and primarily serves to repair DNA rather than induce mutations.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucic acid syndrome, is a rare genetic disorder caused by mutations in the EBR (erythrina-binding protein) gene. This gene provides instructions for making a protein called erythrina-binding protein, which is involved in the development and function of the nervous system. Mutations in the EBR gene can lead to the production of a faulty or absent erythrina-binding protein, which can disrupt the normal functioning of the nervous system and cause a range of symptoms, including muscle weakness, vision loss, and developmental delays.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism, also known as erucic acid syndrome, is caused by mutations in the EBR gene.\n2. The EBR gene is responsible for providing instructions to make a protein called erythrina-binding protein.\n3. Erythrina-binding protein is involved in the development and function of the nervous system.\n4. Mutations in the EBR gene can result in a faulty or absent erythrina-binding protein.\n5. A disrupted erythrina-binding protein can lead to symptoms such as muscle weakness, vision loss, and developmental delays.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism, also known as erucic acid syndrome, is caused by mutations in the EBR gene.",
      "The EBR gene is responsible for providing instructions to make a protein called erythrina-binding protein.",
      "Erythrina-binding protein is involved in the development and function of the nervous system.",
      "Mutations in the EBR gene can result in a faulty or absent erythrina-binding protein.",
      "A disrupted erythrina-binding protein can lead to symptoms such as muscle weakness, vision loss, and developmental delays."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is not known as erucic acid syndrome and is not caused by mutations in the EBR gene. Erucism is the irritation caused by contact with the hairs or bristles of some caterpillar and moth larvae.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the EBR gene and erythrina-binding protein cannot be verified because those terms do not align with standard genetic terminology. If EBR and erythrina-binding protein are fictional or not widely accepted terms, there could be no accurate validation or correction without proper scientific context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat a variety of conditions, including:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is used to reduce blood pressure in patients with mild to moderate hypertension.\n2. Heart failure: Hydrochlorothiazide can help reduce the workload on the heart by removing excess fluid and sodium from the body, which can help improve cardiac function in patients with heart failure.\n3. Edema (swelling): Hydrochlorothiazide is used to treat edema (swelling) caused by excess fluid accumulation in the body, which can occur due to various conditions such as liver disease, kidney disease, or other underlying medical conditions.\n4. Nephrotic syndrome: Hydrochlorothiazide can help reduce the amount of protein in the urine in patients with nephrotic syndrome, a condition characterized by excessive loss of protein in the urine.\n5. Type 2 diabetes: Hydrochlorothiazide can help improve glycemic control in patients with type 2 diabetes by increasing insulin sensitivity and improving glucose uptake in the body.\n6. Hyperlipidemia (high cholesterol): Hydrochlorothiazide can help reduce the levels of total cholesterol, LDL cholesterol (the \"bad\" cholesterol), and triglycerides in the blood, which can help reduce the risk of cardiovascular disease.\n7. Kidney stones: Hydrochlorothiazide can help prevent the formation of kidney stones by reducing the concentration of minerals in the urine and increasing the volume of urine.\n8. Cystitis: Hydrochlorothiazide can help treat cystitis, a bladder infection caused by bacteria, by increasing the amount of urine produced and reducing the concentration of bacteria in the urine.\n9. Interstitial cystitis: Hydrochlorothiazide can help treat interstitial cystitis, a chronic bladder condition characterized by pain and inflammation in the bladder wall, by reducing inflamm",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used as a treatment for mild to moderate hypertension.\n2. It can help improve cardiac function in patients with heart failure by removing excess fluid and sodium from the body.\n3. Hydrochlorothiazide is used to treat edema caused by conditions such as liver disease or kidney disease.\n4. It can help reduce the amount of protein in the urine in patients with nephrotic syndrome.\n5. Hydrochlorothiazide can help improve glycemic control in patients with type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used as a treatment for mild to moderate hypertension.",
      "It can help improve cardiac function in patients with heart failure by removing excess fluid and sodium from the body.",
      "Hydrochlorothiazide is used to treat edema caused by conditions such as liver disease or kidney disease.",
      "It can help reduce the amount of protein in the urine in patients with nephrotic syndrome.",
      "Hydrochlorothiazide can help improve glycemic control in patients with type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is generally not used to reduce the amount of protein in the urine in patients with nephrotic syndrome. Instead, medications like ACE inhibitors or angiotensin receptor blockers are more commonly used for reducing proteinuria in this condition.\n5. FALSE [correction]: Hydrochlorothiazide does not improve glycemic control in patients with type 2 diabetes; in fact, it can potentially increase blood sugar levels.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon-based materials, such as silicon-based hydrogels, have been developed for the treatment of urinary incontinence, particularly stress urinary incontinence (SUI). These materials are designed to mimic the natural properties of the bladder and urethra, providing support and structure to the tissues surrounding the urethra, which can help to prevent leakage.\nSilicon-based hydrogels are typically made of a cross-linked network of silicon molecules that are cross-linked to form a gel-like material. These materials have been shown to have several advantages over traditional treatments for SUI, including:\n1. Biocompatibility: Silicon-based hydrogels are biocompatible, meaning they do not cause an immune response or rejection in the body.\n2. Durability: Silicon-based hydrogels can remain in place for an extended period, providing long-term support for the tissues surrounding the urethra.\n3. Adjustable stiffness: The stiffness of silicon-based hydrogels can be adjusted to match the natural stiffness of the bladder and urethra, providing optimal support and stability.\n4. Minimally invasive delivery: Silicon-based hydrogels can be delivered to the body through minimally invasive procedures, such as a catheter or needle injection, reducing the risk of complications and improving recovery time.\n5. Reversible: Silicon-based hydrogels are reversible, meaning they can be removed or adjusted as needed, providing flexibility in treatment options.\nWhile silicon-based hydrogels have shown promise in the treatment of SUI, further research is needed to fully understand their safety and efficacy in humans. However, they offer a promising alternative to traditional treatments, such as surgery, and may provide a more minimally invasive and long-lasting solution for patients with SUI.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials, such as silicon-based hydrogels, have been developed for the treatment of urinary incontinence, particularly stress urinary incontinence (SUI).\n2. Silicon-based hydrogels are designed to mimic the natural properties of the bladder and urethra.\n3. Silicon-based hydrogels are biocompatible, meaning they do not cause an immune response or rejection in the body.\n4. The stiffness of silicon-based hydrogels can be adjusted to match the natural stiffness of the bladder and urethra.\n5. Silicon-based hydrogels can be delivered to the body through minimally invasive procedures like catheter or needle injection.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials, such as silicon-based hydrogels, have been developed for the treatment of urinary incontinence, particularly stress urinary incontinence (SUI).",
      "Silicon-based hydrogels are designed to mimic the natural properties of the bladder and urethra.",
      "Silicon-based hydrogels are biocompatible, meaning they do not cause an immune response or rejection in the body.",
      "The stiffness of silicon-based hydrogels can be adjusted to match the natural stiffness of the bladder and urethra.",
      "Silicon-based hydrogels can be delivered to the body through minimally invasive procedures like catheter or needle injection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN  While silicon-based materials are often biocompatible, without specific evidence or research for the specific hydrogels mentioned, this statement is difficult to confirm definitively.\n4. UNKNOWN  Adjusting the stiffness of hydrogels to match body tissues is a common goal in biomaterials development, but whether the specific silicon-based hydrogels achieve this cannot be determined without more context.\n5. UNKNOWN  Many hydrogels are designed for minimally invasive delivery, but whether this is true for the silicon-based hydrogels in question cannot be confirmed without specific information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a controversial association between the lunar cycle (the cycle of the moon's phases) and the risk of rupture of intracranial aneurysms. Some studies have suggested that the incidence of aneurysm rupture may be higher during certain phases of the moon cycle, particularly during the full moon. However, these findings are not consistent across all studies and the evidence is still limited and inconclusive.\nOne study published in 2016 analyzed data from over 1,000 patients with ruptured aneurysms and found that the risk of rupture was higher during the full moon phase compared to other phases of the moon cycle. Another study published in 2018 found similar results, with a higher incidence of aneurysm rupture during the full moon phase.\nHowever, other studies have found no association between the lunar cycle and aneurysm rupture. A review of 22 studies on the topic published in 2019 found that the evidence was inconsistent and inconclusive.\nIt is important to note that the association between the lunar cycle and aneurysm rupture is still a topic of debate and more research is needed to confirm or refute this association. Additionally, it is worth noting that the lunar cycle is just one of many potential risk factors for aneurysm rupture, and other factors such as aneurysm size, location, and genetic predisposition are also important.\nIn summary, while some studies suggest that there may be an association between the lunar cycle and aneurysm rupture, the evidence is still limited and inconclusive, and more research is needed to fully understand this relationship.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies suggest that the incidence of intracranial aneurysm rupture may be higher during the full moon phase of the lunar cycle.\n2. A study published in 2016 found a higher risk of aneurysm rupture during the full moon phase when analyzing data from over 1,000 patients.\n3. Another study in 2018 reported a higher incidence of aneurysm rupture coinciding with the full moon phase.\n4. A review of 22 studies published in 2019 concluded that the evidence of an association between the lunar cycle and aneurysm rupture was inconsistent and inconclusive.\n5. Factors aside from the lunar cycle, such as aneurysm size, location, and genetic predisposition, are important in the risk of aneurysm rupture.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies suggest that the incidence of intracranial aneurysm rupture may be higher during the full moon phase of the lunar cycle.",
      "A study published in 2016 found a higher risk of aneurysm rupture during the full moon phase when analyzing data from over 1,000 patients.",
      "Another study in 2018 reported a higher incidence of aneurysm rupture coinciding with the full moon phase.",
      "A review of 22 studies published in 2019 concluded that the evidence of an association between the lunar cycle and aneurysm rupture was inconsistent and inconclusive.",
      "Factors aside from the lunar cycle, such as aneurysm size, location, and genetic predisposition, are important in the risk of aneurysm rupture."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nWithout more detail on the 2016 and 2018 studies (such as the name of the journals, authors, or their findings), it's not possible for me to verify the specific claims about an association between the full moon phase and aneurysm rupture in statements 1, 2, and 3. However, statement 4 is plausible since a review study would include an assessment of the available literature on the topic, and it's reasonable to conclude there might be inconsistencies and inconclusive evidence regarding this association. Statement 5 is true because it is well-established in medical literature that factors like aneurysm size, location, and genetic predisposition play a significant role in the risk of aneurysm rupture.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein (also known as ELAVL1) is known to regulate the splicing process in various cell types. HuR is a RNA-binding protein that plays a critical role in the regulation of mRNA splicing, particularly in the nucleus. It recognizes and binds to specific pre-mRNA sequences and enhances the splicing efficiency of certain exons, leading to the production of alternative splice variants. HuR has been shown to regulate the splicing of mRNAs involved in various biological processes, including cell proliferation, differentiation, and survival. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein, also known as ELAVL1, is involved in the regulation of the splicing process.\n2. HuR is an RNA-binding protein that plays a critical role in regulating mRNA splicing.\n3. HuR protein enhances the splicing efficiency of certain exons, leading to the production of alternative splice variants.\n4. The splicing regulated by HuR is associated with biological processes such as cell proliferation, differentiation, and survival.\n5. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein, also known as ELAVL1, is involved in the regulation of the splicing process.",
      "HuR is an RNA-binding protein that plays a critical role in regulating mRNA splicing.",
      "HuR protein enhances the splicing efficiency of certain exons, leading to the production of alternative splice variants.",
      "The splicing regulated by HuR is associated with biological processes such as cell proliferation, differentiation, and survival.",
      "Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HuR protein, also known as ELAVL1, is involved in the regulation of mRNA stability and translation, not primarily the splicing process.\n2. TRUE\n3. UNKNOWN: While HuR is known to affect mRNA stability and translation, whether it specifically enhances the splicing efficiency leading to alternative splice variants can vary depending on the context and specific mechanisms, which are not universally established.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "The prothymosin alpha c-terminal peptide (PCT) has been shown to have a variety of functions in the body. Some of the known functions of PCT include:\n1. Regulation of protein synthesis: PCT has been shown to stimulate protein synthesis in various cell types, including muscle cells, and may play a role in regulating the balance between protein synthesis and degradation.\n2. Cell signaling: PCT has been shown to interact with a number of cell surface receptors and intracellular signaling proteins, including the epidermal growth factor receptor (EGFR), the platelet-derived growth factor receptor (PDGFR), and the insulin receptor. These interactions may play a role in regulating cell growth, differentiation, and survival.\n3. Anti-inflammatory effects: PCT has been shown to have anti-inflammatory effects in various models of inflammation, including colitis and arthritis.\n4. Neuroprotection: PCT has been shown to have neuroprotective effects in various models of neurodegeneration, including Alzheimer's disease and Parkinson's disease.\n5. Cardiovascular protection: PCT has been shown to have cardiovascular protective effects in various models of cardiovascular disease, including hypertension and atherosclerosis.\n6. Immune modulation: PCT has been shown to modulate the immune response in various models, including autoimmune diseases such as multiple sclerosis and type 1 diabetes.\n7. Tumor suppression: PCT has been shown to have tumor suppressive effects in various models of cancer, including breast, lung, and prostate cancer.\n8. Cell adhesion and migration: PCT has been shown to regulate cell adhesion and migration in various cell types, including cancer cells.\n9. Angiogenesis: PCT has been shown to regulate angiogenesis, the formation of new blood vessels, in various models, including cancer and cardiovascular disease.\n10. Stem cell regulation: PCT has been shown to regulate stem cell maintenance and differentiation in various models, including hematopoietic stem cells and embry",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (PCT) is known to stimulate protein synthesis in various cell types.\n2. PCT interacts with cell surface receptors and intracellular signaling proteins such as EGFR, PDGFR, and the insulin receptor.\n3. Prothymosin alpha c-terminal peptide has demonstrated anti-inflammatory effects in models of inflammation like colitis and arthritis.\n4. PCT has shown neuroprotective effects in models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.\n5. The peptide has been observed to have cardiovascular protective effects in models of cardiovascular diseases, including hypertension and atherosclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (PCT) is known to stimulate protein synthesis in various cell types.",
      "PCT interacts with cell surface receptors and intracellular signaling proteins such as EGFR, PDGFR, and the insulin receptor.",
      "Prothymosin alpha c-terminal peptide has demonstrated anti-inflammatory effects in models of inflammation like colitis and arthritis.",
      "PCT has shown neuroprotective effects in models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.",
      "The peptide has been observed to have cardiovascular protective effects in models of cardiovascular diseases, including hypertension and atherosclerosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific references or established context, it's difficult to confirm the role of Prothymosin alpha c-terminal peptide (PCT) in stimulating protein synthesis in various cell types.\n\n2. UNKNOWN: The interaction of PCT with cell surface receptors like EGFR, PDGFR, and the insulin receptor needs to be verified with scientific literature as it is not common knowledge.\n\n3. UNKNOWN: The purported anti-inflammatory effects of Prothymosin alpha c-terminal peptide in models of diseases such as colitis and arthritis cannot be validated without reference to specific scientific studies or data.\n\n4. UNKNOWN: The neuroprotective effects of PCT in models of neurodegenerative diseases like Alzheimer's disease and Parkinson's disease require evidence from peer-reviewed research for validation.\n\n5. UNKNOWN: The observation of cardiovascular protective effects of the peptide in models of cardiovascular diseases like hypertension and atherosclerosis is a scientific assertion that requires verification through research studies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the N-terminal peptide (amino acids 1-20) of cystatin C. This peptide has been shown to be the primary component responsible for the aggregation and fibril formation of cystatin C under conditions of oxidative stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. The N-terminal peptide (amino acids 1-20) of cystatin C plays a pivotal role in its fibrillization.\n2. The N-terminal peptide (amino acids 1-20) of cystatin C is responsible for the aggregation and fibril formation of the protein.\n3. Human cystatin C fibrillization occurs under conditions of oxidative stress.",
    "llama-2-7b-chat-hf_fact": [
      "The N-terminal peptide (amino acids 1-20) of cystatin C plays a pivotal role in its fibrillization.",
      "The N-terminal peptide (amino acids 1-20) of cystatin C is responsible for the aggregation and fibril formation of the protein.",
      "Human cystatin C fibrillization occurs under conditions of oxidative stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nNote: The statements about cystatin C are consistent with scientific knowledge regarding the role of the N-terminal region in the protein's fibrillization and aggregation, as well as the influence of oxidative stress on these processes. However, without the ability to check the most recent research data or details from the passage from which these statements are extracted, it's important to acknowledge that scientific understanding can evolve, and the truthfulness of these statements may be contingent on the context in which they are discussed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1 (Hypoxia-Inducible Factor-1 alpha) increases after the administration of the cytoprotective prodrug amifostine (ethyol). Amifostine is a prodrug that is converted to the active compound ethylhydroxyurea (EHU) within cells, which then inhibits the activity of the enzyme hypoxia-inducible factor prolyl hydroxylase (HIF-PHD), leading to the stabilization and accumulation of HIF-1. This increase in HIF-1 leads to the activation of genes involved in adaptive responses to hypoxia, such as angiogenesis, glucose metabolism, and cell survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1 increases after the administration of the prodrug amifostine (ethyol).\n2. Amifostine is converted to the active compound ethylhydroxyurea (EHU) within cells.\n3. The active compound from amifostine inhibits the activity of the enzyme hypoxia-inducible factor prolyl hydroxylase (HIF-PHD).\n4. Inhibition of HIF-PHD by the active compound from amifostine leads to stabilization and accumulation of HIF-1.\n5. The activation of genes involved in adaptive responses to hypoxia, like angiogenesis, glucose metabolism, and cell survival, is a consequence of increased HIF-1 levels.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1 increases after the administration of the prodrug amifostine (ethyol).",
      "Amifostine is converted to the active compound ethylhydroxyurea (EHU) within cells.",
      "The active compound from amifostine inhibits the activity of the enzyme hypoxia-inducible factor prolyl hydroxylase (HIF-PHD).",
      "Inhibition of HIF-PHD by the active compound from amifostine leads to stabilization and accumulation of HIF-1.",
      "The activation of genes involved in adaptive responses to hypoxia, like angiogenesis, glucose metabolism, and cell survival, is a consequence of increased HIF-1 levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: It is known that HIF-1 levels increase in response to hypoxia, and drugs like amifostine that modulate cellular responses to hypoxia can hypothetically lead to increased HIF-1. However, without specific study data directly linking amifostine to increased HIF-1, this remains a scientifically reasonable statement but without direct evidence provided here.\n2. TRUE: Amifostine is indeed metabolized within cells to form the active compound, which is ethylhydroxyurea (EHU).\n3. UNKNOWN: There isn't enough information provided here to confirm whether the active metabolite of amifostine inhibits HIF-PHD. This would need to be supported by specific biochemical or pharmacological data.\n4. TRUE: If the statement in number 3 was true, then the inhibition of HIF-PHD would prevent the normal degradation of HIF-1, leading to its stabilization and accumulation.\n5. TRUE: The activation of genes that help the cell adapt to hypoxic conditions is one of the known consequences of increased HIF-1 levels. This is a well-studied pathway in cellular biology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone proteins. These marks are involved in the regulation of gene expression, particularly for active genes, and are associated with the elongation of RNA polymerase II (RNAPII) during transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks.\n3. The H3K4me3 marks are involved in the regulation of gene expression.\n4. These marks are particularly associated with active genes.\n5. H3K4me3 marks are related to the elongation of RNA polymerase II during transcription.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks.",
      "The H3K4me3 marks are involved in the regulation of gene expression.",
      "These marks are particularly associated with active genes.",
      "H3K4me3 marks are related to the elongation of RNA polymerase II during transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Set7 (also known as Setd7 or Set9) is a histone methyltransferase that specifically targets lysine 4 of histone 3, but it catalyzes the addition of a single methyl group (monomethylation), not trimethylation. \n2. FALSE [correction]: Set7 is responsible for the deposition of histone 3 lysine 4 monomethylation (H3K4me1), not trimethylation (H3K4me3).\n3. TRUE: The H3K4me3 mark, although not deposited by Set7, is involved in the regulation of gene expression.\n4. TRUE: H3K4me3 marks are generally associated with actively transcribed genes.\n5. UNKNOWN: While H3K4me3 marks are associated with active transcription and are enriched at promoters, the statement about their specific relation to the elongation of RNA polymerase II is not detailed enough to determine its accuracy without additional context. Generally, H3K36me3 is more commonly associated with the elongation phase of RNA polymerase II.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is a cytoplasmic protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized in the cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized in the cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\n[Explanation]: The statement concerning the localization of the protein encoded by the gene DNAJC11 requires specific biochemical knowledge or data to verify. Without additional context or access to scientific resources, the subcellular localization of this particular protein cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UEs) are depleted among copy number variants (CNVs). UEs are short, conserved sequences that are found throughout the genome, and they are typically less prone to copy number variations compared to other regions of the genome. Studies have shown that UEs are enriched in regions of the genome that are less prone to CNVs, and that CNVs are less likely to overlap with UEs. This is thought to be due to the fact that UEs are often located in regions of the genome that are under strong selective pressure to maintain their sequence fidelity, which can reduce the likelihood of CNVs occurring in these regions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UEs) are short, conserved sequences found throughout the genome.\n2. UEs are typically less prone to copy number variations compared to other regions of the genome.\n3. Studies have indicated that UEs are enriched in regions of the genome that are less prone to CNVs.\n4. Copy number variants (CNVs) are less likely to overlap with UEs.\n5. UEs are often located in regions of the genome under strong selective pressure to maintain sequence fidelity.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UEs) are short, conserved sequences found throughout the genome.",
      "UEs are typically less prone to copy number variations compared to other regions of the genome.",
      "Studies have indicated that UEs are enriched in regions of the genome that are less prone to CNVs.",
      "Copy number variants (CNVs) are less likely to overlap with UEs.",
      "UEs are often located in regions of the genome under strong selective pressure to maintain sequence fidelity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ultraconserved elements (UEs) are long, conserved sequences found throughout the genome.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Haspin kinase is a protein that plays a crucial role in the regulation of mitosis, particularly in the proper separation of chromosomes during cell division. The substrate of Haspin kinase during mitosis is primarily the histone H3. Haspin kinase phosphorylates histone H3 on specific residues, leading to the formation of a stable chromatin structure that is essential for proper chromosome separation and proper execution of mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Haspin kinase regulates mitosis and the proper separation of chromosomes during cell division.\n2. The primary substrate of haspin kinase during mitosis is the histone H3.\n3. Haspin kinase phosphorylates histone H3 on specific residues.\n4. The phosphorylation of histone H3 by haspin kinase contributes to the formation of a stable chromatin structure.\n5. A stable chromatin structure is essential for proper chromosome separation during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "Haspin kinase regulates mitosis and the proper separation of chromosomes during cell division.",
      "The primary substrate of haspin kinase during mitosis is the histone H3.",
      "Haspin kinase phosphorylates histone H3 on specific residues.",
      "The phosphorylation of histone H3 by haspin kinase contributes to the formation of a stable chromatin structure.",
      "A stable chromatin structure is essential for proper chromosome separation during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE - Haspin kinase is known to specifically phosphorylate histone H3 at threonine 3 (H3T3) during mitosis.\n3. TRUE\n4. FALSE [correction]: The phosphorylation of histone H3 by haspin kinase does not directly contribute to the formation of a stable chromatin structure. Instead, it creates a specific mark that recruits other proteins to ensure proper chromosome segregation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a mechanism that is distinct from other viruses. They replicate by infecting the host cell's RNA-dependent RNA polymerase, which is responsible for transcribing the host cell's genetic material into RNA. The viroid RNA acts as a template for the host cell's RNA-dependent RNA polymerase, which synthesizes new viroid RNA molecules through a process called \"transcriptional replication.\" This means that the viroid RNA acts as a template for the host cell's own RNA polymerase, allowing the viroid to replicate its genetic material without the need for a separate replication mechanism. This unique replication mechanism is what allows viroids to infect and replicate within host cells without the need for a host cell membrane or other cellular structures.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules.\n2. Viroids replicate by infecting the host cell's RNA-dependent RNA polymerase.\n3. The host cell's RNA-dependent RNA polymerase is responsible for transcribing the host cell's genetic material into RNA.\n4. Viroid RNA serves as a template for synthesis of new viroid RNA molecules through a process called \"transcriptional replication.\"\n5. Viroids replicate their genetic material without the need for a separate replication mechanism.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules.",
      "Viroids replicate by infecting the host cell's RNA-dependent RNA polymerase.",
      "The host cell's RNA-dependent RNA polymerase is responsible for transcribing the host cell's genetic material into RNA.",
      "Viroid RNA serves as a template for synthesis of new viroid RNA molecules through a process called \"transcriptional replication.\"",
      "Viroids replicate their genetic material without the need for a separate replication mechanism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids replicate by taking advantage of the host cell's RNA polymerase, but their replication does not directly involve the host's RNA-dependent RNA polymerase. Viroids actually hijack the host's RNA polymerase II, which is typically used for transcribing DNA into messenger RNA (mRNA).\n3. FALSE [correction]: RNA-dependent RNA polymerase is responsible for replicating RNA from an RNA template, which occurs in some viruses. However, this does not include transcribing the host cell's genetic material into RNA as that is done by DNA-dependent RNA polymerases, notably RNA polymerase II for mRNA synthesis.\n4. FALSE [correction]: The process involving viroid RNA serving as a template for new viroid RNA through host machinery is called \"rolling-circle replication,\" not \"transcriptional replication.\"\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD). Fibronectin is a extracellular matrix protein that plays a crucial role in muscle development and maintenance, and its levels have been found to be altered in the serum of DMD patients.\nStudies have shown that fibronectin levels are significantly reduced in the serum of DMD patients compared to healthy controls, particularly during the early stages of the disease. This reduction is thought to be due to the loss of muscle fibers and the subsequent decrease in fibronectin production.\nThe use of fibronectin as a biomarker for DMD has several advantages, including its ease of measurement, the sensitivity of the assay, and its potential to detect the disease at an early stage. Additionally, fibronectin levels have been found to be correlated with disease severity and progression, making it a useful tool for monitoring disease progression and response to treatment.\nHowever, it is important to note that the use of fibronectin as a biomarker for DMD is still in its early stages, and further research is needed to validate its clinical utility. Nevertheless, the identification of fibronectin as a potential biomarker for DMD represents an exciting area of research that may lead to the development of new diagnostic and therapeutic strategies for this devastating disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Fibronectin is an extracellular matrix protein that is involved in muscle development and maintenance.\n3. Fibronectin levels are significantly reduced in the serum of DMD patients compared to healthy controls.\n4. The levels of fibronectin are correlated with the severity and progression of Duchenne muscular dystrophy.\n5. Studies suggest that measuring fibronectin can potentially detect DMD at an early stage.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Fibronectin is an extracellular matrix protein that is involved in muscle development and maintenance.",
      "Fibronectin levels are significantly reduced in the serum of DMD patients compared to healthy controls.",
      "The levels of fibronectin are correlated with the severity and progression of Duchenne muscular dystrophy.",
      "Studies suggest that measuring fibronectin can potentially detect DMD at an early stage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Fibronectin has been identified in research as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. TRUE: Fibronectin is indeed an extracellular matrix protein that plays a significant role in cell adhesion, growth, migration, and differentiation, which are all relevant to muscle development and maintenance.\n3. FALSE [correction]: Fibronectin levels are typically increased, not reduced, in the serum of DMD patients compared to healthy controls, reflecting the muscle damage and repair process.\n4. TRUE: The levels of fibronectin have been shown to be correlated with the severity and progression of Duchenne muscular dystrophy in some studies.\n5. TRUE: Due to its correlation with disease severity and progression, there is a suggestion in research that measuring fibronectin levels could potentially help in early detection of DMD.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. ENCODE (ENCyclopedia Of DNA Elements): A large-scale epigenomics project that aims to map all the functional elements in the human genome.\n2. Roadmap Epigenomics: A project that aims to create a comprehensive map of the epigenetic marks in various organisms, including humans.\n3. The Human Epigenome Project: A project that aims to create a detailed map of the epigenetic marks in human cells and tissues.\n4. The Mouse Epigenome Project: A project that aims to create a detailed map of the epigenetic marks in mouse cells and tissues.\n5. The Epigenomics of Disease Project: A project that aims to identify epigenetic changes associated with various diseases, including cancer, diabetes, and neurological disorders.\n6. The Epigenetic Regulation of Stem Cell Pluripotency Project: A project that aims to understand the epigenetic mechanisms that regulate stem cell pluripotency and differentiation.\n7. The Epigenetic Regulation of Gene Expression Project: A project that aims to understand the epigenetic mechanisms that regulate gene expression and their role in various biological processes.\n8. The Epigenetic Modification of DNA Repair Project: A project that aims to understand the epigenetic mechanisms that regulate DNA repair and their role in maintaining genome stability.\n9. The Epigenetic Regulation of Cell Fate Determination Project: A project that aims to understand the epigenetic mechanisms that regulate cell fate determination and differentiation.\n10. The Epigenetic Regulation of Aging Project: A project that aims to understand the epigenetic mechanisms that regulate aging and age-related diseases.\nThese projects have generated a large amount of data on various epigenetic marks, including histone modifications, DNA methylation, and non-coding RNA expression, which are contained in the DeepBlue data server.",
    "llama-2-7b-chat-hf_fact_raw": "1. ENCODE (ENCyclopedia Of DNA Elements) is a large-scale epigenomics project that aims to map all the functional elements in the human genome, and its data is contained in the DeepBlue epigenomic data server.\n2. The Roadmap Epigenomics project, which aims to create a comprehensive map of epigenetic marks in various organisms including humans, contributes data to the DeepBlue epigenomic data server.\n3. Data from The Human Epigenome Project, which aims to map epigenetic marks in human cells and tissues, are included in the DeepBlue epigenomic data server.\n4. The DeepBlue epigenomic data server contains information from The Mouse Epigenome Project, which focuses on mapping epigenetic marks in mouse cells and tissues.\n5. The Epigenomics of Disease Project aims to identify epigenetic changes associated with diseases and contributes its data to the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_fact": [
      "ENCODE (ENCyclopedia Of DNA Elements) is a large-scale epigenomics project that aims to map all the functional elements in the human genome, and its data is contained in the DeepBlue epigenomic data server.",
      "The Roadmap Epigenomics project, which aims to create a comprehensive map of epigenetic marks in various organisms including humans, contributes data to the DeepBlue epigenomic data server.",
      "Data from The Human Epigenome Project, which aims to map epigenetic marks in human cells and tissues, are included in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server contains information from The Mouse Epigenome Project, which focuses on mapping epigenetic marks in mouse cells and tissues.",
      "The Epigenomics of Disease Project aims to identify epigenetic changes associated with diseases and contributes its data to the DeepBlue epigenomic data server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Roadmap Epigenomics Project primarily provides its data through its own resources and databases such as the NIH Roadmap Epigenomics Mapping Consortium. It is not specifically stated that its data contributes to the DeepBlue epigenomic data server.\n3. UNKNOWN: Without specific information about the inclusion of data from The Human Epigenome Project in the DeepBlue server, the relationship between these two cannot be determined.\n4. UNKNOWN: The statement about the DeepBlue epigenomic data server containing information from The Mouse Epigenome Project is uncertain without further information regarding their data sharing and integration.\n5. UNKNOWN: The sharing of data from The Epigenomics of Disease Project with the DeepBlue epigenomic data server cannot be determined as true or false without more context or evidence of such a collaboration.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "One tool that employs self-organizing maps (SOM) for analyzing synonymous codon usage is the \"Synonymous Codon Usage Analysis\" tool (SCUA) developed by Dr. David Mount. SCUA uses SOM to visualize and analyze the patterns of synonymous codon usage in a given DNA sequence, and to identify potential functional or evolutionary significance of these patterns.",
    "llama-2-7b-chat-hf_fact_raw": "1. The tool \"Synonymous Codon Usage Analysis\" (SCUA) employs self-organizing maps for analyzing synonymous codon usage.\n2. SCUA was developed by Dr. David Mount.\n3. SCUA visualizes and analyzes patterns of synonymous codon usage in DNA sequences.\n4. SCUA can identify potential functional or evolutionary significance of codon usage patterns.",
    "llama-2-7b-chat-hf_fact": [
      "The tool \"Synonymous Codon Usage Analysis\" (SCUA) employs self-organizing maps for analyzing synonymous codon usage.",
      "SCUA was developed by Dr. David Mount.",
      "SCUA visualizes and analyzes patterns of synonymous codon usage in DNA sequences.",
      "SCUA can identify potential functional or evolutionary significance of codon usage patterns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microtubule-Associated Protein 1 Light Chain 1, also known as EB1) is a protein that plays a crucial role in the regulation of microtubule dynamics and cellular behavior. It is a component of the plus-end tracking protein EB1, which is involved in the regulation of microtubule stability, dynamics, and organization in various cell types. MINDY-1/EB1 is overexpressed in many cancer types and has been implicated in cancer progression and metastasis. It is also a potential therapeutic target for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a protein involved in the regulation of microtubule dynamics and cellular behavior.\n2. MINDY-1 is a component of the plus-end tracking protein EB1.\n3. The protein is involved in the regulation of microtubule stability, dynamics, and organization.\n4. MINDY-1/EB1 is overexpressed in many cancer types.\n5. MINDY-1/EB1 has been implicated in cancer progression and metastasis and is considered a potential therapeutic target for cancer treatment.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a protein involved in the regulation of microtubule dynamics and cellular behavior.",
      "MINDY-1 is a component of the plus-end tracking protein EB1.",
      "The protein is involved in the regulation of microtubule stability, dynamics, and organization.",
      "MINDY-1/EB1 is overexpressed in many cancer types.",
      "MINDY-1/EB1 has been implicated in cancer progression and metastasis and is considered a potential therapeutic target for cancer treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 is not a protein; it is likely a confusion with another molecule, as MINDY-1 does not match known proteins involved with microtubules.\n2. FALSE [correction]: As MINDY-1 is not recognized as a component of the plus-end tracking protein complex, this statement is incorrect. EB1 is actually a protein that associates with the plus ends of microtubules and regulates their dynamics independently.\n3. UNKNOWN: Without clear identification of the protein \"MINDY-1\", it is not possible to confirm its involvement in microtubule regulation.\n4. UNKNOWN: Since the identity of MINDY-1 is unclear, any claims about its expression in cancer cannot be confirmed.\n5. UNKNOWN: Without proper identification of MINDY-1, its implication in cancer progression and potential as a therapeutic target cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. PhyloBayes: This software package uses a Bayesian approach to infer the evolutionary history of a gene or genomic region, including the identification of conserved and non-conserved regions.\n2. PhastCons: This software package uses a hidden Markov model to predict the degree of conservation across a genomic region, based on a database of multiple alignments.\n3. ProbCons: This software package uses a probabilistic approach to identify conserved genomic regions, based on a database of multiple alignments and a model of evolutionary change.\n4. GERP: This software package uses a hidden Markov model to predict the degree of conservation across a genomic region, based on a database of multiple alignments.\n5. MEME: This software package uses a hidden Markov model to identify conserved genomic regions, based on a database of multiple alignments and a model of evolutionary change.\n6. DNaseI: This software package uses a hidden Markov model to predict the degree of conservation across a genomic region, based on a database of DNaseI footprints.\n7. conserved sequence block (CSB): This software package uses a hidden Markov model to identify conserved genomic regions, based on a database of multiple alignments and a model of evolutionary change.\n8. GLIMMER: This software package uses a hidden Markov model to predict the degree of conservation across a genomic region, based on a database of multiple alignments and a model of evolutionary change.\n9.MAGMA: This software package uses a hidden Markov model to predict the degree of conservation across a genomic region, based on a database of multiple alignments and a model of evolutionary change.\n10. HMMER: This software package uses a hidden Markov model to identify conserved genomic regions, based on a database of multiple alignments and a model of evolutionary change.\nPlease note that this is not an exhaustive list and there are many other software packages available for the analysis of conserved genomic loci.",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a software package that uses a Bayesian approach to identify conserved and non-conserved regions in the evolutionary history of genes or genomic regions.\n2. PhastCons is a software package that predicts the degree of conservation across a genomic region with a hidden Markov model based on multiple alignments.\n3. ProbCons is a software package that identifies conserved genomic regions using a probabilistic approach and a database of multiple alignments.\n4. GERP is a software package that employs a hidden Markov model to assess conservation across genomic regions using a database of multiple alignments.\n5. MEME is a software package that identifies conserved genomic regions with a hidden Markov model based on multiple alignments and a model of evolutionary change.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a software package that uses a Bayesian approach to identify conserved and non-conserved regions in the evolutionary history of genes or genomic regions.",
      "PhastCons is a software package that predicts the degree of conservation across a genomic region with a hidden Markov model based on multiple alignments.",
      "ProbCons is a software package that identifies conserved genomic regions using a probabilistic approach and a database of multiple alignments.",
      "GERP is a software package that employs a hidden Markov model to assess conservation across genomic regions using a database of multiple alignments.",
      "MEME is a software package that identifies conserved genomic regions with a hidden Markov model based on multiple alignments and a model of evolutionary change."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ProbCons is a software package designed for aligning multiple protein sequences and does not focus on identifying conserved genomic regions. It uses a probabilistic model to produce an alignment that reflects the most likely evolutionary history.\n4. FALSE [correction]: GERP (Genomic Evolutionary Rate Profiling) is a software package that identifies conserved elements in multiple alignments by comparing observed substitution rates to expected neutral rates, but it does not use a hidden Markov model for this purpose.\n5. FALSE [correction]: MEME (Multiple Em for Motif Elicitation) is a software package designed to discover motifs in groups of related DNA or protein sequences and does not employ a hidden Markov model to identify conserved genomic regions. It uses statistical models to identify repeating patterns, or motifs, that are likely to have a biological significance.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. PIEZO2-related craniofacial syndrome: A rare genetic disorder characterized by craniofacial abnormalities, such as cleft palate, microcephaly, and eye abnormalities.\n2. Neurological disorders: Mutations in the PIEZO2 gene have been linked to a variety of neurological disorders, including epilepsy, intellectual disability, and autism spectrum disorder.\n3. Hearing loss: PIEZO2 mutations can also cause hearing loss, particularly in the high-frequency range.\nThese diseases are caused by mutations in the PIEZO2 gene, which leads to dysfunction of the Piezo2 ion channel and disrupts normal cellular signaling and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. PIEZO2-related craniofacial syndrome is associated with the PIEZO2 gene and is characterized by craniofacial abnormalities such as cleft palate and microcephaly.\n2. Mutations in the PIEZO2 gene have been linked to neurological disorders, including epilepsy, intellectual disability, and autism spectrum disorder.\n3. Hearing loss, particularly in the high-frequency range, can be caused by mutations in the PIEZO2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "PIEZO2-related craniofacial syndrome is associated with the PIEZO2 gene and is characterized by craniofacial abnormalities such as cleft palate and microcephaly.",
      "Mutations in the PIEZO2 gene have been linked to neurological disorders, including epilepsy, intellectual disability, and autism spectrum disorder.",
      "Hearing loss, particularly in the high-frequency range, can be caused by mutations in the PIEZO2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While mutations in the PIEZO2 gene are associated with a variety of physical conditions, including musculoskeletal problems, there is no strong evidence directly linking these mutations to neurological disorders like epilepsy, intellectual disability, and autism spectrum disorder. These disorders are typically associated with other genetic factors.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components, such as collagen and fibronectin, through the proteasome pathway. This process is important for maintaining tissue homeostasis and contributing to various physiological processes, including tissue repair and remodeling.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix components.\n2. Collagen and fibronectin are among the ECM components affected by ERAP1-ERAP2 dimerization.\n3. The degradation process involving ERAP1-ERAP2 dimerization takes place through the proteasome pathway.\n4. This degradation process is important for maintaining tissue homeostasis.\n5. ERAP1-ERAP2 dimerization contributes to physiological processes like tissue repair and remodeling.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix components.",
      "Collagen and fibronectin are among the ECM components affected by ERAP1-ERAP2 dimerization.",
      "The degradation process involving ERAP1-ERAP2 dimerization takes place through the proteasome pathway.",
      "This degradation process is important for maintaining tissue homeostasis.",
      "ERAP1-ERAP2 dimerization contributes to physiological processes like tissue repair and remodeling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nRationale: ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) and ERAP2 (Endoplasmic Reticulum Aminopeptidase 2) are enzymes known to be involved in the processing of antigens for presentation by MHC class I molecules. However, the statements provided go beyond general knowledge and pertain to specific scientific findings that are not common knowledge. Therefore, without access to the specific passage or scientific literature being referenced, the truthfulness of these statements cannot be accurately determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of gallbladder function in non-damaged gallbladders.\nR-spondin 1 is a secreted protein that is produced by the gallbladder and plays a role in the regulation of bile secretion. It promotes the differentiation and proliferation of cholangiocytes, the cells that line the bile ducts in the gallbladder, and stimulates the production of bile. R-spondin 1 also inhibits the activity of the transcription factor C/EBP, which is involved in the regulation of gene expression in cholangiocytes. By inhibiting C/EBP, R-spondin 1 promotes the expression of genes involved in bile secretion and storage.\nNoggin, on the other hand, is a protein that is produced by the gallbladder and inhibits the activity of BMP (bone morphogenetic protein) signaling. BMP signaling is involved in the regulation of cholangiocyte proliferation and differentiation, as well as the formation of bile ducts. Noggin binds to BMP ligands and prevents them from activating their receptors, thereby inhibiting BMP signaling. This can help to regulate the proliferation and differentiation of cholangiocytes and maintain the proper structure and function of the gallbladder.\nIn non-damaged gallbladders, R-spondin 1 and Noggin work together to regulate bile secretion and gallbladder function. R-spondin 1 promotes the production of bile by stimulating the differentiation and proliferation of cholangiocytes, while Noggin inhibits the activity of BMP signaling to regulate the proliferation and differentiation of these cells. This balance of R-spondin 1 and Noggin activity helps to maintain the proper function of the gallbladder and prevent abnormalities in bile secretion and gallbladder function.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is a secreted protein that regulates bile secretion in the gallbladder.\n2. R-spondin 1 promotes the differentiation and proliferation of cholangiocytes, which are cells that line the bile ducts in the gallbladder.\n3. R-spondin 1 inhibits the activity of the transcription factor C/EBP, involved in the regulation of gene expression in cholangiocytes.\n4. Noggin is a protein that inhibits BMP signaling, which is involved in cholangiocyte proliferation and differentiation, as well as the formation of bile ducts.\n5. Noggin maintains the proper structure and function of the gallbladder by preventing BMP ligands from activating their receptors.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is a secreted protein that regulates bile secretion in the gallbladder.",
      "R-spondin 1 promotes the differentiation and proliferation of cholangiocytes, which are cells that line the bile ducts in the gallbladder.",
      "R-spondin 1 inhibits the activity of the transcription factor C/EBP, involved in the regulation of gene expression in cholangiocytes.",
      "Noggin is a protein that inhibits BMP signaling, which is involved in cholangiocyte proliferation and differentiation, as well as the formation of bile ducts.",
      "Noggin maintains the proper structure and function of the gallbladder by preventing BMP ligands from activating their receptors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: R-spondin 1 is not specifically known for regulating bile secretion in the gallbladder. It is involved in cell signaling and stem cell proliferation, particularly in the Wnt signaling pathway, which is more generally implicated in various developmental processes and diseases.\n2. FALSE [correction]: R-spondin 1 is known for enhancing Wnt signaling, which can lead to proliferation of various cell types. However, the specific role of R-spondin 1 in the differentiation and proliferation of cholangiocytes is not well-established and would need to be verified by scientific research specific to that context.\n3. UNKNOWN: The statement is very specific and without further context or scientific references, it is difficult to verify the accuracy of R-spondin 1's interaction with the transcription factor C/EBP in cholangiocytes.\n4. TRUE: Noggin is an established antagonist of BMP (bone morphogenetic protein) signaling, which is involved in various developmental processes, including those mentioned in the statement.\n5. FALSE [correction]: While Noggin does inhibit BMP signaling, the specific function of maintaining the proper structure and function of the gallbladder by such mechanism would require evidence from the scientific literature. Noggin is known more generally for its roles in embryonic development and tissue patterning.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that requires four subunits to function: NOX5A, NOX5B, NOX5C, and NOX5D. These subunits work together to generate reactive oxygen species (ROS) in the cell.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected in the regulation of iron metabolism. Furin is a protease enzyme that processes several proteins involved in iron metabolism, including the iron exporter ferroportin, which is responsible for releasing iron from cells into the circulation. Hepcidin, on the other hand, is a hormone produced in the liver that regulates iron absorption and recycling in the body by binding to ferroportin and inducing its degradation, thereby reducing iron release from cells. Therefore, furin plays a role in the processing and activation of hepcidin, which in turn regulates iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme involved in the regulation of iron metabolism.\n2. Furin processes several proteins including the iron exporter ferroportin.\n3. Ferroportin is responsible for releasing iron from cells into the circulation.\n4. Hepcidin is a hormone produced in the liver that regulates iron absorption and recycling by binding to ferroportin and inducing its degradation.\n5. Furin plays a role in the processing and activation of hepcidin, which regulates iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme involved in the regulation of iron metabolism.",
      "Furin processes several proteins including the iron exporter ferroportin.",
      "Ferroportin is responsible for releasing iron from cells into the circulation.",
      "Hepcidin is a hormone produced in the liver that regulates iron absorption and recycling by binding to ferroportin and inducing its degradation.",
      "Furin plays a role in the processing and activation of hepcidin, which regulates iron homeostasis in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease enzyme involved in various cellular processes, including the activation of other proteins, but not directly in the regulation of iron metabolism.\n2. FALSE [correction]: Furin does process several precursor proteins to their mature forms, but ferroportin is not one of them.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Furin may be involved in the processing and activation of various proteins, however, there is no direct evidence that furin plays a role in the processing and activation of hepcidin itself. Hepcidin is regulated by different mechanisms in response to iron levels in the body.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis-gluconeogenesis (GNG) cluster, which includes genes involved in the breakdown and synthesis of glucose and other sugars. This cluster contains around 30 genes and is responsible for the majority of glucose metabolism in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis-gluconeogenesis (GNG) cluster.\n2. The GNG cluster includes genes involved in the breakdown and synthesis of glucose and other sugars.\n3. The GNG cluster in yeast contains around 30 genes.\n4. This cluster is responsible for the majority of glucose metabolism in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis-gluconeogenesis (GNG) cluster.",
      "The GNG cluster includes genes involved in the breakdown and synthesis of glucose and other sugars.",
      "The GNG cluster in yeast contains around 30 genes.",
      "This cluster is responsible for the majority of glucose metabolism in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The largest metabolic gene cluster in yeast is not the glycolysis-gluconeogenesis (GNG) cluster, it is typically the genes involved in ribosome biogenesis.\n2. TRUE\n3. FALSE [correction]: The exact number of genes in the glycolysis-gluconeogenesis (GNG) cluster may vary depending on the species of yeast, but generally, the cluster does not contain around 30 genes. The number of genes specifically involved in these pathways is smaller. For example, in Saccharomyces cerevisiae (brewer's yeast), there are approximately 10 genes directly involved in glycolysis.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Myeloid cells Involved in Transcriptional regulation) is a long non-coding RNA (lncRNA) that plays a crucial role in the regulation of gene expression in myeloid cells, particularly in the context of hematopoiesis and immune response. Here are some of the key roles of LIMT lncRNA:\n1. Regulation of gene expression: LIMT lncRNA can bind to DNA and regulate the expression of nearby genes, particularly those involved in myeloid cell differentiation and function.\n2. Modulation of inflammation: LIMT lncRNA has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, such as TNF-alpha and CCL2, in myeloid cells.\n3. Maintenance of immune homeostasis: LIMT lncRNA has been implicated in the regulation of immune cell populations and the maintenance of immune homeostasis, particularly in the context of cancer.\n4. Modulation of stem cell self-renewal: LIMT lncRNA has been shown to regulate the self-renewal of hematopoietic stem cells and the maintenance of their quiescence.\n5. Regulation of cellular differentiation: LIMT lncRNA has been implicated in the regulation of myeloid cell differentiation, particularly the differentiation of monocytes and macrophages.\nOverall, the role of LIMT lncRNA is to act as a regulatory molecule that fine-tunes the expression of genes involved in myeloid cell function and immune response, and dysregulation of LIMT lncRNA has been implicated in a variety of diseases, including cancer and autoimmune disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA is involved in the regulation of gene expression in myeloid cells.\n2. LIMT lncRNA can bind to DNA and regulate the expression of nearby genes.\n3. LIMT lncRNA inhibits the production of pro-inflammatory cytokines and chemokines such as TNF-alpha and CCL2 in myeloid cells.\n4. LIMT lncRNA is implicated in the maintenance of immune homeostasis, particularly in the context of cancer.\n5. LIMT lncRNA regulates the self-renewal of hematopoietic stem cells and the maintenance of their quiescence.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA is involved in the regulation of gene expression in myeloid cells.",
      "LIMT lncRNA can bind to DNA and regulate the expression of nearby genes.",
      "LIMT lncRNA inhibits the production of pro-inflammatory cytokines and chemokines such as TNF-alpha and CCL2 in myeloid cells.",
      "LIMT lncRNA is implicated in the maintenance of immune homeostasis, particularly in the context of cancer.",
      "LIMT lncRNA regulates the self-renewal of hematopoietic stem cells and the maintenance of their quiescence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - LIMT (LincRNA Identified in Myeloid cells during Tolerance) lncRNA has been implicated in the functional regulation of gene expression in myeloid cells.\n2. UNKNOWN - The specific interactions of LIMT lncRNA with DNA are not described here. Many long non-coding RNAs (lncRNAs) can regulate gene expression, but whether LIMT directly binds to DNA to regulate nearby genes requires specific evidence not provided in these statements.\n3. TRUE - LIMT lncRNA has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, such as TNF-alpha and CCL2, which are critical for the regulation of immune responses in myeloid cells.\n4. TRUE - LIMT lncRNA is implicated in immune homeostasis through its role in regulating gene expression and inflammatory responses, which could be relevant in the context of cancer and other diseases.\n5. UNKNOWN - There is no information provided here to indicate whether LIMT lncRNA is directly involved in the regulation of hematopoietic stem cell self-renewal and quiescence. This is a specific biological process that would require explicit evidence to confirm LIMT's role.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis. Some of the popular ones include:\n1. \"SNPset\": This package provides a comprehensive set of tools for SNP set analysis, including enrichment analysis, gene-set enrichment analysis, and pathway analysis.\n2. \"GSEA\": Gene Set Enrichment Analysis (GSEA) is a bioconductor package that performs gene-set enrichment analysis for a list of SNPs. It uses a weighted gene co-expression network to identify overrepresented gene sets.\n3. \"Plink\": Plink is a popular package for genome-wide association studies (GWAS) that can also be used for SNP enrichment analysis. It can perform both uncorrected and corrected enrichment analysis.\n4. \"Enrichr\": Enrichr is a bioconductor package that provides a comprehensive framework for SNP enrichment analysis. It can perform both gene-set and pathway-based enrichment analysis.\n5. \"MAS5\": MAS5 is a package for the analysis of genetic association studies. It can perform both uncorrected and corrected enrichment analysis for SNPs.\n6. \"SNPAnalyzeR\": SNPAnalyzeR is a package for the analysis of genome-wide association studies (GWAS) and next-generation sequencing data. It can perform both uncorrected and corrected enrichment analysis for SNPs.\n7. \"GCTA\": GCTA is a package for genome-wide association studies (GWAS) that can also be used for SNP enrichment analysis. It can perform both uncorrected and corrected enrichment analysis.\n8. \"HaploReg\": HaploReg is a package for the analysis of genetic association studies in the context of haplotypes. It can perform both uncorrected and corrected enrichment analysis for SNPs.\nIt's worth noting that these packages have different functionalities and methods for enrichment analysis, so it's important to choose the one that best fits your research question and data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"SNPset\" package is used for SNP set analysis, including enrichment analysis within the R/Bioconductor ecosystem.\n2. \"GSEA\" (Gene Set Enrichment Analysis) is a Bioconductor package used for gene-set enrichment analysis for a list of SNPs.\n3. The \"Plink\" package can be used for SNP enrichment analysis and is popular for genome-wide association studies (GWAS).\n4. \"Enrichr\" is a Bioconductor package that provides a framework for both gene-set and pathway-based SNP enrichment analysis.\n5. \"GCTA\" is a package that can be used for both genome-wide association studies and SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The \"SNPset\" package is used for SNP set analysis, including enrichment analysis within the R/Bioconductor ecosystem.",
      "\"GSEA\" (Gene Set Enrichment Analysis) is a Bioconductor package used for gene-set enrichment analysis for a list of SNPs.",
      "The \"Plink\" package can be used for SNP enrichment analysis and is popular for genome-wide association studies (GWAS).",
      "\"Enrichr\" is a Bioconductor package that provides a framework for both gene-set and pathway-based SNP enrichment analysis.",
      "\"GCTA\" is a package that can be used for both genome-wide association studies and SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: \"GSEA\" (Gene Set Enrichment Analysis) is commonly used for gene-set enrichment analysis for gene expression data, not specifically for a list of SNPs. It is not a Bioconductor package but rather a standalone software developed by the Broad Institute.\n3. TRUE, though to clarify, \"Plink\" is not actually a package but a standalone software tool mainly used for GWAS.\n4. FALSE [correction]: \"Enrichr\" is a web-based tool, not a Bioconductor package, and is primarily used for gene-set enrichment analysis, not specifically SNP enrichment analysis.\n5. TRUE, \"GCTA\" (Genome-wide Complex Trait Analysis) is a software tool used for GWAS and estimates the genetic variance, but it is not specifically designed for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are intermediate progenitors that differentiate into ependymal cells in the developing brain. The key players involved in radial glial specification to ependymal cells include:\n1. Notch signaling: Notch is a transcription factor that plays a crucial role in the specification of radial glial cells to ependymal cells. Notch signaling regulates the expression of genes involved in ependymal cell fate and promotes the proliferation and differentiation of radial glial cells.\n2. Wnt signaling: Wnt signaling also plays a crucial role in the specification of radial glial cells to ependymal cells. Wnt signaling regulates the expression of genes involved in ependymal cell fate and promotes the proliferation and differentiation of radial glial cells.\n3. Shh signaling: Shh signaling is involved in the regulation of radial glial cell fate and differentiation. Shh signaling promotes the proliferation and differentiation of radial glial cells and regulates the expression of genes involved in ependymal cell fate.\n4. BMP signaling: BMP signaling is also involved in the regulation of radial glial cell fate and differentiation. BMP signaling promotes the differentiation of radial glial cells into ependymal cells and regulates the expression of genes involved in ependymal cell fate.\n5. FGF signaling: FGF signaling is involved in the regulation of radial glial cell fate and differentiation. FGF signaling promotes the proliferation and differentiation of radial glial cells and regulates the expression of genes involved in ependymal cell fate.\n6. EGFR signaling: EGFR signaling is involved in the regulation of radial glial cell fate and differentiation. EGFR signaling promotes the proliferation and differentiation of radial glial cells and regulates the expression of genes involved in ependymal cell fate.\n7. PI3K/Akt signaling: PI3K/Akt signaling is involved in the regulation of radial glial cell fate and differentiation. PI3K/Akt signaling promotes the proliferation and differentiation of radial glial cells and regulates the",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glial cells differentiate into ependymal cells in the developing brain.\n2. Notch signaling plays a crucial role in the specification of radial glial cells to ependymal cells.\n3. Wnt signaling is involved in the regulation of radial glial cell fate and differentiation into ependymal cells.\n4. Shh (Sonic Hedgehog) signaling promotes the proliferation and differentiation of radial glial cells into ependymal cells.\n5. BMP (Bone Morphogenetic Protein) signaling promotes the differentiation of radial glial cells into ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glial cells differentiate into ependymal cells in the developing brain.",
      "Notch signaling plays a crucial role in the specification of radial glial cells to ependymal cells.",
      "Wnt signaling is involved in the regulation of radial glial cell fate and differentiation into ependymal cells.",
      "Shh (Sonic Hedgehog) signaling promotes the proliferation and differentiation of radial glial cells into ependymal cells.",
      "BMP (Bone Morphogenetic Protein) signaling promotes the differentiation of radial glial cells into ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nScientific understanding of cellular differentiation processes, especially in the developing brain, is quite complex and can involve many signaling pathways. While points 1, 2, 3, and 5 are generally supported by scientific research indicating that Notch, Wnt, and BMP signaling are involved in the differentiation of radial glial cells, the role of Shh signaling specifically in promoting the proliferation and differentiation of radial glial cells into ependymal cells is less clear without additional context. Therefore, statement 4 is marked as UNKNOWN because, while Shh signaling is crucial for various developmental processes in the brain, its specific role in the differentiation of radial glial cells into ependymal cells could vary and would require additional context or research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a brain tumor that originates from glial cells. These tumors are characterized by the lack of expression of certain markers, including:\n1. Tumor suppressor proteins: Triple negative gliomas do not express the tumor suppressor proteins TP53, PTEN, or CDKN2A.\n2. Receptors: These tumors do not express the epidermal growth factor receptor (EGFR), which is a common target for cancer therapy.\n3. Cyclin-dependent kinases (CDKs): Triple negative gliomas do not express CDK4 or CDK6, which are involved in cell cycle regulation.\n4. Hormone receptors: These tumors do not express estrogen receptors (ER) or progesterone receptors (PR), which are involved in hormone-mediated signaling.\n5. Methylation status: Triple negative gliomas are often characterized by a specific methylation profile, which can be used as a diagnostic marker.\n6. Genetic mutations: Triple negative gliomas often have genetic mutations in genes such as PIK3CA, AKT1, and MAP3K5, which can contribute to their aggressive behavior.\n7. Expression of pro-inflammatory cytokines: Triple negative gliomas often express high levels of pro-inflammatory cytokines, such as IL-6 and IL-8, which can promote the growth and progression of the tumor.\n8. Lack of EGFRvIII expression: Triple negative gliomas do not express the mutated form of the epidermal growth factor receptor (EGFRvIII), which is a common marker for glioblastoma.\n9. Poor prognosis: Triple negative gliomas have a poorer prognosis compared to other types of gliomas, likely due to their aggressive biology and lack of targeted therapies.\nIt's important to note that the exact characteristics of triple negative gliomas can vary depending on the specific tumor and the individual patient. A comprehensive diagnosis should be made by a trained medical professional based on a combination of clinical, imaging, and molecular studies",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by the lack of expression of tumor suppressor proteins TP53, PTEN, or CDKN2A.\n2. These tumors do not express the epidermal growth factor receptor (EGFR).\n3. Triple negative gliomas do not express CDK4 or CDK6, which are involved in cell cycle regulation.\n4. They lack expression of hormone receptors such as estrogen receptors (ER) and progesterone receptors (PR).\n5. Triple negative gliomas often have a specific methylation profile that can be used as a diagnostic marker.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas are characterized by the lack of expression of tumor suppressor proteins TP53, PTEN, or CDKN2A.",
      "These tumors do not express the epidermal growth factor receptor (EGFR).",
      "Triple negative gliomas do not express CDK4 or CDK6, which are involved in cell cycle regulation.",
      "They lack expression of hormone receptors such as estrogen receptors (ER) and progesterone receptors (PR).",
      "Triple negative gliomas often have a specific methylation profile that can be used as a diagnostic marker."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The term \"triple negative\" is usually used in the context of breast cancer, not gliomas, and refers to the lack of expression of ER, PR, and HER2/neu. The description provided doesn't match common terminology for gliomas or their characterization by the proteins mentioned.\n2. UNKNOWN: The statement cannot be verified as true or false without more context, as not all gliomas necessarily fit this profile. Some gliomas may express EGFR.\n3. TRUE: CDK4 and CDK6 are indeed involved in cell cycle regulation, and their amplification can occur in gliomas, but the absence of their expression in \"triple negative\" gliomas is not well-defined without clarification since \"triple negative\" isn't a standard term for gliomas.\n4. FALSE [correction]: The mention of hormone receptors (ER, PR) more accurately applies to breast cancer, not gliomas. Gliomas are typically not categorized by hormone receptor status.\n5. TRUE: Gliomas can have specific methylation profiles, which can be useful in diagnosis and classification. However, it is important to note that this is true for gliomas generally, not just a subset called \"triple negative,\" since this terminology is not standard for gliomas.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase II-associated protein AZ1) is a protein that is involved in the regulation of DNA metabolism and chromosome stability. It is a component of the topoisomerase II complex, which is responsible for relaxing DNA supercoils and resolving topological constraints in DNA. TOPAZ1 plays a critical role in the maintenance of genome stability by regulating the activity of topoisomerase II and preventing the formation of DNA double-strand breaks. It is also involved in the regulation of transcriptional elongation and RNA polymerase II processivity.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 stands for Topoisomerase II-associated protein AZ1.\n2. TOPAZ1 is involved in the regulation of DNA metabolism and chromosome stability.\n3. It is a component of the topoisomerase II complex.\n4. The topoisomerase II complex is responsible for relaxing DNA supercoils and resolving topological constraints in DNA.\n5. TOPAZ1 plays a role in preventing the formation of DNA double-strand breaks.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 stands for Topoisomerase II-associated protein AZ1.",
      "TOPAZ1 is involved in the regulation of DNA metabolism and chromosome stability.",
      "It is a component of the topoisomerase II complex.",
      "The topoisomerase II complex is responsible for relaxing DNA supercoils and resolving topological constraints in DNA.",
      "TOPAZ1 plays a role in preventing the formation of DNA double-strand breaks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TOPAZ1 stands for Testis and Ovary Specific PAZ Domain Containing 1.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The expression of GATA-1 isoforms is controlled by the GATA-1 gene. The GATA-1 gene encodes for multiple isoforms of the GATA-1 transcription factor, which are produced through alternative splicing. The splicing of the GATA-1 gene is regulated by various factors, including transcription factors and other regulatory proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The expression of GATA-1 isoforms is controlled by the GATA-1 gene.\n2. Multiple isoforms of the GATA-1 transcription factor are produced through alternative splicing.\n3. The splicing of the GATA-1 gene is regulated by various factors, including transcription factors and other regulatory proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The expression of GATA-1 isoforms is controlled by the GATA-1 gene.",
      "Multiple isoforms of the GATA-1 transcription factor are produced through alternative splicing.",
      "The splicing of the GATA-1 gene is regulated by various factors, including transcription factors and other regulatory proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a sequencing-based method used to identify and characterize the expression of microRNAs (miRNAs) in a given sample. miRNAs are small non-coding RNAs that play important roles in regulating gene expression by binding to messenger RNAs (mRNAs) and preventing their translation into proteins. MIRA-seq is a next-generation sequencing (NGS) technology that allows for the high-throughput analysis of miRNA expression in a variety of biological samples, including cells, tissues, and bodily fluids.\nThe MIRA-seq protocol typically involves the following steps:\n1. Sample preparation: The sample is first prepared by isolating the RNA from the cells or tissues of interest. This is typically done using standard RNA isolation techniques.\n2. Library preparation: The RNA is then converted into a sequencing library using a series of enzymatic reactions that generate complementary DNA (cDNA) molecules. These cDNA molecules are then amplified and sequenced using NGS technology.\n3. Data analysis: The resulting sequencing data is then analyzed using specialized software that can identify and quantify the expression of different miRNAs in the sample. This analysis can provide insights into the regulation of gene expression at the level of miRNA-mRNA interactions and can help identify potential biomarkers for a variety of diseases.\nOverall, MIRA-seq is a powerful tool for understanding the complex regulatory networks that control gene expression at the level of miRNAs and has the potential to reveal new insights into the molecular mechanisms underlying a wide range of biological processes and diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a sequencing-based method used to identify and characterize the expression of microRNAs (miRNAs).\n2. miRNAs are small non-coding RNAs that regulate gene expression by binding to messenger RNAs (mRNAs) and inhibiting their translation into proteins.\n3. MIRA-seq is a form of next-generation sequencing (NGS) technology.\n4. The MIRA-seq protocol includes isolating RNA from the sample, converting it into a sequencing library, and amplifying and sequencing the cDNA molecules.\n5. The data from MIRA-seq is analyzed with specialized software to identify and quantify the expression of different miRNAs.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a sequencing-based method used to identify and characterize the expression of microRNAs (miRNAs).",
      "miRNAs are small non-coding RNAs that regulate gene expression by binding to messenger RNAs (mRNAs) and inhibiting their translation into proteins.",
      "MIRA-seq is a form of next-generation sequencing (NGS) technology.",
      "The MIRA-seq protocol includes isolating RNA from the sample, converting it into a sequencing library, and amplifying and sequencing the cDNA molecules.",
      "The data from MIRA-seq is analyzed with specialized software to identify and quantify the expression of different miRNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq is not usually associated with microRNA (miRNA) sequencing. It typically stands for \"Methylation-based Inference of Regulatory Activity Sequencing\" which is used to infer gene regulatory activities based on methylation status. MiRNA sequencing does involve specific methods but they are often just referred to as miRNA-seq.\n2. TRUE\n3. TRUE - Assuming MIRA-seq refers to a general sequencing method, it would utilize next-generation sequencing (NGS) technologies.\n4. UNKNOWN - Without a specific protocol, it's not possible to confirm the exact steps for MIRA-seq as the term doesn't typically refer to microRNA sequencing; it is more commonly associated with assays for gene regulation based on methylation and the specifics would differ depending on the target and method of sequencing.\n5. UNKNOWN - While the statement could be true for a general sequencing method analyzing miRNAs, the specificity of MIRA-seq to miRNA expression and the exact software used would depend on the specific sequencing protocol employed. If MIRA-seq is referred to in another context, such as gene regulatory activity based on methylation, different specialized software would be used.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication used to treat Cryopyrin-associated periodic syndromes (CAPS), which are a group of rare genetic disorders that cause recurring episodes of fever, pain, and inflammation. Specifically, ARCALYST is indicated for the treatment of cryopyrin-associated periodic syndrome (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells syndrome (MWS).",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is a prescription medication.\n2. ARCALYST is used to treat Cryopyrin-associated periodic syndromes (CAPS).\n3. CAPS is a group of rare genetic disorders.\n4. CAPS disorders cause recurring episodes of fever, pain, and inflammation.\n5. ARCALYST is indicated for the treatment of Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells syndrome (MWS).",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is a prescription medication.",
      "ARCALYST is used to treat Cryopyrin-associated periodic syndromes (CAPS).",
      "CAPS is a group of rare genetic disorders.",
      "CAPS disorders cause recurring episodes of fever, pain, and inflammation.",
      "ARCALYST is indicated for the treatment of Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells syndrome (MWS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations involve the exchange of a portion of one acrocentric chromosome (chromosomes 1, 3, 4, 5, 7, 9, 10, and 11) for a non-acrocentric chromosome (chromosomes 6, 13, 14, 15, 17, 21, and 22). Therefore, the human acrocentric chromosomes involved in Robertsonian translocations are:\n1. Chromosome 1\n2. Chromosome 3\n3. Chromosome 4\n4. Chromosome 5\n5. Chromosome 7\n6. Chromosome 9\n7. Chromosome 10\n8. Chromosome 11\nNote that these are the only acrocentric chromosomes found in the human genome, and they are characterized by their distinctive banding patterns and gene content.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 1 is considered an acrocentric chromosome involved in Robertsonian translocations.\n2. Chromosome 3 is considered an acrocentric chromosome involved in Robertsonian translocations.\n3. Chromosome 4 is considered an acrocentric chromosome involved in Robertsonian translocations.\n4. Chromosome 5 is considered an acrocentric chromosome involved in Robertsonian translocations.\n5. Chromosome 7 is considered an acrocentric chromosome involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 1 is considered an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 3 is considered an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 4 is considered an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 5 is considered an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 7 is considered an acrocentric chromosome involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromosome 1 is not considered an acrocentric chromosome. Acrocentric chromosomes in humans include chromosomes 13, 14, 15, 21, and 22, which are involved in Robertsonian translocations.\n2. FALSE [correction]: Chromosome 3 is not considered an acrocentric chromosome.\n3. FALSE [correction]: Chromosome 4 is not considered an acrocentric chromosome.\n4. FALSE [correction]: Chromosome 5 is not considered an acrocentric chromosome.\n5. FALSE [correction]: Chromosome 7 is not considered an acrocentric chromosome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific analysis you want to perform. Here are a few options:\n1. `pediatricBrainTumor`: This package provides a comprehensive set of tools for the analysis of pediatric brain tumors, including data preprocessing, feature selection, and classification. It includes a variety of algorithms for tumor segmentation, including k-means clustering, hierarchical clustering, and density-based clustering.\n2. `brainTumor`: This package provides a range of functions for analyzing brain tumor data, including data preprocessing, feature selection, and survival analysis. It includes tools for identifying gene expression patterns in brain tumors and for predicting patient survival outcomes.\n3. `rbrainTumor`: This package provides a set of functions for analyzing brain tumor data, including data preprocessing, feature selection, and survival analysis. It includes tools for identifying gene expression patterns in brain tumors and for predicting patient survival outcomes.\n4. `pediatricTumor`: This package provides a set of functions for analyzing pediatric tumor data, including data preprocessing, feature selection, and classification. It includes tools for identifying gene expression patterns in pediatric tumors and for predicting patient outcomes.\n5. `TumorClassifier`: This package provides a set of functions for classifying tumor samples into different categories based on their gene expression profiles. It includes tools for identifying gene expression patterns in tumor samples and for predicting patient outcomes.\nIt's important to note that these packages are just a few examples of the many R packages available for analyzing brain tumor data, and you may find other packages that are more suitable for your specific research question. It's always a good idea to explore different packages and evaluate their functionality before selecting the one that best fits your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. The `pediatricBrainTumor` R package includes algorithms for tumor segmentation such as k-means clustering, hierarchical clustering, and density-based clustering.\n2. The `brainTumor` R package provides functions for analyzing brain tumor data and predicting patient survival outcomes.\n3. The `rbrainTumor` R package includes tools for identifying gene expression patterns in brain tumors.\n4. The `pediatricTumor` R package includes tools for predicting patient outcomes based on the analysis of pediatric tumor data.\n5. The `TumorClassifier` R package is designed for classifying tumor samples based on gene expression profiles.",
    "llama-2-7b-chat-hf_fact": [
      "The `pediatricBrainTumor` R package includes algorithms for tumor segmentation such as k-means clustering, hierarchical clustering, and density-based clustering.",
      "The `brainTumor` R package provides functions for analyzing brain tumor data and predicting patient survival outcomes.",
      "The `rbrainTumor` R package includes tools for identifying gene expression patterns in brain tumors.",
      "The `pediatricTumor` R package includes tools for predicting patient outcomes based on the analysis of pediatric tumor data.",
      "The `TumorClassifier` R package is designed for classifying tumor samples based on gene expression profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information on the contents of the `pediatricBrainTumor` R package, it is not possible to determine the accuracy of the statement.\n2. UNKNOWN: Similarly, without specific information on the contents of the `brainTumor` R package, the truthfulness of the statement regarding functions for analyzing brain tumor data and predicting patient survival outcomes cannot be determined.\n3. UNKNOWN: The existence and features of an `rbrainTumor` R package are not confirmed without additional context.\n4. UNKNOWN: The features and functionalities of a `pediatricTumor` R package cannot be assessed without more information.\n5. UNKNOWN: The capabilities of the `TumorClassifier` R package in classifying tumor samples cannot be established without further context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Yes, NEMO (Nuclear Envelope-Associated protein) is a zinc finger protein. It contains multiple zinc finger domains, which are responsible for its DNA-binding activity and play a crucial role in its function in the immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO stands for Nuclear Envelope-Associated protein.\n2. NEMO is a zinc finger protein.\n3. The zinc finger domains of NEMO are responsible for its DNA-binding activity.\n4. NEMO plays a role in the immune response.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO stands for Nuclear Envelope-Associated protein.",
      "NEMO is a zinc finger protein.",
      "The zinc finger domains of NEMO are responsible for its DNA-binding activity.",
      "NEMO plays a role in the immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO stands for NF-kappaB Essential MOdulator.\n2. UNKNOWN\n3. FALSE [correction]: NEMO does not have zinc finger domains; it is not a DNA-binding protein but plays a role in the NF-kappaB signaling pathway.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a transcriptional elongation factor that plays a role in the initiation of transcription in eukaryotic cells. It has been shown to interact with nucleosomes and influence their positioning on the DNA, particularly during transcriptional elongation. TFIIS can either displace or stabilize nucleosomes, depending on the context, and its activity can affect the rate of transcriptional elongation.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS is a transcriptional elongation factor that has a role in the initiation of transcription in eukaryotic cells.\n2. TFIIS has been shown to interact with nucleosomes.\n3. TFIIS can influence nucleosome positioning on DNA.\n4. The activity of TFIIS can affect the rate of transcriptional elongation.\n5. TFIIS's interaction with nucleosomes can result in their displacement or stabilization.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS is a transcriptional elongation factor that has a role in the initiation of transcription in eukaryotic cells.",
      "TFIIS has been shown to interact with nucleosomes.",
      "TFIIS can influence nucleosome positioning on DNA.",
      "The activity of TFIIS can affect the rate of transcriptional elongation.",
      "TFIIS's interaction with nucleosomes can result in their displacement or stabilization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFIIS is a transcriptional elongation factor that has a role in the elongation phase of transcription in eukaryotic cells, not in initiation.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Origins of replication near yeast centromeres typically fire later than those further away from the centromere. This is because the centromere region has a specialized chromatin structure and epigenetic marks that inhibit the initiation of DNA replication until late in the cell cycle. This delay in replication initiation helps to ensure proper chromosome segregation during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication near yeast centromeres typically fire later than those further away from the centromere.\n2. The centromere region has a specialized chromatin structure.\n3. Epigenetic marks inhibit the initiation of DNA replication near yeast centromeres.\n4. DNA replication near yeast centromeres is delayed until late in the cell cycle.\n5. The delay in replication initiation near yeast centromeres helps to ensure proper chromosome segregation during cell division.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication near yeast centromeres typically fire later than those further away from the centromere.",
      "The centromere region has a specialized chromatin structure.",
      "Epigenetic marks inhibit the initiation of DNA replication near yeast centromeres.",
      "DNA replication near yeast centromeres is delayed until late in the cell cycle.",
      "The delay in replication initiation near yeast centromeres helps to ensure proper chromosome segregation during cell division."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Epigenetic marks are not known to inhibit the initiation of DNA replication near yeast centromeres directly; it is the specialized chromatin structure that is associated with the regulation of replication timing.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as GAGAs (glycosylated arginine glycine-rich sequences), are short sequences found in the protein coding regions of mammalian genes. These sequences are known to play a role in the regulation of mRNA stability and translation. Some of the properties of mammalian GA-sequences include:\n1. Glycosylation: Mammalian GA-sequences are glycosylated, meaning they are modified with carbohydrate molecules. This modification can affect the stability and function of the sequence.\n2. Arginine-glycine richness: GA-sequences are characterized by a high content of arginine and glycine residues. This sequence composition is thought to be important for their function in regulating mRNA stability.\n3. Stability: GA-sequences have been shown to be stable in the cell, with a half-life that is longer than that of the surrounding protein-coding sequence.\n4. Splicing regulation: GA-sequences can affect the splicing of adjacent exons, leading to changes in the final mRNA product.\n5. Translation regulation: GA-sequences can also affect translation initiation and elongation, leading to changes in protein expression.\n6. Cell type-specific expression: GA-sequences are differentially expressed in different cell types, with some sequences being more highly expressed in certain tissues or cell types.\n7. Developmental regulation: GA-sequences have been shown to be developmentally regulated, with some sequences being more highly expressed during specific stages of development.\n8. Disease association: GA-sequences have been implicated in a number of diseases, including cancer and neurodegenerative disorders.\n9. Regulation of microRNA binding: GA-sequences can interact with microRNAs (miRNAs), leading to changes in miRNA binding and function.\n10. Regulation of chromatin structure: GA-sequences can also affect chromatin structure, leading to changes in gene expression.\nIt is worth noting that the properties of GA-sequences can vary depending on the specific sequence and the cellular context in which they are found. Further",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are glycosylated, which means they have carbohydrate molecules attached to them.\n2. GA-sequences are rich in arginine and glycine residues.\n3. In mammalian cells, GA-sequences have a longer half-life compared to the surrounding protein-coding sequence.\n4. Mammalian GA-sequences can influence the splicing of adjacent exons.\n5. GA-sequences can affect the initiation and elongation processes of translation in mammalian cells.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are glycosylated, which means they have carbohydrate molecules attached to them.",
      "GA-sequences are rich in arginine and glycine residues.",
      "In mammalian cells, GA-sequences have a longer half-life compared to the surrounding protein-coding sequence.",
      "Mammalian GA-sequences can influence the splicing of adjacent exons.",
      "GA-sequences can affect the initiation and elongation processes of translation in mammalian cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (The term \"GA-sequences\" is vague without additional context or definition. It could refer to a specific type of sequence within mammalian genes that could be glycosylated, or it could be an incorrect description altogether.)\n2. UNKNOWN (Without context, GA-sequences could refer to something specific in the literature that I'm not aware of, and so whether these sequences are rich in arginine and glycine residues is not something that can be determined from the statement provided.)\n3. UNKNOWN (The stability or half-life of GA-sequences within mammalian cells can't be assessed without specific information or research evidence.)\n4. UNKNOWN (Whether mammalian GA-sequences influence splicing would require specific scientific evidence.)\n5. UNKNOWN (The impact of GA-sequences on translation initiation and elongation is not determinable without further context or research data.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "The mouse genome contains 10 Groucho-related genes (GRGs), also known as Groucho-like genes (GLGs). These genes are:\n1. Groucho (Gr)\n2. Grhl1 (Groucho-like 1)\n3. Grhl2 (Groucho-like 2)\n4. Grhl3 (Groucho-like 3)\n5. Grhl4 (Groucho-like 4)\n6. Grhl5 (Groucho-like 5)\n7. Grhl6 (Groucho-like 6)\n8. Grhl7 (Groucho-like 7)\n9. Grhl8 (Groucho-like 8)\n10. Grhl9 (Groucho-like 9)\nNote: The number of GRGs may vary slightly depending on the source and method of gene annotation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains 10 Groucho-related genes (GRGs).\n2. These genes are also referred to as Groucho-like genes (GLGs).\n3. The GRGs include genes ranging from Groucho (Gr) to Grhl9 (Groucho-like 9).\n4. The list of GRGs provided includes Grhl1 through Grhl9.\n5. The number of GRGs in the mouse genome may differ based on the source and method of gene annotation.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains 10 Groucho-related genes (GRGs).",
      "These genes are also referred to as Groucho-like genes (GLGs).",
      "The GRGs include genes ranging from Groucho (Gr) to Grhl9 (Groucho-like 9).",
      "The list of GRGs provided includes Grhl1 through Grhl9.",
      "The number of GRGs in the mouse genome may differ based on the source and method of gene annotation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nWithout specific knowledge or the ability to verify the exact number of Groucho-related genes (GRGs) or Groucho-like genes (GLGs) in the mouse genome, and lacking context for statement 3 and 4, it's not possible to confirm the accuracy of statements 1-4. Statement 5 is generally true for any genome as the number of recognized genes can vary with different sources and methods of annotation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is composed of several subunits, and only one of them carries RNA cleavage activity. The RNA cleavage activity is carried by the RNAPII subunit called RPB1 (RNA polymerase II subunit B1). RPB1 is responsible for cleaving the RNA transcript after transcriptional termination, resulting in the formation of mature RNA molecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II is composed of several subunits.\n2. Only one subunit of RNA polymerase II has RNA cleavage activity.\n3. The RNA polymerase II subunit that carries RNA cleavage activity is called RPB1.\n4. RPB1 is responsible for cleaving the RNA transcript after transcriptional termination.\n5. The cleavage of the RNA transcript by RPB1 leads to the formation of mature RNA molecules.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II is composed of several subunits.",
      "Only one subunit of RNA polymerase II has RNA cleavage activity.",
      "The RNA polymerase II subunit that carries RNA cleavage activity is called RPB1.",
      "RPB1 is responsible for cleaving the RNA transcript after transcriptional termination.",
      "The cleavage of the RNA transcript by RPB1 leads to the formation of mature RNA molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: None of the subunits of RNA polymerase II have RNA cleavage activity. The cleavage and polyadenylation of RNA transcripts are typically carried out by separate enzymatic complexes, not by RNA polymerase II itself.\n3. FALSE [correction]: RPB1, the largest subunit of RNA polymerase II, does not have an RNA cleavage activity. It is primarily involved in the polymerization of RNA.\n4. FALSE [correction]: RPB1 does not cleave the RNA transcript after transcriptional termination. The cleavage and addition of a poly(A) tail to the 3' end of the pre-mRNA transcript are carried out by the cleavage and polyadenylation specificity factor (CPSF) and other associated factors.\n5. FALSE [correction]: The cleavage of the RNA transcript is not performed by RPB1. Instead, it is processed by other proteins and enzymes that specialize in RNA cleavage and subsequent steps to form mature RNA molecules.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the RPS6KA3 gene. The RPS6KA3 gene provides instructions for making a protein called ribosomal protein S6 kinase alpha 3 (RPS6KA3), which is involved in the regulation of protein synthesis and cell growth. Mutations in the RPS6KA3 gene can lead to the development of Ohdo syndrome, which is characterized by a range of symptoms including intellectual disability, growth delays, and various physical abnormalities.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder.\n2. Mutations in the RPS6KA3 gene are the cause of Ohdo syndrome.\n3. The RPS6KA3 gene is responsible for making a protein called ribosomal protein S6 kinase alpha 3.\n4. The RPS6KA3 protein is involved in the regulation of protein synthesis and cell growth.\n5. Symptoms of Ohdo syndrome include intellectual disability, growth delays, and various physical abnormalities.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder.",
      "Mutations in the RPS6KA3 gene are the cause of Ohdo syndrome.",
      "The RPS6KA3 gene is responsible for making a protein called ribosomal protein S6 kinase alpha 3.",
      "The RPS6KA3 protein is involved in the regulation of protein synthesis and cell growth.",
      "Symptoms of Ohdo syndrome include intellectual disability, growth delays, and various physical abnormalities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the SALL1 or KAT6B genes are more commonly associated with Ohdo syndrome, though there are different types of Ohdo syndrome with different genetic causes.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "The R/Bioconductor package \"psychgene\" has been developed for the analysis of psychiatric disease genes. This package provides a set of tools and functions for the analysis of genetic data in the context of psychiatric disorders, including gene-level association testing, pathway analysis, and gene-environment interaction analysis. It also includes a collection of pre-processed gene expression data from psychiatric studies, which can be used for downstream analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package named \"psychgene\" is designed for the analysis of psychiatric disease genes.\n2. \"Psychgene\" includes tools and functions for gene-level association testing.\n3. \"Psychgene\" includes tools and functions for pathway analysis.\n4. \"Psychgene\" offers tools and functions for gene-environment interaction analysis.\n5. \"Psychgene\" contains a collection of pre-processed gene expression data from psychiatric studies.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package named \"psychgene\" is designed for the analysis of psychiatric disease genes.",
      "\"Psychgene\" includes tools and functions for gene-level association testing.",
      "\"Psychgene\" includes tools and functions for pathway analysis.",
      "\"Psychgene\" offers tools and functions for gene-environment interaction analysis.",
      "\"Psychgene\" contains a collection of pre-processed gene expression data from psychiatric studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements pertain to the functionality of a bioinformatics software package, \"psychgene,\" in the R/Bioconductor ecosystem. Without specific documentation for the \"psychgene\" package, it is not possible to accurately verify these claims. Package functionalities in bioinformatics can be quite varied and specific, and without access to the actual documentation or knowledge of this package, I cannot confirm or deny these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "The \"swirl sign\" is a radiological sign that can be observed on CT or MRI scans of the brain after an intracerebral hemorrhage (ICH). It is characterized by a spiral or swirling pattern of blood flow within the hematoma, which is the area of bleeding in the brain.\nThe swirl sign is caused by the movement of blood within the hematoma, which can occur due to various factors such as the flow of blood through the blood vessels in the hematoma, or the movement of the hematoma itself due to the forces of gravity or the movement of the brain. The sign is more commonly observed on CT scans, but can also be seen on MRI scans.\nThe swirl sign can be an important diagnostic indicator of the severity of the ICH, as it can indicate the location and extent of the bleeding. It can also help doctors to determine the appropriate treatment strategy, such as the type of surgery or the use of medications to control the bleeding.\nIn general, the swirl sign is more commonly observed in ICHs that are located in the deeper regions of the brain, such as the basal ganglia or the cerebellum. It is less commonly seen in ICHs that are located in the superficial regions of the brain, such as the frontal or temporal lobes.\nOverall, the swirl sign is a useful radiological sign that can help doctors to diagnose and manage ICHs more effectively.",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign can be observed on CT or MRI scans of the brain after an intracerebral hemorrhage.\n2. It is characterized by a spiral or swirling pattern of blood flow within the hematoma.\n3. The swirl sign is caused by the movement of blood within the hematoma, which may be influenced by gravity or brain movement.\n4. The swirl sign is an indicator of the severity of the intracerebral hemorrhage, helping to identify the location and extent of the bleeding.\n5. The swirl sign is more commonly observed in hemorrhages in the deeper regions of the brain, such as the basal ganglia or cerebellum.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign can be observed on CT or MRI scans of the brain after an intracerebral hemorrhage.",
      "It is characterized by a spiral or swirling pattern of blood flow within the hematoma.",
      "The swirl sign is caused by the movement of blood within the hematoma, which may be influenced by gravity or brain movement.",
      "The swirl sign is an indicator of the severity of the intracerebral hemorrhage, helping to identify the location and extent of the bleeding.",
      "The swirl sign is more commonly observed in hemorrhages in the deeper regions of the brain, such as the basal ganglia or cerebellum."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is characterized by a heterogeneous appearance within a hematoma with areas of mixed density, indicating ongoing bleeding or the presence of different ages of blood products, not necessarily by a spiral or swirling pattern of blood flow.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase III subunit 1) expression is induced by a variety of factors, including:\n1. Abiotic stressors: ROF1 is induced in response to abiotic stressors such as drought, heat, cold, and oxidative stress.\n2. Hormones: ROF1 expression is regulated by plant hormones, including ethylene, auxin, and cytokinin.\n3. Light: ROF1 expression is light-dependent and is induced by exposure to blue light.\n4. Developmental cues: ROF1 is also expressed in response to developmental cues, such as the onset of flowering and the formation of floral organs.\n5. Defense against pathogens: ROF1 is involved in the defense against bacterial and fungal pathogens, and its expression is induced in response to infection.\n6. Interaction with other genes: ROF1 expression can be induced by the interaction with other genes, such as the transcription factor WRKY70, which is involved in the regulation of defense-related genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by abiotic stressors like drought, heat, cold, and oxidative stress.\n2. Plant hormones such as ethylene, auxin, and cytokinin regulate Arabidopsis ROF1 expression.\n3. Arabidopsis ROF1 expression is light-dependent and is induced by exposure to blue light.\n4. The onset of flowering and formation of floral organs are developmental cues that induce Arabidopsis ROF1 expression.\n5. Arabidopsis ROF1 plays a role in defense against bacterial and fungal pathogens, and its expression increases in response to infection.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by abiotic stressors like drought, heat, cold, and oxidative stress.",
      "Plant hormones such as ethylene, auxin, and cytokinin regulate Arabidopsis ROF1 expression.",
      "Arabidopsis ROF1 expression is light-dependent and is induced by exposure to blue light.",
      "The onset of flowering and formation of floral organs are developmental cues that induce Arabidopsis ROF1 expression.",
      "Arabidopsis ROF1 plays a role in defense against bacterial and fungal pathogens, and its expression increases in response to infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Arabidopsis ROF1 (AtFKBP62) has been reported to be induced by various abiotic stressors including heat, which is consistent with it being triggered by stresses like drought, heat, cold, and oxidative stress.\n  \n2. UNKNOWN: The regulation of Arabidopsis ROF1 (AtFKBP62) by specific hormones such as ethylene, auxin, and cytokinin is not universally documented in the provided context, and without specific literature references, it is challenging to confirm or deny this statement. The regulation of genes in Arabidopsis can be complex and highly context-dependent.\n\n3. UNKNOWN: Without explicit evidence or reference to specific studies regarding light-dependent expression of Arabidopsis ROF1 and its induction by blue light, this statement's accuracy cannot be verified.\n\n4. UNKNOWN: The statement that the onset of flowering and formation of floral organs induce Arabidopsis ROF1 expression is specific and would require a direct citation from relevant research for confirmation.\n\n5. TRUE: Arabidopsis ROF1 is known to play a role in plant immunity and has been shown to be upregulated in response to pathogen infection, so it can be involved in defense against bacterial and fungal pathogens.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed. The hippocampus is a complex brain structure involved in various cognitive processes, including memory formation, spatial navigation, and emotion regulation. Studies have used various proteomics techniques, such as two-dimensional gel electrophoresis (2DGE), mass spectrometry (MS), and label-free quantification, to identify and quantify proteins in the hippocampus of mice.\nSome of the key findings from these studies include:\n1. Identification of proteins involved in synaptic plasticity and neurotransmission, such as N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and synaptotagmin.\n2. Detection of proteins involved in the regulation of gene expression, such as transcription factors, histone modifications, and splicing factors.\n3. Analysis of proteins involved in oxidative stress and inflammation, such as glutathione peroxidase, catalase, and nuclear factor kappa B (NF-B).\n4. Identification of proteins involved in the regulation of the cytoskeleton and cell adhesion, such as actin, tubulin, and cadherins.\n5. Detection of proteins involved in the regulation of cell cycle and proliferation, such as cyclin-dependent kinases (CDKs) and cyclins.\n6. Analysis of proteins involved in the regulation of apoptosis and autophagy, such as Bcl-2 family proteins and LC3.\n7. Identification of proteins involved in the regulation of energy metabolism, such as ATP synthase and glycolytic enzymes.\n8. Detection of proteins involved in the regulation of the immune response, such as major histocompatibility complex (MHC) proteins and T cell receptors.\n9. Analysis of proteins involved in the regulation of the circadian rhythm, such as PER1, PER2, and BMAL1.\n10. Identification of proteins involved in the regulation of neurodegenerative diseases, such as amyloid-",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using proteomics techniques such as two-dimensional gel electrophoresis, mass spectrometry, and label-free quantification.\n2. Proteins involved in synaptic plasticity and neurotransmission like NMDA and AMPA receptors have been identified in the mouse hippocampus.\n3. Studies have detected proteins in the mouse hippocampus that are involved in the regulation of gene expression, including transcription factors.\n4. Proteins related to oxidative stress and inflammation such as glutathione peroxidase and catalase have been analyzed in the mouse hippocampus proteome.\n5. Proteomics studies have identified proteins in the mouse hippocampus involved in the regulation of energy metabolism, including ATP synthase.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed using proteomics techniques such as two-dimensional gel electrophoresis, mass spectrometry, and label-free quantification.",
      "Proteins involved in synaptic plasticity and neurotransmission like NMDA and AMPA receptors have been identified in the mouse hippocampus.",
      "Studies have detected proteins in the mouse hippocampus that are involved in the regulation of gene expression, including transcription factors.",
      "Proteins related to oxidative stress and inflammation such as glutathione peroxidase and catalase have been analyzed in the mouse hippocampus proteome.",
      "Proteomics studies have identified proteins in the mouse hippocampus involved in the regulation of energy metabolism, including ATP synthase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll of these statements are consistent with our current understanding of proteomics studies in neuroscience, especially within the context of the mouse hippocampus. It is well known that the techniques mentioned in statement 1 are used for proteome analysis, and the proteins involved in synaptic plasticity, neurotransmission, gene expression regulation, response to oxidative stress and inflammation, and energy metabolism are indeed relevant to hippocampal function and have been studied within this context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are characterized by a prominent centromere and a short arm that is much shorter than the long arm. Mouse chromosomes are metacentric, meaning that the centromere is located near the center of the chromosome and the arms are roughly equal in length.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have a prominent centromere with a short arm that is much shorter than the long arm.\n3. Mouse chromosomes are metacentric.\n4. Metacentric chromosomes have a centromere located near the center, with arms that are roughly equal in length.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have a prominent centromere with a short arm that is much shorter than the long arm.",
      "Mouse chromosomes are metacentric.",
      "Metacentric chromosomes have a centromere located near the center, with arms that are roughly equal in length."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are predominantly acrocentric.\n2. TRUE\n3. FALSE [correction]: Mouse chromosomes are not metacentric; they are acrocentric.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs in clinical trials for the treatment of pancreatic cancer. Some of the most notable ones include:\n1. ONC205: ONC205 is an siRNA-based drug that targets a specific protein called p53, which is mutated in many pancreatic cancers. ONC205 is being developed by OncoGenex Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n2. RX-0201: RX-0201 is an siRNA-based drug that targets a protein called KRAS, which is commonly mutated in pancreatic cancer. RX-0201 is being developed by Rexahn Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n3. BSI-201: BSI-201 is an siRNA-based drug that targets a protein called Bcl-2, which is overexpressed in many pancreatic cancers. BSI-201 is being developed by BioSpectra Inc. and is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\n4. GlycoMimetics' GMI-1271: GMI-1271 is an siRNA-based drug that targets a protein called PD-L1, which is overexpressed in many pancreatic cancers. GMI-1271 is being developed by GlycoMimetics and is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\nIt's important to note that these drugs are still in the early stages of clinical development, and more research is needed to determine their safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. ONC205 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.\n2. RX-0201 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.\n3. BSI-201 is an siRNA-based drug in Phase 1 clinical trials for the treatment of pancreatic cancer.\n4. GMI-1271 is an siRNA-based drug in Phase 1 clinical trials for the treatment of pancreatic cancer.\n5. ONC205 targets the protein p53, which is mutated in many pancreatic cancers.",
    "llama-2-7b-chat-hf_fact": [
      "ONC205 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.",
      "RX-0201 is an siRNA-based drug in Phase 2 clinical trials for the treatment of pancreatic cancer.",
      "BSI-201 is an siRNA-based drug in Phase 1 clinical trials for the treatment of pancreatic cancer.",
      "GMI-1271 is an siRNA-based drug in Phase 1 clinical trials for the treatment of pancreatic cancer.",
      "ONC205 targets the protein p53, which is mutated in many pancreatic cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: BSI-201 (also known as iniparib) is not an siRNA-based drug; it was a small molecule drug originally thought to be a PARP inhibitor that has been investigated in clinical trials for the treatment of various cancers including pancreatic cancer, but it advanced to Phase 3 trials before being discontinued in this indication due to lack of evidence of efficacy.\n4. FALSE [correction]: GMI-1271 is not an siRNA-based drug; it is a small molecule E-selectin antagonist that has been investigated in clinical trials, but its focus has been on conditions such as acute myeloid leukemia, not specifically pancreatic cancer.\n5. FALSE [correction]: The statement specifies that ONC205 targets p53, which would be unusual for siRNA therapy as these typically target RNA to knockdown gene expression. Additionally, without specifying the mechanism of ONC205 or factual evidence of its specific targeting, and given that p53 is a tumor suppressor protein and is often deleted or mutated in cancers rather than overexpressed, it is unlikely that siRNA would be used to target a mutated form of p53. More generally, ONC201, not ONC205, is known to indirectly affect the p53 pathway.\n\nSince the therapeutic landscape for drugs is continually evolving and specific details about trials and mechanisms can be intricate and subject to confidentiality, verifying statements about drugs in development and their clinical trial status requires access to the most recent and detailed information from clinical trial registries, company press releases, scientific publications, or regulatory agencies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (H+/Ca2+-activated K+ channel pore-forming subunit) is a type of ion channel that is activated by changes in intracellular calcium levels. HPG channels are primarily found in the plasma membrane of certain cells, including neurons and muscle cells, and play a role in regulating the flow of potassium ions (K+) across the cell membrane in response to changes in intracellular calcium levels.\nWhen intracellular calcium levels increase, the HPG channel pore opens, allowing potassium ions to flow out of the cell, leading to a depolarization of the cell membrane and an increase in the excitability of the cell. This can play a role in various physiological processes, including muscle contraction, neurotransmission, and secretion.\nConversely, when intracellular calcium levels decrease, the HPG channel pore closes, and potassium ion flow is reduced, leading to a hyperpolarization of the cell membrane and a decrease in the excitability of the cell.\nOverall, the HPG channel is an important regulator of cellular excitability and plays a key role in the regulation of various physiological processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG stands for H+/Ca2+-activated K+ channel pore-forming subunit.\n2. HPG channels are triggered by changes in intracellular calcium levels.\n3. HPG channels are primarily located in the plasma membrane of neurons and muscle cells.\n4. The opening of HPG channels allows potassium ions to flow out of the cell when intracellular calcium levels increase.\n5. HPG channels are an important regulator of cellular excitability and are involved in physiological processes such as muscle contraction, neurotransmission, and secretion.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG stands for H+/Ca2+-activated K+ channel pore-forming subunit.",
      "HPG channels are triggered by changes in intracellular calcium levels.",
      "HPG channels are primarily located in the plasma membrane of neurons and muscle cells.",
      "The opening of HPG channels allows potassium ions to flow out of the cell when intracellular calcium levels increase.",
      "HPG channels are an important regulator of cellular excitability and are involved in physiological processes such as muscle contraction, neurotransmission, and secretion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HPG does not stand for H+/Ca2+-activated K+ channel pore-forming subunit. HPG is not a standard abbreviation for this channel. The proper term for a channel that is activated by calcium levels is \"BK channel\" or \"Maxi-K channel,\" whose scientific nomenclature is KCa1.1.\n2. FALSE [correction]: Without proper context or a known expansion for \"HPG,\" it's unknown whether it refers to channels triggered by intracellular calcium levels. BK channels (KCa1.1), which are calcium-activated potassium channels, are indeed triggered by changes in intracellular calcium levels.\n3. UNKNOWN: Without clarification on what \"HPG\" refers to, the information about where these channels are located is unclear.\n4. UNKNOWN: Since the definition of \"HPG\" is unknown, we cannot determine the function of these channels or what happens when they open.\n5. UNKNOWN: Without the correct identification of \"HPG,\" we cannot confirm that it regulates cellular excitability or is involved in the mentioned physiological processes. However, the described functions align with the role of BK channels (KCa1.1) in the body.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes (959N) initiative is a large-scale effort to sequence the genomes of all known species of nematode worms, which are a group of microscopic worms that are ubiquitous in soil, plants, and animals. The initiative was launched in 2016 and is led by the University of California, Berkeley, in collaboration with several other institutions and organizations.\nNematodes are important model organisms in biology and medicine, and their genomes are expected to provide valuable insights into the evolution of multicellularity, the regulation of development and behavior, and the interactions between organisms and their environments. The 959N initiative aims to sequence the genomes of over 950 species of nematodes, including both free-living and parasitic species, and to make the resulting data freely available to the scientific community.\nThe 959N initiative is using a variety of sequencing technologies, including Illumina and PacBio, to generate high-quality genomes for the different nematode species. The project also involves a number of computational and bioinformatic tools to analyze the genomic data and to identify functional elements, such as genes, regulatory elements, and repeats.\nOverall, the 959 Nematode Genomes initiative is a major effort to advance our understanding of nematode biology and to provide a comprehensive view of the diversity of nematode genomes. The project has the potential to lead to new insights into the evolution of multicellularity, the regulation of development and behavior, and the interactions between organisms and their environments, and to inform the development of new strategies for controlling nematode parasites that infect plants and animals.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of all known species of nematode worms.\n2. The initiative was launched in 2016 and is led by the University of California, Berkeley.\n3. The initiative involves collaboration with several other institutions and organizations.\n4. The 959N initiative plans to sequence over 950 species of nematodes, including free-living and parasitic species.\n5. The project uses sequencing technologies such as Illumina and PacBio.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of all known species of nematode worms.",
      "The initiative was launched in 2016 and is led by the University of California, Berkeley.",
      "The initiative involves collaboration with several other institutions and organizations.",
      "The 959N initiative plans to sequence over 950 species of nematodes, including free-living and parasitic species.",
      "The project uses sequencing technologies such as Illumina and PacBio."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 959 Nematode Genomes Project or 959N, is named after the number of cells in the hermaphrodite Caenorhabditis elegans but doesn't aim to sequence all known species of nematode worms, only a representative set to understand the genomic diversity across the phylum Nematoda.\n2. UNKNOWN\n3. TRUE: Large-scale genomic initiatives typically involve collaboration with multiple institutions and organizations.\n4. FALSE [correction]: The initiative does not plan to sequence over 950 species of nematodes. The name \"959\" refers to the number of cells in C. elegans and not the number of species; the project may aim to include a diverse set of species, but not necessarily over 950.\n5. TRUE: It's common for genomic initiatives to use sequencing technologies, and Illumina and PacBio are popular platforms for such tasks.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data, including:\n1. NIPTtools: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and visualization.\n2. PrenatalTesting: This package provides a comprehensive set of functions for analyzing NIPT data, including data preprocessing, statistical analysis, and visualization.\n3. NIPT: This package provides a simple and easy-to-use interface for analyzing NIPT data, including data cleaning, filtering, and visualization.\n4. Prenatals: This package provides a set of functions for analyzing NIPT data, including data preprocessing, statistical analysis, and visualization.\n5. NIPTworkflow: This package provides a workflow for analyzing NIPT data, including data preprocessing, statistical analysis, and visualization.\nThese packages can be used to analyze various types of NIPT data, including cell-free DNA (cfDNA) and placental DNA, and can be used for various purposes, such as identifying genetic disorders, assessing fetal risk, and monitoring pregnancy outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. NIPTtools is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. PrenatalTesting is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n3. NIPT is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n4. Prenatals is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n5. NIPTworkflow is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
    "llama-2-7b-chat-hf_fact": [
      "NIPTtools is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "PrenatalTesting is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "NIPT is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "Prenatals is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "NIPTworkflow is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: As of my knowledge cutoff in March 2023, an R package with the specific name \"PrenatalTesting\" developed for analyzing Non-invasive prenatal testing (NIPT) data was not widely recognized or standard. This could be a hypothetical package or an error in the statement.\n3. FALSE [correction]: An R package named simply \"NIPT\" may not exist. If it does, it is not among the well-known R packages for analyzing Non-invasive prenatal testing (NIPT) data. Packages often have more specific names.\n4. FALSE [correction]: As of my knowledge cutoff in March 2023, an R package with the name \"Prenatals\" developed for analyzing Non-invasive prenatal testing (NIPT) data does not appear to be widely recognized or standard.\n5. UNKNOWN: Without further information or an established context, it is not possible to confirm whether \"NIPTworkflow\" is actually an R package developed for analyzing Non-invasive prenatal testing (NIPT) data. It is plausible as a name for such a package, but whether it exists or not cannot be determined from the available information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbachs syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach-Koenig syndrome, is a rare genetic disorder characterized by a range of developmental and behavioral abnormalities. The disorder is caused by mutations in the PTEN gene, which encodes a protein that plays a critical role in regulating cell growth and division.\nThe main features of Achenbach's syndrome include:\n1. Short stature: Individuals with Achenbach's syndrome are short-statured, with an average height of around 4 feet 6 inches (137 cm) in adulthood.\n2. Intellectual disability: Achenbach's syndrome is often associated with mild to moderate intellectual disability, which can range from mild cognitive impairment to more severe intellectual disability.\n3. Autism spectrum disorder: Many individuals with Achenbach's syndrome have been diagnosed with autism spectrum disorder (ASD), which is characterized by difficulties with social interaction, communication, and repetitive behaviors.\n4. Behavioral problems: Achenbach's syndrome is also associated with a range of behavioral problems, including anxiety, hyperactivity, and mood disorders.\n5. Facial dysmorphism: Individuals with Achenbach's syndrome may have distinctive facial features, including a flat nose, small ears, and a narrow forehead.\n6. Skeletal abnormalities: The disorder can also cause skeletal abnormalities, such as short limbs, joint contractures, and scoliosis.\n7. Increased risk of cancer: Individuals with Achenbach's syndrome have an increased risk of developing certain types of cancer, including breast, ovarian, and thyroid cancer.\n8. Cardiovascular problems: Achenbach's syndrome can also increase the risk of cardiovascular problems, including high blood pressure, heart valve problems, and cardiac arrhythmias.\n9. Immunodeficiency: Some individuals with Achenbach's syndrome may have immunodeficiency, which can increase the risk of infections.\n10. Other health problems: The disorder can also cause a range of other health problems, including",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is also known as Achenbach-Koenig syndrome.\n2. The disorder is caused by mutations in the PTEN gene.\n3. Individuals with Achenbach's syndrome can have an average height of around 4 feet 6 inches (137 cm) in adulthood.\n4. Many individuals with Achenbach's syndrome have been diagnosed with autism spectrum disorder (ASD).\n5. Individuals with Achenbach's syndrome have an increased risk of developing certain types of cancer, including breast, ovarian, and thyroid cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is also known as Achenbach-Koenig syndrome.",
      "The disorder is caused by mutations in the PTEN gene.",
      "Individuals with Achenbach's syndrome can have an average height of around 4 feet 6 inches (137 cm) in adulthood.",
      "Many individuals with Achenbach's syndrome have been diagnosed with autism spectrum disorder (ASD).",
      "Individuals with Achenbach's syndrome have an increased risk of developing certain types of cancer, including breast, ovarian, and thyroid cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not known as Achenbach-Koenig syndrome. It is actually called paroxysmal hand hematoma, a condition that causes spontaneous bruising in the hand.\n2. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the PTEN gene. The cause is not well understood, but it is not linked to genetic abnormalities such as mutations in the PTEN gene.\n3. FALSE [correction]: This statement does not apply to Achenbach's syndrome. The disorder does not typically affect height, as it is primarily associated with spontaneous bruising of the hands or fingers.\n4. FALSE [correction]: There is no established connection between Achenbach's syndrome and diagnoses of autism spectrum disorder (ASD). Achenbach's syndrome pertains to hand bruising without an established link to neurodevelopmental disorders.\n5. FALSE [correction]: Achenbach's syndrome does not come with an increased risk of developing certain types of cancer. The PTEN gene mutations are associated with PTEN hamartoma tumor syndrome, which does involve cancer risks, but this is a separate condition from Achenbach's syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms used for the detection of long repeat expansions, including:\n1. RepeatMasker: This is a widely used algorithm for identifying repetitive elements in a DNA sequence. It uses a combination of heuristic and machine learning-based approaches to identify repeats and can be used to detect both short and long repeat expansions.\n2. GATK (Genome Analysis Toolkit): This is a popular software package for genomics analysis that includes tools for detecting repeat expansions. The RepeatMasker module in GATK can be used to identify long repeat expansions in a DNA sequence.\n3. LINE-1 Repeat Finder: This is a specialized tool for detecting LINE (Long Interspersed Nuclear Elements) repeat expansions, which are a type of long repeat. It uses a combination of heuristic and machine learning-based approaches to identify LINE repeats and can be used to detect both short and long repeat expansions.\n4. VarScan: This is a software package for variant detection and genotyping that can also be used for the detection of long repeat expansions. It uses a Bayesian approach to identify repeats and can be used to detect both short and long repeat expansions.\n5. RepeatProphet: This is a tool for predicting repeat expansions in a DNA sequence. It uses a combination of heuristic and machine learning-based approaches to identify repeats and can be used to detect both short and long repeat expansions.\n6. RIP (Repeat Induced Point) PCR: This is a laboratory technique that can be used to detect long repeat expansions by amplifying specific repeats using the polymerase chain reaction (PCR) technique.\n7. Southern blot: This is a laboratory technique that can be used to detect long repeat expansions by separating DNA fragments by size and probing them with a labeled probe specific to the repeat of interest.\n8. Fluorescence in situ hybridization (FISH): This is a laboratory technique that can be used to detect long repeat expansions by hybridizing labeled probes to specific repeats in a DNA sample and visualizing them under a fluorescent microscope.\nIt's worth noting that the choice of algorithm will depend",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm for identifying repetitive elements in DNA sequences.\n2. The Genome Analysis Toolkit (GATK) includes tools for detecting repeat expansions.\n3. LINE-1 Repeat Finder is a specialized tool for detecting Long Interspersed Nuclear Elements (LINE) repeat expansions.\n4. VarScan is a software package that can be used for identifying repeats and genotyping.\n5. Fluorescence in situ hybridization (FISH) is a laboratory technique for detecting long repeat expansions by visualizing them under a fluorescent microscope.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm for identifying repetitive elements in DNA sequences.",
      "The Genome Analysis Toolkit (GATK) includes tools for detecting repeat expansions.",
      "LINE-1 Repeat Finder is a specialized tool for detecting Long Interspersed Nuclear Elements (LINE) repeat expansions.",
      "VarScan is a software package that can be used for identifying repeats and genotyping.",
      "Fluorescence in situ hybridization (FISH) is a laboratory technique for detecting long repeat expansions by visualizing them under a fluorescent microscope."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Genome Analysis Toolkit (GATK) is known for its tools for SNP and indel calling and for performing variant analysis in next-generation sequencing data, but it is not specifically focused on detecting repeat expansions.\n3. TRUE\n4. FALSE [correction]: VarScan is a software package designed for the detection and analysis of variants in next-generation sequencing data, including somatic mutations and copy number alterations, but it is not specifically for identifying repeat expansions.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth and progression of certain types of brain tumors, including:\n1. Glioblastoma: Neuroligin-3 is overexpressed in a majority of glioblastomas, and its overexpression has been associated with increased tumor aggressiveness and poorer prognosis.\n2. Medulloblastoma: Neuroligin-3 is also overexpressed in medulloblastoma, a type of pediatric brain tumor that arises in the cerebellum.\n3. Astrocytoma: Neuroligin-3 has been found to be overexpressed in some types of astrocytoma, including glioblastoma multiforme.\nIn summary, neuroligin-3 promotes the growth and progression of certain types of brain tumors, including glioblastoma, medulloblastoma, and astrocytoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in a majority of glioblastomas.\n2. Overexpression of neuroligin-3 in glioblastomas has been associated with increased tumor aggressiveness and poorer prognosis.\n3. Neuroligin-3 is overexpressed in medulloblastoma, which is a type of pediatric brain tumor.\n4. Medulloblastoma arises in the cerebellum.\n5. Some types of astrocytoma, including glioblastoma multiforme, have also been found to overexpress neuroligin-3.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in a majority of glioblastomas.",
      "Overexpression of neuroligin-3 in glioblastomas has been associated with increased tumor aggressiveness and poorer prognosis.",
      "Neuroligin-3 is overexpressed in medulloblastoma, which is a type of pediatric brain tumor.",
      "Medulloblastoma arises in the cerebellum.",
      "Some types of astrocytoma, including glioblastoma multiforme, have also been found to overexpress neuroligin-3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements are consistent with scientific findings regarding neuroligin-3 and its association with certain types of brain tumors including glioblastoma and medulloblastoma, as well as its role in tumor aggressiveness. Astrocytoma, including glioblastoma multiforme, have been found to overexpress neuroligin-3. Glioblastomas are known for their high level of molecular heterogeneity and complexity, which includes overexpression of various proteins, and neuroligin-3 could be among those proteins contributing to worse prognosis. Medulloblastoma does indeed arise in the cerebellum, and studies have indicated neuroligin-3's involvement in different types of brain cancer. However, without specific studies cited for each assertion, full validation of each statement would be contingent on the reader's access to the latest research literature.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles in bacteria are typically around 10-20 nanometers (nm) in diameter, although their size can vary depending on the species of bacteria and the specific function of the gas vesicle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in bacteria are typically around 10-20 nanometers in diameter.\n2. The size of gas vesicles can vary depending on the species of bacteria.\n3. The size of gas vesicles can also vary depending on their specific function.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in bacteria are typically around 10-20 nanometers in diameter.",
      "The size of gas vesicles can vary depending on the species of bacteria.",
      "The size of gas vesicles can also vary depending on their specific function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles in bacteria are typically much larger, around 45-200 nanometers in diameter.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that are involved in regulating gene expression by modifying chromatin structure. Here are some of the BET proteins:\n1. BET1 (Bromodomain-Containing Protein 1): Also known as BRD1, this protein is a key regulator of gene expression and plays a role in various cellular processes, including cell proliferation, differentiation, and survival.\n2. BET2 (Bromodomain-Containing Protein 2): BRD2 is a transcriptional coactivator that regulates gene expression by recruiting RNA polymerase II and other transcription factors to specific DNA sequences.\n3. BET3 (Bromodomain-Containing Protein 3): BRD3 is a transcriptional repressor that regulates gene expression by recruiting histone-modifying enzymes and other chromatin-modifying proteins to specific DNA sequences.\n4. BET4 (Bromodomain-Containing Protein 4): BRD4 is a transcriptional regulator that plays a role in various cellular processes, including cell proliferation, differentiation, and survival.\n5. BET5 (Bromodomain-Containing Protein 5): BRD5 is a transcriptional regulator that plays a role in various cellular processes, including cell proliferation, differentiation, and survival.\n6. BRDT (Bromodomain-Containing Protein Dendrite-Associated Protein): BRDT is a transcriptional regulator that is involved in the regulation of gene expression, particularly in the context of neuronal development and function.\n7. BET6 (Bromodomain-Containing Protein 6): BRD6 is a transcriptional regulator that plays a role in various cellular processes, including cell proliferation, differentiation, and survival.\n8. BET7 (Bromodomain-Containing Protein 7): BRD7 is a transcriptional regulator that plays a role in various cellular processes, including cell proliferation, differentiation, and survival.\n9. BET8 (Bromodomain-Cont",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are involved in regulating gene expression by modifying chromatin structure.\n2. BRD1, a BET protein, is a key regulator of gene expression and plays a role in cell proliferation, differentiation, and survival.\n3. BRD2, another BET protein, is a transcriptional coactivator that regulates gene expression by recruiting RNA polymerase II to specific DNA sequences.\n4. BRD4 is a transcriptional regulator that is involved in cell proliferation, differentiation, and survival.\n5. BRDT is a BET protein that is involved in the regulation of gene expression in neuronal development and function.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are involved in regulating gene expression by modifying chromatin structure.",
      "BRD1, a BET protein, is a key regulator of gene expression and plays a role in cell proliferation, differentiation, and survival.",
      "BRD2, another BET protein, is a transcriptional coactivator that regulates gene expression by recruiting RNA polymerase II to specific DNA sequences.",
      "BRD4 is a transcriptional regulator that is involved in cell proliferation, differentiation, and survival.",
      "BRDT is a BET protein that is involved in the regulation of gene expression in neuronal development and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: BRDT is a BET protein that is involved in the regulation of gene expression primarily in testis, affecting spermatogenesis and fertility, not specifically neuronal development and function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One popular deep learning algorithm for protein subcellular localization prediction is the \"DeepLoc\" algorithm, which was developed by Zhang et al. in 2018. DeepLoc uses a deep neural network to predict the subcellular localization of proteins based on their amino acid sequences. The algorithm was trained on a large dataset of experimentally determined protein localizations and achieved high accuracy on several benchmark datasets.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" deep learning algorithm has been developed for predicting protein subcellular localization.\n2. The algorithm was developed by Zhang et al. in 2018.\n3. DeepLoc uses a deep neural network for prediction based on amino acid sequences of proteins.\n4. The algorithm was trained on a large dataset of experimentally determined protein localizations.\n5. DeepLoc achieved high accuracy on several benchmark datasets.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" deep learning algorithm has been developed for predicting protein subcellular localization.",
      "The algorithm was developed by Zhang et al. in 2018.",
      "DeepLoc uses a deep neural network for prediction based on amino acid sequences of proteins.",
      "The algorithm was trained on a large dataset of experimentally determined protein localizations.",
      "DeepLoc achieved high accuracy on several benchmark datasets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The \"DeepLoc\" deep learning algorithm was developed by Almagro Armenteros et al. and was published in 2017.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "MULTOVL is a protein that is involved in the regulation of RNA splicing. It is a multivalent protein that binds to the U12-type introns of pre-mRNA and helps to facilitate their splicing. MULTOVL is a component of the spliceosome, the large complex that carries out the splicing reaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is a protein that participates in the regulation of RNA splicing.\n2. MULTOVL is involved in binding to the U12-type introns of pre-mRNA.\n3. MULTOVL facilitates the splicing of U12-type introns.\n4. MULTOVL is a component of the spliceosome complex.\n5. The spliceosome is the complex responsible for carrying out the splicing reaction.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is a protein that participates in the regulation of RNA splicing.",
      "MULTOVL is involved in binding to the U12-type introns of pre-mRNA.",
      "MULTOVL facilitates the splicing of U12-type introns.",
      "MULTOVL is a component of the spliceosome complex.",
      "The spliceosome is the complex responsible for carrying out the splicing reaction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no known protein called MULTOVL; perhaps this is a typographical error or fictional. A protein that participates in RNA splicing is U2AF1.\n2. FALSE [correction]: As MULTOVL is not a known protein, it cannot be involved in binding to the U12-type introns of pre-mRNA. A complex involved in recognizing U12-type introns is the minor spliceosome.\n3. FALSE [correction]: Since MULTOVL is not an established protein, it does not facilitate the splicing of U12-type introns. The splicing of U12-type introns is facilitated by the minor spliceosome.\n4. FALSE [correction]: MULTOVL, not being a recognized protein, is not a component of the spliceosome complex. Proteins such as snRNPs and various other factors constitute the spliceosome complex.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment. Studies have shown that GDF15 levels are increased in response to metformin treatment in various tissues, including the liver, muscle, and adipose tissue.\nElevated GDF15 levels have been associated with improved insulin sensitivity and glucose metabolism, suggesting that it may play a role in the therapeutic effects of metformin. Additionally, GDF15 has been shown to inhibit the activity of the mTOR (mechanistic target of rapamycin) pathway, which is involved in cellular metabolism and growth, and is activated in insulin resistance and type 2 diabetes.\nTherefore, measuring GDF15 levels in response to metformin treatment may provide a useful way to monitor the effectiveness of treatment and potentially identify patients who are likely to respond to this therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.\n2. GDF15 levels are increased in response to metformin treatment in various tissues, including the liver, muscle, and adipose tissue.\n3. Elevated GDF15 levels have been associated with improved insulin sensitivity and glucose metabolism.\n4. GDF15 has been shown to inhibit the activity of the mTOR (mechanistic target of rapamycin) pathway.\n5. The mTOR pathway is involved in cellular metabolism and growth and is activated in insulin resistance and type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.",
      "GDF15 levels are increased in response to metformin treatment in various tissues, including the liver, muscle, and adipose tissue.",
      "Elevated GDF15 levels have been associated with improved insulin sensitivity and glucose metabolism.",
      "GDF15 has been shown to inhibit the activity of the mTOR (mechanistic target of rapamycin) pathway.",
      "The mTOR pathway is involved in cellular metabolism and growth and is activated in insulin resistance and type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GDF15 has been shown to activate the mTOR (mechanistic target of rapamycin) pathway, not inhibit it.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as intron-dependent splicing, occurs when the same intron is spliced back into the RNA molecule after it has been excised during the first round of splicing. This process is more likely to occur in shorter introns, as the RNA molecule has more opportunities to interact with the splicing machinery and be re-spliced. In contrast, non-recursive splicing, also known as intron-independent splicing, is more common in longer introns, where the RNA molecule has less opportunity to interact with the splicing machinery and is less likely to be re-spliced.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Recursive splicing occurs when the same intron is spliced back into the RNA molecule after being excised.\n3. Shorter introns have more opportunities to interact with the splicing machinery and be re-spliced.\n4. Non-recursive splicing is more common in longer introns.\n5. Longer introns have less opportunity to interact with the splicing machinery and are less likely to be re-spliced.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Recursive splicing occurs when the same intron is spliced back into the RNA molecule after being excised.",
      "Shorter introns have more opportunities to interact with the splicing machinery and be re-spliced.",
      "Non-recursive splicing is more common in longer introns.",
      "Longer introns have less opportunity to interact with the splicing machinery and are less likely to be re-spliced."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (While it is normally stated that recursive splicing is more common in longer introns due to the presence of recursive splice sites, without specific data or references provided in the context, we can't definitely say this statement is true or false.)\n2. FALSE [correction]: Recursive splicing occurs when an intron is removed in multiple steps, with parts of the intron being spliced at different times, not when the same intron is spliced back into the RNA molecule after being excised.\n3. UNKNOWN (This statement may not be accurate as shorter introns may indeed be processed more quickly, but the relationship between their size and their interactions with the splicing machinery is not straightforward and would require more context or specific biological evidence.)\n4. TRUE (Longer introns are thought to be processed in a more complex manner and are more likely to undergo recursive splicing due to the presence of recursive splice sites; this contrasts with shorter introns, which are less likely to have such sites.)\n5. FALSE [correction]: This statement seems to conflate the opportunities for recursive splicing with the probability of introns being spliced. Longer introns are indeed less likely to be entirely removed in a single splicing event, which leads to recursive splicing, not necessarily because of less interaction with the splicing machinery but rather due to the presence of recursive splice sites which can be part of the longer introns' structure.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the functional genomics of non-coding RNAs (ncRNAs), particularly long non-coding RNAs (lncRNAs). It stands for \"Transposase-Accessible Chromatin-Endpoint (TALE) Identification of Distal Enhancers.\"\nThe TALE-iD method uses the CRISPR-Cas13 system to identify the functional genomics of ncRNAs by targeting specific genomic regions with a TALEN (transposase-activated latent endonuclease) protein. The TALEN protein recognizes a specific DNA sequence and cleaves the targeted region, leading to the release of the repressed ncRNA. By analyzing the changes in gene expression after TALEN-mediated cleavage, researchers can identify the functional genomics of the targeted ncRNA.\nThe TALE-iD method has been used to study the function of lncRNAs in various biological processes, including cell differentiation, development, and disease. It has also been used to identify novel lncRNA-mediated regulatory mechanisms and to develop new therapeutic strategies for diseases such as cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is a method used for identifying the functional genomics of non-coding RNAs.\n2. TALE-iD specifically targets long non-coding RNAs (lncRNAs).\n3. TALE-iD stands for \"Transposase-Accessible Chromatin-Endpoint Identification of Distal Enhancers.\"\n4. The method employs the CRISPR-Cas13 system and a TALEN protein to target and cleave specific genomic regions.\n5. TALE-iD has been utilized in research related to cell differentiation, development, and disease, including cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is a method used for identifying the functional genomics of non-coding RNAs.",
      "TALE-iD specifically targets long non-coding RNAs (lncRNAs).",
      "TALE-iD stands for \"Transposase-Accessible Chromatin-Endpoint Identification of Distal Enhancers.\"",
      "The method employs the CRISPR-Cas13 system and a TALEN protein to target and cleave specific genomic regions.",
      "TALE-iD has been utilized in research related to cell differentiation, development, and disease, including cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TALE-iD is not a method used for identifying the functional genomics of non-coding RNAs. TALE-iD typically stands for transcription activator-like effector nuclease followed by \"-iD,\" which generally does not indicate a specific method. The description seems incorrect or incomplete.\n2. UNKNOWN: Without the correct context for what \"TALE-iD\" is, it's not possible to determine with certainty whether it specifically targets long non-coding RNAs (lncRNAs). However, TALENs have been used to target specific DNA sequences, which could in theory include lncRNAs.\n3. FALSE [correction]: \"TALE-iD\" does not stand for \"Transposase-Accessible Chromatin-Endpoint Identification of Distal Enhancers.\" This seems to be an incorrect or invented acronym and does not relate to the known applications of TALEN technology.\n4. FALSE [correction]: The method involving CRISPR-Cas13 and TALEN proteins described here does not seem to relate to the acronym TALE-iD. CRISPR-Cas13 targets RNA, and TALENs target DNA but the combination described is not directly associated with a known method named TALE-iD.\n5. UNKNOWN: Without an accurate description of TALE-iD, it is uncertain to which extent or whether it has been utilized in research related to cell differentiation, development, and disease, including cancer. TALENs have been used in such research, but whether \"TALE-iD\" refers to a specific method or example of their use is unclear.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: CL-Image is a Lisp image processing library that provides a variety of image processing functions, including filtering, resizing, and thresholding. It is designed to be easy to use and can be applied to a wide range of image formats.\n2. ImageTk: ImageTk is a Lisp image processing library that provides a simple and efficient way to manipulate and analyze images. It includes a variety of image processing functions, including filtering, resizing, and color manipulation.\n3. Lisp-Image: Lisp-Image is a Lisp image processing library that provides a comprehensive set of image processing functions, including filtering, resizing, and thresholding. It also includes a number of advanced features, such as support for multiple image formats and a built-in graphics display.\n4. Image-Lisp: Image-Lisp is a Lisp image processing library that provides a wide range of image processing functions, including filtering, resizing, and color manipulation. It also includes a number of advanced features, such as support for multiple image formats and a built-in graphics display.\n5. Lisp-Image-Tools: Lisp-Image-Tools is a collection of Lisp functions for image processing. It includes a variety of image processing functions, including filtering, resizing, and thresholding. It is designed to be easy to use and can be applied to a wide range of image formats.\nThese are some of the popular Lisp frameworks for image processing, but there are many others available as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp image processing library with functions such as filtering, resizing, and thresholding.\n2. ImageTk is a Lisp image processing library that allows for image manipulation and analysis.\n3. Lisp-Image is a Lisp image processing library with a comprehensive set of functions and supports multiple image formats.\n4. Image-Lisp is a Lisp image processing library with a range of functions and a built-in graphics display.\n5. Lisp-Image-Tools is a collection of Lisp functions designed for image processing.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp image processing library with functions such as filtering, resizing, and thresholding.",
      "ImageTk is a Lisp image processing library that allows for image manipulation and analysis.",
      "Lisp-Image is a Lisp image processing library with a comprehensive set of functions and supports multiple image formats.",
      "Image-Lisp is a Lisp image processing library with a range of functions and a built-in graphics display.",
      "Lisp-Image-Tools is a collection of Lisp functions designed for image processing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ImageTk is a Python imaging library that is an add-on to the Python Imaging Library (PIL), allowing for image objects to be displayed in Tkinter applications.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: Without specific information on the libraries named \"CL-Image\", \"Lisp-Image\", \"Image-Lisp\", and \"Lisp-Image-Tools\", it is impossible to verify the claims about those libraries, hence the \"UNKNOWN\" responses. Their names suggest that they might be related to Lisp programming, but without concrete information on these particular libraries, their existence and the veracity of those statements cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "In Saccharomyces cerevisiae (baker's yeast), approximately 700-800 genes are thought to be the result of an ancient whole genome duplication. This event, known as the \"yeast whole genome duplication\" (WGD), occurred around 1,000-2,000 million years ago and resulted in the duplication of approximately 30% of the yeast genome. These duplicated genes are known as \"homeologs\" and are often involved in similar biological processes, indicating that they have maintained similar functions despite the duplication event.",
    "llama-2-7b-chat-hf_fact_raw": "1. Approximately 700-800 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. The whole genome duplication in Saccharomyces cerevisiae occurred around 1,000-2,000 million years ago.\n3. Approximately 30% of the yeast genome was duplicated during the whole genome duplication event.\n4. The duplicated genes in Saccharomyces cerevisiae are referred to as \"homeologs\".\n5. These homeologs in Saccharomyces cerevisiae are often involved in similar biological processes.",
    "llama-2-7b-chat-hf_fact": [
      "Approximately 700-800 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "The whole genome duplication in Saccharomyces cerevisiae occurred around 1,000-2,000 million years ago.",
      "Approximately 30% of the yeast genome was duplicated during the whole genome duplication event.",
      "The duplicated genes in Saccharomyces cerevisiae are referred to as \"homeologs\".",
      "These homeologs in Saccharomyces cerevisiae are often involved in similar biological processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The whole genome duplication in Saccharomyces cerevisiae is estimated to have occurred approximately 100 million years ago.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor  (Esrrb) binds to the complex of estrogen and nuclear receptor coactivator 1 (NRC1).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein that plays a crucial role in the regulation of gene expression, particularly in the context of chromatin remodeling. It is involved in the recruitment of chromatin-modifying complexes to specific genomic regions, and helps to mediate the exchange of nucleosomes on target DNA sequences. ZCCHC17 has been implicated in a variety of cellular processes, including transcriptional activation, repression, and cell fate determination, and has been linked to a range of diseases, including cancer and developmental disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.\n2. It plays a role in the regulation of gene expression through chromatin remodeling.\n3. ZCCHC17 is involved in recruiting chromatin-modifying complexes to specific genomic regions.\n4. The protein facilitates the exchange of nucleosomes on target DNA sequences.\n5. ZCCHC17 has been implicated in a range of diseases, including cancer and developmental disorders.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.",
      "It plays a role in the regulation of gene expression through chromatin remodeling.",
      "ZCCHC17 is involved in recruiting chromatin-modifying complexes to specific genomic regions.",
      "The protein facilitates the exchange of nucleosomes on target DNA sequences.",
      "ZCCHC17 has been implicated in a range of diseases, including cancer and developmental disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nNote: While statements 1, 2, and 3 about ZCCHC17 (also known as nuclear zinc finger protein ZCCHC17 or paraspeckle protein 1) are consistent with the general functions of zinc finger proteins and chromatin remodeling factors, the specific roles described in statements 4 and 5 would require more information from scientific studies that confirm these precise functions and implications in various diseases for ZCCHC17. Without this specific information, I cannot verify the accuracy of statements 4 and 5.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is composed of several proteins in human cells. The main proteins that make up the NPC are:\n1. Nucleoporin 1 (Nup1): This protein forms the central channel of the NPC and is responsible for nucleocytoplasmic transport.\n2. Nucleoporin 2 (Nup2): This protein is involved in the formation of the nuclear pore basket and is important for the transport of small molecules across the NPC.\n3. Nucleoporin 3 (Nup3): This protein is a key component of the NPC and plays a role in the transport of large molecules and proteins.\n4. Nucleoporin 4 (Nup4): This protein is involved in the formation of the nuclear pore basket and is important for the transport of small molecules across the NPC.\n5. Nucleoporin 5 (Nup5): This protein is a key component of the NPC and plays a role in the transport of large molecules and proteins.\n6. Nucleoporin 6 (Nup6): This protein is involved in the formation of the nuclear pore basket and is important for the transport of small molecules across the NPC.\n7. Nucleoporin 7 (Nup7): This protein is a key component of the NPC and plays a role in the transport of large molecules and proteins.\n8. Nucleoporin 8 (Nup8): This protein is involved in the formation of the nuclear pore basket and is important for the transport of small molecules across the NPC.\n9. Nucleoporin 9 (Nup9): This protein is a key component of the NPC and plays a role in the transport of large molecules and proteins.\n10. Nucleoporin 10 (Nup10): This protein is involved in the formation of the nuclear pore basket and is important for the transport of small molecules across the NPC.\nThese proteins work together to form a complex that spans the nuclear envelope and regulates the transport of molecules between the nucleus and cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) is composed of several proteins in human cells.\n2. Nucleoporin 1 (Nup1) forms the central channel of the NPC and is responsible for nucleocytoplasmic transport.\n3. Nucleoporin 2 (Nup2) and Nucleoporin 4 (Nup4) are involved in the formation of the nuclear pore basket and the transport of small molecules across the NPC.\n4. Nucleoporin 3 (Nup3), Nucleoporin 5 (Nup5), Nucleoporin 7 (Nup7), and Nucleoporin 9 (Nup9) play a role in the transport of large molecules and proteins across the NPC.\n5. The NPC spans the nuclear envelope and regulates the transport of molecules between the nucleus and cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) is composed of several proteins in human cells.",
      "Nucleoporin 1 (Nup1) forms the central channel of the NPC and is responsible for nucleocytoplasmic transport.",
      "Nucleoporin 2 (Nup2) and Nucleoporin 4 (Nup4) are involved in the formation of the nuclear pore basket and the transport of small molecules across the NPC.",
      "Nucleoporin 3 (Nup3), Nucleoporin 5 (Nup5), Nucleoporin 7 (Nup7), and Nucleoporin 9 (Nup9) play a role in the transport of large molecules and proteins across the NPC.",
      "The NPC spans the nuclear envelope and regulates the transport of molecules between the nucleus and cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The nuclear pore complex does not have a component known specifically as Nucleoporin 1 (Nup1) that forms the central channel. The central transport channel of the NPC is formed by multiple nucleoporins, and Nup1 is not a standard nomenclature for any of them.\n3. UNKNOWN: The standard nomenclature does not identify nucleoporins as Nup2 or Nup4. The specific roles of these hypothetical proteins in the formation of the nuclear pore basket and transport of small molecules across the NPC cannot be verified without more context or proper scientific references.\n4. UNKNOWN: As with statement 3, the standard nomenclature for nucleoporins does not include Nup3, Nup5, Nup7, or Nup9. Specific roles of these proteins cannot be confirmed without more information or proper scientific references, and the nomenclature does not match with the recognized names for nucleoporins.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor. Specifically, it is a camptothecin-class topoisomerase II inhibitor, which binds to the enzyme and prevents it from relaxing the supercoils in DNA, leading to DNA damage and cell death.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. It belongs to the camptothecin class of topoisomerase II inhibitors.\n3. Gepotidacin binds to the enzyme topoisomerase II.\n4. The binding of gepotidacin to topoisomerase II prevents the enzyme from relaxing supercoils in DNA.\n5. The result of gepotidacin binding to topoisomerase II can lead to DNA damage and cell death.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "It belongs to the camptothecin class of topoisomerase II inhibitors.",
      "Gepotidacin binds to the enzyme topoisomerase II.",
      "The binding of gepotidacin to topoisomerase II prevents the enzyme from relaxing supercoils in DNA.",
      "The result of gepotidacin binding to topoisomerase II can lead to DNA damage and cell death."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a topoisomerase inhibitor, but it specifically targets bacterial type II topoisomerases, namely DNA gyrase and topoisomerase IV, not topoisomerase II.\n2. FALSE [correction]: Gepotidacin does not belong to the camptothecin class of topoisomerase inhibitors. Camptothecins are a class of compounds that inhibit the enzyme DNA topoisomerase I, not type II.\n3. FALSE [correction]: Since gepotidacin targets bacterial topoisomerases, namely DNA gyrase and topoisomerase IV, it would not bind to eukaryotic topoisomerase II.\n4. TRUE: The binding of gepotidacin to bacterial DNA gyrase and topoisomerase IV prevents these enzymes from relaxing supercoils in DNA, which is necessary for DNA replication and other cellular processes.\n5. TRUE: Inhibition of bacterial DNA gyrase or topoisomerase IV by gepotidacin can lead to DNA damage and ultimately bacterial cell death, which is the desired therapeutic outcome when this drug is used to treat bacterial infections.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Small Molecule Wrapper) is a computational tool used in drug discovery and design to predict the binding of small molecules to their target proteins. It is a machine learning-based approach that uses a combination of molecular dynamics simulations and machine learning algorithms to predict the binding affinity of small molecules to their target proteins.\nThe tool uses a \"wrapper\" approach, where it takes as input a set of small molecules and predicts their binding affinity to a target protein. Canvas SPW can be used to predict the binding affinity of small molecules to a wide range of protein targets, including enzymes, receptors, and ion channels.\nThe tool works by first generating a set of possible binding modes for the small molecule within the protein binding site using molecular dynamics simulations. These binding modes are then used as inputs to a machine learning model, which predicts the binding affinity of the small molecule to the target protein. The model is trained on a set of known binding affinities for small molecules to the target protein, and it can be used to predict the binding affinity of new small molecules as well.\nOne of the key advantages of Canvas SPW is its ability to predict the binding affinity of small molecules to protein targets with high accuracy, even for proteins with high-affinity ligands. This makes it a valuable tool for drug discovery and design, as it can help identify potential lead compounds with high binding affinity for a target protein.\nIn summary, Canvas SPW is a powerful tool for predicting the binding affinity of small molecules to protein targets, and it has the potential to greatly accelerate the drug discovery process by identifying promising lead compounds more quickly and efficiently.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a computational tool used in drug discovery to predict the binding of small molecules to target proteins.\n2. Canvas SPW utilizes a machine learning-based approach combining molecular dynamics simulations with machine learning algorithms.\n3. The tool is capable of predicting the binding affinity of small molecules to a range of protein targets, including enzymes, receptors, and ion channels.\n4. It generates possible binding modes through molecular dynamics simulations, which are used as inputs for a machine learning model to predict binding affinity.\n5. Canvas SPW is trained on known binding affinities and can predict the binding affinity of new small molecules to the target protein.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a computational tool used in drug discovery to predict the binding of small molecules to target proteins.",
      "Canvas SPW utilizes a machine learning-based approach combining molecular dynamics simulations with machine learning algorithms.",
      "The tool is capable of predicting the binding affinity of small molecules to a range of protein targets, including enzymes, receptors, and ion channels.",
      "It generates possible binding modes through molecular dynamics simulations, which are used as inputs for a machine learning model to predict binding affinity.",
      "Canvas SPW is trained on known binding affinities and can predict the binding affinity of new small molecules to the target protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements about \"Canvas SPW\" require specific knowledge about this computational tool which is not part of public knowledge as of my last update. If \"Canvas SPW\" exists and has the described functionality, then the statements might be true, but without specific information or context about this tool, it is not possible to determine the truthfulness of the statements. They could be based on a hypothetical or proprietary tool, and thus I cannot provide a true/false verdict or corrections.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (stimulator of interferon genes) agonists are small molecules or compounds that activate the STING pathway, leading to the production of interferons and the activation of antiviral and anti-cancer responses. Some examples of STING agonists include:\n1. Poly(I:C): A synthetic analog of viral double-stranded RNA, poly(I:C) is a commonly used STING agonist that activates the innate immune response.\n2. CpG oligonucleotides: CpG oligonucleotides are synthetic DNA molecules that contain the characteristic CpG dinucleotide motif found in bacterial DNA. They are potent STING agonists that activate the immune response.\n3. DNA-based vaccines: Some DNA-based vaccines, such as the HPV vaccine, contain STING agonists that activate the immune response upon administration.\n4. Small molecule agonists: Several small molecule agonists of STING have been identified, including the compound STING-activating compound (SAC) and the synthetic compound ML-803.\n5. Toll-like receptor (TLR) agonists: TLR agonists, such as flagellin, can activate the STING pathway and induce an immune response.\n6. Cyclic dinucleotides (CDNs): CDNs, such as c-di-GMP, are produced by STING and can activate the immune response directly.\n7. Small interfering RNA (siRNA): siRNA can activate the STING pathway and induce an immune response by degrading specific mRNAs.\n8. RNA-binding proteins: RNA-binding proteins, such as RIG-I, can activate the STING pathway by recognizing specific RNA structures.\n9. Antibodies: Antibodies can activate the STING pathway by cross-linking STING and stimulating its activity.\n10. Protein-based agonists: Protein-based agonists, such as STING-binding protein (SBP",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly(I:C) is a synthetic analog of viral double-stranded RNA and a STING agonist that activates the innate immune response.\n2. CpG oligonucleotides are synthetic DNA molecules containing CpG motifs and are potent STING agonists.\n3. Some DNA-based vaccines contain STING agonists and activate the immune response upon administration.\n4. Small molecule agonists, such as STING-activating compound (SAC) and ML-803, have been identified as STING activators.\n5. Cyclic dinucleotides (CDNs) like c-di-GMP are produced by STING and activate the immune response directly.",
    "llama-2-7b-chat-hf_fact": [
      "Poly(I:C) is a synthetic analog of viral double-stranded RNA and a STING agonist that activates the innate immune response.",
      "CpG oligonucleotides are synthetic DNA molecules containing CpG motifs and are potent STING agonists.",
      "Some DNA-based vaccines contain STING agonists and activate the immune response upon administration.",
      "Small molecule agonists, such as STING-activating compound (SAC) and ML-803, have been identified as STING activators.",
      "Cyclic dinucleotides (CDNs) like c-di-GMP are produced by STING and activate the immune response directly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CpG oligonucleotides are synthetic DNA molecules containing unmethylated CpG motifs that act as immune adjuvants through toll-like receptor 9 (TLR9), not STING.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Cyclic dinucleotides (CDNs) like c-di-GMP are not produced by STING; they are recognized by and activate the STING pathway, leading to an immune response. STING itself does not produce these molecules, but rather, they are typically produced by bacteria and act as signaling molecules within bacterial cells or as a trigger for the host immune system when detected.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Splicing-dependent Localization of CAGE) is a computational method used to predict the subcellular localization of proteins based on their splicing events. It is a type of machine learning approach that uses the splicing events of a protein to predict its localization in the cell.\nThe method works by analyzing the splicing events of a protein and identifying the splicing patterns that are associated with specific subcellular localizations. These patterns are then used to train a machine learning model, which can then be used to predict the localization of new proteins based on their splicing events.\nSLIC-CAGE uses a combination of feature extraction methods, such as hidden Markov models and support vector machines, to identify the splicing patterns that are associated with specific localizations. It can also incorporate additional information, such as protein sequence and structural data, to improve the accuracy of the predictions.\nOne of the main advantages of SLIC-CAGE is that it can predict the localization of proteins in a specific cell type or tissue, which can be useful for understanding the regulation of cellular processes and the progression of diseases. It can also be used to identify potential drug targets and to design new drugs that target specific subcellular localizations.\nOverall, SLIC-CAGE is a powerful tool for predicting the subcellular localization of proteins and has the potential to be used in a wide range of biological and medical applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a computational method that predicts the subcellular localization of proteins based on their splicing events.\n2. It employs a machine learning approach for prediction.\n3. SLIC-CAGE utilizes feature extraction methods including hidden Markov models and support vector machines for identifying splicing patterns.\n4. The method has the capability to include protein sequence and structural data to enhance prediction accuracy.\n5. SLIC-CAGE can be used to predict protein localization in specific cell types or tissues.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a computational method that predicts the subcellular localization of proteins based on their splicing events.",
      "It employs a machine learning approach for prediction.",
      "SLIC-CAGE utilizes feature extraction methods including hidden Markov models and support vector machines for identifying splicing patterns.",
      "The method has the capability to include protein sequence and structural data to enhance prediction accuracy.",
      "SLIC-CAGE can be used to predict protein localization in specific cell types or tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM domain-containing protein 3) is a protein that plays multiple roles in various cellular processes, including:\n1. Nuclear localization and transcriptional regulation: LEM-3 is a nuclear protein that binds to specific DNA sequences and regulates the expression of target genes.\n2. Chromatin remodeling: LEM-3 can interact with chromatin-remodeling complexes and facilitate the reorganization of chromatin structure, which is important for proper gene expression.\n3. Cell cycle progression: LEM-3 has been shown to regulate the G1/S checkpoint and promote cell cycle progression by interacting with key regulators of the cell cycle, such as CDKs (cyclin-dependent kinases) and Cdc6.\n4. Apoptosis: LEM-3 has been implicated in the regulation of apoptosis, with some studies suggesting that it can promote apoptosis in certain contexts, while others have found that it can inhibit apoptosis.\n5. Cancer: LEM-3 has been implicated in cancer development and progression, with some studies suggesting that it may play a role in tumorigenesis and others finding that it may be a potential tumor suppressor.\n6. Stem cell maintenance: LEM-3 has been shown to be involved in the regulation of stem cell self-renewal and differentiation, with some studies suggesting that it may play a role in maintaining stem cell populations.\n7. DNA damage response: LEM-3 has been implicated in the response to DNA damage, with some studies suggesting that it may play a role in the repair of DNA double-strand breaks.\n8. Autophagy: LEM-3 has been shown to regulate autophagy, a process by which cells degrade and recycle damaged or dysfunctional organelles and proteins.\n9. Metabolism: LEM-3 has been implicated in the regulation of metabolic pathways, with some studies suggesting that it may play a role in the regulation of glucose metabolism and energy production.\nIn summary, LEM-3 is a multifunctional protein that plays a wide range of roles in various cellular processes, including transcriptional regulation, chromatin remodeling",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 (LEM domain-containing protein 3) is a nuclear protein that has a role in transcriptional regulation by binding to specific DNA sequences.\n2. The protein LEM-3 is involved in chromatin remodeling by interacting with chromatin-remodeling complexes.\n3. LEM-3 is known to regulate the G1/S checkpoint in cell cycle progression by interacting with cyclin-dependent kinases (CDKs) and Cdc6.\n4. It has been suggested that LEM-3 can either promote or inhibit apoptosis in different contexts.\n5. Studies have shown that LEM-3 plays a role in the response to DNA damage, particularly in the repair of DNA double-strand breaks.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 (LEM domain-containing protein 3) is a nuclear protein that has a role in transcriptional regulation by binding to specific DNA sequences.",
      "The protein LEM-3 is involved in chromatin remodeling by interacting with chromatin-remodeling complexes.",
      "LEM-3 is known to regulate the G1/S checkpoint in cell cycle progression by interacting with cyclin-dependent kinases (CDKs) and Cdc6.",
      "It has been suggested that LEM-3 can either promote or inhibit apoptosis in different contexts.",
      "Studies have shown that LEM-3 plays a role in the response to DNA damage, particularly in the repair of DNA double-strand breaks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The detailed function of LEM domain-containing protein 3 (LEM-3) on transcriptional regulation by binding to specific DNA sequences is not specified enough without a reference to a specific study or scientific literature.\n2. UNKNOWN: The role of LEM-3 in chromatin remodeling through interaction with chromatin-remodeling complexes is not explicitly established without supporting scientific literature or studies.\n3. FALSE [correction]: LEM-3 is known to regulate DNA repair processes, particularly in the context of DNA double-strand breaks, but there is no widely-established direct interaction with cyclin-dependent kinases (CDKs) and Cdc6 to regulate the G1/S checkpoint.\n4. TRUE: It is common for proteins involved in cell cycle regulation and DNA repair to have context-dependent roles in promoting or inhibiting apoptosis.\n5. TRUE: LEM-3 has been implicated in the repair of DNA double-strand breaks, which is a crucial component of the cellular response to DNA damage.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a biomedical scientist, I must inform you that there is no such thing as \"tmVar.\" It is possible that you may be referring to a gene or protein that has a similar name, but without more context or information, it is difficult to provide a definitive answer.\nCould you please provide more details or context about what you are referring to?",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There is no comprehensive database of somatic mutations in normal cells. Somatic mutations are mutations that occur in non-reproductive cells in a tissue or organism, and they are often specific to cancer cells. While there are several databases that catalogue somatic mutations in cancer cells, such as The Cancer Genome Atlas (TCGA) and the National Cancer Institute's (NCI) Genomic Data Commons (GDC), these databases do not typically include information on somatic mutations in normal cells.\nHowever, there are some recent studies that have attempted to identify somatic mutations in normal tissues, such as the \"normal tissue sequencing\" project by the TCGA consortium. This project aims to identify somatic mutations in a variety of normal tissues, including blood, bone marrow, and organ tissues, in order to better understand the genetic changes that occur in these tissues as we age and in response to environmental factors.\nIt's worth noting that while there are no comprehensive databases of somatic mutations in normal cells, there are several databases that catalogue genetic variations in the general population, such as the ExAC (Exome Aggregation Consortium) database and the 1000 Genomes Project. These databases contain information on genetic variations, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations, in a large number of individuals. However, these databases do not typically include information on somatic mutations, which are specific to cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no comprehensive database of somatic mutations in normal cells.\n2. The Cancer Genome Atlas (TCGA) and the Genomic Data Commons (GDC) catalogue somatic mutations in cancer cells, not normal cells.\n3. The TCGA consortium has a \"normal tissue sequencing\" project aimed at identifying somatic mutations in various normal tissues.\n4. The ExAC database and the 1000 Genomes Project catalogue genetic variations in the general population.\n5. Somatic mutations occur in non-reproductive cells in a tissue or organism.",
    "llama-2-7b-chat-hf_fact": [
      "There is no comprehensive database of somatic mutations in normal cells.",
      "The Cancer Genome Atlas (TCGA) and the Genomic Data Commons (GDC) catalogue somatic mutations in cancer cells, not normal cells.",
      "The TCGA consortium has a \"normal tissue sequencing\" project aimed at identifying somatic mutations in various normal tissues.",
      "The ExAC database and the 1000 Genomes Project catalogue genetic variations in the general population.",
      "Somatic mutations occur in non-reproductive cells in a tissue or organism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are comprehensive databases of somatic mutations in normal cells, such as the \"Human Somatic Variation Database\" (dbVar) at NCBI.\n2. TRUE\n3. FALSE [correction]: The TCGA consortium does not have a project specifically termed \"normal tissue sequencing\"; however, it does include the sequencing of matched normal samples alongside tumor samples to distinguish somatic mutations from germline variations.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that are implemented in Java. Here are some of them:\n1. JGraphT: JGraphT is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n2. GraphStream: GraphStream is a Java library for graph processing that provides a flexible and efficient way to perform graph computations. It supports a wide range of graph algorithms and can be used for both small and large-scale graphs.\n3. Weave: Weave is a Java library for graph processing that provides a simple and efficient way to perform graph computations. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n4. GraphCrunch: GraphCrunch is a Java library for graph processing that provides a fast and efficient way to perform graph computations. It supports a wide range of graph algorithms and can be used for both small and large-scale graphs.\n5. JGraph: JGraph is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n6. GraphMol: GraphMol is a Java library for molecular graph analysis that provides a simple and efficient way to perform graph-based computations on molecular structures. It supports a wide range of graph algorithms and can be used for both small and large-scale molecules.\n7. Graphite: Graphite is a Java library for graph processing that provides a fast and efficient way to perform graph computations. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n8. JGraphAlgorithms: JGraphAlgorithms is a Java library for graph algorithms that provides a simple and efficient way to perform a wide range of graph algorithms. It supports both directed and undirected graphs and can be used for both small and large-scale graphs.\n9. GraphCompute: GraphCompute is a Java library for graph computing that provides a fast and efficient way to perform graph computations. It supports a wide range of graph algorithms and can be used for both small and large-scale graphs.\n10. JGraphCompute: JGraphCompute is a Java library for",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library designed for graph theory operations including the creation, manipulation, and analysis of graphs.\n2. GraphStream is a Java library used for graph processing and supports various graph algorithms for small to large-scale graphs.\n3. Weave is a Java library for graph processing supporting a variety of graph algorithms for directed and undirected graphs.\n4. GraphCrunch is a Java library for graph processing that offers fast and efficient graph computations compatible with small and large-scale graphs.\n5. GraphMol is a Java library focused on molecular graph analysis, facilitating graph-based computations on molecular structures.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library designed for graph theory operations including the creation, manipulation, and analysis of graphs.",
      "GraphStream is a Java library used for graph processing and supports various graph algorithms for small to large-scale graphs.",
      "Weave is a Java library for graph processing supporting a variety of graph algorithms for directed and undirected graphs.",
      "GraphCrunch is a Java library for graph processing that offers fast and efficient graph computations compatible with small and large-scale graphs.",
      "GraphMol is a Java library focused on molecular graph analysis, facilitating graph-based computations on molecular structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Weave is not known to be a Java library for graph processing. There is a visual analytics platform named Weave for interactive data analysis but it is not exclusively specialized in graph processing.\n4. FALSE [correction]: GraphCrunch is not a Java library. It is software used for comparing graph structures, but it is not specifically designed for graph processing or algorithms within Java.\n5. FALSE [correction]: GraphMol does not seem to exist as a Java library focused on molecular graph analysis. However, There is an open-source chemistry toolkit called RDKit that includes an API for molecules that uses graph-based representations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform is an advanced diagnostic tool that integrates several advances in molecular biology and synthetic biology to enable fast, sensitive, and multiplexed detection of pathogens. The four advances integrated into the SHERLOCKv2 platform are:\n1. CRISPR-Cas13: SHERLOCKv2 uses the CRISPR-Cas13 system to detect pathogens by targeting specific RNA molecules. CRISPR-Cas13 is a type of RNA-guided endonuclease that can be programmed to recognize and cleave specific RNA sequences.\n2. DNA-templated RNA synthesis: SHERLOCKv2 uses DNA-templated RNA synthesis to generate RNA molecules that are complementary to the target pathogen's RNA. This approach allows for the rapid and specific synthesis of RNA probes that can be used to detect the pathogen.\n3. Multiplexed detection: SHERLOCKv2 allows for the multiplexed detection of multiple pathogens by using different CRISPR-Cas13 systems to target different RNA molecules. This enables the detection of multiple pathogens in a single reaction, making it faster and more efficient than traditional methods.\n4. Nucleic acid amplification: SHERLOCKv2 uses nucleic acid amplification, such as PCR (polymerase chain reaction), to amplify the target RNA molecules before detection. This amplification step allows for the detection of very low levels of pathogens in a sample, making the assay more sensitive than traditional methods.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses the CRISPR-Cas13 system to detect specific RNA sequences of pathogens.\n2. SHERLOCKv2 employs DNA-templated RNA synthesis for the creation of RNA probes that target the RNA of pathogens.\n3. The platform allows for multiplexed detection, enabling the identification of multiple pathogens in one reaction.\n4. SHERLOCKv2 includes a nucleic acid amplification process like PCR for amplifying target RNA molecules prior to detection.\n5. The use of CRISPR-Cas13 and DNA-templated RNA synthesis in SHERLOCKv2 is specifically for fast, sensitive, and multiplexed detection of pathogens.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses the CRISPR-Cas13 system to detect specific RNA sequences of pathogens.",
      "SHERLOCKv2 employs DNA-templated RNA synthesis for the creation of RNA probes that target the RNA of pathogens.",
      "The platform allows for multiplexed detection, enabling the identification of multiple pathogens in one reaction.",
      "SHERLOCKv2 includes a nucleic acid amplification process like PCR for amplifying target RNA molecules prior to detection.",
      "The use of CRISPR-Cas13 and DNA-templated RNA synthesis in SHERLOCKv2 is specifically for fast, sensitive, and multiplexed detection of pathogens."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: SHERLOCKv2 does not use DNA-templated RNA synthesis for creating RNA probes. It uses a CRISPR RNA (crRNA) that guides the Cas13 to the specific RNA sequence to be detected in the pathogen.\n3. TRUE\n4. TRUE: SHERLOCKv2 involves an isothermal amplification process like recombinase polymerase amplification (RPA), which is a nucleic acid amplification method like PCR but performed at a constant temperature.\n5. TRUE: The combination of CRISPR-Cas13 and RPA (or similar isothermal amplification) in SHERLOCKv2 is indeed for fast, sensitive, and potentially multiplexed detection of pathogens.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a heuristic algorithm used to solve the Traveling Salesman Problem (TSP), which is a classic problem in computer science and operations research that involves finding the shortest possible tour that visits a set of cities and returns to the starting city. The algorithm was first proposed by David H. Wolfe in 1990.\nThe Bartender algorithm works by simulating the behavior of a bartender who is serving drinks to customers at a bar. The customers arrive at the bar in a random order, and the bartender serves them drinks in a particular order based on their arrival time. The algorithm uses this simple process to generate a tour that visits a set of cities in the most efficient way possible.\nHere is a high-level overview of how the Bartender algorithm works:\n1. Initialize the tour: The algorithm starts by randomly selecting a city as the first stop on the tour.\n2. Simulate the arrival of customers: The algorithm then simulates the arrival of customers at the bar in a random order. Each customer is assigned a random arrival time, and the algorithm serves them a drink in the order they arrive.\n3. Generate the tour: Based on the order in which the customers arrive, the algorithm generates a tour that visits each city in the most efficient way possible. The algorithm uses a simple heuristic to determine the order in which to visit each city, based on the distance between the city and the current location of the tour.\n4. Repeat steps 2 and 3: The algorithm repeats steps 2 and 3 until all customers have been served a drink.\n5. Output the tour: Once the algorithm has generated a complete tour, it outputs the sequence of cities that make up the tour.\nThe Bartender algorithm is a simple and efficient heuristic for solving the Traveling Salesman Problem. It is based on a clever observation about the way that customers arrive at a bar, and it has been shown to produce high-quality solutions in many cases. However, it is not the best algorithm for solving the TSP in all cases, and other algorithms may produce better solutions in some situations.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is a heuristic used to solve the Traveling Salesman Problem (TSP).\n2. David H. Wolfe proposed the Bartender algorithm in 1990.\n3. The Bartender algorithm simulates the behavior of a bartender serving drinks to customers arriving in a random order.\n4. The Bartender algorithm starts by randomly selecting a city as the first stop on the tour and proceeds to serve the simulated customers in the order they arrive.\n5. The Bartender algorithm was designed to generate a tour that visits each city in an efficient manner based on a heuristic related to the distance between cities.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is a heuristic used to solve the Traveling Salesman Problem (TSP).",
      "David H. Wolfe proposed the Bartender algorithm in 1990.",
      "The Bartender algorithm simulates the behavior of a bartender serving drinks to customers arriving in a random order.",
      "The Bartender algorithm starts by randomly selecting a city as the first stop on the tour and proceeds to serve the simulated customers in the order they arrive.",
      "The Bartender algorithm was designed to generate a tour that visits each city in an efficient manner based on a heuristic related to the distance between cities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no widely recognized heuristic known as the Bartender algorithm for solving the Traveling Salesman Problem (TSP). One of the well-known heuristics for the TSP is the Nearest Neighbor algorithm.\n2. FALSE [correction]: Since the Bartender algorithm is not a recognized heuristic for the TSP, the statement about David H. Wolfe proposing it in 1990 is incorrect. I have no information about an individual by this name related to the TSP heuristics in existing literature.\n3. FALSE [correction]: Since the Bartender algorithm does not exist as a heuristic for the TSP, it cannot simulate the behavior of a bartender or any other specific scenario.\n4. FALSE [correction]: Since the Bartender algorithm is not a genuine heuristic for the TSP, the statement about its method (starting by randomly selecting a city) is incorrect.\n5. FALSE [correction]: The Bartender algorithm, not being a recognized method for the TSP, was not designed to generate tours based on a heuristic related to the distance between cities. Heuristics such as the Nearest Neighbor, the Christofides algorithm, or the Genetic Algorithm do address this type of optimization for the TSP.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree Online: This is a popular web-based platform for creating and managing family trees. It offers features such as intuitive navigation, automatic merging of data, and the ability to create custom reports.\n2. Family Tree Builder: This is another popular web-based platform for creating and managing family trees. It offers features such as a user-friendly interface, automatic merging of data, and the ability to create custom reports.\n3. MyHeritage: This is a web-based platform that allows users to create and manage their family trees, as well as connect with other users and discover new relatives. It offers features such as a user-friendly interface, automatic merging of data, and the ability to create custom reports.\n4. GenoPro: This is a web-based platform for creating and managing family trees, as well as genealogy databases. It offers features such as a user-friendly interface, automatic merging of data, and the ability to create custom reports.\n5. FamilySearch: This is a web-based platform for creating and managing family trees, as well as accessing historical records and connecting with other users. It offers features such as a user-friendly interface, automatic merging of data, and the ability to create custom reports.\n6. WeRelate: This is a web-based platform for creating and managing family trees, as well as connecting with other users and discovering new relatives. It offers features such as a user-friendly interface, automatic merging of data, and the ability to create custom reports.\n7. WikiTree: This is a web-based platform for creating and managing family trees, as well as connecting with other users and discovering new relatives. It offers features such as a user-friendly interface, automatic merging of data, and the ability to create custom reports.\n8. Gramps: This is a web-based platform for creating and managing family trees, as well as genealogy databases. It offers features such as a user-friendly interface, automatic merging of data, and the ability to create custom reports.\n9. FamilyTreeMaker: This is a web-based platform for creating and managing family trees, as well as connecting with other users and discovering new relatives. It offers features such as a user-friend",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Online is a web-based platform for creating and managing family trees.\n2. Family Tree Builder is a web-based platform for creating and managing family trees.\n3. MyHeritage is a web-based platform that allows users to create and manage their family trees and connect with other users.\n4. GenoPro is a web-based platform for creating family trees and genealogy databases.\n5. FamilySearch is a web-based platform that provides access to historical records and allows users to create and manage family trees.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Online is a web-based platform for creating and managing family trees.",
      "Family Tree Builder is a web-based platform for creating and managing family trees.",
      "MyHeritage is a web-based platform that allows users to create and manage their family trees and connect with other users.",
      "GenoPro is a web-based platform for creating family trees and genealogy databases.",
      "FamilySearch is a web-based platform that provides access to historical records and allows users to create and manage family trees."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Family Tree Builder is not exclusively web-based; it is a software that is downloaded and installed on a user's computer for creating and managing family trees.\n3. TRUE\n4. FALSE [correction]: GenoPro is not a web-based platform; it is genealogy software that requires downloading and installing on a user's computer.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. ToxinDB: A comprehensive database of toxins from various sources, including spider venoms. It contains information on the toxin structure, function, and pharmacological activity.\n2. Spider Toxin Database (SpTox): A database of spider venom toxins, including their chemical structure, biological activity, and pharmacological potential.\n3. Venom-Tox: A database of venom peptides and toxins from various species, including spiders, snakes, and scorpions. It provides information on the toxin structure, function, and potential applications.\n4. ToxinWeb: A comprehensive database of toxins from various sources, including spider venoms. It contains information on the toxin structure, function, and pharmacological activity, as well as links to related databases and resources.\n5. Natural Products Alert: A database of natural products, including spider venom toxins, with information on their chemical structure, biological activity, and pharmacological potential.\n6. ToxinNet: A database of toxins from various sources, including spider venoms, with information on their structure, function, and pharmacological activity.\n7. VenomTox: A database of venom peptides and toxins from various species, including spiders, snakes, and scorpions. It provides information on the toxin structure, function, and potential applications.\n8. ToxinDB-Toxins: A database of toxins from various sources, including spider venoms, with information on their structure, function, and pharmacological activity.\n9. Spider Toxin Information System (STIS): A database of spider venom toxins, including their chemical structure, biological activity, and pharmacological potential.\n10. Venom Toxin Database (VTD): A database of venom peptides and toxins from various species, including spiders, snakes, and scorpions. It provides information on the toxin structure, function, and potential applications.\nThese databases are valuable resources for researchers studying spider-venom toxins and their potential applications in medicine and",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a comprehensive database that includes information on toxins from various sources, including spider venoms.\n2. Spider Toxin Database (SpTox) is a database specifically for spider venom toxins and includes data on their chemical structure and biological activity.\n3. Venom-Tox is a database that contains information on venom peptides and toxins from different species like spiders, snakes, and scorpions.\n4. ToxinWeb is a database that provides information on toxin structure, function, and pharmacological activity for toxins from various sources, including spider venoms.\n5. Natural Products Alert is a database that features information on natural products, including spider venom toxins, and details their chemical structure and biological activity.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a comprehensive database that includes information on toxins from various sources, including spider venoms.",
      "Spider Toxin Database (SpTox) is a database specifically for spider venom toxins and includes data on their chemical structure and biological activity.",
      "Venom-Tox is a database that contains information on venom peptides and toxins from different species like spiders, snakes, and scorpions.",
      "ToxinWeb is a database that provides information on toxin structure, function, and pharmacological activity for toxins from various sources, including spider venoms.",
      "Natural Products Alert is a database that features information on natural products, including spider venom toxins, and details their chemical structure and biological activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN [No widely recognized database called Spider Toxin Database (SpTox) is known as of my knowledge cutoff date, but the statement may refer to a specific or niche database not widely recognized or newly created. The existence of a database of this name cannot be substantiated without current data.]\n3. TRUE [Assuming Venom-Tox refers to a real database; venom databases typically include a wide range of species like spiders, snakes, and scorpions. However, without a widely recognized database known as Venom-Tox as of my knowledge cutoff date, this cannot be conclusively verified.]\n4. UNKNOWN [As of my knowledge cutoff date, no specific database named ToxinWeb is recognized. This statement's accuracy depends on whether such a database exists and is accurately described here.]\n5. TRUE [Natural Products Alert (NAPRALERT) is a database that includes information on natural products, and it could potentially include spider venom toxins among its entries, as they are natural products. The database does contain information on chemical structures and biological activity of natural products.]",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, Axitinib has been shown to prolong survival in patients with pancreatic cancer. Axitinib is a tyrosine kinase inhibitor that targets VEGF receptors and has been shown to inhibit the growth of new blood vessels in tumors, which can slow down the growth of pancreatic cancer.\nSeveral clinical trials have been conducted to evaluate the efficacy and safety of Axitinib in patients with pancreatic cancer, including a phase 3 clinical trial known as the \"AFFINITY\" trial. The results of this trial, which were published in the New England Journal of Medicine in 2018, showed that Axitinib significantly improved overall survival in patients with advanced pancreatic cancer compared to standard chemotherapy. Specifically, the median overall survival was 11.9 months in the Axitinib arm compared to 9.8 months in the chemotherapy arm.\nAdditionally, a phase 2 clinical trial published in the Journal of Clinical Oncology in 2019 found that Axitinib was well-tolerated and showed evidence of anti-tumor activity in patients with metastatic pancreatic cancer.\nOverall, the available data suggest that Axitinib may be a promising therapeutic option for patients with pancreatic cancer, particularly those with advanced disease. However, larger and longer-term studies are needed to confirm these findings and establish the long-term safety and efficacy of Axitinib in this patient population.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor that targets VEGF receptors.\n2. The \"AFFINITY\" trial was a phase 3 clinical trial that evaluated the efficacy of Axitinib in patients with pancreatic cancer.\n3. Results from the \"AFFINITY\" trial published in the New England Journal of Medicine in 2018 indicated that Axitinib improved overall survival in patients with advanced pancreatic cancer compared to standard chemotherapy.\n4. The median overall survival was 11.9 months for patients treated with Axitinib versus 9.8 months for those receiving chemotherapy, according to the \"AFFINITY\" trial results.\n5. A phase 2 clinical trial reported in the Journal of Clinical Oncology in 2019 found Axitinib to be well-tolerated and to exhibit anti-tumor activity in patients with metastatic pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor that targets VEGF receptors.",
      "The \"AFFINITY\" trial was a phase 3 clinical trial that evaluated the efficacy of Axitinib in patients with pancreatic cancer.",
      "Results from the \"AFFINITY\" trial published in the New England Journal of Medicine in 2018 indicated that Axitinib improved overall survival in patients with advanced pancreatic cancer compared to standard chemotherapy.",
      "The median overall survival was 11.9 months for patients treated with Axitinib versus 9.8 months for those receiving chemotherapy, according to the \"AFFINITY\" trial results.",
      "A phase 2 clinical trial reported in the Journal of Clinical Oncology in 2019 found Axitinib to be well-tolerated and to exhibit anti-tumor activity in patients with metastatic pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no record of a phase 3 clinical trial named \"AFFINITY\" evaluating the efficacy of Axitinib in patients with pancreatic cancer. Axitinib has been studied in other cancers like renal cell carcinoma, and the \"AFFINITY\" trial could refer to a study in another context but not pancreatic cancer.\n3. FALSE [correction]: Given that the \"AFFINITY\" trial mentioned above is not documented for pancreatic cancer, no official results from such a study were published in the New England Journal of Medicine in 2018 indicating that Axitinib improved overall survival in these patients.\n4. FALSE [correction]: Since the \"AFFINITY\" trial pertaining to Axitinib and advanced pancreatic cancer hasn't been documented, the stated median overall survival times are invalidated in this context.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein L) regulates F-actin dynamics through its interaction with actin-related protein 2/3 (ARP2/3) complex. MLP binds to the ARP2/3 complex and inhibits its activity, thereby reducing the actin polymerization and F-actin dynamics.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Microtubule-associated protein L) regulates F-actin dynamics.\n2. MLP interacts with the actin-related protein 2/3 (ARP2/3) complex.\n3. MLP binding to the ARP2/3 complex inhibits its activity.\n4. Inhibition of ARP2/3 complex activity by MLP reduces actin polymerization.\n5. Reduced actin polymerization by MLP influences F-actin dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Microtubule-associated protein L) regulates F-actin dynamics.",
      "MLP interacts with the actin-related protein 2/3 (ARP2/3) complex.",
      "MLP binding to the ARP2/3 complex inhibits its activity.",
      "Inhibition of ARP2/3 complex activity by MLP reduces actin polymerization.",
      "Reduced actin polymerization by MLP influences F-actin dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MAP (Microtubule-associated protein) regulates F-actin dynamics. MLP (Myocardial LIM protein) tends to refer to a different protein that is involved in muscle-related functions.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE (Based on the corrected statement 1 that MAP, not MLP, regulates F-actin dynamics, it is true that reduced actin polymerization would influence F-actin dynamics as actin polymerization is a key aspect of F-actin structure and function.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "The number of pseudokinases in the human kinome is not a well-defined or universally agreed upon value, as the definition and classification of pseudokinases can vary depending on the source and the criteria used. However, it is generally estimated that there are around 10-20 pseudokinases in the human kinome.\nPseudokinases are proteins that have some structural and functional similarities to kinases, but they do not have the active site required for phosphorylation. They are often involved in various cellular processes, including signal transduction, cytoskeleton organization, and protein-protein interactions.\nSome examples of pseudokinases in the human kinome include:\n1. ACK1 (Adaptor-related protein kinase 1): A pseudokinase that plays a role in regulation of cytoskeleton organization and cell adhesion.\n2. CK2 (Casein kinase 2): A pseudokinase that is involved in various cellular processes, including transcriptional regulation, cell signaling, and protein phosphorylation.\n3. PDK1 (Phosphatidylinositol 3-kinase-related kinase 1): A pseudokinase that plays a role in regulation of cell survival, growth, and metabolism.\n4. TAK1 (TGF-beta-activated kinase 1): A pseudokinase that is involved in regulation of cell growth, differentiation, and survival in response to TGF-beta signaling.\n5. Tpl2 (Tpl2-like kinase 1): A pseudokinase that is involved in regulation of cell survival, growth, and inflammation.\n6. CK1 (Casein kinase 1): A pseudokinase that is involved in regulation of various cellular processes, including transcriptional regulation, cell signaling, and protein phosphorylation.\n7. MAPK7 (Mitogen-activated protein kinase 7): A pseudokinase that is involved in regulation of cell growth, differentiation, and survival in response to mitogenic signals.\n8. RIPK1 (Receptor-interacting serine/threonine kinase 1",
    "llama-2-7b-chat-hf_fact_raw": "1. It is generally estimated that there are around 10-20 pseudokinases in the human kinome.\n2. Pseudokinases do not have the active site required for phosphorylation.\n3. Pseudokinases are often involved in various cellular processes, including signal transduction and protein-protein interactions.\n4. ACK1 (Adaptor-related protein kinase 1) is a pseudokinase involved in regulation of cytoskeleton organization and cell adhesion.\n5. CK2 (Casein kinase 2) is a pseudokinase involved in transcriptional regulation, cell signaling, and protein phosphorylation.",
    "llama-2-7b-chat-hf_fact": [
      "It is generally estimated that there are around 10-20 pseudokinases in the human kinome.",
      "Pseudokinases do not have the active site required for phosphorylation.",
      "Pseudokinases are often involved in various cellular processes, including signal transduction and protein-protein interactions.",
      "ACK1 (Adaptor-related protein kinase 1) is a pseudokinase involved in regulation of cytoskeleton organization and cell adhesion.",
      "CK2 (Casein kinase 2) is a pseudokinase involved in transcriptional regulation, cell signaling, and protein phosphorylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: It is generally estimated that there are around 50-100 pseudokinases in the human kinome.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ACK1 (Activated Cdc42-associated kinase 1) is not a pseudokinase; it is an active tyrosine kinase involved in various cellular processes including regulation of the cytoskeleton and cell adhesion.\n5. FALSE [correction]: CK2 (Casein kinase 2) is not a pseudokinase; it is a serine/threonine-protein kinase involved in various cellular processes, including transcriptional regulation, cell signaling, and protein phosphorylation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE (apolipoprotein E) mimetics are small molecules that mimic the structure and function of the apolipoprotein E protein, which plays a crucial role in lipid metabolism and inflammation. Here are three examples of apoE mimetics:\n1. A-42: A-42 is a synthetic peptide that mimics the amino acid sequence of the apolipoprotein E protein. It has been shown to reduce inflammation and improve insulin sensitivity in animal models of obesity and type 2 diabetes.\n2. GW3965: GW3965 is a small molecule inhibitor of the enzyme acetyl-CoA carboxylase (ACC), which is involved in fatty acid synthesis. By inhibiting ACC, GW3965 reduces the production of fatty acids, which can help to improve insulin sensitivity and reduce inflammation.\n3. CERTONA: CERTONA is a small molecule that mimics the structure of the apolipoprotein E protein and has been shown to reduce inflammation and improve insulin sensitivity in animal models of obesity and type 2 diabetes. It has also been shown to have anti-inflammatory effects in models of arthritis and other inflammatory diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. A-42 is a synthetic peptide designed to mimic the amino acid sequence of apolipoprotein E.\n2. GW3965 is a small molecule inhibitor of the enzyme acetyl-CoA carboxylase (ACC).\n3. CERTONA is a small molecule developed to imitate the structure of the apolipoprotein E protein and has demonstrated anti-inflammatory effects in various disease models.",
    "llama-2-7b-chat-hf_fact": [
      "A-42 is a synthetic peptide designed to mimic the amino acid sequence of apolipoprotein E.",
      "GW3965 is a small molecule inhibitor of the enzyme acetyl-CoA carboxylase (ACC).",
      "CERTONA is a small molecule developed to imitate the structure of the apolipoprotein E protein and has demonstrated anti-inflammatory effects in various disease models."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: A-42 likely refers to Amyloid beta 42, which is a peptide involved in Alzheimer's disease, not a mimic of the apolipoprotein E.\n2. FALSE [correction]: GW3965 is actually a liver X receptor (LXR) agonist, not an inhibitor of the enzyme acetyl-CoA carboxylase (ACC).\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (SAM and HD-like protein 1) is an enzyme that plays a critical role in regulating the innate immune response to viral infections. There are sex differences in SAMHD1 activity, with studies suggesting that females have higher levels of SAMHD1 activity compared to males. This higher activity has been observed in various tissues, including the brain, liver, and peripheral blood mononuclear cells.\nOne study found that female mice had higher levels of SAMHD1 protein and activity in the brain compared to males, which was associated with increased resistance to West Nile virus infection. Another study found that female human peripheral blood mononuclear cells had higher levels of SAMHD1 activity compared to males, which was associated with better control of human immunodeficiency virus (HIV) replication.\nThe mechanisms underlying these sex differences in SAMHD1 activity are not fully understood, but may involve differences in gene expression, protein stability, or post-translational modifications. Further research is needed to elucidate the underlying mechanisms and to determine the implications of these sex differences for the immune response to viral infections.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 is an enzyme involved in the regulation of the innate immune response to viral infections.\n2. Studies suggest that females have higher levels of SAMHD1 activity than males.\n3. Female mice were found to have higher levels of SAMHD1 protein and activity in the brain compared to male mice.\n4. Increased SAMHD1 activity in female mice was associated with increased resistance to West Nile virus infection.\n5. Female human peripheral blood mononuclear cells demonstrated higher levels of SAMHD1 activity compared to those in males, which correlated with a better control of HIV replication.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 is an enzyme involved in the regulation of the innate immune response to viral infections.",
      "Studies suggest that females have higher levels of SAMHD1 activity than males.",
      "Female mice were found to have higher levels of SAMHD1 protein and activity in the brain compared to male mice.",
      "Increased SAMHD1 activity in female mice was associated with increased resistance to West Nile virus infection.",
      "Female human peripheral blood mononuclear cells demonstrated higher levels of SAMHD1 activity compared to those in males, which correlated with a better control of HIV replication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (Runt-related transcription factor 2) has been shown to inhibit the differentiation of astrocytes. RUNX2 is a transcription factor that plays a crucial role in the regulation of cell fate decisions, including the differentiation of neural progenitor cells into astrocytes. Studies have shown that RUNX2 inhibits the expression of genes involved in astrocyte differentiation and function, such as GFAP (glial fibrillary acidic protein) and AQP4 (aquaporin 4), and promotes the proliferation of neural progenitor cells. Therefore, RUNX2 can act as a negative regulator of astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 (Runt-related transcription factor 2) inhibits the differentiation of astrocytes.\n2. RUNX2 is a transcription factor that influences the regulation of cell fate decisions.\n3. Studies indicate RUNX2 suppresses the expression of genes pertinent to astrocyte differentiation and function.\n4. GFAP (glial fibrillary acidic protein) and AQP4 (aquaporin 4) are genes involved in astrocyte differentiation inhibited by RUNX2.\n5. RUNX2 promotes the proliferation of neural progenitor cells.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 (Runt-related transcription factor 2) inhibits the differentiation of astrocytes.",
      "RUNX2 is a transcription factor that influences the regulation of cell fate decisions.",
      "Studies indicate RUNX2 suppresses the expression of genes pertinent to astrocyte differentiation and function.",
      "GFAP (glial fibrillary acidic protein) and AQP4 (aquaporin 4) are genes involved in astrocyte differentiation inhibited by RUNX2.",
      "RUNX2 promotes the proliferation of neural progenitor cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RUNX2 (Runt-related transcription factor 2) promotes the differentiation of osteoblasts and is generally not associated with inhibiting the differentiation of astrocytes.\n2. TRUE\n3. FALSE [correction]: RUNX2 is not typically involved in the differentiation of astrocytes; it is primarily known for its role in bone development and osteoblast differentiation.\n4. UNKNOWN: While GFAP and AQP4 are indeed genes involved in astrocyte function, the statement regarding their regulation by RUNX2 cannot be confirmed as RUNX2 is not normally involved in astrocyte differentiation.\n5. TRUE: RUNX2 has been shown to play a role in the proliferation and differentiation of neural progenitor cells, but primarily in the context of osteogenesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed in the shoulder joint. It involves removing a portion of the humeral head (the ball-shaped end of the humerus bone) and replacing it with an artificial component. The procedure is often performed to treat degenerative conditions such as osteoarthritis or avascular necrosis that have caused pain and limited mobility in the shoulder joint.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cobb-Stainsby excision arthroplasty is a surgical procedure performed in the shoulder joint.\n2. The procedure involves removing a portion of the humeral head.\n3. Cobb-Stainsby excision arthroplasty is used to treat degenerative conditions such as osteoarthritis.\n4. It is also used to treat avascular necrosis in the shoulder joint.\n5. The purpose of the procedure is to alleviate pain and improve mobility in the shoulder.",
    "llama-2-7b-chat-hf_fact": [
      "Cobb-Stainsby excision arthroplasty is a surgical procedure performed in the shoulder joint.",
      "The procedure involves removing a portion of the humeral head.",
      "Cobb-Stainsby excision arthroplasty is used to treat degenerative conditions such as osteoarthritis.",
      "It is also used to treat avascular necrosis in the shoulder joint.",
      "The purpose of the procedure is to alleviate pain and improve mobility in the shoulder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cobb-Stainsby excision arthroplasty is a surgical procedure primarily performed in the hip joint, not the shoulder joint.\n2. TRUE: In the Cobb-Stainsby excision arthroplasty of the hip, it involves removing a portion of the femoral head (corresponding to the humerus in the shoulder, but it's the femoral head in the hip).\n3. TRUE: This procedure is indeed used to treat degenerative conditions, such as osteoarthritis, but in the hip.\n4. TRUE: Avascular necrosis, which can occur in various joints including the hip, can be addressed by this procedure.\n5. TRUE: The purpose of the procedure is indeed to alleviate pain and improve mobility, albeit in the hip rather than the shoulder.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased motility and invasiveness. GRHL2 has been shown to promote EMT by repressing the expression of epithelial markers and activating mesenchymal markers, such as vimentin and N-cadherin. Over-expression of GRHL2 has been implicated in various types of cancer, including breast, lung, and colon cancer, and is thought to contribute to the development of cancer metastasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT).\n2. GRHL2 over-expression leads to a loss of cell-cell adhesion and gain of mesenchymal characteristics in epithelial cells.\n3. GRHL2 represses the expression of epithelial markers and activates mesenchymal markers, including vimentin and N-cadherin.\n4. GRHL2 over-expression has been implicated in various types of cancer such as breast, lung, and colon cancer.\n5. GRHL2 over-expression is thought to contribute to the development of cancer metastasis.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT).",
      "GRHL2 over-expression leads to a loss of cell-cell adhesion and gain of mesenchymal characteristics in epithelial cells.",
      "GRHL2 represses the expression of epithelial markers and activates mesenchymal markers, including vimentin and N-cadherin.",
      "GRHL2 over-expression has been implicated in various types of cancer such as breast, lung, and colon cancer.",
      "GRHL2 over-expression is thought to contribute to the development of cancer metastasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 typically works against epithelial-to-mesenchymal transition (EMT) and is involved in maintaining epithelial characteristics.\n2. FALSE [correction]: Over-expression of GRHL2 usually leads to the maintenance of cell-cell adhesion and epithelial characteristics, not the gain of mesenchymal characteristics.\n3. FALSE [correction]: GRHL2 typically promotes the expression of epithelial markers and represses mesenchymal markers, working in opposition to EMT. The actual effects of GRHL2 can depend on the context and cell type, so it's not universally correct to say it represses epithelial markers.\n4. TRUE: GRHL2 over-expression has been implicated in various types of cancer, including breast, lung, and colon cancer.\n5. FALSE [correction]: Over-expression of GRHL2 is typically thought to suppress cancer metastasis by inhibiting EMT. However, the role of GRHL2 can be complex and context-dependent, and it may have different effects in different types of cancer or under different conditions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer. Some of the T-UCRs that have been implicated in lung cancer include:\n1. Circular RNA (circRNA) 0010264: This T-UCR has been shown to be upregulated in non-small cell lung cancer (NSCLC) and promotes the proliferation and migration of lung cancer cells.\n2. CircRNA:0006259: This T-UCR has been shown to be upregulated in NSCLC and regulates the epithelial-mesenchymal transition (EMT) process in lung cancer cells.\n3. CircRNA:0006460: This T-UCR has been shown to be upregulated in NSCLC and inhibits the activity of the tumor suppressor protein, p53.\n4. CircRNA:0007054: This T-UCR has been shown to be upregulated in NSCLC and regulates the expression of the oncogene, c-Myc.\n5. CircRNA:0007496: This T-UCR has been shown to be upregulated in NSCLC and regulates the expression of the oncogene, EGFR.\nThese are just a few examples of T-UCRs that have been implicated in lung cancer, and further research is needed to fully understand their roles in the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer.\n2. Circular RNA (circRNA) 0010264 has been shown to be upregulated in non-small cell lung cancer (NSCLC).\n3. CircRNA:0006259 regulates the epithelial-mesenchymal transition (EMT) process in lung cancer cells.\n4. CircRNA:0006460 inhibits the activity of the tumor suppressor protein, p53, in NSCLC.\n5. CircRNA:0007054 regulates the expression of the oncogene c-Myc in NSCLC.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer.",
      "Circular RNA (circRNA) 0010264 has been shown to be upregulated in non-small cell lung cancer (NSCLC).",
      "CircRNA:0006259 regulates the epithelial-mesenchymal transition (EMT) process in lung cancer cells.",
      "CircRNA:0006460 inhibits the activity of the tumor suppressor protein, p53, in NSCLC.",
      "CircRNA:0007054 regulates the expression of the oncogene c-Myc in NSCLC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer, as they can play a role in cancer development and progression.\n2. UNKNOWN - While circular RNA (circRNA) 0010264 could be upregulated in non-small cell lung cancer (NSCLC), without specific research or evidence provided in the statements, we cannot verify if this particular circRNA has been shown to be upregulated in NSCLC.\n3. UNKNOWN - CircRNA:0006259 could regulate the epithelial-mesenchymal transition (EMT) process in lung cancer cells, but again, without specific evidence, the statement cannot be confirmed.\n4. UNKNOWN - Without specific evidence or research about CircRNA:0006460, the claim that it inhibits the activity of the tumor suppressor protein, p53, in NSCLC cannot be validated.\n5. UNKNOWN - Similarly, the statement that CircRNA:0007054 regulates the expression of the oncogene c-Myc in NSCLC is not verifiable without more specific evidence or research information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151, also known as free fatty acid receptor 1 (FFA1), is an orphan G protein-coupled receptor that has been identified as a novel target for the treatment of metabolic disorders, including obesity and type 2 diabetes. Here are some key findings about GPR151:\n1. GPR151 is primarily expressed in the brain, pancreas, and adipose tissue, where it plays a role in regulating energy homeostasis and glucose metabolism.\n2. GPR151 functions as a negative regulator of glucose-stimulated insulin secretion and is involved in the regulation of glucose-stimulated signaling pathways in pancreatic beta cells.\n3. Activation of GPR151 by its endogenous ligands, such as free fatty acids, inhibits the activity of the enzyme acetyl-CoA carboxylase (ACC), which is involved in the degradation of fatty acids. This leads to increased fatty acid synthesis and storage in adipose tissue.\n4. GPR151 also regulates glucose metabolism by inhibiting the activity of the enzyme histone deacetylase (HDAC) and increasing the expression of genes involved in glucose uptake and metabolism in adipose tissue.\n5. GPR151 has been shown to play a role in the regulation of appetite and food intake, with activation of the receptor leading to decreased food intake and body weight in animal models.\n6. GPR151 has been identified as a potential therapeutic target for the treatment of metabolic disorders, including obesity and type 2 diabetes. Small molecule agonists of GPR151 have been shown to improve glucose tolerance and insulin sensitivity in animal models of these diseases.\n7. GPR151 has also been implicated in the regulation of inflammation and immune responses, with activation of the receptor leading to suppression of pro-inflammatory cytokine production and immune cell activation.\n8. GPR151",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is primarily expressed in the brain, pancreas, and adipose tissue.\n2. It serves as a negative regulator of glucose-stimulated insulin secretion from pancreatic beta cells.\n3. Activation of GPR151 by endogenous ligands inhibits the activity of acetyl-CoA carboxylase, which is involved in fatty acid synthesis.\n4. The receptor plays a role in regulating appetite and food intake, leading to decreased food intake and body weight in animal models.\n5. GPR151 has been identified as a potential therapeutic target for treating metabolic disorders such as obesity and type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is primarily expressed in the brain, pancreas, and adipose tissue.",
      "It serves as a negative regulator of glucose-stimulated insulin secretion from pancreatic beta cells.",
      "Activation of GPR151 by endogenous ligands inhibits the activity of acetyl-CoA carboxylase, which is involved in fatty acid synthesis.",
      "The receptor plays a role in regulating appetite and food intake, leading to decreased food intake and body weight in animal models.",
      "GPR151 has been identified as a potential therapeutic target for treating metabolic disorders such as obesity and type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific research or evidence provided for GPR151's expression in these tissues, I cannot verify the accuracy of this statement.\n2. UNKNOWN: The function of GPR151 as a regulator of insulin secretion requires specific scientific evidence, which is not provided here.\n3. UNKNOWN: The role of GPR151 in the regulation of acetyl-CoA carboxylase and fatty acid synthesis cannot be confirmed without relevant scientific research or data.\n4. UNKNOWN: The effect of GPR151 activation on appetite and food intake in animal models is not verifiable without referencing specific studies or experimental results.\n5. UNKNOWN: Identifying GPR151 as a potential therapeutic target for metabolic disorders would be based on scientific research, which is not provided in this specific context; therefore, the accuracy of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone intradermal quadrivalent vaccine contains the following attenuated live viruses:\n* FluB (H3N2)\n* FluA (H1N1)\n* FluB (H3N2)\n* FluA (H1N1)\nThese viruses are attenuated, meaning they have been weakened or modified so that they can stimulate an immune response without causing disease. The vaccine is designed to provide protection against four different strains of the flu virus: two influenza A strains (H1N1 and H3N2) and two influenza B strains (Victoria and Yamagata).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.\n2. The vaccine includes an attenuated version of the FluB (H3N2) virus.\n3. The vaccine includes an attenuated version of the FluA (H1N1) virus.\n4. The Fluzone intradermal quadrivalent vaccine is designed to protect against two influenza A strains: H1N1 and H3N2.\n5. The Fluzone intradermal quadrivalent vaccine is designed to protect against two influenza B strains: Victoria and Yamagata.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.",
      "The vaccine includes an attenuated version of the FluB (H3N2) virus.",
      "The vaccine includes an attenuated version of the FluA (H1N1) virus.",
      "The Fluzone intradermal quadrivalent vaccine is designed to protect against two influenza A strains: H1N1 and H3N2.",
      "The Fluzone intradermal quadrivalent vaccine is designed to protect against two influenza B strains: Victoria and Yamagata."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) viruses, not attenuated live viruses.\n2. FALSE [correction]: The vaccine includes an inactivated version of the FluB (H3N2) virus, not attenuated. Additionally, H3N2 is an influenza A virus, not influenza B.\n3. FALSE [correction]: The vaccine includes an inactivated version of the FluA (H1N1) virus, not attenuated.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE) in the promoter region, specifically in the -257 A/G polymorphism. This polymorphism is thought to affect the transcriptional activity of the TNFR2 gene and contribute to the development of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n2. The promoter region of the TNFR2 gene is specifically associated with SLE.\n3. The -257 A/G polymorphism in the TNFR2 gene is associated with SLE.\n4. The -257 A/G polymorphism in the TNFR2 gene may affect the gene's transcriptional activity.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "The promoter region of the TNFR2 gene is specifically associated with SLE.",
      "The -257 A/G polymorphism in the TNFR2 gene is associated with SLE.",
      "The -257 A/G polymorphism in the TNFR2 gene may affect the gene's transcriptional activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TNFR2 gene has been reported to be associated with susceptibility to systemic lupus erythematosus (SLE) in various studies, but the strength of the association can vary between populations.\n2. UNKNOWN: Without more information or a specific reference, it is difficult to confirm the association of the promoter region of the TNFR2 gene with SLE. Typically, associations with diseases are made with specific regions, but without concrete evidence provided here, this statement's accuracy cannot be determined.\n3. UNKNOWN: The statement about the -257 A/G polymorphism in the TNFR2 gene being associated with SLE requires specific scientific evidence or study results which are not provided here. As this information is missing, the truth value of this statement cannot be determined.\n4. TRUE: Polymorphisms in genes, such as the -257 A/G polymorphism, can affect the transcriptional activity of a gene. While this statement is generally true in the context of gene regulation, the specific effects of the -257 A/G polymorphism on TNFR2 gene's transcriptional activity would require referencing specific scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. However, researchers are actively working on developing a peanut allergy vaccine, and several clinical trials are underway to evaluate its safety and efficacy.\nOne of the most promising approaches to developing a peanut allergy vaccine involves using a combination of peanut protein and adjuvants, such as aluminum hydroxide, to stimulate the immune system and promote tolerance to peanut proteins. This approach is based on the concept of oral immunotherapy, which involves gradually increasing the dose of an allergen to which a person is exposed in order to build up tolerance.\nSeveral clinical trials have been conducted to evaluate the safety and efficacy of peanut allergy vaccines, including a phase 1/2 trial conducted by Stapel et al. (2017) and a phase 2 trial conducted by Speranza et al. (2018). These trials have shown promising results, with some participants experiencing a significant reduction in peanut allergy symptoms after receiving the vaccine.\nHowever, it is important to note that the development of a peanut allergy vaccine is still in its early stages, and more research is needed to determine its long-term safety and efficacy. Additionally, it is not clear how effective the vaccine will be in preventing anaphylaxis, the most severe form of peanut allergy.\nIn summary, while there is currently no licensed vaccine available for the prevention of peanut allergy, researchers are actively working on developing one, and several clinical trials are underway to evaluate its safety and efficacy.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff date.\n2. Researchers are actively working on developing a peanut allergy vaccine.\n3. Clinical trials are being conducted to evaluate the safety and efficacy of a peanut allergy vaccine.\n4. One approach to developing a peanut allergy vaccine involves using peanut protein and adjuvants like aluminum hydroxide.\n5. A phase 1/2 trial was conducted by Stapel et al. in 2017 and a phase 2 trial by Speranza et al. in 2018 to evaluate peanut allergy vaccines.",
    "llama-2-7b-chat-hf_fact": [
      "There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff date.",
      "Researchers are actively working on developing a peanut allergy vaccine.",
      "Clinical trials are being conducted to evaluate the safety and efficacy of a peanut allergy vaccine.",
      "One approach to developing a peanut allergy vaccine involves using peanut protein and adjuvants like aluminum hydroxide.",
      "A phase 1/2 trial was conducted by Stapel et al. in 2017 and a phase 2 trial by Speranza et al. in 2018 to evaluate peanut allergy vaccines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nExplanation:\n1. As of the knowledge cutoff date, there is indeed no licensed vaccine available specifically for the prevention of peanut allergy.\n2. Researchers are known to be actively working on various treatments and potential vaccines for allergies, including peanut allergies.\n3. Clinical trials are a typical part of the vaccine development process, and it is likely that such trials are ongoing for peanut allergy vaccines to evaluate their safety and efficacy.\n4. One common approach in vaccine development involves the use of the allergenic protein itself (or parts of it) in combination with adjuvants like aluminum hydroxide to enhance the immune response, and this approach may be applied to vaccine candidates for peanut allergies as well.\n5. The specific details on the trials conducted by Stapel et al. in 2017 and Speranza et al. in 2018 are not provided in common knowledge and would require verification from clinical trial records or scientific publications. Therefore, without additional context, the truth of this statement is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome, specifically at Xq28. This means that the Fxy gene is located on the long arm of the X chromosome at position 28.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. The Fxy gene is specifically positioned at Xq28.\n3. Xq28 indicates that the Fxy gene is located on the long arm of the X chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "The Fxy gene is specifically positioned at Xq28.",
      "Xq28 indicates that the Fxy gene is located on the long arm of the X chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the use of a modified dATP molecule, methidiumpropyl-EDTA (MPE), as a tracer for DNA synthesis. During DNA replication, MPE is incorporated into the growing DNA strand as a modified base, replacing thymine. The MPE residue is then detected and quantified using mass spectrometry, allowing for the measurement of DNA synthesis rates and the analysis of DNA replication dynamics.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPE-seq uses a modified dATP molecule, methidiumpropyl-EDTA (MPE), as a tracer for DNA synthesis.\n2. During DNA replication in MPE-seq, MPE is incorporated into the DNA strand as a modified base.\n3. In MPE-seq, methidiumpropyl-EDTA replaces thymine during DNA replication.\n4. Mass spectrometry is used to detect and quantify the MPE residue in MPE-seq.\n5. MPE-seq allows measurement of DNA synthesis rates and analysis of DNA replication dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "MPE-seq uses a modified dATP molecule, methidiumpropyl-EDTA (MPE), as a tracer for DNA synthesis.",
      "During DNA replication in MPE-seq, MPE is incorporated into the DNA strand as a modified base.",
      "In MPE-seq, methidiumpropyl-EDTA replaces thymine during DNA replication.",
      "Mass spectrometry is used to detect and quantify the MPE residue in MPE-seq.",
      "MPE-seq allows measurement of DNA synthesis rates and analysis of DNA replication dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MPE-seq uses a modified dATP molecule, methidiumpropyl-EDTA-Fe(II) (MPE), as a cleaving agent that targets DNA during replication, not as a tracer.\n2. FALSE [correction]: During DNA replication in MPE-seq, MPE does not get incorporated into the DNA strand; instead, it intercalates into the DNA at the replication fork and upon activation, cleaves the new strand, not as a modified base.\n3. FALSE [correction]: In MPE-seq, methidiumpropyl-EDTA does not replace thymine or any other base during DNA replication, it acts as a cleaving agent that intercalates into the DNA.\n4. UNKNOWN (The method of detection could be mass spectrometry, but it is more commonly known that gel electrophoresis or similar methods are used following MPE-seq to analyze the cleaved DNA fragments; unless specific literature citation is provided regarding the use of mass spectrometry, this statement cannot be confirmed.)\n5. TRUE (MPE-seq is indeed used to investigate DNA replication dynamics, including the measurements of DNA synthesis rates.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a variety of programming languages depending on the specific implementation and the research question being addressed. However, some popular programming languages used in GWAS analysis include:\n1. R: R is a popular language for statistical computing and graphics, and is widely used in the analysis of genetic data. Many R packages, such as PLINK, GCTA, and MASS, provide functions for conducting GWAS.\n2. Python: Python is a versatile language that is widely used in bioinformatics and genomics. Libraries such as scikit-learn, scipy, and pandas provide functions for implementing GWAS.\n3. MATLAB: MATLAB is a high-level programming language that is commonly used in bioinformatics and genomics for data analysis and visualization.\n4. SAS: SAS (Statistical Analysis System) is a software suite that is widely used in bioinformatics and genomics for data analysis and statistical modeling. GWAS can be implemented using the SAS language.\nIt's worth noting that GWAR can be implemented using different programming languages, and the choice of language will depend on the research question, the size and complexity of the data, and the preferences of the researcher.",
    "llama-2-7b-chat-hf_fact_raw": "1. R is used for statistical computing and graphics in GWAS analysis.\n2. Python is utilized in bioinformatics and genomics for GWAS implementation.\n3. MATLAB is a high-level programming language used in bioinformatics and genomics.\n4. SAS software suite is used in bioinformatics and genomics for GWAS.\n5. GWAS can be implemented in different programming languages based on researcher preferences and project specifics.",
    "llama-2-7b-chat-hf_fact": [
      "R is used for statistical computing and graphics in GWAS analysis.",
      "Python is utilized in bioinformatics and genomics for GWAS implementation.",
      "MATLAB is a high-level programming language used in bioinformatics and genomics.",
      "SAS software suite is used in bioinformatics and genomics for GWAS.",
      "GWAS can be implemented in different programming languages based on researcher preferences and project specifics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: SAS software suite is primarily used for advanced analytics, multivariate analyses, business intelligence, data management, and predictive analytics. It is not specifically known for bioinformatics and genomics for GWAS.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as verubecestat) is an oral BET (bromodomain and extraterminal) inhibitor that has been investigated for the treatment of amyotrophic lateral sclerosis (ALS). While early clinical trials suggested that xaliproden may have potential as an ALS treatment, more recent studies have yielded mixed results.\nIn 2019, a phase II clinical trial sponsored by the pharmaceutical company Biogen found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo. Specifically, the study found that the mean rate of decline in the ALS Functional Rating Scale (ALSFRS-R) was similar between the xaliproden and placebo groups over a 24-week treatment period.\nHowever, the study did identify some encouraging trends in the xaliproden group, including improved cognitive function and reduced muscle cramping. Additionally, a post-hoc analysis of the data suggested that patients with a specific genetic mutation associated with ALS (the C9ORF72 repeat expansion) may have experienced a greater benefit from xaliproden treatment.\nIt is important to note that the results of this study were not conclusive, and more research is needed to determine the efficacy and safety of xaliproden in the treatment of ALS. Additionally, the drug is still being studied in ongoing clinical trials, and its potential as an ALS treatment may be optimized through combination therapy with other drugs or through the use of different dosing regimens.\nIn summary, while the current evidence suggests that xaliproden may have limited efficacy as a standalone treatment for ALS, further research is needed to fully understand its potential as an ALS treatment and to identify the most effective ways to use it in clinical practice.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden has been investigated for the treatment of amyotrophic lateral sclerosis (ALS).\n2. In 2019, a phase II clinical trial by Biogen found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo.\n3. The phase II clinical trial found that the mean rate of decline in the ALS Functional Rating Scale (ALSFRS-R) was similar between the xaliproden and placebo groups over a 24-week treatment period.\n4. Some trends observed in the study were improved cognitive function and reduced muscle cramping in the xaliproden group.\n5. Post-hoc analysis suggested that patients with the C9ORF72 genetic mutation associated with ALS may have experienced greater benefits from xaliproden treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden has been investigated for the treatment of amyotrophic lateral sclerosis (ALS).",
      "In 2019, a phase II clinical trial by Biogen found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo.",
      "The phase II clinical trial found that the mean rate of decline in the ALS Functional Rating Scale (ALSFRS-R) was similar between the xaliproden and placebo groups over a 24-week treatment period.",
      "Some trends observed in the study were improved cognitive function and reduced muscle cramping in the xaliproden group.",
      "Post-hoc analysis suggested that patients with the C9ORF72 genetic mutation associated with ALS may have experienced greater benefits from xaliproden treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (There is no verifiable information provided about a phase II clinical trial by Biogen in 2019 related to xaliproden. As of my knowledge cutoff date, I cannot confirm or refute this without additional context or data.)\n3. UNKNOWN (This statement depends on the specifics of the trial mentioned in statement 2, which cannot be confirmed with the information provided.)\n4. UNKNOWN (Whether trends of improved cognitive function and reduced muscle cramping were observed in the xaliproden group would depend on data from the clinical trial, which has not been provided.)\n5. UNKNOWN (Post-hoc analysis indicating that patients with the C9ORF72 genetic mutation may have benefited from xaliproden treatment can't be verified without specific data or results from the study mentioned.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic line that expresses the gene for the enzyme acetylcholinesterase (AChE) under the control of the albumin promoter. In this line, the transgene is inserted into chromosome 1.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic line that expresses the gene for acetylcholinesterase (AChE).\n2. In the LiPS-A3S line, the transgene is controlled by the albumin promoter.\n3. The transgene in the LiPS-A3S line is inserted into chromosome 1.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic line that expresses the gene for acetylcholinesterase (AChE).",
      "In the LiPS-A3S line, the transgene is controlled by the albumin promoter.",
      "The transgene in the LiPS-A3S line is inserted into chromosome 1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific context or a source that describes the characteristics of the LiPS-A3S line, such as a scientific article or a genetics database, it is not possible to determine the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that can be used for predicting drug synergy. Here are some of the popular ones:\n1. DeepSynth: DeepSynth is a deep learning-based tool for predicting drug synergy. It uses a combination of molecular descriptors and graph-based representations to predict the activity of drug combinations.\n2. Drug2Drug: Drug2Drug is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict the activity of drug combinations.\n3. Synergizer: Synergizer is a deep learning-based tool for predicting drug synergy. It uses a combination of molecular descriptors and graph-based representations to predict the activity of drug combinations.\n4. DrugCombination: DrugCombination is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs. It uses a combination of CNNs and RNNs to predict the activity of drug combinations.\n5. ChEA-Net: ChEA-Net is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs. It uses a combination of CNNs and RNNs to predict the activity of drug combinations.\n6. Drug-Drug-Interaction Prediction (DDIP): DDIP is a deep learning-based tool for predicting drug synergy. It uses a combination of molecular descriptors and graph-based representations to predict the activity of drug combinations.\n7. DeepDrug: DeepDrug is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs. It uses a combination of CNNs and RNNs to predict the activity of drug combinations.\n8. DrugSynergizer: DrugSynergizer is a deep learning-based tool for predicting drug synergy. It uses a combination of molecular descriptors and graph-based representations to predict the activity of drug combinations.\n9. Chemical-based Deep Learning (CDL): CDL is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs. It uses a combination of CNNs and RNNs to predict the",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynth is a tool that predicts drug synergy using molecular descriptors and graph-based representations.\n2. Drug2Drug utilizes convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict drug synergy.\n3. DrugCombination is a model that employs a combination of CNNs and RNNs for the prediction of drug synergy.\n4. Drug-Drug-Interaction Prediction (DDIP) predicts drug synergy through molecular descriptors and graph-based representations.\n5. DeepDrug is a deep learning model that uses CNNs and RNNs to analyze the chemical structure of drugs for predicting drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynth is a tool that predicts drug synergy using molecular descriptors and graph-based representations.",
      "Drug2Drug utilizes convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict drug synergy.",
      "DrugCombination is a model that employs a combination of CNNs and RNNs for the prediction of drug synergy.",
      "Drug-Drug-Interaction Prediction (DDIP) predicts drug synergy through molecular descriptors and graph-based representations.",
      "DeepDrug is a deep learning model that uses CNNs and RNNs to analyze the chemical structure of drugs for predicting drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN - While the name 'DrugCombination' suggests it might involve drug synergy prediction, there is not enough information given to determine the specifics of the methodology used or whether it indeed uses CNNs and RNNs.\n4. FALSE [correction]: Drug-Drug Interaction Prediction (DDIP) typically refers to predicting the likelihood of interactions between drugs, which may or may not involve synergistic effects. The statement that it predicts drug synergy using molecular descriptors and graph-based representations might be an incomplete or incorrect description of DDIP's function.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "A cloud-based platform called \"cloud-GWAS\" has been developed for comparing genome-wide association studies (GWAS). Cloud-GWAS is an open-source, web-based platform that allows researchers to compare GWAS results across different studies and populations, and to identify novel associations and patterns of association. The platform uses a distributed computing framework to process large amounts of genomic data and to perform statistical analyses, making it easy to compare GWAS results from different studies and to identify potential signals of association that may have been missed in individual studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. \"cloud-GWAS\" is a cloud-based platform developed for comparing genome-wide association studies (GWAS).\n2. Cloud-GWAS is an open-source platform.\n3. The platform is web-based and allows researchers to compare GWAS results across different studies and populations.\n4. Cloud-GWAS utilizes a distributed computing framework to process genomic data.\n5. The platform is designed to perform statistical analyses and identify novel associations in GWAS results.",
    "llama-2-7b-chat-hf_fact": [
      "\"cloud-GWAS\" is a cloud-based platform developed for comparing genome-wide association studies (GWAS).",
      "Cloud-GWAS is an open-source platform.",
      "The platform is web-based and allows researchers to compare GWAS results across different studies and populations.",
      "Cloud-GWAS utilizes a distributed computing framework to process genomic data.",
      "The platform is designed to perform statistical analyses and identify novel associations in GWAS results."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nSince \"cloud-GWAS\" is not a well-known standard term or platform that can be universally verified as of my knowledge cut-off date, I cannot confirm the veracity of these statements without additional context or a reference to a specific instance of this platform if it exists. Therefore, all the statements are classified as UNKNOWN. If \"cloud-GWAS\" is indeed a specific software or service that has been developed after my last update, then one would need current information to verify these claims.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a bispecific antibody that targets both CD3 and CD19, and it has been shown to be effective in preclinical studies against B-cell malignancies, including non-Hodgkin lymphoma (NHL). However, there is limited information available on its efficacy against sarcomas.\nSarcomas are a type of cancer that arise from the mesenchymal tissues, such as bone, cartilage, and connective tissue. They are relatively rare, accounting for approximately 1% of all adult cancers, and they can be challenging to treat due to their aggressive nature and resistance to conventional therapies.\nWhile CMB305 has shown promise in preclinical studies against B-cell malignancies, there is no evidence to suggest that it is effective against sarcomas. In fact, there have been no clinical trials conducted with CMB305 in patients with sarcomas. Therefore, it is uncertain whether CMB305 would be effective in treating sarcomas, and further research is needed to determine its potential in this context.\nIn summary, while CMB305 has shown promise in preclinical studies against B-cell malignancies, there is limited information available on its efficacy against sarcomas, and further research is needed to determine its potential in this area.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a bispecific antibody that targets both CD3 and CD19.\n2. CMB305 has been effective in preclinical studies against B-cell malignancies, including non-Hodgkin lymphoma (NHL).\n3. Sarcomas account for approximately 1% of all adult cancers.\n4. Sarcomas arise from mesenchymal tissues such as bone, cartilage, and connective tissue.\n5. There have been no clinical trials conducted with CMB305 in patients with sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a bispecific antibody that targets both CD3 and CD19.",
      "CMB305 has been effective in preclinical studies against B-cell malignancies, including non-Hodgkin lymphoma (NHL).",
      "Sarcomas account for approximately 1% of all adult cancers.",
      "Sarcomas arise from mesenchymal tissues such as bone, cartilage, and connective tissue.",
      "There have been no clinical trials conducted with CMB305 in patients with sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There have been clinical trials conducted with CMB305 in patients with sarcomas.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Ehlers-Danlos syndrome (EDS), is a group of connective tissue disorders that affect the body's connective tissue, which provides support and structure to various organs, joints, and tissues. The manifestations of the Saint's Triad can vary in severity and can affect different parts of the body, including:\n1. Hypermobility: People with EDS have an excessive range of motion in their joints, which can lead to joint instability and dislocation.\n2. Skin hyperextensibility: The skin of individuals with EDS is highly elastic and can stretch further than normal, leading to skin that appears to be \"overly loose.\"\n3. Tissue fragility: The connective tissue in people with EDS is weakened, making it prone to injury and tearing. This can lead to bruising, bleeding, and other tissue damage.\nThese manifestations can have a significant impact on an individual's quality of life, affecting their ability to perform daily activities, participate in sports, and maintain their overall health and well-being.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad refers to a group of connective tissue disorders known as Ehlers-Danlos syndrome (EDS).\n2. EDS affects the body's connective tissue which provides support and structure to various organs, joints, and tissues.\n3. People with EDS have an excessive range of motion in their joints, which can lead to joint instability and dislocation.\n4. The skin of individuals with EDS is highly elastic and can stretch further than normal.\n5. The connective tissue in people with EDS is weakened, making it prone to injury and tearing.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad refers to a group of connective tissue disorders known as Ehlers-Danlos syndrome (EDS).",
      "EDS affects the body's connective tissue which provides support and structure to various organs, joints, and tissues.",
      "People with EDS have an excessive range of motion in their joints, which can lead to joint instability and dislocation.",
      "The skin of individuals with EDS is highly elastic and can stretch further than normal.",
      "The connective tissue in people with EDS is weakened, making it prone to injury and tearing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The term \"Saint's Triad\" does not refer to Ehlers-Danlos syndrome (EDS). The Saint's Triad is not a recognized term for a group of connective tissue disorders, such as EDS.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients. Studies have shown that high levels of LY6K expression are associated with improved overall survival, disease-free survival, and response to chemotherapy in NSCLC patients. This is thought to be due to the anti-inflammatory and anti-tumorigenic effects of LY6K, which can help to suppress the growth and progression of cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K expression are associated with improved overall survival in NSCLC patients.\n3. High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.\n4. High levels of LY6K expression are associated with a better response to chemotherapy in NSCLC patients.\n5. LY6K is thought to have anti-inflammatory and anti-tumorigenic effects that suppress the growth and progression of cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K expression are associated with improved overall survival in NSCLC patients.",
      "High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.",
      "High levels of LY6K expression are associated with a better response to chemotherapy in NSCLC patients.",
      "LY6K is thought to have anti-inflammatory and anti-tumorigenic effects that suppress the growth and progression of cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with a poorer prognosis for non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are generally associated with a decreased overall survival in NSCLC patients.\n3. FALSE [correction]: High levels of LY6K expression are generally associated with decreased disease-free survival in NSCLC patients.\n4. UNKNOWN: The effect of LY6K expression on the response to chemotherapy in NSCLC patients can vary and may depend on other factors; there is no standardized answer without specific research data.\n5. FALSE [correction]: LY6K is often reported to have pro-tumorigenic effects that promote the growth and progression of cancer cells.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the CDK (cyclin-dependent kinase) inhibitor p21 is dephosphorylated, leading to the activation of CDKs and the progression of cytokinesis. Here are some other CDK targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (CDK1): CDK1 is a key regulator of the cell cycle and is inhibited by p21. During cytokinesis, p21 is dephosphorylated, leading to the activation of CDK1 and the progression of cytokinesis.\n2. Cyclin B: Cyclin B is a regulatory protein that binds to CDK1 and promotes the progression of the cell cycle. During cytokinesis, cyclin B is dephosphorylated, leading to its inactivation and the arrest of the cell cycle.\n3. Cyclin D: Cyclin D is another regulatory protein that binds to CDK4/6 and promotes the progression of the cell cycle. During cytokinesis, cyclin D is dephosphorylated, leading to its inactivation and the arrest of the cell cycle.\n4. CDC25A: CDC25A is a phosphatase that regulates the activity of CDK1. During cytokinesis, CDC25A is dephosphorylated, leading to the activation of CDK1 and the progression of cytokinesis.\n5. Aurora A: Aurora A is a protein that regulates the separation of chromosomes during cytokinesis. During cytokinesis, Aurora A is dephosphorylated, leading to its activation and the proper separation of chromosomes.\n6. Polo-like kinase 1 (Plk1): Plk1 is a protein that regulates the separation of chromosomes during cytokinesis. During cytokinesis, Plk1 is dephosphorylated, leading to its activation and the proper separation of chromosomes.\n7. Polo-like kinase 4 (Plk4): Plk4 is another protein that regulates the separation of chromosomes during cytokines",
    "llama-2-7b-chat-hf_fact_raw": "1. CDK inhibitor p21 is dephosphorylated during cytokinesis.\n2. Cyclin-dependent kinase 1 (CDK1) is activated during cytokinesis when p21 is dephosphorylated.\n3. Cyclin B is dephosphorylated during cytokinesis, leading to its inactivation.\n4. Cyclin D becomes dephosphorylated during cytokinesis, resulting in its inactivation.\n5. CDC25A is dephosphorylated during cytokinesis, which leads to the activation of CDK1.",
    "llama-2-7b-chat-hf_fact": [
      "CDK inhibitor p21 is dephosphorylated during cytokinesis.",
      "Cyclin-dependent kinase 1 (CDK1) is activated during cytokinesis when p21 is dephosphorylated.",
      "Cyclin B is dephosphorylated during cytokinesis, leading to its inactivation.",
      "Cyclin D becomes dephosphorylated during cytokinesis, resulting in its inactivation.",
      "CDC25A is dephosphorylated during cytokinesis, which leads to the activation of CDK1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CDK inhibitor p21 is not known to be dephosphorylated during cytokinesis; it acts as a CDK inhibitor by binding to and inhibiting CDK activity.\n2. FALSE [correction]: Cyclin-dependent kinase 1 (CDK1) is not necessarily activated during cytokinesis when p21 is dephosphorylated because the role of p21 generally involves the inhibition of CDKs, not activation. Also, the activation of CDK1 is typically regulated by cyclins and not solely dependent on the phosphorylation state of p21.\n3. UNKNOWN: While cyclin B is associated with CDK1 and regulates the cell cycle, the specifics of its phosphorylation state during cytokinesis are not provided in the standard literature and could vary depending on the cellular context.\n4. FALSE [correction]: Cyclin D is not typically implicated in the process of cytokinesis which is controlled largely by cyclin B/CDK1 complex. Phosphorylation of cyclin D doesn't directly relate to its inactivation since it is a regulatory subunit - it usually gets degraded when its associated CDK is inactivated.\n5. FALSE [correction]: CDC25A is a phosphatase that removes inhibitory phosphates from CDKs like CDK1, leading to their activation. However, CDC25A itself doesn't need to be dephosphorylated to activate CDK1. In fact, the phosphorylation state of CDC25A can regulate its activity, with certain phosphorylation events leading to its activation or degradation.\n",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that selectively inhibits the activity of the protein kinase CK2 (casein kinase 2), which is involved in various cellular processes, including protein phosphorylation, transcriptional regulation, and cell signaling. CK2 is overexpressed in many cancer types, and Xanamem has been investigated as a potential anti-cancer drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug that selectively inhibits the activity of the protein kinase CK2.\n2. Protein kinase CK2 is involved in protein phosphorylation, transcriptional regulation, and cell signaling.\n3. CK2 is overexpressed in many cancer types.\n4. Xanamem has been investigated as a potential anti-cancer drug.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug that selectively inhibits the activity of the protein kinase CK2.",
      "Protein kinase CK2 is involved in protein phosphorylation, transcriptional regulation, and cell signaling.",
      "CK2 is overexpressed in many cancer types.",
      "Xanamem has been investigated as a potential anti-cancer drug."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xanamem is a drug that has been designed to block the production of cortisol in the brain, not to inhibit the activity of protein kinase CK2.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Xanamem has been investigated for its effects on cortisol and potential use in treating conditions like Alzheimers disease, not as an anti-cancer drug.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the interaction between Hof1 and Cyk3 is involved in the regulation of cellular stress responses, particularly in response to oxidative stress. Hof1 is a transmembrane protein that functions as a sensor of oxidative stress, while Cyk3 is a protein kinase that plays a key role in signaling downstream of Hof1. The interaction between Hof1 and Cyk3 is necessary for the proper activation of Cyk3 in response to oxidative stress, leading to the activation of various cellular stress response pathways.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast is involved in the regulation of cellular stress responses.\n2. This interaction is particularly involved in response to oxidative stress in yeast.\n3. Hof1 is a transmembrane protein that functions as a sensor of oxidative stress.\n4. Cyk3 is a protein kinase that plays a key role in signaling downstream of Hof1.\n5. Proper activation of Cyk3 in response to oxidative stress requires the interaction with Hof1.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast is involved in the regulation of cellular stress responses.",
      "This interaction is particularly involved in response to oxidative stress in yeast.",
      "Hof1 is a transmembrane protein that functions as a sensor of oxidative stress.",
      "Cyk3 is a protein kinase that plays a key role in signaling downstream of Hof1.",
      "Proper activation of Cyk3 in response to oxidative stress requires the interaction with Hof1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hof1 is not a transmembrane protein but a protein involved in cytokinesis. It does not function as a sensor of oxidative stress; its primary role is in cell division.\n4. FALSE [correction]: Cyk3 is not a protein kinase but rather a protein that interacts with Hof1 during cytokinesis. It plays a role in cell wall remodeling and closure of the mother-bud neck in yeast.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-bet and Eomesodermin (Eomes) are two T-box transcription factors that have been implicated in gastric cancer. T-bet is a transcription factor that regulates the expression of genes involved in immune response and inflammation, while Eomes is a transcription factor that regulates the expression of genes involved in epithelial-to-mesenchymal transition (EMT) and cancer stem cell maintenance. Both T-bet and Eomes have been shown to be overexpressed in gastric cancer, and their overexpression has been linked to poor prognosis and cancer recurrence.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet and Eomesodermin (Eomes) are T-box transcription factors implicated in gastric cancer.\n2. T-bet regulates the expression of genes involved in immune response and inflammation.\n3. Eomes regulates the expression of genes involved in epithelial-to-mesenchymal transition (EMT) and cancer stem cell maintenance.\n4. Both T-bet and Eomes have been shown to be overexpressed in gastric cancer.\n5. Overexpression of T-bet and Eomes has been linked to poor prognosis and cancer recurrence in gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet and Eomesodermin (Eomes) are T-box transcription factors implicated in gastric cancer.",
      "T-bet regulates the expression of genes involved in immune response and inflammation.",
      "Eomes regulates the expression of genes involved in epithelial-to-mesenchymal transition (EMT) and cancer stem cell maintenance.",
      "Both T-bet and Eomes have been shown to be overexpressed in gastric cancer.",
      "Overexpression of T-bet and Eomes has been linked to poor prognosis and cancer recurrence in gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: T-bet and Eomes are indeed T-box transcription factors, and they have been implicated in various types of cancer, including gastric cancer.\n\n2. TRUE: T-bet is known to regulate the expression of genes involved in immune responses and inflammation, which can contribute to cancer progression.\n\n3. UNKNOWN: Eomes is involved in regulating immune cells and has been studied in cancer, but it is not clear from this statement alone whether it is specifically implicated in regulating genes involved in EMT and cancer stem cell maintenance without additional context or research evidence.\n\n4. UNKNOWN: The particular expression pattern of T-bet and Eomes in gastric cancer would depend on the results from specific studies. The statement could be true, but without specific research data presented, it's not possible to confirm.\n\n5. UNKNOWN: The link between overexpression of T-bet and Eomes and poor prognosis or cancer recurrence in gastric cancer is research-specific. This kind of statement would require specific studies to verify whether such correlations exist.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI is a composite measure that takes into account various clinical and laboratory parameters, including:\n1. Serology (antibody levels)\n* Anti-nuclear antibody (ANA) titer\n* Anti-double-stranded DNA (dsDNA) antibody level\n* Anti-Smith antibody (Sm) level\n2. Organ involvement\n* Renal involvement (e.g., proteinuria, hematuria, or kidney damage)\n* Neuropsychiatric involvement (e.g., seizures, psychosis, or cognitive impairment)\n* Cardiovascular involvement (e.g., hypertension, pericarditis, or myocarditis)\n* Respiratory involvement (e.g., interstitial pneumonitis or pleuritis)\n* Musculoskeletal involvement (e.g., arthritis or muscle weakness)\n3. Laboratory abnormalities\n* Erythrocyte sedimentation rate (ESR)\n* C-reactive protein (CRP) level\n* Lymphocyte counts\n* Platelet counts\nThe LSI is calculated by assigning points for each parameter based on a predetermined scoring system, with higher scores indicating more severe disease. The LSI has been shown to be a useful tool for monitoring disease activity and assessing the response to treatment in patients with SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI includes clinical and laboratory parameters such as serology and organ involvement.\n3. Antibody levels assessed by the LSI include anti-nuclear antibody (ANA) titer, anti-double-stranded DNA (dsDNA) antibody level, and anti-Smith antibody (Sm) level.\n4. The LSI accounts for organ involvement through indicators such as renal involvement, neuropsychiatric involvement, and cardiovascular involvement.\n5. The scoring system in the LSI assigns points for each parameter, with higher scores indicating more severe disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI includes clinical and laboratory parameters such as serology and organ involvement.",
      "Antibody levels assessed by the LSI include anti-nuclear antibody (ANA) titer, anti-double-stranded DNA (dsDNA) antibody level, and anti-Smith antibody (Sm) level.",
      "The LSI accounts for organ involvement through indicators such as renal involvement, neuropsychiatric involvement, and cardiovascular involvement.",
      "The scoring system in the LSI assigns points for each parameter, with higher scores indicating more severe disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is no widely recognized standardized tool known as the Lupus Severity Index (LSI) specifically used to assess the severity of systemic lupus erythematosus (SLE); therefore, the veracity of the statement cannot be ascertained. The common tools for assessing SLE activity include the SLE Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index.\n\n2. UNKNOWN: Assuming that the LSI is a hypothetical or less known scale, the statement that it includes clinical and laboratory parameters such as serology and organ involvement could be plausible, as these are typical parameters included in disease severity assessments for SLE. However, since the LSI is not a well-known or standardized tool, the exact parameters it includes cannot be confirmed.\n\n3. UNKNOWN: Given that the existence of the LSI is not confirmed, whether it assesses specific antibody levels such as ANA, anti-dsDNA, or anti-Smith, cannot be determined. Typical assessments for SLE do often consider these antibodies, but we cannot say for sure if they are included in the hypothetical LSI.\n\n4. UNKNOWN: Similar to statement 2, while organ involvement is common in the assessment of SLE disease activity and severity, the specifics of whether LSI considers renal, neuropsychiatric, and cardiovascular involvement is not known due to the lack of information on the LSI itself.\n\n5. UNKNOWN: Since the LSI's existence and structure are not established, the scoring system and its methodology for indicating disease severity cannot be confirmed. However, it is customary for SLE assessment tools to assign points for each parameter with higher scores indicating more severe disease. But without specific knowledge of the LSI, this cannot be applied.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several human disorders, including:\n1. Intellectual disability: De novo mutations in ZSWIM6 have been identified as a cause of intellectual disability in several individuals.\n2. Autism spectrum disorder: Some studies have suggested that mutations in ZSWIM6 may contribute to the development of autism spectrum disorder.\n3. Epilepsy: ZSWIM6 mutations have been identified in individuals with epilepsy, suggesting that the gene may play a role in the regulation of neuronal excitability.\n4. Neurodevelopmental disorders: ZSWIM6 mutations have been found to be associated with a range of neurodevelopmental disorders, including ADHD, Tourette's syndrome, and Rett syndrome.\n5. Cancer: ZSWIM6 has been shown to be involved in the development and progression of certain types of cancer, including breast cancer and ovarian cancer.\nIt's important to note that the frequency and severity of these disorders can vary widely among individuals with ZSWIM6 mutations, and not all individuals with a mutation in this gene will develop these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 have been identified as a cause of intellectual disability in several individuals.\n2. Studies suggest that ZSWIM6 mutations may contribute to the development of autism spectrum disorder.\n3. Individuals with epilepsy have been found to have ZSWIM6 mutations, implying a potential role for the gene in regulating neuronal excitability.\n4. Mutations in ZSWIM6 are associated with a range of neurodevelopmental disorders, including ADHD, Tourette's syndrome, and Rett syndrome.\n5. ZSWIM6 is involved in the development and progression of certain types of cancer, such as breast cancer and ovarian cancer.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 have been identified as a cause of intellectual disability in several individuals.",
      "Studies suggest that ZSWIM6 mutations may contribute to the development of autism spectrum disorder.",
      "Individuals with epilepsy have been found to have ZSWIM6 mutations, implying a potential role for the gene in regulating neuronal excitability.",
      "Mutations in ZSWIM6 are associated with a range of neurodevelopmental disorders, including ADHD, Tourette's syndrome, and Rett syndrome.",
      "ZSWIM6 is involved in the development and progression of certain types of cancer, such as breast cancer and ovarian cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: De novo mutations in genes like ZSWIM6 have been linked to intellectual disability.\n2. TRUE: While direct causality might be complex to establish, there is scientific literature suggesting an association between mutations in ZSWIM6 and autism spectrum disorder, potentially contributing to its development.\n3. UNKNOWN: Without specific study references or more detailed information, the relationship between ZSWIM6 mutations and epilepsy cannot be decisively confirmed as true or false.\n4. UNKNOWN: Although there may be studies exploring the links between ZSWIM6 mutations and various neurodevelopmental disorders, there isn't enough information provided here to definitively confirm the connection to ADHD, Tourette's syndrome, and Rett syndrome.\n5. UNKNOWN: The role of ZSWIM6 in cancer development and progression is not clear from the statement provided, and specific studies would need to be referenced to accurately confirm or deny this claim.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify neurodegenerative diseases based on the type of protein aggregates they contain. It can be used to classify diseases such as:\n* Alzheimer's disease (AD): contains amyloid- (A) aggregates\n* Parkinson's disease (PD): contains -synuclein aggregates\n* Progressive supranuclear palsy (PSP): contains tau protein aggregates\n* Frontotemporal dementia (FTD): contains TDP-43 protein aggregates\n* Lewy body dementia (LBD): contains -synuclein and ubiquitin protein aggregates.\nNote: This is not an exhaustive list and there may be other diseases that can be classified using the Koos Classification system.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification system is used to classify neurodegenerative diseases.\n2. Alzheimer's disease contains amyloid- (A) aggregates.\n3. Parkinson's disease contains -synuclein aggregates.\n4. Progressive supranuclear palsy contains tau protein aggregates.\n5. Frontotemporal dementia contains TDP-43 protein aggregates.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification system is used to classify neurodegenerative diseases.",
      "Alzheimer's disease contains amyloid- (A) aggregates.",
      "Parkinson's disease contains -synuclein aggregates.",
      "Progressive supranuclear palsy contains tau protein aggregates.",
      "Frontotemporal dementia contains TDP-43 protein aggregates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Kooij Classification System, not \"Koos,\" is used for ADHD and is not typically used for neurodegenerative diseases. There are other classification systems for neurodegenerative diseases, but they are not widely known as the Koos Classification.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphoinositide 3-kinase). In vivo, AZD8601 has been shown to have a range of effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo.\n2. Induction of apoptosis: AZD8601 has been shown to induce apoptosis (programmed cell death) in cancer cells, which can lead to a decrease in tumor volume.\n3. Inhibition of angiogenesis: AZD8601 has been shown to inhibit the formation of new blood vessels, which are essential for tumor growth and survival.\n4. Enhancement of chemotherapy: AZD8601 has been shown to enhance the effectiveness of chemotherapy drugs in treating cancer, both in vitro and in vivo.\n5. Immune modulation: AZD8601 has been shown to modulate the immune response, including the activation of immune cells and the production of cytokines.\n6. Neuroprotection: AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.\n7. Cardiovascular protection: AZD8601 has been shown to have cardiovascular protective effects in animal models of cardiovascular disease, such as hypertension and atherosclerosis.\n8. Anti-inflammatory effects: AZD8601 has been shown to have anti-inflammatory effects in various animal models of inflammation.\nIt is important to note that the effects of AZD8601 can vary depending on the specific experimental conditions and the type of cancer or disease being studied. Further research is needed to fully understand the in vivo effects of AZD8601 and its potential as a therapeutic agent.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is an inhibitor of the enzyme phosphoinositide 3-kinase (PI3K).\n2. AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, in in vivo studies.\n3. AZD8601 has been demonstrated to induce apoptosis in cancer cells.\n4. AZD8601 has been shown to inhibit angiogenesis, which is essential for tumor growth and survival.\n5. AZD8601 has been observed to have neuroprotective effects in animal models of neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is an inhibitor of the enzyme phosphoinositide 3-kinase (PI3K).",
      "AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, in in vivo studies.",
      "AZD8601 has been demonstrated to induce apoptosis in cancer cells.",
      "AZD8601 has been shown to inhibit angiogenesis, which is essential for tumor growth and survival.",
      "AZD8601 has been observed to have neuroprotective effects in animal models of neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of the enzyme phosphoinositide 3-kinase (PI3K). AZD8601 is actually a modified mRNA formulation used for vascular endothelial growth factor A (VEGF-A) protein expression.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: AZD8601 is a specific drug compound and my knowledge cut-off date is in 2023, so the status and research findings related to AZD8601 beyond that are not within my domain of information. Therefore, I cannot determine the truth of statements relating to specific effects or studies without current data beyond my last update. Statements about its specific effects, such as in vivo studies, apoptosis induction, and neuroprotective effects, would require up-to-date scientific literature to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Spatially-Organized Histone Fragmentation) are created through a process called histone fragmentation, which involves the breakage of histone proteins into smaller fragments. This process can occur through various mechanisms, including:\n1. DNA damage: When DNA is damaged, histones can become fragmented as a result of the repair process.\n2. Chromatin remodeling: Chromatin remodeling complexes can also fragment histones as they move along the DNA template, creating SAHFs.\n3. Transcriptional elongation: During transcriptional elongation, RNA polymerase II can also fragment histones, leading to the creation of SAHFs.\n4. Ubiquitination: Ubiquitination of histones can also lead to their fragmentation, resulting in the formation of SAHFs.\nThese mechanisms can lead to the formation of SAHFs in specific genomic regions, such as gene promoters, gene bodies, or other regulatory regions, and play a role in various cellular processes, including gene regulation, DNA repair, and cell cycle progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs are created through a process known as histone fragmentation.\n2. DNA damage can cause histones to become fragmented, which may result in the formation of SAHFs.\n3. Chromatin remodeling complexes can fragment histones leading to SAHFs creation.\n4. Histone fragmentation can occur during transcriptional elongation by RNA polymerase II, contributing to the creation of SAHFs.\n5. Ubiquitination of histones can lead to their fragmentation and subsequent formation of SAHFs.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs are created through a process known as histone fragmentation.",
      "DNA damage can cause histones to become fragmented, which may result in the formation of SAHFs.",
      "Chromatin remodeling complexes can fragment histones leading to SAHFs creation.",
      "Histone fragmentation can occur during transcriptional elongation by RNA polymerase II, contributing to the creation of SAHFs.",
      "Ubiquitination of histones can lead to their fragmentation and subsequent formation of SAHFs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SAHFs (Senescence-Associated Heterochromatin Foci) are not created through a process known as histone fragmentation. They are formed by a reorganization of chromatin during the process of cellular senescence, and this involves specific changes in histone modifications, not fragmentation.\n2. TRUE: DNA damage can trigger cellular senescence, which is associated with the formation of SAHFs. These structures are believed to help enforce the stable silencing of proliferation-promoting genes.\n3. UNKNOWN: While chromatin remodeling complexes are involved in the reorganization of chromatin, which could include the formation of SAHFs, the specific statement that these complexes fragment histones to create SAHFs is not well established and lacks specific evidence.\n4. FALSE [correction]: Histone fragmentation during transcriptional elongation is not a recognized process leading to the creation of SAHFs. SAHFs formation is associated with chromatin reorganization during senescence, and transcriptional elongation is related to gene expression, not histone fragmentation and SAHFs synthesis.\n5. UNKNOWN: While ubiquitination is a post-translational modification that can lead to histone regulation and is involved in chromatin dynamics, whether it specifically leads to histone fragmentation and subsequent SAHFs formation is not clearly established in the scientific literature.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95/Discs-large/ZO-1) domain is a protein module found in the SATB1 (Sex-determining region Y-box 1) transcription factor. The PDZ domain of SATB1 is involved in the regulation of protein-protein interactions and plays a crucial role in the nuclear localization and stability of the protein. It acts as a molecular \"hand\" that binds to specific phosphorylated serine/threonine residues on target proteins, which helps to recruit and anchor SATB1 to specific subcellular locations. In addition, the PDZ domain can also interact with other proteins to modulate the activity of SATB1 and regulate its function in various cellular processes, including cell fate determination, differentiation, and migration.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein module found in the SATB1 transcription factor.\n2. The PDZ domain of SATB1 is involved in the regulation of protein-protein interactions.\n3. The PDZ domain in SATB1 is crucial for the nuclear localization and stability of the protein.\n4. The PDZ domain binds to specific phosphorylated serine/threonine residues on target proteins.\n5. The PDZ domain's interactions can modulate the activity of SATB1 and regulate its function in processes like cell fate determination, differentiation, and migration.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein module found in the SATB1 transcription factor.",
      "The PDZ domain of SATB1 is involved in the regulation of protein-protein interactions.",
      "The PDZ domain in SATB1 is crucial for the nuclear localization and stability of the protein.",
      "The PDZ domain binds to specific phosphorylated serine/threonine residues on target proteins.",
      "The PDZ domain's interactions can modulate the activity of SATB1 and regulate its function in processes like cell fate determination, differentiation, and migration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is not exclusive to the SATB1 transcription factor, it is a common protein interaction module found in many different proteins.\n2. TRUE: PDZ domains, in general, are known to be involved in the regulation of protein-protein interactions.\n3. UNKNOWN: The specific role of the PDZ domain in the nuclear localization and stability of SATB1 is not common knowledge and would require specific scientific literature to confirm.\n4. FALSE [correction]: PDZ domains typically bind to specific sequences at the C-termini of target proteins, often consisting of hydrophobic residues followed by a hydrophilic residue (not necessarily phosphorylated serine/threonine).\n5. UNKNOWN: While PDZ domains play roles in various cellular processes, the statement's specificity to SATB1's PDZ domain and the detailed processes such as cell fate determination, differentiation, and migration would require validation from scientific research specific to SATB1.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS (Blood Lymphocyte Immunophenotyping by Image Analysis) technique is based on the analysis of immunophenotyping data, which is the study of the expression of cell surface proteins on immune cells. In the BLISS technique, immunophenotyping data is analyzed using image analysis software to identify and quantify specific cell surface proteins on lymphocytes. The technique is particularly useful for analyzing the expression of cell surface proteins on T cells and B cells, which are important immune cells that play a central role in the immune response.\nThe BLISS technique involves several steps:\n1. Cell isolation: Lymphocytes are isolated from peripheral blood or other tissues using various methods, such as density gradient centrifugation or magnetic bead separation.\n2. Staining: The isolated lymphocytes are stained with antibodies that recognize specific cell surface proteins of interest, such as CD4, CD8, or CD20. The antibodies are usually labeled with fluorescent dyes or other markers that allow for their visualization using a fluorescence microscope.\n3. Image acquisition: The lymphocytes are then fixed and mounted on a microscope slide, and images are acquired using a fluorescence microscope. The images are typically captured using a digital camera connected to the microscope.\n4. Image analysis: The acquired images are then analyzed using image analysis software, such as FlowJo or FACSDIVA. The software allows for the identification and quantification of specific cell surface proteins on the lymphocytes.\n5. Data interpretation: The results of the analysis are then interpreted to identify any changes in the expression of cell surface proteins on the lymphocytes. This information can be used to understand the immune response and to identify any abnormalities or disorders.\nThe BLISS technique has several advantages over other methods of immunophenotyping, including its high sensitivity and specificity, as well as its ability to analyze large numbers of cells quickly and easily. It has been used to study a wide range of immune-related disorders, including autoimmune diseases, cancer, and infectious diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is based on analyzing immunophenotyping data to study the expression of cell surface proteins on immune cells.\n2. Immunophenotyping data in the BLISS technique is analyzed using image analysis software to identify and quantify specific cell surface proteins on lymphocytes.\n3. The BLISS technique uses staining of lymphocytes with antibodies labeled with fluorescent dyes or markers for visualization under a fluorescence microscope.\n4. The lymphocytes' images for the BLISS technique are captured using a digital camera connected to the fluorescence microscope.\n5. The BLISS technique has been utilized in the study of immune-related disorders, including autoimmune diseases, cancer, and infectious diseases.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is based on analyzing immunophenotyping data to study the expression of cell surface proteins on immune cells.",
      "Immunophenotyping data in the BLISS technique is analyzed using image analysis software to identify and quantify specific cell surface proteins on lymphocytes.",
      "The BLISS technique uses staining of lymphocytes with antibodies labeled with fluorescent dyes or markers for visualization under a fluorescence microscope.",
      "The lymphocytes' images for the BLISS technique are captured using a digital camera connected to the fluorescence microscope.",
      "The BLISS technique has been utilized in the study of immune-related disorders, including autoimmune diseases, cancer, and infectious diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The BLISS technique, or Barcode Labeling for Imaging of Single Samples, generally involves labeling DNA or RNA rather than analyzing the expression of cell surface proteins on immune cells. \n2. FALSE [correction]: The BLISS technique typically involves the labeling of nucleic acids with barcodes for spatially-resolved detection in tissue samples or cells, not the use of image analysis software to identify and quantify cell surface proteins on lymphocytes.\n3. FALSE [correction]: The BLISS technique is not primarily focused on the use of fluorescent antibody staining for visualization under a fluorescence microscope but is based on in situ barcode labeling and sequencing of nucleic acids.\n4. FALSE [correction]: While capturing images with a digital camera connected to a microscope may occur in various techniques, the BLISS technique specifically involves the ligation of barcoded adapters to nucleic acids which are then imaged and sequenced to provide spatially-resolved molecular information.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Here are three NK3R (neurokinin 3 receptor) antagonists:\n1. A-803460: A potent and selective NK3R antagonist that has been used to study the role of NK3R in various physiological processes, including pain and inflammation.\n2. CP-93,893: A selective NK3R antagonist that has been shown to have analgesic and anti-inflammatory effects in animal models of pain and inflammation.\n3. GR 127935: A potent and selective NK3R antagonist that has been used to study the role of NK3R in the regulation of gastric acid secretion and has been shown to have potential as a treatment for gastrointestinal disorders such as gastroesophageal reflux disease (GERD).",
    "llama-2-7b-chat-hf_fact_raw": "1. A-803460 is a potent and selective NK3R antagonist.\n2. CP-93,893 is a selective NK3R antagonist with analgesic and anti-inflammatory effects demonstrated in animal models.\n3. GR 127935 is a potent and selective NK3R antagonist with potential as a treatment for gastrointestinal disorders such as GERD.",
    "llama-2-7b-chat-hf_fact": [
      "A-803460 is a potent and selective NK3R antagonist.",
      "CP-93,893 is a selective NK3R antagonist with analgesic and anti-inflammatory effects demonstrated in animal models.",
      "GR 127935 is a potent and selective NK3R antagonist with potential as a treatment for gastrointestinal disorders such as GERD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: GR 127935 is a potent and selective antagonist for the 5-HT1B and 5-HT1D receptors, not NK3R, and it has been investigated for its potential to treat migraines and other disorders, not specifically gastrointestinal disorders like GERD.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, a cholera vaccine developed by GlaxoSmithKline (GSK), has been shown to provide protection against moderate to severe cholera in clinical trials.\nThe protective efficacy of Vaxchora against moderate to severe cholera was demonstrated in a phase 3 clinical trial conducted in Bangladesh, where the vaccine was evaluated in a population at high risk of cholera infection. The trial showed that Vaxchora provided 77% protection against moderate to severe cholera in individuals who received a single dose of the vaccine, and 85% protection in those who received a two-dose schedule.\nAdditionally, a phase 2b clinical trial conducted in Africa showed that Vaxchora provided 60% protection against cholera in individuals who received a single dose of the vaccine.\nIt is important to note that these efficacy results are based on observational studies and may not reflect the vaccine's performance in real-world settings, where other factors such as the presence of other infections, nutritional status, and access to healthcare may influence the vaccine's effectiveness.\nOverall, the available evidence suggests that Vaxchora is effective in providing protection against moderate to severe cholera in high-risk populations, although further research is needed to confirm these findings and to determine the long-term durability of protection provided by the vaccine.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a cholera vaccine developed by GlaxoSmithKline (GSK).\n2. A phase 3 clinical trial in Bangladesh showed that Vaxchora provided 77% protection against moderate to severe cholera with a single dose.\n3. The same phase 3 trial indicated that Vaxchora provided 85% protection against moderate to severe cholera with a two-dose schedule.\n4. A phase 2b clinical trial in Africa demonstrated that Vaxchora provided 60% protection against cholera with a single dose.\n5. The efficacy results from trials may not necessarily reflect Vaxchora's performance in real-world settings.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a cholera vaccine developed by GlaxoSmithKline (GSK).",
      "A phase 3 clinical trial in Bangladesh showed that Vaxchora provided 77% protection against moderate to severe cholera with a single dose.",
      "The same phase 3 trial indicated that Vaxchora provided 85% protection against moderate to severe cholera with a two-dose schedule.",
      "A phase 2b clinical trial in Africa demonstrated that Vaxchora provided 60% protection against cholera with a single dose.",
      "The efficacy results from trials may not necessarily reflect Vaxchora's performance in real-world settings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vaxchora is a cholera vaccine developed by PaxVax, not GlaxoSmithKline (GSK).\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine, also known as the Shanchol vaccine, which was approved by the Food and Drug Administration (FDA) in 2016.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US is an oral vaccine.\n2. The oral cholera vaccine is known as the Shanchol vaccine.\n3. The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2016.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US is an oral vaccine.",
      "The oral cholera vaccine is known as the Shanchol vaccine.",
      "The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2016."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The oral cholera vaccine approved in the US is known as Vaxchora, not Shanchol.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the X-linked genes encoding the immunoglobulin heavy chain (IGH) and/or the T-cell receptor (TCR) beta chain. These genes are located on the X chromosome and play a critical role in the development and function of the adaptive immune system. Approximately 70% of CVID cases in Europeans are caused by mutations in these genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the genes encoding the immunoglobulin heavy chain (IGH) and/or the T-cell receptor (TCR) beta chain.\n2. The genes responsible for the most common cause of CVID in Europeans are located on the X chromosome.\n3. These genes are crucial for the development and function of the adaptive immune system.\n4. Approximately 70% of CVID cases in Europeans are attributed to mutations in the X-linked genes IGH and TCR beta chain.",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the genes encoding the immunoglobulin heavy chain (IGH) and/or the T-cell receptor (TCR) beta chain.",
      "The genes responsible for the most common cause of CVID in Europeans are located on the X chromosome.",
      "These genes are crucial for the development and function of the adaptive immune system.",
      "Approximately 70% of CVID cases in Europeans are attributed to mutations in the X-linked genes IGH and TCR beta chain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common known monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the gene encoding inducible T-cell co-stimulator (ICOS).\n2. FALSE [correction]: ICOS, the gene most commonly involved in monogenic CVID, is not located on the X chromosome but rather on chromosome 2.\n3. TRUE: Genes like IGH and TCR, and also including ICOS, are crucial for the development and function of the adaptive immune system.\n4. FALSE [correction]: It is not accurate to state that approximately 70% of CVID cases in Europeans are attributed to mutations in the IGH and TCR beta chain genes, as most cases of CVID are not linked to a single gene and are considered polygenic or multifactorial in origin.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to be mutated or downregulated in many cases of Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. The IFIT1 gene encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), which plays a role in the regulation of gene expression and the immune response. Studies have shown that IFIT1 is involved in the regulation of T cell activation and differentiation, and that mutations or downregulation of IFIT1 can lead to an imbalance in the immune response, contributing to the development of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene has been found to be mutated or downregulated in many cases of Systemic Lupus Erythematosus (SLE).\n2. The IFIT1 gene encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1).\n3. IFIT1 is involved in the regulation of gene expression and the immune response.\n4. IFIT1 plays a role in the regulation of T cell activation and differentiation.\n5. Mutations or downregulation of the IFIT1 gene can contribute to the development of Systemic Lupus Erythematosus (SLE).",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene has been found to be mutated or downregulated in many cases of Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1).",
      "IFIT1 is involved in the regulation of gene expression and the immune response.",
      "IFIT1 plays a role in the regulation of T cell activation and differentiation.",
      "Mutations or downregulation of the IFIT1 gene can contribute to the development of Systemic Lupus Erythematosus (SLE)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nExplanation:\n1. While IFIT1 gene has been studied in the context of its role in immune response, the specific claim that it is mutated or downregulated in many cases of SLE would require specific scientific data or studies to confirm, which is not provided here.\n2. The IFIT1 gene does indeed encode the interferon-induced protein with tetratricopeptide repeats 1, which is part of a family of proteins involved in the immune response to viral infection.\n3. IFIT1 is known to be involved in the response to viral infection as part of the interferon-regulated gene expression and therefore plays a role in immune response regulation generally.\n4. The role of IFIT1 specific to T cell activation and differentiation is not stated in the provided statements, and this is a very specific function that would require supportive data from scientific research for confirmation.\n5. Mutations or downregulation in genes associated with the immune response, such as IFIT1, can contribute to autoimmune diseases like SLE; however, the specific claim about IFIT1 might again need specific scientific studies for confirmation. The statement in general aligns with the understanding of genetic influences on autoimmune disorders.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure used to assess the severity of elbow pain and stiffness in patients with various elbow conditions, such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis). The score is used to evaluate the effectiveness of treatment interventions, such as physical therapy, medication, or surgery, and to monitor the progression of the condition over time. The LES consists of 11 items that assess the severity of pain and stiffness in the elbow, as well as the patient's ability to perform various activities, such as gripping, lifting, and bending. The scores are then used to calculate a total score, which can range from 0 to 100, with higher scores indicating greater severity of symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow pain and stiffness in patients.\n2. It is applied to conditions such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis).\n3. The LES evaluates the effectiveness of various treatment interventions.\n4. The score is used to monitor the progression of elbow conditions over time.\n5. The Liverpool Elbow Score ranges from 0 to 100, with higher scores indicating greater severity of symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow pain and stiffness in patients.",
      "It is applied to conditions such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis).",
      "The LES evaluates the effectiveness of various treatment interventions.",
      "The score is used to monitor the progression of elbow conditions over time.",
      "The Liverpool Elbow Score ranges from 0 to 100, with higher scores indicating greater severity of symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Liverpool Elbow Score ranges from 0 to 100, with higher scores indicating less severity of symptoms or better elbow function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a large-scale genomics project launched in 2012 in the UK with the aim of analyzing the genomes of 100,000 patients with rare and common diseases, including cancer. The project was completed in 2019 and has provided valuable insights into the genetic basis of various diseases, including sarcoma.\nSarcoma is a rare and complex type of cancer that affects connective tissue, including bone, muscle, and fat. It accounts for approximately 1% of all adult cancers and 15% of all pediatric cancers. The 100,000 Genomes Project has provided several efforts to better understand the genetic landscape of sarcoma, including:\n1. Identification of novel genetic mutations: The project has identified novel genetic mutations in sarcoma tumors, including those in genes not previously implicated in the disease. These findings have provided new insights into the genetic heterogeneity of sarcoma and have the potential to lead to the development of new diagnostic markers and therapeutic targets.\n2. Development of new diagnostic tests: The project has developed new diagnostic tests that can identify genetic mutations in sarcoma tumors, including those that are specific to certain subtypes of the disease. These tests have the potential to improve diagnostic accuracy and guide personalized treatment strategies.\n3. Investigation of the molecular mechanisms underlying sarcoma development and progression: The project has provided insights into the molecular mechanisms underlying sarcoma development and progression, including the role of genetic mutations, epigenetic alterations, and environmental factors. These findings have the potential to lead to the development of new therapeutic strategies targeting these mechanisms.\n4. Identification of potential therapeutic targets: The project has identified potential therapeutic targets in sarcoma, including genes and proteins that are involved in key cellular processes such as cell division, growth, and survival. These findings have the potential to lead to the development of new targeted therapies for sarcoma.\n5. Improved understanding of the clinical and molecular heterogeneity of sarcoma: The project",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2012 in the UK.\n2. The 100,000 Genomes Project aimed to analyze the genomes of 100,000 patients with rare and common diseases, including cancer, and was completed in 2019.\n3. Sarcoma accounts for approximately 1% of all adult cancers and 15% of all pediatric cancers.\n4. The 100,000 Genomes Project has identified novel genetic mutations in sarcoma tumors.\n5. The project developed new diagnostic tests that can identify genetic mutations in sarcoma tumors.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2012 in the UK.",
      "The 100,000 Genomes Project aimed to analyze the genomes of 100,000 patients with rare and common diseases, including cancer, and was completed in 2019.",
      "Sarcoma accounts for approximately 1% of all adult cancers and 15% of all pediatric cancers.",
      "The 100,000 Genomes Project has identified novel genetic mutations in sarcoma tumors.",
      "The project developed new diagnostic tests that can identify genetic mutations in sarcoma tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in 2013 in the UK.\n2. TRUE \n3. TRUE \n4. UNKNOWN \n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, protein ALEX1 (Armadillo-like Expressed in Xenopus 1) contains multiple armadillo repeats. Armadillo repeats are a type of structural motif found in proteins that are involved in protein-protein interactions and are characterized by a conserved sequence of about 40-60 amino acids. ALEX1 is a protein that is involved in the regulation of gene expression and contains multiple armadillo repeats in its structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains multiple armadillo repeats. \n2. Armadillo repeats are involved in protein-protein interactions. \n3. Armadillo repeats are characterized by a conserved sequence of about 40-60 amino acids. \n4. ALEX1 is involved in the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains multiple armadillo repeats.",
      "Armadillo repeats are involved in protein-protein interactions.",
      "Armadillo repeats are characterized by a conserved sequence of about 40-60 amino acids.",
      "ALEX1 is involved in the regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n\nExplanation:\nThe specificity of protein ALEX1 containing armadillo repeats and its function in regulation of gene expression is not standard knowledge and would require specific scientific literature to confirm, hence the UNKNOWN responses. Armadillo repeats and their role in protein-protein interactions and their characteristic amino acid sequence length are general knowledge in the field of molecular biology, making those statements TRUE.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Enzymes that remove histone modifications include:\n1. Histone demethylases: remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples include histone demethylases KDM4B and KDM5A.\n2. Histone acetyltransferases (HATs): add acetyl groups to histone proteins, leading to increased chromatin accessibility and gene expression. Examples include HATs p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): remove acetyl groups from histone proteins, leading to decreased chromatin accessibility and gene expression. Examples include HDAC1 and HDAC2.\n4. Lysine-specific demethylase 1 (LSD1): removes methyl groups from histone H3 lysine 4 (H3K4), leading to changes in chromatin structure and gene expression.\n5. Arginine methyltransferases: add methyl groups to histone arginine residues, leading to changes in chromatin structure and gene expression. Examples include PRMT5 and PRMT6.\n6. Protein arginine methyltransferase 1 (PRMT1): adds methyl groups to histone arginine residues, leading to changes in chromatin structure and gene expression.\n7. Histone ubiquitin ligases: remove histone proteins from chromatin, leading to changes in chromatin structure and gene expression. Examples include HUL5 and UBA1.\n8. Ubiquitin-protein ligase complexes: remove histone proteins from chromatin, leading to changes in chromatin structure and gene expression. Examples include the Nedd4-ubiquitin ligase complex and the Mus81-ubiquitin ligase complex.\n9. Histone chaperones: help to fold and stabilize histone proteins, leading to changes in chromatin structure and gene expression. Examples include HSP90 and HSP70.\n10. Histone-folding proteins: help to fold and stabilize histone proteins, leading to changes in chromatin structure and gene expression. Examples include HOPS and HFC4",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases such as KDM4B and KDM5A are enzymes that remove methyl groups from histone proteins.\n2. Histone acetyltransferases like p300 and CBP can add acetyl groups to histone proteins.\n3. Histone deacetylases (HDACs), including HDAC1 and HDAC2, are enzymes that remove acetyl groups from histone proteins.\n4. Lysine-specific demethylase 1 (LSD1) is an enzyme that removes methyl groups from histone H3 lysine 4 (H3K4).\n5. Protein arginine methyltransferase 1 (PRMT1) adds methyl groups to histone arginine residues.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases such as KDM4B and KDM5A are enzymes that remove methyl groups from histone proteins.",
      "Histone acetyltransferases like p300 and CBP can add acetyl groups to histone proteins.",
      "Histone deacetylases (HDACs), including HDAC1 and HDAC2, are enzymes that remove acetyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) is an enzyme that removes methyl groups from histone H3 lysine 4 (H3K4).",
      "Protein arginine methyltransferase 1 (PRMT1) adds methyl groups to histone arginine residues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Head CT scans, like any other medical imaging procedure, carry a small risk of increasing the risk of brain tumors. However, the risk is considered to be very low.\nThe International Agency for Research on Cancer (IARC) has classified CT scans as \"possibly carcinogenic to humans,\" based on limited evidence in humans and sufficient evidence in animals. The IARC notes that the evidence is limited to studies in animals, and more research is needed to determine the potential cancer-causing effects in humans.\nThe possible mechanisms by which CT scans may increase the risk of brain tumors include:\n1. Ionizing radiation: CT scans use ionizing radiation, which can damage DNA and increase the risk of cancer. However, the amount of radiation exposure from a CT scan is typically very low, and the risk of cancer is considered to be small.\n2. Genetic instability: CT scans can cause genetic instability in cells, which may increase the risk of cancer.\n3. Inflammation: CT scans can cause inflammation in the brain, which may increase the risk of cancer.\nIt is important to note that the risk of brain tumors from CT scans is still very low, and the benefits of the scan often outweigh the risks. However, if you have concerns about the potential risks of CT scans, you should discuss them with your doctor.",
    "llama-2-7b-chat-hf_fact_raw": "1. The International Agency for Research on Cancer (IARC) has classified CT scans as \"possibly carcinogenic to humans.\"\n2. CT scans use ionizing radiation, which can damage DNA.\n3. Excessive exposure to ionizing radiation from CT scans is considered to increase the risk of cancer.\n4. CT scans can cause genetic instability in cells.\n5. CT scans can lead to inflammation in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "The International Agency for Research on Cancer (IARC) has classified CT scans as \"possibly carcinogenic to humans.\"",
      "CT scans use ionizing radiation, which can damage DNA.",
      "Excessive exposure to ionizing radiation from CT scans is considered to increase the risk of cancer.",
      "CT scans can cause genetic instability in cells.",
      "CT scans can lead to inflammation in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There is no established evidence that CT scans cause inflammation in the brain. However, the concern with CT scans primarily relates to the ionizing radiation and its potential to damage DNA and increase the risk of cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency. It is a transcription factor that is expressed in early embryonic development and is important for the maintenance of neural progenitor cells and their ability to differentiate into different neural cell types.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.\n2. Otx2 is a transcription factor.\n3. Otx2 is expressed in early embryonic development.\n4. Otx2 is important for the maintenance of neural progenitor cells.\n5. Otx2 helps neural progenitor cells differentiate into different neural cell types.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency.",
      "Otx2 is a transcription factor.",
      "Otx2 is expressed in early embryonic development.",
      "Otx2 is important for the maintenance of neural progenitor cells.",
      "Otx2 helps neural progenitor cells differentiate into different neural cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is associated with neural development and is essential for the development of the brain and sensory organs, but it is not directly associated with \"neural pluripotency.\" Oct4, not Otx2, is typically associated with pluripotency.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region has multiple DNase I hypersensitive sites (DHSs), which are regions of DNA that are more susceptible to cleavage by the enzyme DNase I. The exact number of DHSs in the beta globin locus region can vary depending on the specific strain of mouse and the method used to identify them, but there are typically several dozen to several hundred DHSs in this region. These sites are often associated with regulatory elements, such as enhancers and silencers, that play important roles in the control of beta globin gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region contains multiple DNase I hypersensitive sites (DHSs).\n2. DNase I hypersensitive sites are areas of DNA more susceptible to cleavage by the enzyme DNase I.\n3. The number of DNase I hypersensitive sites in the murine beta globin locus can vary depending on the mouse strain and identification method.\n4. Typically, there can be several dozen to several hundred DNase I hypersensitive sites in the murine beta globin locus region.\n5. These DNase I hypersensitive sites are often associated with regulatory elements like enhancers and silencers that control beta globin gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region contains multiple DNase I hypersensitive sites (DHSs).",
      "DNase I hypersensitive sites are areas of DNA more susceptible to cleavage by the enzyme DNase I.",
      "The number of DNase I hypersensitive sites in the murine beta globin locus can vary depending on the mouse strain and identification method.",
      "Typically, there can be several dozen to several hundred DNase I hypersensitive sites in the murine beta globin locus region.",
      "These DNase I hypersensitive sites are often associated with regulatory elements like enhancers and silencers that control beta globin gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: While the murine beta globin locus does contain multiple DNase I hypersensitive sites, saying there can be several dozen to several hundred is likely an exaggeration. Typically, a specific gene locus such as the beta globin locus will have a much more limited and defined number of DNase I hypersensitive sites.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Sure, here are some European influenza vaccines that are currently available or have been approved for use in the European region:\n1. Fluarix Tetra (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of influenza virus (two A strains and two B strains).\n2. Flulaval (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of influenza virus (two A strains and one B strain).\n3. AggreVax (Sanofi Pasteur): This is a quadrivalent vaccine that protects against four strains of influenza virus (two A strains and two B strains).\n4. FluMist (MedImmune): This is a live, attenuated influenza vaccine that is given as a nasal spray and protects against two strains of influenza virus (one A strain and one B strain).\n5. Influvac Tetral (Bio Farma): This is a quadrivalent vaccine that protects against four strains of influenza virus (two A strains and two B strains).\n6. Vaxigrip Tetra (Sanofi Pasteur): This is a quadrivalent vaccine that protects against four strains of influenza virus (two A strains and two B strains).\n7. Focetria (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of influenza virus (two A strains and one B strain).\n8. Fluvirin (Novartis): This is a trivalent vaccine that protects against three strains of influenza virus (two A strains and one B strain).\n9. Agrippal (Sanofi Pasteur): This is a quadrivalent vaccine that protects against four strains of influenza virus (two A strains and two B strains).\n10. Fluad (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of influenza virus (two A strains and two B strains), and also contains an adjuvant called MF5",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent influenza vaccine by GlaxoSmithKline that protects against two A strains and two B strains of the influenza virus.\n2. Flulaval is a trivalent influenza vaccine by GlaxoSmithKline that protects against two A strains and one B strain of the influenza virus.\n3. AggreVax is a quadrivalent influenza vaccine by Sanofi Pasteur that protects against two A strains and two B strains of the influenza virus.\n4. FluMist is a live, attenuated influenza vaccine by MedImmune given as a nasal spray that protects against one A strain and one B strain of the influenza virus.\n5. Vaxigrip Tetra is a quadrivalent influenza vaccine by Sanofi Pasteur that protects against two A strains and two B strains of the influenza virus.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent influenza vaccine by GlaxoSmithKline that protects against two A strains and two B strains of the influenza virus.",
      "Flulaval is a trivalent influenza vaccine by GlaxoSmithKline that protects against two A strains and one B strain of the influenza virus.",
      "AggreVax is a quadrivalent influenza vaccine by Sanofi Pasteur that protects against two A strains and two B strains of the influenza virus.",
      "FluMist is a live, attenuated influenza vaccine by MedImmune given as a nasal spray that protects against one A strain and one B strain of the influenza virus.",
      "Vaxigrip Tetra is a quadrivalent influenza vaccine by Sanofi Pasteur that protects against two A strains and two B strains of the influenza virus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Flulaval is a quadrivalent influenza vaccine by GlaxoSmithKline that protects against two A strains and two B strains of the influenza virus.\n3. FALSE [correction]: There is no vaccine known as AggreVax by Sanofi Pasteur. The company does produce a quadrivalent influenza vaccine but under different brand names, such as Fluzone Quadrivalent.\n4. FALSE [correction]: FluMist is a live, attenuated influenza vaccine by AstraZeneca (formerly MedImmune) given as a nasal spray that protects against four strains of the influenza virus, typically two A strains and two B strains.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include viruses such as measles virus, mumps virus, and respiratory syncytial virus (RSV). Their genome is composed of several segments of RNA, each of which encodes a different protein. The segments are connected by non-coding regions called introns, and the entire genome is transcribed in a negative-sense direction, meaning that the RNA molecule is complementary to the mRNA transcript that is produced.",
    "llama-2-7b-chat-hf_fact_raw": "1. The paramyxovirus genome is composed of negative-sense RNA.\n2. Paramyxoviruses include viruses such as measles virus, mumps virus, and respiratory syncytial virus (RSV).\n3. The paramyxovirus genome is made up of several segments of RNA.\n4. Each segment of the paramyxovirus genome encodes a different protein.\n5. The RNA segments in the paramyxovirus genome are connected by non-coding regions called introns.",
    "llama-2-7b-chat-hf_fact": [
      "The paramyxovirus genome is composed of negative-sense RNA.",
      "Paramyxoviruses include viruses such as measles virus, mumps virus, and respiratory syncytial virus (RSV).",
      "The paramyxovirus genome is made up of several segments of RNA.",
      "Each segment of the paramyxovirus genome encodes a different protein.",
      "The RNA segments in the paramyxovirus genome are connected by non-coding regions called introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The paramyxovirus genome is composed of a single strand of negative-sense RNA, not several segments.\n4. FALSE [correction]: Since the paramyxovirus genome is non-segmented, there are not multiple segments each encoding a different protein. Different proteins are encoded along the single continuous RNA genome.\n5. FALSE [correction]: The paramyxovirus genome does not contain introns as it is composed of RNA and replicates in the cytoplasm. Introns are typically found in the nuclear DNA of eukaryotic cells and are not a feature of the paramyxovirus genome structure.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of plaque psoriasis. It is a topical phosphodiesterase 4 (PDE4) inhibitor that helps to reduce inflammation and slow down the growth of skin cells, thereby improving the symptoms of plaque psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.\n2. Roflumilast is a topical phosphodiesterase 4 (PDE4) inhibitor.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis.",
      "Roflumilast is a topical phosphodiesterase 4 (PDE4) inhibitor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is typically used for the treatment of chronic obstructive pulmonary disease (COPD), not plaque psoriasis. However, it is important to note that there could be ongoing or completed clinical trials evaluating roflumilast cream for different conditions such as plaque psoriasis.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. CpG Island Finder: This tool identifies CpG islands, which are known to be enriched in ncRNA promoters.\n2. ProbeFinder: This tool predicts RNA polymerase II (RNApII) promoter sequences and identifies potential promoter regions in ncRNAs.\n3. RNApromoter: This tool predicts RNApII promoter sequences and visualizes them in the context of the genome.\n4. Promoter Scan: This tool identifies potential promoter regions in ncRNAs by scanning the genome for CpG islands and other features associated with RNApII promoters.\n5. RNAhybrid: This tool predicts the secondary and tertiary structure of RNA molecules, including ncRNAs, and can be used to identify potential promoter regions.\n6. DeepSea: This tool predicts the transcriptional start sites (TSSs) of ncRNAs by analyzing the chromatin structure and gene expression data.\n7. HISAT2: This tool is a spliced aligner that can be used to identify the 5' end of ncRNAs and predict their transcriptional start sites.\n8. STAR: This tool is another spliced aligner that can be used to identify the 5' end of ncRNAs and predict their transcriptional start sites.\n9. Cufflinks: This tool can be used to quantify the expression of ncRNAs and predict their transcriptional start sites.\n10. ARNsplice: This tool predicts the splicing events of ncRNAs and identifies the 5' end of the transcripts.\nThese tools can be used to identify and visualize ncRNA promoters, which are essential for understanding the regulation of ncRNA expression and their role in various cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG Island Finder identifies CpG islands that are often enriched in non-coding RNA (ncRNA) promoters.\n2. ProbeFinder predicts RNA polymerase II (RNApII) promoter sequences in ncRNAs.\n3. RNApromoter predicts and visualizes RNApII promoter sequences in the genomic context.\n4. DeepSea predicts the transcriptional start sites of ncRNAs through chromatin structure and gene expression data analysis.\n5. HISAT2 and STAR are spliced aligners used to identify the 5' end of ncRNAs and predict their transcriptional start sites.",
    "llama-2-7b-chat-hf_fact": [
      "CpG Island Finder identifies CpG islands that are often enriched in non-coding RNA (ncRNA) promoters.",
      "ProbeFinder predicts RNA polymerase II (RNApII) promoter sequences in ncRNAs.",
      "RNApromoter predicts and visualizes RNApII promoter sequences in the genomic context.",
      "DeepSea predicts the transcriptional start sites of ncRNAs through chromatin structure and gene expression data analysis.",
      "HISAT2 and STAR are spliced aligners used to identify the 5' end of ncRNAs and predict their transcriptional start sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ProbeFinder does not predict RNA polymerase II (RNApII) promoter sequences in ncRNAs. Its function is not clearly described in the context provided, therefore the intended purpose cannot be confirmed.\n3. FALSE [correction]: RNApromoter does not exist as a known tool for predicting and visualizing RNA polymerase II (RNApII) promoter sequences in the genomic context. The statement seems vague because there is no widely recognized bioinformatics tool with this exact name.\n4. FALSE [correction]: DeepSea is a machine learning framework that predicts the effects of noncoding variants on chromatin features and gene expression, but it is not specifically described as predicting transcriptional start sites of non-coding RNAs (ncRNAs) through chromatin structure and gene expression data analysis.\n5. FALSE [correction]: HISAT2 and STAR are indeed spliced aligners, but they are generally used for mapping RNA sequencing reads to a reference genome, which helps researchers to study gene expression, gene structure, and splicing. They do not specifically identify the 5' end of ncRNAs or predict their transcriptional start sites; they align RNA-seq reads that may include ncRNAs among other RNA types.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (Systematic Wide-scale Investigation of MicroRNA) is a bioinformatics tool that can identify genes that are differentially expressed between two or more conditions, such as healthy and diseased tissues. In the context of glioblastoma, SWIM has been used to identify genes that are down-regulated in glioblastoma compared to normal brain tissue. Here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. TP53: A tumor suppressor gene that is commonly mutated in glioblastoma.\n2. CDKN2A: A gene that encodes a protein that regulates the cell cycle and is inactivated in many types of cancer, including glioblastoma.\n3. PTEN: A tumor suppressor gene that regulates cell growth and survival, and is often mutated or lost in glioblastoma.\n4. STK11: A gene that encodes a protein that regulates the cell cycle and is inactivated in many types of cancer, including glioblastoma.\n5. APC: A gene that encodes a protein that regulates cell growth and differentiation, and is often mutated in colorectal cancer and other types of cancer, including glioblastoma.\n6. MAP3K5: A gene that encodes a protein that regulates signaling pathways involved in cell growth and survival, and is often amplified or overexpressed in glioblastoma.\n7. MTOR: A gene that encodes a protein that regulates cell growth and metabolism, and is often overexpressed in glioblastoma.\n8. MLH1: A gene that encodes a protein that regulates DNA mismatch repair, and is often mutated in glioblastoma.\n9. MSH2: A gene that encodes a protein that regulates DNA mismatch repair, and is often mutated in glioblastoma.\n10. PML: A gene that encodes a protein that regulates the cell cycle and is involved in the response to DNA damage, and is often mutated in glioblastoma.\nIt's worth noting that these are just a few examples of genes that have been identified as down-regulated in glioblastoma using SWIM,",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53 is a gene identified by SWIM as being commonly mutated and down-regulated in glioblastoma.\n2. CDKN2A, which encodes a protein regulating the cell cycle, is down-regulated in glioblastoma as identified by SWIM.\n3. The PTEN gene, a tumor suppressor that regulates cell growth and survival, is often mutated or lost in glioblastoma according to SWIM findings.\n4. STK11, a gene involved in cell cycle regulation, is inactivated in many types of cancer including glioblastoma and has been identified as down-regulated by SWIM.\n5. APC is a gene down-regulated in glioblastoma that encodes a protein regulating cell growth and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "TP53 is a gene identified by SWIM as being commonly mutated and down-regulated in glioblastoma.",
      "CDKN2A, which encodes a protein regulating the cell cycle, is down-regulated in glioblastoma as identified by SWIM.",
      "The PTEN gene, a tumor suppressor that regulates cell growth and survival, is often mutated or lost in glioblastoma according to SWIM findings.",
      "STK11, a gene involved in cell cycle regulation, is inactivated in many types of cancer including glioblastoma and has been identified as down-regulated by SWIM.",
      "APC is a gene down-regulated in glioblastoma that encodes a protein regulating cell growth and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: STK11 is a gene involved in regulating cellular metabolism and polarity, not directly in cell cycle regulation, and there is insufficient information provided about it being identified as down-regulated by SWIM in glioblastoma.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Several R packages have been developed for studying Transcriptional Activation Domains (TADs), including:\n1. TADb: This package provides a comprehensive framework for the analysis of TADs, including the identification of TAD boundaries, the analysis of chromatin accessibility, and the prediction of gene regulation.\n2. TFbound: This package uses a Bayesian approach to predict the boundaries of TADs based on chromatin accessibility data.\n3. TADtrackR: This package uses a hidden Markov model to identify TADs in chromatin accessibility data.\n4. ChromHMM: This package uses a hidden Markov model to model the chromatin structure and predict TAD boundaries.\n5. TADdetect: This package uses a Bayesian approach to identify TADs based on chromatin accessibility data and other features such as histone modifications.\n6. TADseq: This package provides a workflow for the analysis of TADs in RNA-seq data, including the identification of TAD-associated genes and the analysis of gene expression.\n7. TAD-seq-diff: This package provides a workflow for the analysis of TADs in RNA-seq data from different samples, including the identification of differentially expressed TAD-associated genes.\n8. TAD-seq-predict: This package provides a workflow for the prediction of TADs in RNA-seq data, including the use of machine learning algorithms to identify putative TAD boundaries.\nThese packages provide a range of tools and methods for the analysis of TADs, including the identification of TAD boundaries, the analysis of chromatin accessibility, and the prediction of gene regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package TADb provides a framework for analyzing TADs, including identification of TAD boundaries and prediction of gene regulation.\n2. TFbound is an R package that predicts TAD boundaries using a Bayesian approach based on chromatin accessibility data.\n3. TADtrackR is an R package employing a hidden Markov model to identify TADs in chromatin accessibility data.\n4. ChromHMM is an R package that models chromatin structure and predicts TAD boundaries with a hidden Markov model.\n5. TADseq is an R package designed for RNA-seq data analysis to identify TAD-associated genes and analyze gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "The R package TADb provides a framework for analyzing TADs, including identification of TAD boundaries and prediction of gene regulation.",
      "TFbound is an R package that predicts TAD boundaries using a Bayesian approach based on chromatin accessibility data.",
      "TADtrackR is an R package employing a hidden Markov model to identify TADs in chromatin accessibility data.",
      "ChromHMM is an R package that models chromatin structure and predicts TAD boundaries with a hidden Markov model.",
      "TADseq is an R package designed for RNA-seq data analysis to identify TAD-associated genes and analyze gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: ChromHMM is not an R package but a computational tool that is used to characterize chromatin states using histone modification data. It does not predict TAD (Topologically Associating Domains) boundaries.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "One popular bioconductor tool for accessing bacterial regulatory networks is \"BioCyc\". BioCyc is a comprehensive database of genomic and metabolic information for over 1,000 bacterial species, including information on gene regulation, metabolic pathways, and genomic context. It provides a suite of tools for analyzing and visualizing this data, including the ability to infer regulatory networks and predict gene function.",
    "llama-2-7b-chat-hf_fact_raw": "1. BioCyc is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. BioCyc contains genomic and metabolic information for over 1,000 bacterial species.\n3. The database includes information on gene regulation, metabolic pathways, and genomic context.\n4. BioCyc provides tools for analyzing and visualizing data related to bacterial regulatory networks.\n5. BioCyc offers features that allow the inference of regulatory networks and prediction of gene function.",
    "llama-2-7b-chat-hf_fact": [
      "BioCyc is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "BioCyc contains genomic and metabolic information for over 1,000 bacterial species.",
      "The database includes information on gene regulation, metabolic pathways, and genomic context.",
      "BioCyc provides tools for analyzing and visualizing data related to bacterial regulatory networks.",
      "BioCyc offers features that allow the inference of regulatory networks and prediction of gene function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BioCyc is a collection of pathway/genome databases, not a bioconductor tool. Bioconductor is a separate project that provides tools for the analysis and comprehension of high-throughput genomic data.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are:\n1. Aromatic amino acids: phenylalanine, tyrosine, and tryptophan\n2. Quinones: ubiquinone (coenzyme Q) and menaquinone (vitamin K2)\n3. Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN)\n4. Ergothioneine\nThese compounds are important for various cellular processes, including energy metabolism, antioxidant defense, and the biosynthesis of other molecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. Phenylalanine, tyrosine, and tryptophan are aromatic amino acids that are end products of the shikimate pathway.\n2. Quinones such as ubiquinone (coenzyme Q) and menaquinone (vitamin K2) are end products of the shikimate pathway.\n3. Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are end products of the shikimate pathway.\n4. Ergothioneine is an end product of the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Phenylalanine, tyrosine, and tryptophan are aromatic amino acids that are end products of the shikimate pathway.",
      "Quinones such as ubiquinone (coenzyme Q) and menaquinone (vitamin K2) are end products of the shikimate pathway.",
      "Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are end products of the shikimate pathway.",
      "Ergothioneine is an end product of the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Phenylalanine, tyrosine, and tryptophan are aromatic amino acids that are products of the shikimate pathway but not end products; they serve as precursors for the synthesis of proteins and other molecules.\n2. TRUE\n3. FALSE [correction]: Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are not end products of the shikimate pathway; they are coenzymes derived from riboflavin (vitamin B2).\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that can occur after treatment with dopamine agonists, such as bromocriptine or ropinirole, for conditions such as Parkinson's disease or restless leg syndrome. Cabergoline is a dopamine receptor agonist that is structurally related to bromocriptine and has been shown to have some effects on the growth of pituitary tumors in people with Nelson's syndrome. However, its use for this purpose is not well established and is considered off-label.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is sometimes used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after the use of dopamine agonists.\n3. Bromocriptine and ropinirole are examples of dopamine agonists used for conditions such as Parkinson's disease or restless leg syndrome.\n4. Cabergoline is a dopamine receptor agonist and is structurally related to bromocriptine.\n5. The use of cabergoline for treating Nelsons syndrome is considered off-label.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is sometimes used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after the use of dopamine agonists.",
      "Bromocriptine and ropinirole are examples of dopamine agonists used for conditions such as Parkinson's disease or restless leg syndrome.",
      "Cabergoline is a dopamine receptor agonist and is structurally related to bromocriptine.",
      "The use of cabergoline for treating Nelsons syndrome is considered off-label."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome; it is used to treat conditions like hyperprolactinemia and Parkinson's disease.\n2. FALSE [correction]: Nelson's syndrome is a rare condition that can occur after the removal of the adrenal glands (adrenalectomy), often due to Cushing's disease, not after the use of dopamine agonists.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder characterized by the following main manifestations:\n1. Developmental delay and intellectual disability: Children with Liebenberg syndrome typically experience delays in reaching developmental milestones, such as sitting, standing, and walking, and may have intellectual disability.\n2. Distinctive facial features: People with Liebenberg syndrome often have distinctive facial features, including a small head, narrow eyes, and a short nose.\n3. Skeletal abnormalities: The disorder can cause various skeletal abnormalities, such as short stature, bowed legs, and extra digits (polydactyly).\n4. Neurological problems: Liebenberg syndrome can also cause neurological problems, including seizures, poor muscle tone, and problems with coordination and balance.\n5. Other symptoms: Additional symptoms of Liebenberg syndrome can include hearing loss, vision problems, and an increased risk of infections.\nIt is important to note that the severity of the disorder can vary greatly between individuals, and some people may have a more mild or severe form of the condition. A proper diagnosis and evaluation by a healthcare professional is necessary for accurate assessment and appropriate management of Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder.\n2. Individuals with Liebenberg syndrome may experience developmental delays and intellectual disability.\n3. Distinctive facial features associated with Liebenberg syndrome can include a small head, narrow eyes, and a short nose.\n4. Skeletal abnormalities such as short stature, bowed legs, and extra digits (polydactyly) can occur in Liebenberg syndrome.\n5. Liebenberg syndrome can cause neurological problems, including seizures and poor muscle tone.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder.",
      "Individuals with Liebenberg syndrome may experience developmental delays and intellectual disability.",
      "Distinctive facial features associated with Liebenberg syndrome can include a small head, narrow eyes, and a short nose.",
      "Skeletal abnormalities such as short stature, bowed legs, and extra digits (polydactyly) can occur in Liebenberg syndrome.",
      "Liebenberg syndrome can cause neurological problems, including seizures and poor muscle tone."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no known genetic disorder called Liebenberg syndrome. This could be a confusion with another condition or an entirely fabricated syndrome.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nSince Liebenberg syndrome is not recognized as a medical condition, the remaining statements about its symptoms or characteristics cannot be accurately validated.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "There are several orally bioavailable MPS1 kinase inhibitors that have been identified and developed for the treatment of various diseases, including cancer and neurodegenerative disorders. Here are some examples:\n1. Pirfenidone: Pirfenidone is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and colon cancer.\n2. GDC-0980: GDC-0980 is a highly potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and ovarian cancer.\n3. BMS-911515: BMS-911515 is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and colon cancer.\n4. LY3023414: LY3023414 is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and colon cancer.\n5. RX-0201: RX-0201 is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and colon cancer.\n6. R5528: R5528 is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and colon cancer.\n7. S63845: S63845 is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and colon cancer.\n8. GSK2801: GSK2801 is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and colon cancer.\n9. CHIR",
    "llama-2-7b-chat-hf_fact_raw": "1. Pirfenidone is an MPS1 kinase inhibitor that has been shown to have antitumor activity.\n2. GDC-0980 is an MPS1 kinase inhibitor that has demonstrated antitumor activity in various cancer models, including breast, lung, and ovarian cancer.\n3. BMS-911515 is an MPS1 kinase inhibitor known to have antitumor effects in cancer models such as breast, lung, and colon cancer.\n4. LY3023414 is an MPS1 kinase inhibitor with antitumor activity in cancer models, including breast, lung, and colon cancer.\n5. RX-0201 is an MPS1 kinase inhibitor that exhibits antitumor activity in different cancer models.",
    "llama-2-7b-chat-hf_fact": [
      "Pirfenidone is an MPS1 kinase inhibitor that has been shown to have antitumor activity.",
      "GDC-0980 is an MPS1 kinase inhibitor that has demonstrated antitumor activity in various cancer models, including breast, lung, and ovarian cancer.",
      "BMS-911515 is an MPS1 kinase inhibitor known to have antitumor effects in cancer models such as breast, lung, and colon cancer.",
      "LY3023414 is an MPS1 kinase inhibitor with antitumor activity in cancer models, including breast, lung, and colon cancer.",
      "RX-0201 is an MPS1 kinase inhibitor that exhibits antitumor activity in different cancer models."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Pirfenidone is not an MPS1 kinase inhibitor, it is actually an anti-fibrotic medication used primarily to treat idiopathic pulmonary fibrosis.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: RX-0201, also known as Archexin, is not an MPS1 kinase inhibitor; it is an antisense oligonucleotide that targets the AKT1 mRNA, interfering with its expression and thus showing potential as an antitumor agent in various cancers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Yes, golimumab has been studied for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, but it has not been specifically approved or tested for the treatment of diabetes. Golimumab is a tumor necrosis factor (TNF) inhibitor, which is a class of drugs that work by blocking the action of TNF, a protein that is involved in the immune system and can cause inflammation in the body. While TNF inhibitors have been shown to be effective in treating certain autoimmune diseases, they are not approved for the treatment of diabetes, which is a metabolic disorder rather than an autoimmune disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab has been studied for the treatment of various autoimmune diseases.\n2. Golimumab has not been specifically approved or tested for the treatment of diabetes.\n3. Golimumab is a tumor necrosis factor (TNF) inhibitor.\n4. Tumor necrosis factor inhibitors work by blocking the action of TNF.\n5. Diabetes is classified as a metabolic disorder, not an autoimmune disease.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab has been studied for the treatment of various autoimmune diseases.",
      "Golimumab has not been specifically approved or tested for the treatment of diabetes.",
      "Golimumab is a tumor necrosis factor (TNF) inhibitor.",
      "Tumor necrosis factor inhibitors work by blocking the action of TNF.",
      "Diabetes is classified as a metabolic disorder, not an autoimmune disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE: As of my knowledge cutoff date in 2023, Golimumab has not been approved for the treatment of diabetes. Golimumab is specifically used for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While diabetes is generally classified as a metabolic disorder, type 1 diabetes is considered an autoimmune disease because the immune system attacks and destroys insulin-producing cells in the pancreas.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive mutation in the LMNA gene. This gene encodes for the protein lamin A, which is involved in the structure and maintenance of chromosomes. The mutation leads to a deficiency of lamin A and the accumulation of a toxic form of lamin A, called progerin, which causes the characteristic features of progeria, such as accelerated aging and a shortened lifespan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. The cause of progeria is a mutation in the LMNA gene.\n3. The LMNA gene is related to the encoding of the protein lamin A.\n4. A deficiency of lamin A and the accumulation of a toxic form called progerin is associated with progeria.\n5. Progeria causes characteristic features such as accelerated aging and a shortened lifespan.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "The cause of progeria is a mutation in the LMNA gene.",
      "The LMNA gene is related to the encoding of the protein lamin A.",
      "A deficiency of lamin A and the accumulation of a toxic form called progerin is associated with progeria.",
      "Progeria causes characteristic features such as accelerated aging and a shortened lifespan."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at 12q14 and 12q24 have been associated with several common diseases and conditions, including:\n12q14:\n* Obesity and body mass index (BMI)\n* Type 2 diabetes mellitus (T2DM)\n* Cardiovascular disease (CVD)\n* Hypertension\n* Cancer, including breast, ovarian, and colorectal cancer\n12q24:\n* Prostate cancer\n* Breast cancer\n* Ovarian cancer\n* Colorectal cancer\n* Melanoma\nThese variants may affect the expression of genes involved in metabolism, insulin signaling, inflammation, and cell growth and division, leading to an increased risk of developing these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants at 12q14 are associated with obesity and body mass index (BMI).\n2. Variants at 12q14 are related to an increased risk of Type 2 diabetes mellitus (T2DM).\n3. Variants at 12q14 have been linked to cardiovascular disease (CVD).\n4. Variants at 12q24 are associated with prostate cancer.\n5. Variants at 12q24 have been linked to an increased risk of melanoma.",
    "llama-2-7b-chat-hf_fact": [
      "Variants at 12q14 are associated with obesity and body mass index (BMI).",
      "Variants at 12q14 are related to an increased risk of Type 2 diabetes mellitus (T2DM).",
      "Variants at 12q14 have been linked to cardiovascular disease (CVD).",
      "Variants at 12q24 are associated with prostate cancer.",
      "Variants at 12q24 have been linked to an increased risk of melanoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Variants at 12q14 have been associated with obesity and body mass index (BMI) in numerous genetic studies.\n2. TRUE: Variants at the 12q14 locus have also been related to an increased risk of Type 2 diabetes mellitus (T2DM), as they may influence glucose metabolism and other related metabolic traits.\n3. UNKNOWN: While variants in certain regions of the genome are linked to cardiovascular disease, without specific studies or evidence, it is unclear if variants at 12q14 in particular are associated with cardiovascular disease.\n4. TRUE: Variants at 12q24 have been associated with prostate cancer in genetic studies, suggesting this locus may play a role in the development of the disease.\n5. TRUE: Variants at 12q24 have also been linked to an increased risk of melanoma, which is consistent with findings from genetic research that map certain disease risks to specific loci on the genome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The ligands of the Roundabout (Robo) receptors are members of the Slit (Slit) family of proteins. Slit proteins are secreted signaling molecules that bind to Robo receptors on the surface of neurons and other cells, regulating their signaling pathways and behavior. The specific ligands that bind to each Robo receptor are:\n* Robo1: Slit1, Slit2, and Slit3\n* Robo2: Slit2 and Slit3\n* Robo3: Slit1 and Slit2\nIt's worth noting that there are other ligands that can also interact with Robo receptors, such as the ephrin family of proteins, which can also modulate Robo signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are members of the Slit family of proteins.\n2. Slit proteins bind to Robo receptors on the surface of neurons and other cells.\n3. Robo1 receptors bind with Slit1, Slit2, and Slit3 proteins.\n4. Robo2 receptors bind with Slit2 and Slit3 proteins.\n5. Robo3 receptors bind with Slit1 and Slit2 proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The ligands of the Roundabout (Robo) receptors are members of the Slit family of proteins.",
      "Slit proteins bind to Robo receptors on the surface of neurons and other cells.",
      "Robo1 receptors bind with Slit1, Slit2, and Slit3 proteins.",
      "Robo2 receptors bind with Slit2 and Slit3 proteins.",
      "Robo3 receptors bind with Slit1 and Slit2 proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Robo3 receptors have a role in repulsion by Slit proteins, but they primarily interact with Slit2 and in certain contexts are inhibited by Slit1, rather than having a conventional binding relationship with Slit1 and Slit2 as implied by the statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I plays a role in megakaryopoiesis, the process of developing megakaryocytes (blood cells that give rise to platelets) from hematopoietic stem cells. TFII-I is a transcription factor that is involved in the regulation of gene expression during megakaryocyte differentiation. It is required for the proper expression of genes involved in platelet function and structure, such as the gene encoding the platelet membrane glycoprotein (GMP-140), which is now known as integrin IIb3. TFII-I is also involved in the regulation of genes involved in platelet adhesion and signaling, such as the gene encoding the platelet-derived growth factor receptor  (PDGFR). Overall, TFII-I plays an important role in the regulation of megakaryocyte differentiation and platelet function.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is involved in megakaryopoiesis, the developmental process of megakaryocytes from hematopoietic stem cells.\n2. TFII-I is a transcription factor that regulates gene expression during megakaryocyte differentiation.\n3. TFII-I is required for the proper expression of genes important for platelet function and structure.\n4. The gene encoding the platelet membrane glycoprotein (GMP-140), now known as integrin IIb3, is one such gene regulated by TFII-I.\n5. TFII-I is involved in the regulation of genes related to platelet adhesion and signaling, including the gene encoding the platelet-derived growth factor receptor  (PDGFR).",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is involved in megakaryopoiesis, the developmental process of megakaryocytes from hematopoietic stem cells.",
      "TFII-I is a transcription factor that regulates gene expression during megakaryocyte differentiation.",
      "TFII-I is required for the proper expression of genes important for platelet function and structure.",
      "The gene encoding the platelet membrane glycoprotein (GMP-140), now known as integrin IIb3, is one such gene regulated by TFII-I.",
      "TFII-I is involved in the regulation of genes related to platelet adhesion and signaling, including the gene encoding the platelet-derived growth factor receptor  (PDGFR)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - TFII-I is indeed involved in megakaryopoiesis, which is supported by scientific literature indicating its role in the development of megakaryocytes from hematopoietic stem cells.\n2. TRUE - TFII-I is a transcription factor known to regulate gene expression and is involved in the differentiation of various cells, including megakaryocytes.\n3. TRUE - TFII-I is necessary for the correct expression of genes that are important for both the function and structure of platelets.\n4. FALSE [correction]: Integrin IIb3, also known as glycoprotein IIb/IIIa, is not the same as GMP-140. GMP-140 is better known as P-selectin, a membrane protein stored in the -granules of platelets and released during platelet activation.\n5. UNKNOWN - While TFII-I does regulate genes related to platelet function, the specific involvement in the regulation of the gene encoding for the platelet-derived growth factor receptor  (PDGFR) requires specific evidence from biological research, which is not provided in this context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is responsible for the metabolism of approximately 20-30% of clinically used drugs, including atenolol, and plays a major role in the metabolism of many beta-blockers, such as atenolol, to their active metabolites.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. CYP2D6 is responsible for the metabolism of approximately 20-30% of clinically used drugs.\n3. CYP2D6 plays a major role in the metabolism of many beta-blockers, including atenolol, to their active metabolites.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "CYP2D6 is responsible for the metabolism of approximately 20-30% of clinically used drugs.",
      "CYP2D6 plays a major role in the metabolism of many beta-blockers, including atenolol, to their active metabolites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not primarily metabolized by cytochrome P450 enzymes such as CYP2D6; it is excreted largely unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: While CYP2D6 plays a major role in the metabolism of many beta-blockers, atenolol is not significantly metabolized by CYP2D6 and does not form active metabolites.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a tool used for identifying and quantifying gene fusions in RNA sequencing (RNA-seq) data. Here are some versions of ExpansionHunter:\n1. ExpansionHunter (v1.0): This is the original version of ExpansionHunter, which was released in 2017. It uses a Hidden Markov Model (HMM) to identify gene fusions and can handle both single-end and paired-end RNA-seq data.\n2. ExpansionHunter (v1.1): This version was released in 2018 and includes several improvements over the original version, including improved accuracy and faster performance.\n3. ExpansionHunter (v2.0): This is the latest version of ExpansionHunter, which was released in 2020. It includes several major updates, including the ability to handle multi-read RNA-seq data and improved performance for identifying gene fusions in certain types of samples.\n4. ExpansionHunter-Lite: This is a lightweight version of ExpansionHunter that is designed for use with smaller datasets. It includes a simplified interface and reduced computational requirements, making it easier to use for researchers with limited resources.\n5. ExpansionHunter-Plus: This is an enhanced version of ExpansionHunter that includes additional features and improvements. It includes a more accurate and efficient algorithm for identifying gene fusions, as well as tools for visualizing and interpreting the results.\n6. ExpansionHunter-Pro: This is a professional version of ExpansionHunter that includes all of the features of the other versions, as well as additional tools and resources for advanced researchers. It includes a user-friendly interface and a comprehensive documentation set, making it easier to use for researchers who are new to the software.\n7. ExpansionHunter-Enterprise: This is an enterprise version of ExpansionHunter that is designed for use in large-scale research environments. It includes a scalable architecture and a variety of tools for managing and analyzing large datasets, as well as advanced features such as automated workflows and data visualization tools.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter (v1.0) was released in 2017 and uses a Hidden Markov Model to identify gene fusions.\n2. ExpansionHunter (v1.1) was released in 2018 with improvements in accuracy and performance.\n3. ExpansionHunter (v2.0) was released in 2020 and can handle multi-read RNA-seq data.\n4. ExpansionHunter-Lite is designed for smaller datasets with a simplified interface.\n5. ExpansionHunter-Pro includes a user-friendly interface and comprehensive documentation for researchers.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter (v1.0) was released in 2017 and uses a Hidden Markov Model to identify gene fusions.",
      "ExpansionHunter (v1.1) was released in 2018 with improvements in accuracy and performance.",
      "ExpansionHunter (v2.0) was released in 2020 and can handle multi-read RNA-seq data.",
      "ExpansionHunter-Lite is designed for smaller datasets with a simplified interface.",
      "ExpansionHunter-Pro includes a user-friendly interface and comprehensive documentation for researchers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ExpansionHunter (v1.0) was released in 2017, but it is designed to detect expansions of short tandem repeats (STRs) in genomics data, not to identify gene fusions.\n2. UNKNOWN: Without additional context or a specific source to verify the details of version releases, accuracy, and performance improvements for ExpansionHunter (v1.1), the truth of this statement cannot be determined.\n3. FALSE [correction]: ExpansionHunter is not designed to handle RNA-seq data, multi-read or otherwise. It is specifically tailored for detecting expansions of short tandem repeats (STRs) in DNA sequencing data.\n4. UNKNOWN: ExpansionHunter-Lite does exist, and it is a more lightweight version of the ExpansionHunter tool, but without specific details regarding its design for smaller datasets and a simplified interface, the truth of this statement cannot be established.\n5. UNKNOWN: The existence of an \"ExpansionHunter-Pro\" product with those specific characteristics cannot be established without additional context or a verifiable source.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (a disintegrin and metalloproteinase domain-containing protein 18) is a protein that plays a role in hormone receptor signaling, specifically in the regulation of estrogen receptor (ER) activity. Adamts18 is an endogenous inhibitor of ER activity and can bind to ER (estrogen receptor alpha) and ER (estrogen receptor beta) and suppress their activity. This occurs through a mechanism involving the cleavage of the Adamts18 protein by matrix metalloproteinases (MMPs), leading to the release of an inhibitory fragment that binds to ERs and prevents them from activating downstream signaling pathways. Therefore, Adamts18 can regulate hormone receptor signaling by negatively modulating the activity of ERs in various cell types.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a protein involved in hormone receptor signaling.\n2. Adamts18 acts as an endogenous inhibitor of estrogen receptor (ER) activity.\n3. Adamts18 can bind to both estrogen receptor alpha (ER) and estrogen receptor beta (ER).\n4. The cleavage of Adamts18 by matrix metalloproteinases (MMPs) releases an inhibitory fragment.\n5. The inhibitory fragment from Adamts18 binds to ERs, preventing them from activating downstream signaling pathways.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a protein involved in hormone receptor signaling.",
      "Adamts18 acts as an endogenous inhibitor of estrogen receptor (ER) activity.",
      "Adamts18 can bind to both estrogen receptor alpha (ER) and estrogen receptor beta (ER).",
      "The cleavage of Adamts18 by matrix metalloproteinases (MMPs) releases an inhibitory fragment.",
      "The inhibitory fragment from Adamts18 binds to ERs, preventing them from activating downstream signaling pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without specific information or a passage detailing attributes and functions of Adamts18, the protein's role in hormone receptor signaling and its interactions with estrogen receptors cannot be accurately determined. Therefore, without additional context, the statements remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme histone methyltransferase (HMT) enzyme, specifically targeting the enzyme SETDB1 (also known as Eset or KMT1E). SETDB1 is involved in the methylation of histone H3 lysine 9 (H3K9), which is a repressive mark that silences gene expression. Thiazovivin inhibits the activity of SETDB1, leading to the demethylation of H3K9 and the activation of target genes. This results in the modulation of gene expression, including the reactivation of silenced genes, and the inhibition of cancer cell proliferation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is an inhibitor of the histone methyltransferase (HMT) enzyme.\n2. Thiazovivin specifically targets the enzyme SETDB1 (also known as Eset or KMT1E).\n3. SETDB1 is involved in the methylation of histone H3 lysine 9 (H3K9).\n4. Thiazovivin inhibits the activity of SETDB1, leading to the demethylation of H3K9.\n5. The inhibition of SETDB1 by Thiazovivin can result in the modulation of gene expression and the inhibition of cancer cell proliferation.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is an inhibitor of the histone methyltransferase (HMT) enzyme.",
      "Thiazovivin specifically targets the enzyme SETDB1 (also known as Eset or KMT1E).",
      "SETDB1 is involved in the methylation of histone H3 lysine 9 (H3K9).",
      "Thiazovivin inhibits the activity of SETDB1, leading to the demethylation of H3K9.",
      "The inhibition of SETDB1 by Thiazovivin can result in the modulation of gene expression and the inhibition of cancer cell proliferation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the histone methyltransferase (HMT) enzyme; it is actually a ROCK inhibitor, which is involved in regulating cell adhesion and contraction.\n2. FALSE [correction]: Since Thiazovivin is not an HMT inhibitor, it does not specifically target the enzyme SETDB1 (Eset/KMT1E).\n3. TRUE: SETDB1 is indeed involved in the methylation of histone H3 lysine 9 (H3K9).\n4. FALSE [correction]: Thiazovivin does not target SETDB1 as it is a ROCK inhibitor, not an HMT inhibitor, and therefore does not lead to the demethylation of H3K9 by inhibiting SETDB1.\n5. FALSE [correction]: As Thiazovivin does not inhibit SETDB1, the statement about its effects on gene expression and the inhibition of cancer cell proliferation through SETDB1 inhibition is incorrect. However, Thiazovivin could potentially affect gene expression and cancer cell proliferation through other pathways as a ROCK inhibitor, but this statement is false in the context given.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  }
]